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Distal sensory polyneuropathy (DSP) amongst human immunodeficiency virus (HIV)-infected 
patients is frequently a painful and disabling condition. HIV-associated DSP is either a consequence 
of HIV (HIV-DSP) or antiretroviral-induced toxic neuropathy (ATN). The purpose of this research 
was to investigate the characteristics of HIV-associated DSP over the first 24 weeks of starting cART 
in an African community-based cohort. Apart from studying the longitudinal association of candidate 
risk factors based on previous reports, we focused on two additional aspects. Firstly, the N-
acetyltransferase 2 (NAT2) genotype, which determines an individual‟s acetylation status, influences 
the risk for isoniazid (INH)-associated neuropathy. As INH may predispose to vitamin B6 deficiency 
and the frequency of HIV/TB co-infection is high, we investigated NAT2 genotypes and deduced 
acetylation-phenotypes, vitamin B6 deficiency and the incidence of ATN amongst HIV-infected 
South Africans. Secondly, incident painful ATN usually develops within 12 weeks of starting 
combination antiretroviral therapy (cART). As the timing coincides with the manifestations of the 
immune reconstitution inflammatory syndrome, we hypothesized that immune dysregulation 
involving previously identified pain-associated cytokines, may correlate with incident ATN. 
Therefore, we investigated the longitudinal association of plasma cytokine and their soluble receptor 
concentrations with incident painful ATN within the first 12 weeks of cART initiation.  
Materials and methods 
In a longitudinal observational cohort, adults about to initiate cART at a Cape Town community-
based clinic were clinically screened for peripheral neuropathy by clinicians at a pre-cART visit and 
2-, 4-, 12- and 24 weeks after cART initiation. Two validated instruments were used to define DSP as 
the presence of ≥1 neuropathic symptom and ≥1 neuropathic sign (symptomatic DSP) or ≥2 signs 
without symptoms (asymptomatic DSP). ATN was defined as new symptoms (±signs) or worsening 
in existing symptomatic DSP since cART initiation. NAT2 genotyping was performed using 
polymerase chain reaction restriction fragment length polymorphism analysis, sequencing and 
computational haplotype-predicted acetylation phenotype (rapid, intermediate or slow). Fasting 
vitamin B6 levels [pyridoxal-5‟-phosphate (PLP) and 4-pyridoxic acid (4-PA)] were quantified by 
high performance liquid chromatography. A nested case-control study was included to assess the 
hypothesis that ATN could be associated with immune dysregulation. Cytokines and soluble receptors 
were quantified using multiplex immunometric assays with a particular focus on candidate cytokines 

















IL-2, IL-6]. High-sensitivity C-reactive protein (hs-CRP) and albumin levels were measured by 
immunoturbidimetric assays. Anthropometric data, drug and supplement use, and fasting lipid profiles 
were obtained at baseline, 12- and 24-week visits. Previous medical history, CD4 T-cell counts, week 
24 viral loads and white cell counts were obtained from chart reviews. 
Results 
One hundred and eighty-four individuals were assessed at baseline. The median age was 33 
(interquartile range 26-39); 70% were female. Sixty-three per cent were classified as either World 
Health Organization stage 1 or 2 HIV infection. The median CD4 T-cell count prior to cART 
initiation was 158 cells/mm
3
 (interquartile range 114-196). 
Baseline symptomatic DSP frequency was 17%. Individuals with current/previous INH exposure 
(n=69) had a higher frequency of DSP (p=0.015). Other factors associated with DSP pre-cART were 
increasing age, triglycerides >0.9 mmol/L and hs-CRP >5 g/L. 
A stavudine-containing regimen was started in 57%, zidovudine in 11%, and tenofovir in 32% based 
on the government-sponsored guidelines at the time. One hundred and forty-four individuals 
completed 24 weeks follow-up (22 lost to follow up, 18 excluded). The majority of individuals with 
symptomatic DSP pre-cART experienced improvement in neuropathic symptoms on cART (54%) and 
half of those with asymptomatic DSP showed complete resolution of their neuropathic signs by 24 
weeks.  
Incident ATN occurred in 34% of individuals within 24 weeks of starting cART and did not differ 
significantly between cART regimens. The peak incidence in ATN occurred between 4 and 12 weeks 
after cART. NAT2 acetylation phenotypes were predicted in 165 participants: 16% rapid, 52% 
intermediate and 32% slow. The presence of at least one slow allele positively associated with the 
development of new neuropathic symptoms (p=0.036), an association that was strengthened by a 
history of INH exposure. Overall, vitamin B6 levels showed no association with NAT2 phenotypes. 
However, vitamin B6 deficiency (PLP<25 nmol/L) was present in 53% of individuals at baseline and 
55% at 12 weeks despite standard of care B6 supplementation.  
Overall, candidate cytokine and hs-CRP concentrations increased at 2 weeks compared with baseline 
levels, irrespective of ATN status, returning to baseline concentrations again at 12 weeks. 
Interestingly, individuals who developed ATN had higher pre-cART levels of IL-1 receptor (R)-
antagonist and showed greater increases in soluble (s) IL-2Rα sIL-2Rα and sTNFRII at week 2 and 
sIL-6R at week 12. In those developing ATN, ratios of proinflammatory- vs anti-inflammatory 
cytokines were significantly higher for TNF-α/IL-4 at 2 weeks and IFN-γ/IL-10 at 12 weeks and 


















HIV-DSP and ATN remain clinically significant in Africa and at higher frequencies compared to 
populations from developed countries. The incidence of symptomatic ATN peaked between 4 and 12 
weeks after initiating cART. The development of neuropathic signs on the other hand, increased 
steadily over the 24-week period suggesting, to some degree, a separate pathogenetic mechanism for 
asymptomatic DSP. Despite widespread vitamin B complex supplementation there was a high 
prevalence of suboptimal circulating plasma PLP levels with at least half of the cohort identified as 
being vitamin B6 deficient. Genotype-deduced slow acetylators are prevalent in this population and 
the slow acetylation-phenotype is overrepresented in individuals developing ATN suggestive of a 
contributory role.  
All individuals had a transient but significant burst in both pro- and anti-inflammatory plasma 
cytokine concentrations, as well as hs-CRP levels, within 2-4 weeks after starting cART. In addition, 
those who developed ATN within 12 weeks of starting cART showed evidence of a higher set point of 
subclinical inflammation, albeit in the systemic compartment, even before cART was started. These 
results suggest that those who developed ATN have insults driving chronic subclinical inflammation 
preceding cART. Furthermore, the observed cytokine burst, altered and higher ratios of “pain-
associated” cytokines and concomitant increases in soluble cytokine receptors soon after starting 
cART, may all give rise to neuropathic symptoms via complex direct and indirect signalling 
mechanisms. 
We propose a synergistic, multifactorial model for the development of DSP where HIV-DSP and 
ATN are part of a continuum of a similar pathological process. Increased age, immune dysregulation, 
previous tuberculosis, slow NAT2 acetylation status and micronutrient deficiencies may all contribute 
to increased oxidative stress via several mechanisms through which these factors, in association with 
NRTIs and immune reconstitution, may contribute to the development of neuropathy. 
Preventative strategies should be directed at multiple levels to maintain adequate redox homeostasis; 
in addition to possibly earlier initiation of cART, careful attention to optimizing nutritional status by 
vitamin supplementation prior to commencing cART may provide a simple measure to reduce cellular 
oxidative stress known to augment inflammation, thereby preventing nerve injury. In Southern Africa 
where HIV/tuberculosis co-infection is high, public health care policies should implement the 
recommendations of the developed world regarding pyridoxine supplementation (10-25 mg), prior to 
commencing cART in all individuals. 
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By the end of 2011, 34 million adults and children were estimated to be living with human 
immunodeficiency virus (HIV) worldwide according to the United Nations Programme on 
HIV/AIDS (UNAIDS) and the World Health Organization (WHO) (WHO, 2011). Sub-
Saharan Africa remains the region most heavily affected by this pandemic. It is estimated that 
2.5 million adults and children were newly infected with HIV and 1.7 million deaths due to 
acquired immunodeficiency syndrome (AIDS)-related illnesses (UNAIDS, 2011). Currently, 
there is no cure or vaccine against infection by HIV. However, dramatic scientific progress 
over the past 30 years since the discovery of HIV/AIDS has not only advanced our 
understanding of this deadly pathogen, but also controlled the spread of HIV by the success 
of combination antiretroviral therapy (cART), introduced in 1996. As a result, patients have 
experienced suppression in their viral load with an improved lifespan and prognosis. HIV 
infection has become a chronic illness rather than a fatal disease. Despite the success of 
cART there is unfortunately also increasing recognition of early and more chronic drug-
specific toxicities and complications. Up to 70% of individuals infected with HIV develop 
neurologic complications of the central or peripheral nervous system (Sacktor, 2002). While 
the incidence of many HIV-associated neurological complications such as dementia and 
opportunistic infections has decreased on cART, the prevalence of neuromuscular disorders 
has increased (Morgello et al., 2004, Schifitto et al., 2002, Schifitto et al., 2005). 
Distal sensory polyneuropathy (DSP) is probably one of the most common neurologic 
complications of HIV infection (Barohn et al., 1993, Tagliati et al., 1999). The exact 
pathogenesis of HIV-associated DSP remains ill-defined and is likely multifactorial (Moyle 
and Sadler, 1998). It is now clear that some HIV treatments have inherent neurotoxic 
potential, in particular the nucleoside reverse transcriptase inhibitor (NRTI) class, and more 
specifically the dideoxynucleoside reverse transcriptase inhibitors (dNRTIs) or d-drugs - 
stavudine, didanosine, and zalcitabine (Moyle et al., 1998, Boulle et al., 2007). Despite WHO 
recommendations to reduce and phase out the use of these agents, they remain in use due to 
wide availability, low cost and limited alternatives in resource-limited settings (Hung et al., 
2008).  
The clinical importance of DSP in people living with HIV is the painful symptoms, which 

















individual‟s quality of life (Ellis et al., 2010, Hays et al., 2000). HIV management is 
constantly evolving and the expanding range of different antiretroviral drugs augments the 
likelihood for toxicities and drug–drug interactions (Harrison and Smith, 2011). 
The classification, clinical presentation and prevalence of HIV-associated DSP will now be 
discussed further. 
 
1.2 Classification, clinical presentation and prevalence and of HIV-
associated DSP 
HIV-associated DSP includes two clinically identical distal sensory neuropathies. It can arise 
either as a consequence of the HIV infection (HIV-DSP) or as a treatment-induced toxicity 
related to cART, termed antiretroviral toxic neuropathy (ATN). In many cases, HIV-DSP and 
ATN may coexist, such that an individual with existing HIV-associated DSP may experience 
worsening of neuropathic symptoms after commencing cART. There are limited data on the 
evolution of neuropathic symptoms after the initiation of cART in those who have symptoms 
pre-cART. A reduction of neuropathic intensity after cART initiation has so far only been 
observed in an anecdotal report (Pialoux et al., 1997) and a small prospective study of three 
patients (Markus and Brew, 1998). 
Onset or worsening of DSP following initiation of a d-drug and subsequent improvement 
following d-drug withdrawal, suggests ATN. The natural history of particularly neuropathic 
symptoms, in relation to cART, is therefore valuable in the aetiological diagnosis in HIV-
associated DSP. However, frequently and particularly in cross-sectional studies, the 
distinction between HIV-DSP and ATN has been made simply by the presence or absence of 
cART exposure (Maritz et al., 2010), a categorization that lacks accuracy. A further 
limitation in the literature is that DSP, with or without symptoms, are often grouped together. 
This impacts on prevalence data as well as the study of risk factors. These will be discussed 
further later. 
1.2.1 Prevalence of HIV-associated DSP 
Prior to the availability of cART, the estimated prevalence of DSP amongst ambulatory HIV-
infected individuals was found to be around 14%. However, depending on the stage of HIV 

















disease (Barohn et al., 1993), to 35% amongst hospitalized patients (So et al., 1988). Nearly 
all patients dying of AIDS have pathological abnormalities detectable in peripheral nerves (de 
la Monte et al., 1988). 
After the introduction of cART, the prevalence of HIV-associated DSP increased, probably 
due to the development of ATN (Bacellar et al., 1994). The prevalence of ATN associated 
with NRTI use has ranged from ≈20% to over 60% (Schifitto et al., 2002, Morgello et al., 
2004, Hung et al., 2008, Cherry et al., 2009, Schifitto et al., 2005, Affandi et al., 2008). Most 
prospective studies estimate a one-year incidence of ATN at 20-50% (Hung et al., 2008, 
Schifitto et al., 2002, Schifitto et al., 2005, Simpson et al., 2006). Although data are often 
incomplete soon after cART initiation, it is thought that incident ATN usually peaks within 
the first 90 days after starting a cART regimen containing dNRTIs (Arenas-Pinto et al., 
2008). 
1.2.2 Anatomical considerations 
An anatomical classification of peripheral nerves will be briefly discussed as an introduction 
to clinical symptomatology of HIV-associated DSP. As illustrated in Figure 1.1, peripheral 
nerve fibres can be classified according to size, which correlates with the degree of 
myelination. Large diameter nerve fibres are heavily myelinated and include A-α fibres, 
which mediate motor strength, and A-β fibres mediating touch and vibratory sensation. 
Medium-sized fibres, known as A-γ fibres, are also myelinated and innervate muscle 
spindles. Small fibres include thinly myelinated A-δ fibres and unmyelinated C fibres, which 
innervate skin (somatic fibres) and involuntary muscles, such as cardiac and smooth muscles 
(autonomic fibres). Together, small nerve fibres mediate thermal and nociceptive sensation as 
well as autonomic function (Vinik et al., 2008). 
The sensation of pain is transmitted as an action potential in unmyelinated (C-fibres, burning 
or dull second pain, slow transmission) and thinly myelinated (A-δ fibres, pricking or sharp 
first pain, fast transmission) primary afferent neurons. Nociceptors respond best to potentially 
noxious stimuli [mechanical (touch or pressure), thermal (hot or cold), or chemical 


















Figure 1.1: Anatomical classification of peripheral nerve fibres (Adapted from Vinik et al., 2008) 
Even though small nerve fibres comprise thermal and nociceptive sensation along with 
autonomic functions, small fibre neuropathy typically refers to somatic neuropathy alone and 
the overlap with the term „painful neuropathy‟ is often used. 
1.2.3 Clinical presentation of HIV-associated painful neuropathies 
1.2.3.1 Symptoms 
The clinical presentation of symptomatic DSP is consistent with that of small fibre 
dysfunction and consists of neuropathic pain, paraesthesiae and dysesthesiae (Verma et al., 
2004). Sensory symptoms are bilateral, symmetrical in distribution and of gradual onset. In 
the early stages, the patient describes neuropathic symptoms, such as „aching‟ or „burning‟ 
pain, „numbness‟, „tingling‟ or „pins and needles‟ in the soles of both feet or toes (Cornblath 
and McArthur, 1988). 
In a length-dependent fashion it ascends from the lower extremities over weeks to months 
(generally at least 4 weeks) to involve the feet and lower legs bilaterally (Fuller et al., 1993); 
hands are much less commonly involved (Keswani et al., 2002, Verma et al., 2004, Watters et 
al., 2004). This pattern of distal onset and proximal progression of the pain in the upper 
and/or lower extremities is referred to as a “glove and stocking” length-dependent 

















perform activities of daily living may become increasingly difficult (Dorsey and Morton, 
2006). Individuals may avoid wearing socks or shoes, and those suffering from severe 
symptoms may find difficulty in walking or standing for prolonged periods (Harrison and 
McArthur, 1995). Weakness is not a presenting symptom, unless the individual has advanced 
HIV disease (Keswani et al., 2002). 
The most disabling aspect of DSP is related to neuropathic pain. In a large South African 
cross-sectional study, approximately half of the individuals with signs of DSP suffered from 
pain (Maritz et al., 2010). Of those with neuropathic symptoms, 90% had positive sensory 
symptoms (pain and/or paraesthesiae) graded as at least moderately-severe [Visual Analogue 
Scale (VAS)  4/10] in 70% of these individuals. The pain may be both spontaneous and 
dependent on stimuli, including hyperalgesia, i.e. lowered pain threshold to noxious stimuli 
and allodynia, i.e. pain induced by non-painful stimuli such as rubbing (Keswani et al., 2002). 
ATN and HIV-DSP share identical clinical features. However, some authors have suggested 
that in HIV-DSP, symptom onset is slow and insidious. Paraesthesiae and numbness often 
precede burning or aching painful symptoms (Moyle and Sadler, 1998). In contrast, ATN is 
more likely to be sub-acute in onset and rapidly progressive with pain as an early feature, 
particularly in individuals with moderate to severe immunosuppression (Berger et al., 1993, 
Moyle and Sadler, 1998).  
1.2.3.2 Neuropathic signs in HIV-associated DSP 
The neurological examination may show symmetrical neuropathic signs with or without 
altered sensory function in a distal to proximal gradient. Although all sensory modalities may 
be affected it is most evident in those related to small fibre axons, namely pain and 
temperature, and less common in large fibre axons, viz. proprioception and vibration (Brew, 
2003). Hence, examination often reveals reduced pinprick and thermal sensation in a distally 
symmetrical distribution, predominantly in the toes and feet and may even show hyperalgesia 
or allodynia in the affected area (Keswani et al., 2002, Gonzalez-Duarte et al., 2008). 
Vibration sensibility may be reduced at the toes but proprioception is often normal. Other 
neuropathic signs of DSP include absent or depressed ankle reflexes relative to the knees and 
even generalized hypo- or areflexia (Gonzalez-Duarte et al., 2008). Muscle strength may be 

















et al., 2000). An antalgic gait may result as a consequence of pain or increased sensitivity at 
the soles of the feet (Verma et al., 2005). 
Some individuals with a clinical diagnosis of DSP have minimal neurological signs when 
compared to the severity of neuropathic symptoms, suggesting predominant involvement of 
small nerve fibres. In contrast, others with clinical signs of DSP have no symptoms (Verma, 
2001). While it has been suggested that DSP may be asymptomatic in its early stage (England 
et al., 2005), Schifitto et al. demonstrated in a longitudinal analysis (the DANA cohort) that 
asymptomatic DSP was not a significant predictor of subsequently developing symptomatic 
DSP (Schifitto et al., 2002). 
1.2.3.3 Differential diagnosis of distal sensory polyneuropathies 
In the general HIV-uninfected population, predominantly sensory polyneuropathy may be 
found in a range of medical conditions, including diabetes and a pre-diabetic state, vitamin 
deficiencies such as vitamin B12 deficiency, hepatitis C, immune-mediated and connective 
tissue disorders such as Sjögren‟s disease, dysthyroidism, dyslipidaemia, chronic renal 
failure, celiac disease, drug exposure including isoniazid (INH)-, statin- and chemotherapy, 
industrial toxins and alcohol, rare hereditary diseases, and paraneoplastic or paraproteinemic 
syndromes (Pardo et al., 2001, Tavee and Zh u, 2009). 
Although HIV-infected individuals may develop other peripheral nerve manifestations, they 
rarely present as a symmetrical length-dependant pure sensory neuropathy. However, care 
should be taken with the history as immune-mediated vasculitic and inflammatory 
neuropathies may initially manifest as mononeuritis multiplex or asymmetrical distal painful 
neuropathy before progressing to a symmetrical polyneuropathy (Brew, 2003). 
 
1.3 Clinical relevance of painful neuropathy 
Pain associated with DSP substantially affects quality of life. Patients with painful DSP 
report considerable interference in sleep, recreational activities, mobility, social relationships 
and mood (Benbow et al., 1998, Galer et al., 2000, Hays et al., 2000). Approximately 50-70% 
of individuals experiencing chronic pain report sleep disturbances, such as insomnia, middle 
of night awakening, and restlessness (Morin et al., 1998, Gore et al., 2005). These individuals 

















2003). Over 20% of individuals suffer from major depression due to the chronicity of pain, 
loss of function, emotional burden, and reduced quality of life (Fishbain et al., 1997). Patients 
with co-morbid depression also tend to report higher levels of pain, are less active and report 
greater functional disability (Gore et al., 2005). 
The pain associated with HIV-associated DSP has been found refractory to most currently 
used drugs. This may be due to unique mechanisms of pain compared to other predominantly 
small fibre neuropathies, such as diabetic neuropathy or post-herpetic neuralgia. Also, a high 
placebo response observed in individuals participating in many HIV trials may have 
contributed to the futility of the trials. 
Generally, four major classes of pharmacotherapeutic agents are used for symptomatic relief 
of neuropathic pain: antidepressants (amitriptyline, duloxetine, venlafaxine) (Kieburtz et al., 
1998, Shlay et al., 1998), anti-epileptic drugs (carbamazepine, gabapentin, lamotrigine, 
pregabalin) (Hahn et al., 2004, Simpson et al., 2010, Simpson et al., 2003, Simpson et al., 
2000), disease modifying agents (nerve growth factor, acetyl-L-carnitine) (McArthur et al., 
2000, Youle et al., 2007) and topical agents (capsaicin, lignocaine) (Kieburtz et al., 1998, 
Kemper et al., 1998, Estanislao et al., 2004a). However, evidence based data showing 
analgesic efficacy superior to placebo in the context of painful HIV-associated DSP exist 
only for smoked cannabis, nerve growth factor and high dose (8%) topical capsaicin 
(Simpson et al., 2008, Clifford et al., 2012, McArthur et al., 2000). Although there is no 
evidence for efficacy, many physicians use non-steroidal anti-inflammatories, paracetamol 
and opioids to treat neuropathic pain (Simpson and Tagliati, 1995, Gonzalez-Duarte et al., 
2008). Careful attention should also be given to treating an underlying depression. 
 
1.4 Pathological features of HIV-associated DSP 
DSP is associated with degeneration of long axons in their distal regions (Pardo et al., 2001). 
This pattern of distal axonal degeneration is often termed „dying back‟, a term that carries the 
implication that the distal regions of axons degenerate first, and over time the process 
progresses in a centripetal fashion. Although the density of both small and large myelinated 
fibres is reduced, a distinctive feature of HIV-associated DSP is the early loss of 

















back‟ neuropathies the changes during the phase of frank axonal breakdown are nonspecific, 
and are therefore sometimes also termed Wallerian-like degeneration. 
1.4.1 ‘Dying back’ or Wallerian degeneration 
As illustrated in Figure 1.2, Wallerian degeneration describes an experimental model that 
refers to the process of axonal breakdown distal to any type of axonal injury. It is 
characterized by granular disintegration of the axonal cytoskeleton and a sequence of changes 
in both the myelin sheath and Schwann cell (Purves et al., 2001). The disintegration of the 
axonal cytoskeleton was traditionally thought to result from an atrophic process exclusively 
caused by failure to deliver nutrients to these distal parts (Waller, 1850). However, increasing 
evidence suggests that Wallerian degeneration is a regulated, active autodestructive 
programme akin to apoptotic cell death (Buckmaster et al., 1995, Ikegami and Koike, 2003, 
Coleman, 2005, Osterloh et al., 2012). 
 
Figure 1.2: Wallerian degeneration (Purves et al., 2001) 
The relationship between Wallerian degeneration and „dying back‟ neuropathies has long 
since been a subject of debate. A hypothesis has therefore been developed for the mechanism 
of „dying back‟ degeneration, linking it to Wallerian degeneration. Hereby, two alternative 
models based on the directionality of degeneration have been proposed to explain why 
several neuropathies show greater axonal degeneration at their distal ends. Both models are 
supported by experimental evidence (Beirowski et al., 2005). 
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The „dying back‟ model proposes that degeneration of each axon starts at the distal end and 
moves retrogradely. Therefore, the initial episode of Wallerian-like degeneration in a given 
distal axon is followed at some subsequent time by another episode more proximally in the 
fibre, thereby sequentially amputating another portion of the axon in a distal to proximal 
fashion (Griffin and McArthur, 1998, Coleman, 2005). The focal lesion model suggests that 
focal lesions may trigger Wallerian degeneration of distal axons in an anterograde direction, 
while proximal axons remain intact. Wallerian degeneration can also be triggered by a focal 
block of axonal transport, therefore the “lesion” does not necessarily need to transect the 
axon (Griffin and McArthur, 1998, Coleman, 2005). 
1.4.2 Histopathological features of HIV-associated DSP 
Pathological abnormalities in peripheral nerves are frequently detectable in patients dying of 
AIDS (de la Monte et al., 1988, Mah et al., 1988). Two histopathological studies done on post 
mortem nerve biopsies revealed moderate to severe demyelination and axonal degeneration 
with relatively few epineurial or endoneurial perivascular mononuclear inflammatory 
infiltrates (T-cells and macrophages) in at least half, irrespective of whether they had 
symptomatic DSP (de la Monte et al., 1988, Mah et al., 1988). Immunohistochemistry 
showed evidence of macrophage activation with local release of pro-inflammatory cytokines 
such as tumour necrosis factor-α (TNF-α) in areas of axonal degeneration in over 60% of 
specimens (Bradley et al., 1998, Rizzuto et al., 1995, Nagano et al., 1996, de la Monte et al., 
1988, Tyor et al., 1995). In addition, the proximal ascending spinal sensory axons arising 
from the second-order neurons also show degeneration in patients dying of AIDS (Griffin and 
McArthur, 1998). Studies also reported inflammation in the dorsal root ganglia with 
prominent macrophage and T-lymphocyte infiltration, loss of neuronal cells and fibrosis 
(Rizzuto et al., 1995, Nagano et al., 1996, de la Monte et al., 1988, Jones et al., 2005). Viral 
inclusions were not observed (de la Monte et al., 1988). Clustering of lymphocyte satellite 
cells (Nagoette nodules) is frequently seen to accompany neurophagia and ganglion cell 
degeneration within the dorsal root ganglia (Keswani et al., 2002, Nagano et al., 1996).  
Neuropathological studies suggest that both HIV-DSP and ATN share similar features. 
However, prominent mitochondrial abnormalities such as vacuolization with loss of cristae 
and disorganized matrix have been shown in association with exposure to NRTIs (Dalakas et 


















1.5 Diagnostic Methods to identify DSP  
Many different outcome measures have been used to quantify or assess the qualitative 
severity of neuropathic symptoms in clinical trials. These include questionnaires on sensory 
symptoms, functional scales, quantitative clinical examinations, electrophysiological studies 
measuring sural sensory nerve action potentials (SNAP), computerized sensory examinations 
such as quantitative sensory threshold testing (QST), and epidermal nerve fibre density 
quantification on skin biopsy. Each of these measures has its strengths and weaknesses 
(Barohn et al., 1996, Devigili et al., 2008, Herrmann et al., 1999, Tagliati et al., 1999, 
Chavanet et al., 1989). 
The closest to a gold standard for the clinical diagnosis of sensory neuropathy is a skin biopsy 
for the determination of epidermal nerve fibre density. It is a sensitive and valid marker of 
nerve fibre damage with a high diagnostic efficiency (Herrmann et al., 1999, Lauria et al., 
2005). Epidermal nerve fibre quantification has been employed as a reference standard for 
validation of DSP instruments (Cherry et al., 2005) and has been used as an outcome measure 
in drug trials (Polydefkis et al., 2002), as well as in clinical practice (Devigili et al., 2008). 
Reduced epidermal nerve fibre density is a sign of epidermal denervation. This occurs 
typically in a length dependent fashion in HIV-infected patients with neuropathic signs, 
whether they are symptomatic or asymptomatic. Immunocytochemical staining is done with 
antibodies against the panaxonal marker, protein-gene-product 9.5, in order to visualise the 
innervation of the epidermis (McArthur et al., 1998, Devigili et al., 2008). This technique 
also shows that small fibres penetrating the stratum spinosum layer undergo morphologic 
changes such as axonal swelling preceding the degeneration of small nerve fibres. It has been 
suggested that individuals with reduced leg epidermal nerve fibre densities, whether they 
have asymptomatic DSP or no clinical neuropathy, appear to be at an estimated 14-fold 
greater risk of conversion to symptomatic DSP (Herrmann et al., 2006).  
Interestingly, even though symptomatic DSP presents clinically in a distal-to-proximal 
fashion, the epidermal nerve fibre density ratio between thigh and distal leg was shown to be 
similar irrespective of whether the patient had symptoms. This finding argues against an 
exclusively length-dependant epidermal nerve fibre loss and is consistent with the 

















system which includes the dorsal root ganglia (Herrmann et al., 1999). However, some 
individuals with a clinical diagnosis of small fibre neuropathy may have what is currently 
regarded as normal epidermal nerve fibre densities (Tagliati et al., 1999, Lauria et al., 2005). 
Although the histological assessment of epidermal nerve fibre density requires a minimally 
invasive skin biopsy procedure, it requires significant resources including expertise to process 
and interpret histology. 
Electrophysiological studies of nerve conduction may show an axonal, length-dependent, 
sensory polyneuropathy with small SNAPs (Keswani et al., 2002). Importantly however, 
normal nerve conduction studies do not necessarily exclude the diagnosis of HIV-DSP, as 
they primarily survey the function of large-diameter afferent nerve fibres and sural SNAPs 
may be normal in a small fibre neuropathy such as HIV-DSP. Electrophysiological studies 
such as nerve conduction and QST require specialized equipment (Lauria et al., 2005). 
Furthermore, a receiver operating characteristic curve analysis confirmed a significantly 
higher performance of skin biopsy compared to QST, although this study was flawed by the 
absence of an absolute gold standard (Devigili et al., 2008). 
Due to these limitations, field or epidemiological studies rely on the availability and validity 
of clinical tools to diagnose DSP. The routine use of specialized equipment or techniques for 
fieldwork is not feasible in many research settings. Clinical epidemiological research in 
peripheral neuropathy requires easily performed, low-cost, non-invasive, reliable and 
validated measures of peripheral nerve function. A practical screening tool for detecting HIV-
associated DSP in many settings would be a simple, standardized set of clinical criteria. This 
allows DSP screening where specialized investigations are unavailable. However, there is 
poor agreement on the clinical definition for small fibre neuropathy to be used in clinical 
research (Brew, 2003). The use of a formal case definition across future research studies 
would ensure greater consistency in reporting of neuropathy rates and risk factors. 
1.5.1 Proposed definitions of small fibre neuropathy 
A study of the predictive value of any test used to diagnose small fibre neuropathy is affected 
by the absence of a generally accepted gold standard against which the performance of such a 
diagnostic test may be compared (Benatar, 2006). Without a gold standard, estimation of the 
specificity and sensitivity of a diagnostic test is not possible. In 2005, the Polyneuropathy 

















sensory polyneuropathy to standardise and facilitate clinical and epidemiological research 
studies. The proposed definition was based on peer-reviewed publications and expert opinion 
(England et al., 2005). The clinical definition consisted of neuropathic symptoms, including 
numbness, burning, paraesthesiae, dysesthesiae and allodynia, with the presence of signs 
including decreased pin sensation, decreased vibration sense, and attenuated deep tendon 
reflexes. The Task Force recognised that deep tendon reflex abnormalities may not be 
necessary for the diagnosis of small fibre neuropathy (England et al., 2005). 
Different definitions for clinical research studies and epidemiologic studies were proposed, 
and definitions were ranked by estimated ordinal likelihood for disease. For field or 
epidemiologic studies such as the study that we have undertaken, the definition with the 
highest likelihood for sensory neuropathy included a combination of clinical neuropathic 
symptoms, decreased or absent ankle reflexes and decreased distal sensation (either pin or 
vibration) (England et al., 2005). For clinical studies the recommendations were to use a 
combination of neuropathic symptoms, signs, and electrodiagnostic findings. Abnormal 
electrodiagnostic studies increase the likelihood of the presence of distal symmetrical 
polyneuropathy and provide a higher level of specificity to the case definition (England et al., 
2005). However, Benatar argued that the definition proposed by the Polyneuropathy Task 
Force was based on diagnostic modalities that overlapped with the reference tests used in the 
studies (incorporation bias), thereby artificially increasing sensitivity and specificity of the 
tests (Benatar, 2006). Also, most of the best evidence available is restricted to diabetic 
peripheral neuropathy and therefore possibly not valid in another population or setting such 
as HIV-associated DSP (Benatar, 2006).  
As an alternative, Devigili et al. proposed a diagnostic standard for small fibre neuropathy in 
individuals with normal large-fibre function and nerve conduction studies. It required 
abnormalities in two of the following three tests: distal small fibre sensory examination, 
thermal QST threshold, and distal leg epidermal nerve fibre density (Devigili et al., 2008). 
Similarly, due to the lack of an independent reference standard, these proposed diagnostic 
criteria also suffered from incorporation bias. 
Despite these diagnostic problems, for this community-based research, two different 

















1.5.2 Clinical tools 
1.5.2.1 Total Neuropathy Score (TNS) 
The Total Neuropathy Score (TNS) is a validated composite measure of peripheral nerve 
function developed in diabetic neuropathy, and used in prospective studies of diabetic and 
toxic neuropathies (Cornblath et al., 1999). The TNS combines information obtained from 
grading symptoms, signs (reflexes, pinprick sensibility, vibration sense and motor function), 
nerve conduction studies and QST, and provides a comprehensive and easily obtained 
measure for detecting and quantifying DSP. Inter- and intrarater reliability of the TNS was 
excellent (0.966 and 0.986, respectively), with a strong positive correlation to other validated 
measures of neuropathy in patients with diabetes, including the neuropathy symptom score 
and the neurologic impairment score (Cornblath et al., 1999).  
A reduced version of the TNS (rTNS) was developed specifically for the diagnosis of 
chemotherapy-induced painful sensory polyneuropathy (Cavaletti et al., 2003). This version 
did not include QST testing and also did not score motor or autonomic symptoms, but was 
validated against the same clinical tools as the original TNS and confirmed as an effective 
and faster alternative to the original TNS (Cavaletti et al., 2003). Furthermore it demonstrated 
good concordance with epidermal nerve fibre density measurement (ρ=-0.26, p <0.01), 
supporting its reliability as a screening tool for DSP (Zhou et al., 2007). 
Another modified version of the TNS was developed by the original authors based purely on 
clinical neurological assessment (mTNS) which has been utilised in several studies 
(Robinson-Papp et al., 2010, Maritz et al., 2010, Cavaletti et al., 2006, Ellis et al., 2005) (see 
Appendix A). Similar to the rTNS, it was validated against the same clinical tools as the 
original TNS, and was found to have good correlation with these aforementioned widely used 
scores (ρ=0.88, p<0.01) (Cavaletti et al., 2007).  
1.5.2.2 Brief Peripheral Neuropathy Screen (BPNS) 
The Brief Peripheral Neuropathy Screen (BPNS) (see Appendix A) was specifically 
developed for the clinical diagnosis of HIV-associated DSP and has been used as a screening 
tool in several AIDS Clinical Trial Group protocols (McArthur et al., 1998, Cherry et al., 
2005). It is simple and rapid to administer and does not require any specialized equipment. 

















or legs: 1) pain, aching, or burning; 2) pins and needles sensation; and 3) numbness. 
Individuals grade each of these symptoms bilaterally from 0 (absent) to 10 (most severe). It 
also includes an examination of distal lower extremity vibration and ankle reflexes but not 
pin sensibility. It is practical for use in most settings such as busy outpatient clinics, clinical 
trials, and even in resource-constrained communities, although its accuracy when performed 
by non-clinicians (e.g. trained study nurses) is less reliable (Simpson et al., 2006). By using 
the BPNS, a diagnosis of symptomatic DSP, defined as the presence of neuropathic 
symptoms and at least one neuropathic sign, has been shown to correlate well with decreased 
epidermal nerve fibre densities and increased thresholds on QST (Cherry et al., 2005). 
 
1.6 Data on HIV-associated DSP in Africa  
Limited data are available from African populations. A summary of studies performed in 
African populations is included in Table 1.1. The prevalence of symptomatic DSP in cART 
naïve individuals ranged from 11-43% in studies using validated tools to define neuropathy 
(Forna et al., 2007, Maritz et al., 2010, Mehta et al., 2011, Mullin et al., 2011, Oshinaike et 
al., 2012, Sacktor et al., 2009, Shurie and Deribew, 2010, Phillips et al., 2010). 
In the post-cART era there has been 5 longitudinal studies reported, three of which were 
primarily aimed at investigating safety and tolerability of NRTI therapy and not the incidence 
of DSP (Forna et al., 2007, Hawkins et al., 2007, Hoffmann et al., 2008). Therefore, to date 
only two were performed using validated tools to diagnose DSP (Mehta et al., 2011, Sacktor 
et al., 2009). Reported incidences of neuropathic symptoms ranged between 12-38% at 12 
and 6 months respectively. However, the incidence of ATN within the first 12 weeks of 
cART, as well as the impact of cART on pre-existing HIV-DSP has not been previously 


















Table 1.1: Summary of clinical studies on HIV-DSP performed in Africa (Adapted from Phillips et al., 2010) 
 
Group Study cohort Design Cohort size
DSP prevalence/
incidence
DSP definition Risk factors for HIV-associated DSP
Pre cART: African studies
Mehta et al. 2011 Ambulatory clinic patients, Kenya Cross-sectional 199 11% 1 sign + symptoms§
Maritz et al. 2010 Ambulatory patients, South Africa Cross-sectional 331 23% 2 signs + symptoms§
Mullin et al. 2011 Ambulatory clinic patients, Tanzania CD4 count <200 Cross-sectional 81 33% 1 sign + symptoms§ Advancing age, male sex
Ambulatory clinic patients, Tanzania CD4 count ≥200 Cross-sectional 86 21% 1 sign + symptoms§ Advancing age, male sex
Forna et al. 2007 Outpatients commencing cART,home-based care programme, Uganda Cross-sectional 1029 13% 1 sign or symptoms§ Advancing age, TB treatment
Oshinaike et al. 2012 Outpatients, Nigeria Cross-sectional 181 37% 1 sign ± symptoms§ Advancing age
Sacktor et al. 2009 Outpatients commencing cART, Uganda Cross-sectional 102 37% Symptoms§
Outpatients commencing cART, Uganda Cross-sectional 102 43% 1 sign§
Shurie et al. 2010 Outpatients, Ethiopia Cross-sectional 114 11% 1 sign ± symptoms§ Advancing age
Post cART: African studies
Beadles et al. 2009† cART exposed outpatients, Malawi Retrospective 3341 13% Not specified
Boulle et al. 2007† Outpatients commencing cART, South Africa Retrospective 2679 6% (3 year)¶ Not specified Advancing age, WHO stage, cART > 24 weeks
Van Oosterhout et al. 2005† cART exposed outpatients, Malawi Cross-sectional 264 56% Symptoms
Cettomai et al. 2010 cART exposed outpatients, Kenya Cross-sectional 30 53% 1 sign + symptoms§
Cherry et al. 2010 Ambulatory cART exposed patients, South Africa Cross-sectional 300 62% 1 sign + symptoms§
Mehta et al. 2010 cART exposed outpatients, Kenya Cross-sectional 102 36% 1 sign + symptoms§ Advancing age
Maritz et al. 2010 cART exposed outpatients, South Africa Cross-sectional 267 50% 1 sign + symptoms§ Advancing age, previous TB
Wadley et al. 2010 cART exposed outpatients, South Africa Cross-sectional 395 57% 1 sign + symptoms§ Advancing age, increased height
Mullin et al. 2011 Outpatients cART exposed, Tanzania CD4 count <200 Cross-sectional 81 43% 1 sign + symptoms§ Advancing age, male sex
Outpatients cART exposed, Tanzania CD4 count ≥200 Cross-sectional 78 41% 1 sign + symptoms§
Shurie et al. 2010 Outpatients cART exposed, Ethiopia Cross-sectional 204 48% 1 sign ± symptoms§ Advancing age
Oshinaike et al. 2012 Outpatients cART exposed, Nigeria Cross-sectional 142 42% 1 sign ± symptoms§ Advancing age, d4T exposure
Forna et al. 2007† Outpatients commencing cART, home-based care programme, Uganda Longitudinal 894 36% (3 year)¶ 1 sign or symptoms Advancing age, TB treatment
Hawkins et al. 2007† Outpatients commencing cART, Kenya Longitudinal 1286 21% (1 year)¶ Not specified Advancing age, low CD4+ count
Hoffmann et al. 2008† Outpatients commencing cART, South Africa Longitudinal 788 4% 1 sign ± symptoms
Mehta et al. 2011 Outpatients commencing cART, Kenya Longitudinal 150 12% (1 year)¶ 1 sign + symptoms§ Females
Sacktor et al. 2009 Outpatients commencing cART, Uganda Longitudinal 79 38% (6 month)¶ Symptoms§
Outpatients commencing cART, Uganda Longitudinal 79 31% (6 month)¶ 1 sign§
†   Studies investigating tolerability and clinical events on cART
¶   DSP incidence calculated as cumulative incidence over the period

















Table 1.2: Summary of clinical studies on HIV-DSP performed outside Africa (Adapted from Phillips et al., 2010) 
 
 
Group Study cohort Design Cohort size
DSP prevalence/
incidence
DSP definition Risk factors for HIV-associated DSP
Pre cART: Non-African studies (prior to cART initiation)
Evans et al. 2011 Outpatients commencing cART, USA Cross-sectional 1923 23% 1 sign ± symptoms
Post cART: Non-African studies
Schifitto et al. 2002 Advanced HIV disease, early symptoms of HIV dementia, USA Cross-sectional 272 55% 1 sign ± symptoms§
Morgello et al. 2004 Advanced HIV disease, USA Cross-sectional 187 53% 2 signs ± symptoms§ Advancing age, males
Schifitto et al. 2005 Advanced HIV disease, early symptoms of HIV dementia, USA Cross-sectional 376 67% 1 sign ± symptoms§
Cherry et al. 2006 Ambulatory patients, USA and Australia Cross-sectional 147 52% 1 sign + symptoms§ Advancig age, dNRTI exposure (ddI, d4T)
Pettersen et al. 2006 Outpatients with neurological disease, Canada Cross-sectional 221 46% 2 signs + symptoms§ Advancing age, low CD4+ count, peak viral load, alcohol, 
dNRTI or PI exposureSimpson et al. 2006 cART exposed patients, USA Cross-sectional 101 52% 1 sign + symptoms§ Advancing age, caucasians
Smyth et al. 2007 Outpatients, Australia Cross-sectional 100 42% 1 sign + symptoms§ Advancing age, dNRTI or PI exposure
Affandi et al. 2008 Outpatients, Indonesia Cross-sectional 96 34% 1 sign + symptoms§ Advancing age, increased height, TNF-α genotype
Hung et al. 2008 cART exposed d-drug regimen, USA Cross-sectional 252 23% 1 sign ± symptoms§
Hung et al. 2008 cART exposed non-d-drug regimen, USA Cross-sectional 250 29% 1 sign ± symptoms§
Sithinamsuwan et al. 2008 Outpatients, Thailand Cross-sectional 63 25% 1 sign or symptoms§
Wright et al. 2008 Outpatients, Asia-Pacific countries Cross-sectional 640 20% 1 sign + symptoms§ dNRTI exposure
Cherry et al. 2009 Outpatients, Australia Cross-sectional 100 42% 1 sign + symptoms§ Advancing age, increased height, dNRTI or PI exposure
Cherry et al. 2009 Outpatients, Malaysia Cross-sectional 98 19% 1 sign + symptoms§ Advancing age, increased height, dNRTI or PI exposure
Cherry et al. 2009 Outpatients, Indonesia Cross-sectional 96 34% 1 sign + symptoms§ Advancing age, increased height, dNRTI or PI exposure
Ellis et al. 2010 Outpatients, USA Cross-sectional 1539 57% 1 sign ± symptoms§
Advancing age, immunosuppression, dNRTI exposure, 
current cART use
Banerjee et al. 2011 Outpatients, USA Cross-sectional 436 27% 1 sign ± symptoms§
Advancing age, increased height, diabetes, PI exposure, 
statin use, low nadir CD4+ count, increased triglycerides




Advancing age, peak viral load, low nadir CD4+ count, 
diabetes, caucasians, NRTI or PI exposure
Schifitto et al. 2002 Advanced HIV disease, early symptoms of HIV dementia, USA Longitudinal 89 52% (1 year)¶ 1 sign ± symptoms§ WHO stage, AIDS, low CD4+ count
Schifitto et al. 2005 Advanced HIV disease, early symptoms of HIV dementia, USA Longitudinal 185 40% (1 year)¶ 1 sign + symptoms§ dNRTIs associated with reduced risk
Simpson et al. 2006 cART exposed patients, USA Longitudinal 28 21% (48 week)¶ 1 sign + symptoms§ Caucasians
Hung et al. 2008 cART exposed d-drug regimen, USA Longitudinal 194 27% (1 year)¶ 1 sign ± symptoms§
Hung et al. 2008 cART exposed non-d-drug regimen USA Longitudinal 177 28% (1 year)¶ 1 sign ± symptoms§
Nakamoto et al. 2010 Outpatients, Hawaii Longitudinal 61 31% (4 year)¶ 2 signs ± symptoms§ Advancing age, low nadir CD4+ count
Evans et al. 2011 Outpatients commencing cART, USA Longitudinal 1923 58% (7 year)¶ 1 sign ± symptoms§
Arenas-Pinto et al. 2008 Outpatients commencing cART, Europe and Australia Longitudinal 3195 6% (3 year)¶ Symptoms Advancing age, low CD4+ count, dNRTI exposure
¶   DSP incidence calculated as cumulative incidence over the period

















1.7 Pathophysiology of HIV-associated DSP 
The pathophysiology of HIV-associated DSP is not completely understood, although it is 
likely multifactorial. Neuronal damage secondary to immune activation is the most generally 
accepted pathogenic mechanism, similar to that in HIV-associated dementia (Hoke and 
Cornblath, 2004, Gonzalez-Scarano and Martin-Garcia, 2005). This concept is supported by 
pathological studies that failed to show HIV replication in neurons, but in approximately 50% 
of cases demonstrated abundant macrophage activation and viral replication within the 
macrophages of peripheral nerves and dorsal root ganglia (see section 1.4) (Pardo et al., 2001, 
Gonzalez-Scarano and Martin-Garcia, 2005). Although prominent loss of unmyelinated 
sensory fibres are noted pathologically (see section 1.4), the nature and the site of initial 
injury to the nerves are unknown. In this section, the following will be discussed: 1) The 
direct and indirect mechanisms of nerve injury in HIV-DSP; 2) the pathophysiological 
aspects of ATN; and 3) the role of mitochondrial dysfunction in HIV-associated DSP 
(including HIV-DSP and ATN). 
1.7.1 Direct mechanism of nerve injury in HIV-associated DSP 
Although De la Monte et al. proposed that the neuropathy in AIDS results from direct HIV 
infection of peripheral nerves (de la Monte et al., 1988), there is limited evidence for the 
presence of HIV in peripheral nerve or dorsal root ganglion cells. Ho et al. cultured HIV from 
sural nerve homogenates in only one of three patients with AIDS-related peripheral 
neuropathy whereas HIV was cultured from the cerebrospinal fluid in all three (Ho et al., 
1985). Similarly, Bailey et al. reported electron microscopic evidence of retroviral-like 
inclusions in myelinated sural nerve fibres in only one of six AIDS patients with DSP (Bailey 
et al., 1988). Many other pathologic studies have failed to identify HIV antigens or retroviral-
like particles in the peripheral nerves or dorsal root ganglion cells (de la Monte et al., 1988, 
Rance et al., 1988, Mah et al., 1988). It is now widely accepted that almost all virus 
recovered from peripheral nerve tissue is likely from the resident monocytes/macrophages 
that account for about 10% of the cells in peripheral nerves (Brinley et al., 2001, Jones et al., 
2005). These findings suggest that direct HIV infection of peripheral nerve is an unlikely 
cause of DSP, although viral products such as the major HIV envelope glycoprotein (gp)-120 
has been proposed to have a major role in DSP pathogenesis (Herzberg and Sagen, 2001). 
HIV entry into macrophages and T helper cells is mediated through interaction of the viral 

















receptor 5 (CCR5) and C-X-C chemokine receptor (CXCR4) (Zheng et al., 1999). It has been 
demonstrated in vitro that soluble gp120, in the absence of viral infection can bind to both 
CXCR4 and CCR5 receptors on axonal membranes. This ligation leads to axonal 
degeneration through two independent pathways; the first engages neuronal apoptosis 
indirectly by mediating the activation of Schwann cells, and the second uses direct local 
axonal toxicity by activation of the caspase pathway (Melli et al., 2006). 
The mechanism of neuronal injury in dorsal root ganglion cell bodies is indirect. Gp120 
ligation to the CXCR4 receptor on surrounding Schwann cells results in the upregulation of 
chemokines such as “regulated upon activation, normal T-cell expressed and secreted” 
(RANTES). In turn, Schwann cell secreted RANTES binds to CCR5 on the dorsal root 
ganglia neurons and induces neuronal TNF-α release. TNF-α then binds to TNF receptors and 
results in classical apoptotic neuronal cell death in sensory neurons (Hahn et al., 2008). 
Direct application of gp120 exclusively to axons resulted in ligation of CXCR4 and CCR5 
receptors followed by downstream changes in the mitochondrial transmembrane potential, 
cytochrome c release and caspase activation. This process results in degeneration of distal 
axons, independent from the cell body and without evidence of neuronal apoptosis 
proximally (Melli et al., 2006). In conclusion, several studies have shown that although HIV 
itself may not be the principal pathogenic agent in DSP, viral proteins such as gp120 as well 
as host chemokine and cytokine responses may participate in a multifaceted interaction 
ultimately leading to nerve fibre damage distally and neuronal loss proximally. 
1.7.2 Indirect mechan sm of nerve injury in HIV-associated DSP 
As direct HIV infection of the peripheral nerve has not been convincingly demonstrated, 
research has focused on indirect mechanisms such as the action of chemokines and cytokines. 
Chemokines and cytokines can direct leukocyte trafficking during inflammatory responses 
and also have a role in neural development and the modulation of nervous system responses 
to injury and disease (Lu et al., 2002, Tran and Miller, 2003, Bhangoo et al., 2009). 
Inflammation is a principal characteristic of HIV pathogenesis and it is therefore not 
surprising that cytokines and chemokines appear to be predominant in the pathophysiological 
mechanisms of HIV-associated neural pathology. 
HIV pathogenesis can be explained by a state of chronic immune dysregulation (Herbein et 

















(Herbein and Khan, 2008, Salazar-Gonzalez et al., 1997). Direct immune activation results in 
the generation of polyfunctional effector T-cells able to produce large amounts of pro-
inflammatory and/or pro-apoptotic cytokines such as TNF-α, interleukin (IL)-1β, IL-6 and 
type I interferons. These factors sustain the generalized immune activation and facilitate the 
death of bystander CD4- and CD8 T-cells. Chronic immune activation can also suppress the 
immune system by inhibiting the normal functions of monocytes, B cells, natural killer cells 
and dendritic cells. In addition, it may limit the regenerative potential of T-cells as a result of 
the destruction of the architecture of lymphatic tissues such as bone marrow, thymus and 
lymph nodes (Vanderford et al., 2010). 
Immunopathogenic factors characteristic of HIV immune dysregulation may contribute to the 
indirect mechanism of nerve injury. Firstly, gp120 may cause indirect nerve damage by 
promoting macrophage infiltration in peripheral nerves and the dorsal root ganglia (Wallace 
et al., 2007). Further, a degree of distal axonal degeneration may already exist in HIV-
infected individuals due to inadequate nutritional state, exposure to alcohol and/or substance 
abuse or other nonspecific factors, promoting a leaky blood-nerve-barrier (Griffin and 
McArthur, 1998). As seen in Wallerian-like degeneration, macrophages are activated and 
recruited into the areas of nerve damage. In HIV infection, as a result of chronic immune 
activation and the leaky blood-nerve barrier, the macrophages may show exaggerated 
inflammatory responses in the distal and proximal segments of peripheral nerves (Keswani et 
al., 2002). These activated macrophages within the peripheral nerve cause local release of 
pro-inflammatory neurotoxic cytokines, such as IL-6 and TNF-α that result in nerve injury 
(Keswani et al., 2002, Dalakas et al., 2001). The release of chemoattractant molecules 
recruits more immune cells from the circulation into the damaged nerve, resulting in cycles of 
neuroimmune activation with further release of pro-inflammatory cytokines, nitric oxide and 
reactive oxygen species (ROS) (Trifilieff et al., 2000, Bergsteinsdottir et al., 1991, Taskinen 
and Roytta, 2000, Taskinen et al., 2000). This process can occur despite advanced systemic 
immunosuppression (Nagano et al., 1996, Wesselingh et al., 1994). 
The secondary immune response as a result of nerve injury has multiple effects on peripheral 
nerves and has been extensively researched in animal models. It can directly increase nerve 
excitability by induction of ectopic electrogenesis (Leem and Bove, 2002, Sorkin et al., 
1997), damage myelin (Muijsers et al., 1997, Said and Hontebeyrie-Joskowicz, 1992), and 

















al., 1997, Uncini et al., 1999). Activated macrophages and denervated Schwann cells 
phagocytose myelin debris and secrete a variety of proteases and other enzymes, including 
matrix metalloproteases that damage the basal lamina of endoneurial blood vessels, 
increasing the blood-nerve barrier dysfunction (Shubayev et al., 2006). Exposure of 
peripheral nerve proteins or cryptic epitopes as a result of the neuro-inflammation may lead 
to priming of the immune system to these self-antigens. This in turn can result in a secondary 
bystander „auto-immune‟ response (Watkins and Maier, 2002). 
1.7.3 Pathophysiology of antiretroviral toxic neuropathy (ATN) 
The exact pathogenesis of ATN is not yet established. Various explanations are offered for 
the neurotoxic effects of d-drugs. Mitochondrial dysfunction is associated with exposure to 
NRTIs, and believed to contribute to the pathogenesis of ATN. NRTIs inhibit mitochondrial 
DNA polymerase-γ, which is the only enzyme responsible for replication and repair of the 
mitochondrial genome (Lewis et al., 2003). The role of mitochondrial dysfunction in ATN 
development will be discussed in further detail in section 1.8. 
From animal studies it is evident that peripheral sensory neurons can be strongly excited by 
chemokines and gp120 either by lowering the threshold for action potential generation 
without changing the membrane potential, or by depolarization (Oh et al., 2001). Apart from 
the effect of NRTIs on mitochondria, a recent study in rodents showed that dNRTI treatment 
led to an upregulation of CXCR4 and its ligand, stromal cell-derived factor-1, in sensory 
neurons and dorsal root ganglia (Bhangoo et al., 2009). As such, it is possible that exposure 
of dNRTI to CXCR4-positive neurons is directly linked to chronic neuronal hyperexcitability. 
Therefore, concurrent exposure to gp120 and d-drugs may act synergistically to activate 
chemokine signalling pathways that may result in mechanical hypernociception (Bhangoo et 
al., 2009). 
Although some have suggested that ATN represents the unmasking of subclinical HIV-DSP 
(Simpson and Tagliati, 1995) or that asymptomatic DSP precedes symptomatic DSP (Cherry 
et al., 2003, Martin et al., 2000, Mehta et al., 2010), this was not demonstrated in a 2.5 year 
follow-up study (Schifitto et al., 2002). However, morphologic abnormalities such as axonal 
swelling as well as non-clinical objective measures of DSP, such as epidermal nerve fibre 
densities and QST have been noted in those with neuropathic signs prior to the onset of 

















Immune modulation may also play a role in the pathophysiology of ATN. With the initiation 
of cART there is a phase of immune restoration and in some patients this is early and rapid, 
resulting in immune activation and inflammatory responses that may cause clinical 
deterioration known as the “immune reconstitution inflammatory syndrome” (IRIS) (further 
discussed in section 1.9.4). In the context of HIV-associated peripheral nerve injury, the 
immune activation near peripheral nerves could increase nerve hyperexcitability and damage 
with further release of cytokines, free radicals, and lipid membrane derivatives (Schifitto et 
al., 2005). As incident symptomatic ATN peaks around 3 months (Arenas-Pinto et al., 2008), 
within the period in which IRIS also manifests, one of the hypotheses of this work is that an 
exaggerated cytokine response or immune reconstitution after cART initiation, contributes to 
the immunopathogenesis of ATN. 
To summarize, ATN involves a possible „double-hit‟ process whereby the proximal (dorsal 
root ganglion) and distal (distal intraepidermal nerve fibres) of the peripheral sensory nerves 
are damaged or sensitized directly by viral proteins such as gp120 and/or by HIV-associated 
chronic immune dysregulation. Sensory neurons may then be further compromised by NRTI-
induced mitochondrial toxicity or possible NRTI-induced immune activation driving further 
release of cytokines. 
The discussion will now focus on mitochondria and mitochondrial toxicity in relation to HIV-
associated DSP. 
 
1.8 Mitochondrial dysfunction and the relationship to HIV-
associated DSP 
Mitochondria are double-membrane intracellular organelles found in all human cells with the 
exception of mature red blood cells. These intracellular organelles host a number of essential 
biochemical reactions largely concerned with fuel oxidation and generation of adenosine 
triphosphate (ATP) (Scheffler, 2001). In addition, mitochondria are intimately involved in a 
number of cellular processes including cell differentiation, signalling, and division, ageing 


















Mitochondria contain their own unique circular deoxyribonucleic acid (DNA), referred to as 
mitochondrial DNA (mtDNA) (DiMauro and Schon, 2003, Wallace, 1999), which is 
maternally inherited. Most mitochondria contain at least two copies of mtDNA and the 
number of mitochondria in cells range from a few hundred to hundreds of thousands in 
tissues with high energy demands such as muscle, renal tubular cells and neurons (Chang et 
al., 2011, DiMauro and Schon, 2003, Robin and Wong, 1988). 
Mitochondrial dysfunction contributes to cellular damage. Normal cell metabolism and 
physiological processes including cytokine signal transduction pathways generate oxygen 
free radicals and other ROS during oxidative phosphorylation. Under physiological 
conditions, approximately 1-2% of total molecular oxygen utilized by mitochondria is 
converted into ROS which include superoxide anions and hydrogen peroxidase (Van der 
Watt, 2011). Levels can increase dramatically during times of environmental stress. 
Mitochondria contain antioxidant enzymes that assist in modifying oxidative radicals into 
innocuous molecules, thereby protecting them against damage from ROS. Examples of 
antioxidant enzymes include manganese superoxide dismutase and glutathione peroxidase 
(Mates et al., 1999). These enzyme systems prevent the build up of hydrogen peroxide and 
limit the formation of potentially more reactive species. 
Oxidative stress refers to the consequence of pathological states such as inflammation, where 
there is a disequilibrium between the production of ROS and the levels of antioxidant 
enzymes, favouring the oxidant environment (Betteridge, 2000). Oxidative damage is the 
result of a myriad of biochemical reactions that occur simultaneously. There are two main 
control mechanisms to mitigate or repair oxidative damage: antioxidant defence mechanisms 
such as enzymes and scavenger molecules, as well as extensive metabolic pathways to 
control ROS production. When the control mechanisms are overwhelmed, oxidative damage 
may lead to dysfunction of many cellular organelles. This damage may be cumulative and not 
amenable to repair, particularly in postmitotic cells such as neurons (Galasko and Montine, 
2010). 
Reactive oxygen species can cause damage or mutations to DNA or ribonucleic acid (RNA), 
including mtDNA (Wei and Lee, 2002). The accumulation of mtDNA mutations results in 
further increases in ROS, which in turn may increase tissue susceptibility to accumulating 
mtDNA (Finkel and Holbrook, 2000). At a critical point this will impact on the effective 

















trigger pro-inflammatory cytokine production (Nakahira et al., 2011). Pro-inflammatory 
cytokines generate high levels of ROS, which can cause disruption in the normal balance 
between antioxidants and ROS, shifting cells into a state of oxidative stress. This cycle is 
believed to be a critical factor for the exponential increase in oxidative damage, accumulation 
of somatic mitochondrial mutations and subsequent loss of cellular functions during ageing 
and in diseases associated with mitochondrial cytopathies. 
1.8.1 The effect of antiretroviral therapy on mitochondrial DNA 
The antiretroviral activity of NRTI drugs is determined by their capacity to competitively 
inhibit the RNA-dependent DNA polymerase-γ activity of HIV reverse transcriptase, which 
synthesizes viral DNA from deoxynucleotide triphosphates (Nolan et al., 2003). NRTIs 
undergo triphosphorylation by intracellular kinases (Lewis et al., 2003) and the active tri- (or 
di-) phosphorylated NRTIs compete with endogenous deoxynucleotide triphosphates for 
incorporation by DNA polymerase-γ. When incorporated into the viral nucleic acid chain it 
prematurely terminates the replicating viral strand due to the absence of a 3' hydroxyl group 
for addition of the next nucleotide (Lewis et al., 2003, Kakuda, 2000). 
The degree of toxicity associated with NRTI incorporation has been shown to correlate with 
several factors such as cellular uptake, metabolic activation, the rate and strength of binding 
with host DNA polymerase-γ as well as the kinetics of drug removal (Feng et al., 2001, 
Johnson et al., 2001). Accordingly, NRTIs have been ranked by their potential toxicity to 
inhibit DNA polymerase-γ: zalcitabine (ddC) > didanosine (ddl) > stavudine (d4T) > 
lamivudine (3TC) > tenofovir (TDF) > zidovudine (AZT) > abacavir (ABC), respectively 
(Lewis et al., 2003). Once the NRTI is incorporated into the mtDNA, it stalls further 
replication until it is removed by the proofreading exonuclease. Stavudine has the slowest 
rate of exonuclease removal compared to other NRTIs, suggesting hindrance of repair and 
compounding damage to mtDNA (Lewis et al., 2003). 
Figure 1.3 is a schematic representation of possible mechanisms through which NRTIs can 
affect mtDNA and mitochondrial gene expression. Apart from their direct effect on mtDNA 
polymerase-γ [1], in vivo evidence suggests that NRTI exposure may influence the 
transcription of host mitochondrial RNA [2]. Mallon et al. reported significantly decreased 
mitochondrial gene expression in adipose tissue and blood monocytes after two weeks on 

















content or metabolic parameters such as serum lactate (Mallon et al., 2005a). De novo 
synthesis of pyrimidine nucleotides is coupled to optimal functioning of the mitochondrial 
respiratory chain (Ruckemann et al., 1998). Therefore, any cause of respiratory chain 
dysfunction leads to decreased mitochondrial ATP regeneration, which in turn impairs 
pyrimidine synthesis as well as its nucleotide phosphorylation (Gattermann et al., 2004), 
further compromising the cycle of mitochondrial dysfunction [3 and 4]. NRTIs may also 
compete with endogenous nucleosides for phosphorylation by mitochondrial thymidine 
kinase-2 and may even inhibit its activity in the mitochondria [5]. These factors reduce levels 
of endogenous nucleotides resulting in the decreased synthesis of mtDNA (Cote, 2005, Lynx 
et al., 2006). Mitochondrial DNA depletion has been reported in fat, muscle and nerve tissue 
of HIV-infected individuals experiencing drug-related symptoms of lipoatrophy, myopathy 
and DSP, respectively (Arnaudo et al., 1991, Dalakas et al., 2001, Shikuma et al., 2001). 
 
Figure 1.3: Mechanisms by which NRTI affect mtDNA and mtRNA (From Cote, 2005) 
Much recent attention has been paid to quantifying mtDNA levels. However, the quality of 
mtDNA is also important, but technically challenging to evaluate. It is well documented that 
mtDNA mutations and deletions accumulates over time, and play a role in conditions 
associated with ageing (Payne et al., 2011, Gianni et al., 2004, Alexeyev et al., 2004). As 
summarized, NRTI therapy provides conditions permissive for the accumulation of mtDNA 
mutations, which has been reported longitudinally in peripheral leukocytes, axons and 

















Maagaard et al., 2006). Large mtDNA deletions have been reported in some cases of NRTI-
associated lactic acidosis (Bartley et al., 2001, Walker and Venhoff, 2001). Reduced 
mitochondrial gene expression has been demonstrated in adipocytes exposed to NRTIs 
without significant depletion of mtDNA (McComsey et al., 2008, Mallon et al., 2005b). 
Although at this stage it is unknown whether these deletions occurred prior to HIV infection 
and/or its therapy, the presence of such deletions would, in all likelihood, diminish the 
mitochondria‟s capacity to compensate during NRTI therapy. This may possibly accelerate or 
exacerbate the development of symptoms related to mitochondrial toxicity. 
1.8.2 Clinical manifestations of mitochondrial dysfunction 
Certain principles govern the manifestation of mitochondrial cytopathies whether as a result 
of mitochondrial dysfunction or mtDNA mutations/deletions. Firstly, due to the high reserve 
of oxidative capacity inherent in most tissues, a critical threshold of dysfunctional 
mitochondria need to be present before a tissue manifests with mitochondrial failure (Van der 
Watt, 2011). Mitochondrial dysfunction will manifest earlier in the most metabolically active 
tissues such as nerves, muscle and liver. Secondly, within any cell or tissue there are 
heterogeneous populations of mtDNA with sequence variations known as heteroplasmy. 
Differences in the tissue distribution or tissue load of abnormal mtDNA will influence 
phenotypic manifestations (DiMauro and Schon, 2003). Further, the manifestation of 
mitochondrial cytopathies is not only determined by the functional magnitude of the genetic 
mutation, but also by environmental stressors applied to that tissue (Look et al., 2001). For 
example, the effects of silent genetic variants (e.g. somatic mtDNA mutations) may be 
unmasked only in the presence of significant environmental insults such as HIV infection or 
treatment with drugs that are potentially toxic to mitochondria. As such, a wide range of 
adverse events occurring in individuals with HIV infection, particularly those receiving 
NRTI-based therapy, have been suggested as relating to compromised mitochondrial 
function, either by accumulating mtDNA deletions or through mtDNA depletion (Lewis, 
2005). 
Mitochondrial cytopathies may result in the following clinical manifestations, in no particular 
order: peripheral neuropathy, myopathy, seizures, ataxia, fatigue, weight loss, nausea and 
vomiting, abdominal pain, cardiomyopathy, Fanconi syndrome, pancreatitis, hepatic steatosis 

















dysfunction can present as hyperlactatemia, compensated lactic acidosis or, rarely, as acute 
decompensated lactic acidosis with a high mortality (Lewis, 2005). 
Despite well-documented in vitro studies on mtDNA polymerase-γ inhibition by NRTIs, 
there has been no consistent correlation between mtDNA levels and manifestations of 
mitochondrial toxicity. For example, one study found that stavudine therapy did not decrease 
peripheral blood mononuclear cell (PBMC) mtDNA or -RNA levels (Casula et al., 2004). 
Another found no difference in mtDNA levels in blood and subcutaneous fat between 
individuals with or without peripheral neuropathy or lipoatrophy (Lewis, 2005). Several 
factors may have contributed to the paucity of evidence implicating NRTI-related 
mitochondrial toxicity with mtDNA depletion. The majority of reports to date have studied 
relatively small observational cohorts, often through cross-sectional analysis, thereby limiting 
the conclusions that can be reached [reviewed in (Cote, 2005)]. Another issue is the potential 
time lag between the “event” resulting in mitochondrial damage and the clinical 
manifestation of the toxicity. Also, risk factors including mitochondrial haplotypes may 
render an individual more susceptible to NRTI-related mitochondrial damage. Overall, poor 
correlation between mtDNA levels and the clinical manifestation of mitochondrial toxicity 
strongly suggest additional risk factors to the development of mitochondrial damage and 
dysfunction. 
1.8.3 Host factors influencing susceptibility to mitochondrial dysfunction 
Not all individuals treated with NRTIs develop adverse effects related to mitochondrial 
toxicity, suggesting that host factors influence susceptibility towards mitochondrial 
dysfunction (Maagaard et al., 2006). These may include differences with respect to 
intracellular phosphorylation of NRTIs, drug–drug or drug–nutrient interactions, female sex, 
white race, older age, hepatitis B and C co-infection, nadir CD4 T-cell counts and altered 
renal function (Lichtenstein et al., 2003, Galli et al., 2003, Fleischer et al., 2004, Currier, 
2007, Bonnet et al., 2003, Gervasoni et al., 1999). 
Mitochondrial dysfunction is increasingly postulated as an important component in the 
pathogenesis of neural damage by HIV. Peripheral nerves are first damaged directly by viral 
proteins such as gp120 or sensitized by the aberrant inflammatory response associated with 

















toxicity. The susceptibility to mitochondrial damage may be dependent on factors previously 
described in the literature and is briefly outlined further in this section: 
1.8.3.1 Sex 
Lactic acidosis in stavudine-exposed patients has been reported more frequently in women 
(Bolhaar and Karstaedt, 2007, Moyle et al., 2002, Arenas-Pinto et al., 2008) with a particular 
increased risk in obese African women (Currier, 2007, Boulle et al., 2007). Women might 
also be more susceptible to NRTI-associated lipodystrophy (Gervasoni et al., 1999, Galli et 
al., 2003). 
1.8.3.2 Age 
Senescence has been the most consistent factor shown to be an independent predictor for 
developing HIV-associated DSP (see Table 1.1 and Table 1.2). Senescence is generally 
associated with cumulative somatic mtDNA mutations (Chan, 2006, Payne et al., 2011). As 
oxidative phosphorylation in the mitochondria contributes to the bulk of free radicals and 
other ROS, senescence is the result of accumulation of macromolecular damage from 
oxidative stress (Harman, 2001). Another theory of senescence also involves the 
mitochondria. The lysosomal-mitochondrial axis theory explains the accumulation of 
undegradable oxidative products of oxidative stress that contribute to the ageing of cells due 
to imperfect lysosomal degradation of damaged cells or structures (Brunk and Terman, 2002). 
Accelerated senescence has recently been described in HIV-infected individuals on NRTI 
therapy. Rapid clonal expansion of somatic mtDNA mutations provides a plausible 
mechanism for accelerated ageing in NRTI-treated HIV infection (Payne et al., 2011). 
Further, clinical complications of NRTI therapy appear to be more common in older 
individuals (Smyth et al., 2007, Robinson-Papp et al., 2012). This may be due to older 
individuals harbouring a greater number of age-related somatic mtDNA mutations than 
younger individuals, which rapidly clonally segregate during NRTI therapy (Payne et al., 
2011). For these reasons, the consequences of age-related mtDNA mutations might be even 
more challenging in the future as individuals treated with cART not only become older, but 
also have a long cumulative exposure period to NRTIs, especially in resource-poor settings 

















1.8.3.3 Genetic predisposition 
Certain mitochondrial haplogroups have been associated with increased risk for 
mitochondrial dysfunction. Individuals belonging to mitochondrial haplogroup T, best 
characterized as a European mitochondrial lineage, had a marginally higher incidence of 
NRTI associated neuropathy (Hulgan et al., 2005). This was demonstrated in a cART 
exposed Caucasian case-control cohort where 17% of those who developed DSP (defined as 
the presence of at least one neuropathic symptom or sign) had mtDNA haplogroup T 
compared to 7% of those who did not develop DSP (Hulgan et al., 2005). African mtDNA 
generally have greater variation than that of Caucasian populations and thus present a more 
challenging classification. This may be one reason why fewer association studies have been 
performed and less is known about functional differences in African mtDNA variation. In a 
self-identified non-Hispanic black American cohort, the African mtDNA subhaplogroup L1c 
was an independent predictor of DSP (Canter et al., 2010). However, there are no published 
data from African cohorts to support these results.  
The role of genetic predisposition was also demonstrated in vitro using fibroblasts from 
patients with Kearns-Sayre syndrome, a mitochondrial cytopathy due to mtDNA deletion 
mutations. Increased mtDNA mutations and depletion of mtDNA levels occurred with 
zidovudine treated fibroblasts (Wang et al., 1996). Similarly, subclinical Leber's hereditary 
optic neuropathy, a rare cause of blindness due to inherited mitochondrial mutations, 
manifested in HIV-infected individuals upon starting NRTI therapy (Mackey et al., 2003). 
1.8.3.4 Metabolic syndrome 
In recent years there has been increasing research focusing on the potential role of oxidative 
stress in the metabolic syndrome, defined as the presence of three or more of hypertension, 
dyslipidaemia, dysglycaemia and obesity. There is evidence to support the theory that a 
chronic inflammatory state may play an important role in metabolic syndrome manifestations 
such as hypertension, diabetes and obesity (Urakawa et al., 2003, Ford et al., 2003, Ceriello 
and Motz, 2004). The resultant oxidative stress is believed to be an early event in the 
pathology of these chronic diseases and not simply a consequence or an innocent bystander 
(Roberts and Sindhu, 2009). 
The metabolic syndrome was an independent risk factor for small fibre neuropathy in a 

















syndrome (hypertriglyceridemia and diabetes) were found to be associated with HIV-
associated DSP (Letendre et al., 2009, Banerjee et al., 2011, Ances et al., 2009). High 
triglyceride levels might lead to alterations in mitochondrial membrane permeability and 
energy metabolism, although the mechanism remains unclear. It is thought that 
hypertriglyceridemia activates mitochondrial K
+
 ATP channels resulting in increased resting 
oxidative metabolism (Alberici et al., 2003). This promotes high levels of ROS generation 
and axonal injury. Further, hypertriglyceridemic individuals, with or without metabolic 
syndrome, have increased levels of serum lipoperoxides and low levels of antioxidant 
enzymes (Cardona et al., 2008). 
Therefore, both HIV infection and cART may increase the risk for the metabolic syndrome as 
a result of inflammation and lipid abnormalities. With ageing, metabolic risk factors 
accumulate, further increasing the risk in a cART treated population (Letendre et al., 2009). 
Mitochondrial dysmetabolism may be central to all these factors. 
1.8.3.5 Nutrition 
Underlying nutritional deficiencies may predispose an individual to mitochondrial NRTI 
toxicity through two mechanisms (Look et al., 2001). Firstly, several nutrients are imperative 
elements of mitochondrial flavoproteins and cytochromes, and are therefore needed for 
mitochondria to function normally (Ames, 2004). Secondly, malnutrition increases the 
vulnerability to oxidative stress due to impaired antioxidant defence mechanisms. 
Furthermore, it has previously been shown that oxidative stress stimulates HIV replication in 
vitro (Allard et al., 1998) and that multivitamin supplements may reduce viral replication and 
delay the progression of HIV disease (Fawzi et al., 2004). Absorption and metabolism of 
micronutrients and vitamins (e.g. vitamin B6, B12 and iron) are abnormal in chronic HIV 
infection, and therefore the prevalence of deficiencies may be higher in HIV-infected 
individuals (van Lettow et al., 2003, Karyadi et al., 2000, Tang and Smit, 1998). 
General poor nutritional status has been reported to increase the risk of ATN, although these 
factors are not well characterized (Keswani et al., 2002, Tagliati et al., 1999). Severe 
deficiencies of vitamin E, vitamin B6, thiamine, riboflavin, nicotinic acid and iron have been 
associated with peripheral neuropathy in HIV-infected individuals (Kumar, 2007). The 

















1.8.3.6 HIV infection 
Decreased levels of mtDNA may be present in HIV infected individuals preceding the use of 
NRTI therapy or symptoms. In individuals with untreated HIV infection, samples from 
various tissues show reductions in mtDNA levels compared to age-matched HIV-negative 
individuals (Cote et al., 2002, McComsey et al., 2002, Morgello et al., 1995). For example, 
nerve and muscle biopsies from untreated individuals presenting with HIV-associated DSP or 
myopathy may have low mtDNA levels, abnormalities in mitochondrial ultrastructure or 
show in vitro respiratory chain functional abnormalities (Morgello et al., 1995). These 
findings are similar to those reported with NRTI therapy in nerve and muscle cells. 
Longitudinal measures of mtDNA in HIV-infected individuals showed reduced levels in 
PBMCs compared to HIV-negative individuals. For example, a 43% difference was noted 
prior to initiating NRTI therapy, with a more pronounced reduction after starting NRTIs in 
HIV-infected individuals compared to HIV-negative individuals (C te et al., 2002).  
HIV can directly influence mitochondrial function by activating mitochondrial pathways for 
apoptosis (Van der Watt, 2011). There are two main apoptotic signalling pathways known as 
the „extrinsic‟ and the „intrinsic‟ pathways of apoptosis (Tischner et al., 2010). HIV is 
implicated in both of these pathways. The extrinsic pathway is activated through exogenous 
factors such as viral proteins “Negative regulatory factor” (Nef), Trans-activator of 
transcription (Tat), and gp120, all of which may bind to cell membrane receptors such as the 
Fas receptor (or „death receptor‟). This ligation activates cytoplasmic caspase through a 
cytoplasmic signalling pathway resulting in cell apoptosis. The intrinsic pathway receives 
cues from factors within the cell to facilitate cytochrome C and other pro-apoptotic factors to 
be released from the mitochondria that in turn result in cytoplasmic caspase activation and 
apoptosis (Tischner et al., 2010). Activation stimuli for the intrinsic pathway include viral 
protein R (Vpr), gp-120, Nef and Tat as well as free radicals or cellular DNA damage. HIV 
induced apoptosis has been demonstrated in neurons, CD4 T-cells, haematopoietic cells and 
cardiac myocytes (Kaul and Lipton, 1999, Rasola et al., 2001).  
Apart from these direct viral effects, persistent HIV-associated immune activation might also 
indirectly impact on mtDNA synthesis in cART naive individuals. Casula et al. found 
reduced levels of mtDNA in PBMCs after seroconversion (Casula et al., 2004). Increased 

















IFN-α and IFN-γ, IL-2 and IL-6, were postulated as a cause for the decreased mtDNA levels 
(Shedlock et al., 2008). 
Alternatively, HIV-induced chronic inflammation and immune activation is capable of 
causing oxidative stress through an increase in ROS and a reduction in antioxidant levels 
(Bogden et al., 1990, Buhl et al., 1989, Dworkin et al., 1986, Eck et al., 1989). Studies in 
HIV-infected individuals have shown significantly higher oxidative stress determined by 
increased breath-alkane output and plasma lipid peroxide concentrations, as well as lower 
concentrations of key plasma antioxidants (glutathione, ascorbic acid, alpha tocopherol, beta 
carotene and selenium) compared to non-HIV infected individuals (Constans et al., 1995, 
Delmas-Beauvieux et al., 1996, Kalebic et al., 1991).  
In summary, HIV can have a direct impact on mitochondrial function and can also indirectly 
affect mtDNA levels and mutation load via cytokine release in response to HIV infection. 
These mechanisms potentially increase the vulnerability of mitochondria to the effects of 
NRTI therapy. 
1.8.3.7 Stage of HIV infection and comorbidities 
Emphasis has also been placed on the association between stage of HIV infection and 
mitochondrial dysfunction. Advanced disease with nadir CD4 T-cell counts of less than 100 
cells/mm
3
 has been associated with lipoatrophy as well as DSP (Moyle, 2000, Lichtenstein et 
al., 2003). Studies have demonstrated significantly higher levels of serum TNF-α, soluble 
TNF receptor II, and interferon (IFN)-γ production with lower CD4 T-cell counts, 
particularly when less than 100 cells/mm
3
 (Hestdal et al., 1997, Godfried et al., 1993). 
Therefore it has been speculated that mitochondrial dysfunction could be attributed to an 
increased susceptibility to cell damage due to advanced HIV with subsequent higher levels of 
these cytokines (Anderson et al., 2004). 
Co-morbidities and concomitant medication may increase the risk for mitochondrial 
dysfunction. For example, HIV-infected patients co-infected with hepatitis C and treated with 
ribavirin together with ddI, have a substantially increased risk for lactic acidosis (Bani-Sadr 
et al., 2005, Butt, 2003, Moreno et al., 2004). Two cross-sectional community-based African 
studies have shown that tuberculosis (TB)-HIV co-infection and/or a history of previous TB 
infection in individuals on cART were independently associated with an increased risk of 

















co-infected patients might develop DSP, such as advanced HIV disease with poor nutrition 
and malabsorption, TB, anti-tuberculosis treatment or cART, DSP is mainly observed in 
patients prescribed INH with one of the d-drugs, d4T or ddI (Breen et al., 2006, Dean et al., 
2002, Westreich et al., 2009). INH has been shown to generate free radicals in vitro (Sipe et 
al., 2004), thereby increasing the risk for mitochondrial dysfunction by increasing ROS. 
1.8.3.8 Factors specific to neurons 
In peripheral nerves, numerous factors may contribute to the increased susceptibility to 
oxidative stress and cell damage: 
 Neurons are solely dependent on oxygen and glucose for energy and therefore 
generate ROS in abundance (Romero et al., 1991). As neurons rely mostly on 
aerobic energy production, processes that disrupt oxidative phosphorylation will 
have an effect on neuronal function (Brinkman et al., 1998). Impaired antioxidant 
defences through malnutrition or HIV infection can perturb the normal redox 
balance leading to oxidative stress and cell damage (Price and Thio, 2010). 
 The metabolism of unmyelinated axons is energy-intensive. Even though 
unmyelinated axons have a higher density of mitochondria, they are at an energy 
disadvantage compared to myelinated axons due to the inefficient manner of 
action potential conduction (Lehmann et al., 2011, Ritchie, 1973, Wang et al., 
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may lead to axonal degeneration (Lehmann et al., 2011). 
 The peripheral nervous system is particularly sensitive to damage from oxygen 
radicals. This is as a result of the high levels of polyunsaturated lipids that 
comprise the uniquely specialized neuronal membranes (Romero et al., 1991). 
Data from animal models demonstrate that the oxygen tension of the peripheral 
nervous tissue is relatively low compared with other tissues. It is possible that the 
decreased oxygen partial pressure increases the risk for hypoxia-induced free 
radical generation. Nerves are at risk for the effects of nitric oxide- and ROS as 
antioxidant levels are lower than in other tissues (Romero et al., 1991). For 
example, the concentration of brain glutathione, a major cellular antioxidant, is 

















 It is believed that length-dependency of many peripheral neuropathies are to some 
extent a consequence of distal axons being the most distant from the cell body, 
akin to the last field of an irrigation system getting the least “nutrients” from the 
cell body (Lehmann et al., 2011). As the site of mitochondrial biogenesis of 
peripheral nerves are in the dorsal root ganglion cell bodies, somatic mtDNA 
mutations accumulate and increase as they move distally down the axon over time 
(Lehmann et al., 2011). Therefore, with ageing, the distal axons are probably more 
vulnerable to mitochondrial dysfunction. 
To summarize, both NRTIs and HIV infection itself can directly or indirectly influence 
mitochondrial function in a number of tissues; directly by activating mitochondrial apoptotic 
pathways triggering cell death, or indirectly through immune activation and cytokine 
production. NRTIs can directly or indirectly interfere with mtDNA integrity as described in 
section 1.8.1. Variations in tissue vulnerability to oxidative stress, including antioxidant 
defence and nutrition, inflammatory response related to HIV infection and nerve injury repair 
mechanisms may all influence the neurotoxicity of NRTIs. Therefore, it is not surprising that 
the clinical manifestations of HIV pathology and NRTI-induced mitochondrial toxicity 
should overlap in a number of tissues with high energy demands, including peripheral nerves. 
1.8.4 Can mitochondrial toxicity be measured? 
With the widespread use of d-drugs in cART regimens, and the documentation of cases of 
fatal lactic acidosis, researchers looked for biomarkers that could possibly predict 
mitochondrial toxicity. Mitochondrial oxidative phosphorylation normally removes protons 
generated by the hydrolysis of ATP during the conversion of glucose-6-phosphate to 
pyruvate. Dysfunctional oxidative phosphorylation leads to proton accumulation and lactic 
acidosis. Therefore, blood lactate was investigated as a potential biomarker for mitochondrial 
dysfunction and extensively measured and monitored in large cohorts of individuals on cART 
regimens. A number of studies found a twofold increased risk of lactataemia with d4T- and 
ddI- versus AZT-based regimens [reviewed in (White, 2001)]. However, the data are 
inconsistent in ATN. Increased serum lactate levels were found in some patients with ATN 
(Estanislao et al., 2004b), but others have not found such an association (Maritz et al., 2010, 
Simpson et al., 2010, Simpson et al., 2006). One explanation for these findings may be that 
serum lactate lacks specificity and is influenced by technical and physiologic variability 

















adults on NRTI therapy with hyperlactatemia were symptom-free (Boubaker et al., 2001, 
Brinkman, 2001, Gerard et al., 2000, John and Mallal, 2002, John et al., 2001, Moyle et al., 
2002). 
Studies have also used markers of oxidative stress to demonstrate mitochondrial dysfunction. 
Increased levels of prostaglandin F2-like products, termed F2-isoprostanes, were shown in 
NRTI-treated individuals with symptomatic hyperlactatemia, lactic acidosis, or lipoatrophy 
(McComsey and Morrow, 2003). However, DSP was not associated with increased systemic 
oxidative stress as assessed by quantification of F2-isoprostanes in plasma (Hulgan et al., 
2006). It is possible that oxidative stress related to nerve damage or dysfunction may be 
localized and therefore not of sufficient magnitude to alter systemic lipid peroxidation 
profiles.  
1.8.5 A summary of the destructive cycle of mitochondrial damage in the 
context of HIV-infection 
Oxidative stress as a result of an imbalance between ROS and antioxidants may contribute to 
mtDNA damage, which in turn increases ROS production and leads to further oxidative 
damage. Ageing or cellular senescence results in ROS and free radical damage to the mtDNA 
(Payne et al., 2011). Furthermore, host fact rs may contribute to increased susceptibility to 
free radical mtDNA damage, possibly certain mtDNA haplogroups. Malnutrition and co-
morbid infections such as TB, which commonly occur in HIV-infected individuals, leads to 
an increase in oxidative stress. There is increasing evidence that HIV itself can directly and 
indirectly affect mtDNA and its function (Morgello et al., 1995, Van der Watt, 2011), 
predisposing individuals to mitochondrial toxicity (Lewis et al., 2003). Finally, it is well 
accepted that NRTIs inhibit the function of mitochondrial DNA polymerase-γ, leading to 
mtDNA damage (Lynx et al., 2006). In addition, the rapid clonal segregation of mtDNA 
mutations after NRTI therapy leads to accelerated ageing and increased ROS.  
Figure 1.4 shows the interactive effect of the three main factors resulting in mitochondrial 
damage. Cumulative effects of HIV-infection, oxidative stress and NRTIs on mtDNA 
damage eventually impair mitochondrial function to a critical threshold, which then further 
augments oxidative stress and mtDNA damage. NRTI-containing regimens in predisposed 
individuals such as older or malnourished individuals thus provide the context for multiple 


















Figure 1.4: Cumulative effects of HIV-infection, oxidative stress and NRTIs on mtDNA damage (From 
Cote, 2005) 
 
1.9 Risk factors for the development of HIV-associated DSP 
Prior to the introduction of cART, studies examining the risk factors for HIV-DSP 
consistently found surrogate markers of advanced HIV disease such as low CD4 T-cell count, 
higher viral load, or Mycobacterium avium infection, to be associated with HIV-DSP 
(Woolley et al., 1997, So et al., 1988, Barohn et al., 1993). 
In the cART era, identified risk factors have been less consistent. Factors associated with an 
increased risk of ATN have included increasing age, lower CD4 T-cell counts and higher 
HIV viral load at the time of cART initiation (representing more advanced HIV disease) as 
well as dNRTI exposure (Morgello et al., 2004, Maritz et al., 2010, Lichtenstein et al., 2005). 
A summary of clinical studies examining risk factors associated with the development of 
HIV-associated DSP in the cART era are summarized in Table 1.1 and Table 1.2. These data 
should be interpreted cautiously as various factors limit comparisons such as the use of 
varying diagnostic criteria and variable periods of observation. One of the most consistent 
risk factors for HIV-associated DSP has been increasing age. However, one study reported 
that 5-year increments of older age was only associated with the presence of DSP, but did not 

















a follow-up time period of 48 weeks was insufficient time to reveal any worsening in TNS 
score. 
Earlier studies reported higher HIV load and lower CD4 T-cell counts to be predictors of 
DSP, particularly symptomatic DSP. Some found nadir CD4 T-cell count to be a predictor of 
HIV-DSP, but not the CD4 T-cell count at the time of the cross-sectional analysis 
(Lichtenstein et al., 2005). Furthermore, Simpson et al. failed to establish a correlation 
between CD4 T-cell count and HIV viral load and the presence or progression of DSP, 
although the authors acknowledged that selection bias might have influenced their findings 
(Simpson et al., 2006). 
There are other risk factors that have limited or inconsistent supporting evidence. In first 
world setting these include white race, female sex, hepatitis C co-infection, plasma lactate 
level, impaired renal function and concomitant use of hydroxyurea, interferon-α or the 
protease inhibitor (PI) indinavir. In African cohorts, previous B infection has recurrently 
been found to be a significant risk factor for DSP (Forna et al., 2007, Maritz et al., 2010). 
It is increasingly evident that HIV-associated DSP is a product of multiple intersecting 
pathogenic processes (Brew, 2003). Many of the risk factors pertaining to the development of 
HIV-associated DSP show a definite connection with factors relating to increased risk of 
mitochondrial dysfunction (section 1.8.3). These factors include increased age, metabolic 
syndrome, stage of HIV and consequences of immune dysregulation, NRTI therapy, 
malnutrition and co-morbidities such as TB. 
Particular attention will now be given to TB infection and treatment, malnutrition, NRTI 
therapy and HIV immune dysregulation as risk factors for the development of HIV-associated 
DSP. These are areas of interest for the different study aims. 
1.9.1 Tuberculosis and low vitamin B6 as risk factors for HIV-associated DSP 
TB remains a major cause of morbidity and mortality worldwide. Globally, 9.4 million new 
TB cases occurred in 2009 of which 15% were also HIV-positive. The majority of new cases 
occur in South-East Asia and sub-Saharan Africa with the incidence rate of new disease in 
sub-Saharan Africa estimated at 360 cases per 100 000 population, nearly twice that of 
South-East Asia (WHO, 2012). Thirteen of the 15 countries with the highest estimated TB 

















Province, the TB incidence is >900 per 100 000 population (Wood et al., 2007). Southern 
Africa is the epicentre not only of a TB epidemic, but also of the HIV/AIDS epidemic. The 
African region accounted for 79% of HIV-positive TB cases, of which 31% were from South 
Africa (WHO, 2012). HIV/TB-co-infection probably accounts for the high rates of both new 
and recurrent TB disease as well as the morbidity and mortality associated with TB despite 
the availability of effective anti-TB chemotherapy (Harries et al., 2001). 
Peripheral neuropathy is a well-known adverse event associated with anti-TB chemotherapy 
with a documented frequency ranging from 2% amongst HIV-negative subjects, to 14% 
amongst those with concomitant HIV-infection (Marks et al., 2009, Breen et al., 2006). 
However, our understanding of the pathophysiology of this complication is limited (Argov 
and Mastaglia, 1979). INH is considered the predominant culprit due to the interference with 
vitamin B6 metabolism causing deficiency in biologically active vitamin B6 (Snider, 1980, 
Van der Watt et al., 2011). However, inflammation related to TB itself may play a role. The 
role of TB inflammation, INH therapy and vitamin B6 will be discussed further: 
1.9.1.1 TB inflammation 
The presence of TB-associated DSP is not well described (Paterson, 1913, Money, 1959), but 
has been observed in a prospective cohort of individuals co-infected with HIV, where 
neuropathic symptoms develop prior to initiating INH therapy (Centner, 2012). Although this 
observation was based on patient recall, it is possible that the systemic inflammation 
accompanying TB infection drives oxidative stress and exacerbates HIV-related nerve injury 
and that the phenomenon of TB-associated DSP may be underreported due to INH-related 
neuropathy obscuring its incidence. 
1.9.1.2 Isoniazid 
Isoniazid is a pivotal agent in the treatment of TB in combination with other drugs or alone as 
a prophylactic agent. Following the introduction of INH in 1952, numerous observers noted 
the occurrence of a painful peripheral neuropathy temporally related to INH initiation. Since 
then it has been recognised as the main contributor to DSP in patients on anti-TB treatment 


















INH is metabolised extensively in humans (Hughes et al., 1954). The primary metabolic 
pathway is acetylation of the hydrazide functional group by the drug metabolizing enzyme, 
N-acetyltransferase type 2 (NAT2), which is under the genetic control of a polymorphic 
NAT2 locus (Blum et al., 1991, Evans et al., 1960). The acetylation of acetylhydrazine to 
diacetylehydrazine is also mediated by the NAT2 enzyme (Figure 1.5) (Preziosi, 2007). 
 
Figure 1.5: INH metabolism via NAT2 
1.9.1.3 N-acetyltransferase 2 
Human NAT2 has been localized to the short arm of chromosome 8 (8p22). This gene has two 
exons but the coding region, spanning 870 base pairs (bp) is located in exon 2 and the 
functionally active NAT2 enzyme can be transcribed after transient heterologous transfection 
of exon 2 (Hein et al., 2000). 
At least 52 different NAT2 allelic variants have been identified (University of Louisville, 
2011). The ancestral NAT2*4 haplotype is associated with functionally rapid acetylation 
status and fourteen other NAT2 haplotypes consist of a combination of one single nucleotide 
polymorphism (SNP) or more, occurring at positions 191, 282, 341, 434, 481, 590, 803, 845, 
and 857 of the 870 bp NAT2 coding region. Seven of the nine SNPs (191 G>A, 341 T>C, 434 

















synonymous), whereas two (282 C>T and 481 C>T) do not (synonymous). Except for 341 
T>C, each of the nucleotide substitutions either adds or deletes an endonuclease restriction 
site (University of Louisville, 2011). 
Individuals are rapid, intermediate or slow acetylators depending on their ability to acetylate 
certain NAT2 substrates. Acetylation status has traditionally been differentiated based on 
phenotyping tests, performed with different substrates including caffeine and INH (Kinzig-
Schippers et al., 2005). More recently, genotyping enabled the identification of 52 NAT2 
alleles (University of Louisville, 2011). Individuals phenotyped as rapid acetylators carry two 
alleles associated with high acetylation activity (e.g. NAT2*4 and NAT2*12), intermediate 
acetylators carry one allele associated with high activity, while slow acetylators have two 
alleles associated with low acetylation activity. Several combinations of slow acetylator 
alleles may give rise to the slow acetylation phenotype. Correlative studies between NAT2 
genotypes and INH pharmacokinetics have shown that INH plasma concentrations are higher 
(up to 6-fold higher at short intervals) in those individuals homozygous for low-activity 
associated alleles at the NAT2 locus (Parkin et al., 1997, Kinzig-Schippers et al., 2005). The 
rate of acetylation is therefore considered a critical determinant of both therapeutic efficacy 
and toxicity, with slow acetylators more susceptible to toxicity, but also more likely to benefit 
therapeutically. 
The frequency of acetylator phenotypes varies considerably among racial populations 
(Sabbagh et al., 2008, Hamdy et al., 2003). The geographical distribution of common 
functional variants of NAT2 has been well studied in both European and East Asian 
populations (Upton et al., 2001). In most European Caucasian populations, the proportions of 
slow and fast acetylators are equal, whereas in Alaskan Inuits the majority (95%) are fast 
acetylators; Saudi Arabians are generally slow acetylators (95%). In contrast, data from Sub-
Saharan Africa are limited (Dandara et al., 2003, Patin et al., 2006). Few reports suggest that 
indigenous Africans comprise of approximately 59% fast and 41% slow acetylators (Bach et 
al., 1976, Eidus et al., 1979).  
Most reports used simplified protocols for NAT2 allele detection, omitting analysis of several 
polymorphic positions (such as 191 G>A, 282 C>T, 341 T>C, and 803 A>G). These focused 
on a limited number of “indicator” SNPs, thought to be tightly linked with other SNPs and 
predictive of acetylation phenotype. Allele designation is then based on the presence of the 

















assign different alleles as the same and may lead to misclassification of genotypes and 
deduced phenotypes (Cascorbi and Roots, 1999, Garcia-Martin, 2008). For example, the base 
change 341 T>C which defines the NAT2*5 allelic cluster, does not always occur together 
with 481 C>T. Thus, 481 C>T should not be used to estimate the frequency of the NAT2*5 
allele cluster. Furthermore, the 481 C>T change may sometimes be associated with another 
allelic cluster such as NAT2*6 (defined by 590 G>A). Therefore, while the method of 
detecting “indicator” mutations might have been suitable for Caucasian populations, in an 
African population, it is much more effective to detect individual SNPs. Nonetheless, the fact 
remains that DNA sequencing for the entire intron-exon organization of the NAT2 gene will 
provide the most detailed information about genetic diversity and possible functional effects 
in a population. 
The relevance of establishing NAT2 functional polymorphisms is that certain phenotypes 
modify susceptibility to adverse drug reactions (Krishnamurthy et al., 1967, Preziosi, 2007, 
Matar et al., 2004). Although epidemiological studies have investigated the relationship 
between NAT2 phenotype and individual risk for adverse events such as hepatotoxicity on 
INH (Ohno et al., 2000), NAT2 genotype (as opposed to phenotype) has not been studied 
extensively in relation to the incidence of INH-associated DSP. In Hiratsuka et al., all of two 
cases of INH-associated painful neuropathy occurred in genotypically slow acetylators; 
however, as it formed part of an „adverse event‟ group in the analysis, risk for INH-
associated painful neuropathy was not established. Several intermediate and rapid acetylators, 
who did not experience any INH-related adverse effects, had higher concentrations of INH 
compared to slow acetylators (Hiratsuka et al., 2002). This observed association between 
slow acetylation and INH-related adverse reactions may be attributable to a metabolic process 
unrelated to absolute INH concentrations. 
1.9.1.4 Effect of INH on vitamin B6 (pyridoxine) metabolism 
Vitamin B6 naturally appears in three forms: pyridoxine, pyridoxal and pyridoxamine. They 
are enzymatically interconvertible, and are all phosphorylated to pyridoxal-5‟-phosphate 
(PLP) via a phosphokinase (pyridoxal kinase) dependent on ATP, which is abundant in all 
tissues (Brin, 1978). Absorption by intestinal epithelial cells occurs by a carrier-mediated, 
pH-dependent mechanism that has saturable and non-saturable components. Absorbed dietary 
pyridoxine, pyridoxal and pyridoxamine are phosphorylated to enable metabolic trapping. 

















tissue uptake from the circulation (Kumar, 2007). The major catabolite of ingested vitamin 
B6 is 4-pyridoxic acid (4-PA) and results from oxidation of PLP by either NAD-dependent 
aldehyde dehydrogenase, found in all tissues, or FAD-dependent aldehyde oxidases, found in 
liver and kidneys. Pyridoxic acid, 4-PA, is excreted in the urine and indicates recent vitamin 
intake and does not reflect vitamin stores as it biologically inactive (Brin, 1978). Plasma PLP 
levels are reduced in renal disease, celiac disease, inflammatory bowel disease, rheumatoid 
arthritis and in individuals on anti-tuberculosis regimens that include INH (Chiang et al., 
2005a, Kumar, 2007, Visser et al., 2004) 
Sixty years ago it was recognised that INH-associated DSP was related to a deficiency in 
biologically active pyridoxine (Biehl and Vilter, 1954). The excretion of urinary pyridoxine 
doubled during INH treatment, which suggested that INH combines with pyridoxine to form 
a hydrazone that is excreted in the urine. Although the capacity of pyridoxine to form true 
hydrazones with INH is still being debated, it is accepted that INH forms a complex with 
pyridoxine, resulting in increased pyridoxine excretion (Preziosi, 2007). 
There are, however, other mechanisms that could contribute to the observed neurotoxicity, 
including the inhibitory effect of INH on pyridoxine-dependent enzyme systems. The most 
widely supported view holds that INH combines with PLP via the Schiff base condensation 
between the aldehyde group of PLP and the free amine group of INH to form pyridoxal 
isonicotinoyl hydrazine (Buss and Ponka, 2003, Preziosi, 2007). This irreversible reaction 
prevents the utilisation of pyridoxal by nerve tissue. Pyridoxal sequestration may be 
extensive enough to provoke polyneuropathy, which can sometimes be reversed by 
withdrawing INH, administering pyridoxine, or both (Preziosi, 2007). 
Others have proposed that INH inhibits phosphorylation of pyridoxine by inhibiting 
pyridoxal kinase, thereby reducing PLP production (Tower, 1956, Visser et al., 2004). There 
are multiple enzymatic reactions that depend on PLP as cofactor, including all transaminase 
reactions, deamination and dehydration of serine to produce pyruvate, desulfhydration of 
cysteine, decarboxylation of dihydroxyphenylalanine (dopa) to dopamine and 5-hydroxy 
tryptophan to serotonin, sphingolipid synthesis (an important constituent of myelin structure), 
and the synthesis of neurotransmitters such as gamma-amino butyric acid, noradrenaline and 
adrenaline. Consequently, PLP represents an essential enzyme for energy production 
supplying metabolites to the Krebs tricarboxylic cycle. Function and activity of nervous 

















glucose. When energy supplies fail, dysfunction and permanent structural damage rapidly 
follow (Tower, 1956, Marks, 1975). Vitamin B6 is also directly involved in heme synthesis, 
and vitamin B6 deficiency results in a shortage of heme. Heme deficiency decreases the 
activity and protein content of mitochondrial complex IV and activates nitric oxide 
synthetase, leading to increased levels of ROS (Scholnick et al., 1972, Atamna et al., 2001, 
Ames, 2004). Furthermore, although vitamin B6 is not classified as an antioxidant compound, 
it has been shown to have effective antioxidant properties, protecting cells against the damage 
from ROS, thereby slowing the progression of HIV immunodeficiency (Stocker et al., 2003). 
Another theory is that vitamin B6 disrupts ion gradients, thus accounting for the periaxonal 
swellings observed in individuals with INH-associated painful neuropathy (Jacobs et al., 
1979). However, the exact mechanism whereby vitamin B6 deficiency causes peripheral 
neuropathy is unclear. 
1.9.1.5 Vitamin B6 supplementation 
Humans cannot synthesise pyridoxine, and must therefore obtain this micronutrient from 
exogenous sources via intestinal absorption. Good sources of pyridoxine in the diet include 
spinach, carrots, eggs, flour, potatoes, peas, dairy products, meat and fish (Snider, 1980). For 
normal adults, the recommended daily allowance of pyridoxine is 1–2 mg/day (Snider, 1980, 
Steichen et al., 2006). Individuals considered to be at risk of developing vitamin B6 
deficiency include HIV-infected or malnourished individuals, pregnant and lactating women, 
patients on pyridoxine antagonists such as cycloserine, hydralazine and penicillamine, 
alcoholics, diabetics and the elderly. It is recommended that individuals considered at risk for 
developing peripheral neuropathy due to INH therapy such as those with alcohol dependency, 
malnutrition, diabetes and HIV infection, receive daily pyridoxine supplementation (South 
African Department of Health, 2004, CDC, 2009, WHO, 2012). As INH is metabolised in the 
liver and the acetylation products are excreted by the kidneys, both hepatic and renal 
dysfunction influence the levels of INH and its metabolites, respectively, increasing the 
potential of vitamin B6 deficiency (Goldman and Braman, 1972). 
The South African national guidelines for the management HIV-infected individuals 
recommend supplementation of one to two tablets of vitamin B complex preparation(s) if the 
individual has a poor appetite and/or financial constraints that compromise nutrition (South 

















individuals implies that the amount of vitamin B6 within two tablets of vitamin B complex 
would be sufficient for INH-associated DSP prophylaxis (South African Department of 
Health, 2004). However, the amount of vitamin B6 varies according to the manufacturer, but 
this currently equates to 2–4 mg/day in government-sponsored programmes (Rossiter et al., 
2012). South African guidelines do not recommend additional vitamin B6 supplementation in 
TB/HIV co-infected individuals without evidence of what is described as risk factors such as 
alcohol abuse, pregnancy, diabetes, epilepsy, or those with evidence of peripheral neuropathy 
(Van der Watt et al., 2011). However, HIV infection itself is considered a risk factor for INH-
associated DSP in guidelines from developed countries, recommending vitamin B6 dosages 
greater than 10 mg/day (Chan and Iseman, 2002, WHO, 2009, CDC, 2003, JTC, 1998). A 
previous South African cross-sectional study reported that less than 10% of individuals with 
TB/HIV co-infection were receiving what might therefore be considered as adequate vitamin 
B6 supplementation (daily dosage 25 mg/day) (Maritz et al., 2010). 
1.9.1.6 Neurotoxicity of INH not only related to vitamin B6 deficiency 
Although the precise mechanism of INH neurotoxicity is still not established, the neurotoxic 
effects may not be limited to those mediated by a functional or overt vitamin B6 deficiency. 
Some metabolites such as isonicotinic acid, ammonia, hydrazine and other hydrazine 
derivatives may produce oxygen radicals, which lead to protein damage, and have been 
implicated in neurotoxicity (Timperio et al., 2005). 
Hydrazine is particularly reactive, requiring minutes as opposed to hours to produce 
measurable quantities of radical species. Importantly, hydrazine metabolism and inactivation 
is also dependent upon acetylation, and therefore on an individual‟s acetylator status 
(Timperio et al., 2005). Production of oxygen radicals may be particularly critical when TB is 
treated with INH in the context of concomitant HIV infection, which increases oxidative 
stress in its own right (Allard et al., 1998, Israel et al., 1992). 
1.9.2 NRTI exposure as risk factor for ATN 
Currently, stavudine (d4T) is the most commonly used backbone antiretroviral drug in 
resource-limited settings (Bygrave et al., 2011). A WHO survey on cART-use in 23 
developing countries undertaken in 2006 revealed that 69% of first-line regimens included 
stavudine, representing 53% of all patients on cART, or an estimated 851 000 individuals 

















mitochondrial toxicity, including peripheral neuropathy, have led to the discontinuation of 
stavudine in developed countries in favour of a less toxic alternative. Tenofovir exhibits less 
side effects (Birkus et al., 2002) and has a long intracellular half-life that allows for 
formulation as a once daily regimen (together with lamivudine and efavirenz) (Grim and 
Romanelli, 2003). In randomized trials, tenofovir has demonstrated comparable or greater 
antiviral efficacy and favourable tolerability compared with other first-line NRTIs such as 
stavudine, zidovudine or abacavir (Gallant et al., 2004, Pozniak, 2008). Therefore, the WHO 
revised its cART guidelines in late 2009 to withdraw stavudine. Many countries in southern 
Africa adopted tenofovir in their first line cART regimens (Ford and Calmy, 2010). South 
Africa followed in April 2010. However, stavudine is still used in South Africa and elsewhere 
in resource limited settings and can thus still have a considerable impact on the prevalence of 
ATN. The incidence of treatment-related neurotoxicity appears to be dose-dependent, for 
example, in a retrospective study, stavudine at 80 mg/day vs 60 mg/day increased the odds of 
ATN by a factor of 1.7 (Lichtenstein et al., 2005).  
However, not all studies have shown an association between the use of dNRTIs and the 
development of neuropathy. Although earlier studies intimated a relationship between 
duration of therapy to the development of neuropathy (Boulle et al., 2007, Moyle and Sadler, 
1998), more recent publications are suggesting a different perspective. Arenas-Pinto et al. 
challenged the common supposition that DSP arises from cumulative exposure to NRTIs. 
They found that patients who developed symptomatic DSP tended to do so shortly after 
exposure to antiretroviral therapy, with the risk for DSP peaking at 90 days post exposure, 
after which the risk decreased (Arenas-Pinto et al., 2008). 
Longitudinal studies have demonstrated that dNRTI exposure was associated with a 
decreased risk of developing DSP as viral load was controlled. A trend towards protection 
against symptomatic DSP was observed which seemed paradoxical, although it was thought 
that the restoration of immune function by dNRTIs possibly outweighed the drugs‟ potential 
neurotoxicity (Schifitto et al., 2005). Similar results were reported in another cohort where 
dNRTI use was associated with incident DSP in the first year of their use, but increasing 
duration of exposure was associated with a decreased incidence of DSP (Lichtenstein et al., 
2005). 
An African cross-sectional study found no difference in the proportion of individuals 

















et al., 2010). Neither did they find a significant difference in the median number of months 
on stavudine amongst those with DSP and those without. It is possible that treatment-naïve 
individuals with pain are being judiciously diverted from stavudine therapy masking an effect 
in a cross-sectional design. It was also suggested that if DSP did not develop within the first 
year of d-drug therapy, individuals continuing on d-drugs would have no greater risk of 
developing DSP or worsening in existing DSP, than those not receiving d-drug regimens 
(Arenas-Pinto et al., 2008). However, there are reports of an increased risk for developing 
ATN in the presence of pre-existing neuropathy. (Berger et al., 1993, Moyle and Sadler, 
1998, Dalakas et al., 2001, Blum et al., 1996). Although data are limited, other classes of 
cART drugs, such as protease inhibitors (ritonavir, indinavir, saquinavir) have also been 
associated with the development of neuropathy although they are frequently used in 
combination with dNRTIs (Pettersen et al., 2006, Smyth et al., 2007). 
Based on these findings, it appears that individuals susceptible to the development of d-drug 
associated DSP, usually develop it early which often results in discontinuation of d-drugs. 
The apparent “neuroprotective” effect of subjects on long-term dNRTI regimens may simply 
represent a form of survival bias in those subjects who tolerate the drug (Simpson et al., 
2006). However, with cART, true neuroprotection may exist with recovery in immune 
function and potentially neurological function. 
1.9.3 Malnutrition as risk factor for HIV-associated DSP 
Globally, poor nutritional status and weight loss is common in people with HIV infection 
(van Lettow et al., 2003). These patients frequently suffer from deficiencies of several 
micronutrients such as vitamins A, -C and -E, B-complex, as well as zinc and selenium (van 
Lettow et al., 2003, Tang and Smit, 1998, Karyadi et al., 2000). Micronutrient deficiencies 
and weight loss may be the result of changing metabolic requirements, decreased appetite 
with reduced caloric intake (van Lettow et al., 2003, Villamor et al., 2008), as well as 
abnormal gut integrity affecting nutrient absorption (Anabwani and Navario, 2005, Beach et 
al., 1992). As discussed in section 1.8.3.5, several of these nutrients are fundamental 
components of mitochondrial flavoproteins and cytochromes, which mean they are 
imperative for adequate and proper functioning of mitochondria (Look et al., 2001). Pre-
existing vitamin B6 deficiency could well be exacerbated by INH administration, increasing 
the risk for DSP, and the need for supplementation. Available experience suggests that 

















DSP (Fawzi et al., 2004, Kaiser et al., 2006, Villamor et al., 2008, Isanaka et al., 2012) and 
reduced production of oxidant compounds and reduce oxidative stress (Allard et al., 1998, 
Packer, 1993).  
As discussed in section 1.7.2, inflammation and immune dysregulation likely contribute to 
HIV-associated DSP. Markers of immune activation such as C-reactive protein (CRP) have 
been found to inversely correlate with circulating vitamin B6 levels (Chiang et al., 2005b). 
There is some evidence from studies in rheumatoid arthritis to suggest that inflammation may 
be contributing to impaired vitamin B6 status (Chiang et al., 2005a). In this study it was 
thought that low plasma PLP levels (the most important catalytic form of vitamin B6) was 
unlikely to be due to insufficient intake or excessive vitamin B6 excretion. Rather, that higher 
demands of certain tissues during inflammation resulted in the removal of vitamin B6 
coenzymes from the circulation (Chiang et al., 2005a).  
Serum albumin is not only an objective measure of malnutrition, but also a negative acute-
phase protein that decreases with inflammation (Moshag  et al., 1987, Don and Kaysen, 
2004). Therefore, hypoalbuminaemia may be related to HIV-associated malnutrition and/or 
the chronic inflammatory state in these individuals. Frequencies of hypoalbuminaemia in 
African populations are reported to range from 13-32% (Graham et al., 2007, Dao et al., 
2011). Given that over 90% of PLP is bound to serum albumin while being transported, the 
binding of PLP to albumin will impact on the availability of PLP to tissues. Low serum 
albumin results in the dephosphorylation of plasma PLP into pyridoxal (Merrill and 
Henderson, 1987) and thereby influences plasma PLP concentrations.  
To summarize, the premise that vitamin B6 deficiency has a defining role to play in the 
pathogenesis of HIV-associated DSP is broadly based on two theories; the 
antioxidant/oxidative stress theory resulting in mitochondrial dysfunction, and the 
nutritional/immunological theory which have related and overlapping complex mechanisms 
with a fine balance between redox homeostasis, T-lymphocyte functioning as well as axonal 
damage and repair mechanisms. 
The imbalance in cellular redox homeostasis due to vitamin B6 deficiency leads to oxidative 
stress and subsequent overproduction of ROS. Increased ROS levels may mediate local 
damage and lead to further immune activation with inflammation such as described in section 

















result in reduced concentrations in the plasma. Vitamin B6 deficiency also leads to reduced 
production and decreased activity of T-lymphocytes (Baum et al., 1991, Rall and Meydani, 
1993, Willis-Carr and St Pierre, 1978). This leads to a reduced capacity of lymphocytes to 
respond to relevant stimuli affecting repair mechanisms to local damage. Furthermore, the 
reduced T-lymphocyte effector function as well as the increased ROS levels may accelerate 
HIV disease, leading to a cycle of enhanced immune activation and viral production with 
further micronutrient deficiency. 
1.9.4 Inflammation and cytokines as risk factor for ATN 
Cytokines are very potent small proteins produced by either immune (macrophages, B-cells 
or T-cells) or nonimmune cells (endothelial cells or Schwann cells). They function as cellular 
communicators at an autocrine or paracrine level. Most cytokines are pleiotropic in nature, 
and different cytokines may share similar functions (Vallejo et al., 2010). Cytokines 
produced by T-helper 1 (Th1) cells include IFN-γ, IL-2 and IL-12, and constitute pro-
inflammatory cytokines. Those produced by T-helper 2 (Th2) cells include IL-4, IL-5, and 
IL-10 and are considered anti-inflammatory cytokines (Mosmann and Coffman, 1989). Some 
cytokines such IL-13 and TNF-α are common to both T-helper subsets. 
During inflammation, cytokines are produced and released to act on other cells, often as part 
of a cytokine cascade (Chiang et al., 2007) aiding the immune system in destroying 
pathogens and healing damaged ti sue. Importantly, although the physiological function of 
cytokines may be to restore homeostasis, its uncontrolled, prolonged or excessive production 
may lead to pathological responses and tissue injury. Selected cytokines and their functions 


















Table 1.3: Selected cytokines and their functions (Adapted from Callard and Gearing, 1994, Coico and 
Sunshine, 2009) 
Cytokine Produced by Major function 
IL-1β Monocytes, T-cells, B cells, 
many other cell types 
Mediates host inflammatory response to infection; 
stimulates acute-phase protein synthesis 
IL-2 Naïve T-cells and Th1-cells T-cell growth factor 
IL-4 Th2 cells, mast cells, bone 
marrow stromal cells 
Growth factor for B cells and Th2 CD4 T-cells; inhibits 
Th1 CD4 T-cells; promotes IgE and IgG 
IL-5 Th2 cells, mast cells, B cells Stimulates B cell growth and Ig secretion; growth and 
differentiation factor eosinophils 
IL-6 T-cells, macrophages, 
endothelial cells, 
keratinocytes, mast cells 
Induces acute-phase protein synthesis, T-cell activation 
and IL-2 production; stimulates B cell Ig production and 
hematopoietic progenitor cell growth 
IL-7 Thymic stromal cells, bone 
marrow 
Growth factor for pre-T and pre-B cells 
IL-8 Monocytes, macrophages, 
fibroblasts, keratinocytes, 
endothelial cells 
Mobilizes and activates neutrophils; promotes 
angiogenesis 
IL-10 Th2 cells, macrophages, B cells Inhibits production of Th1 cells and macrophage 
function 
IL-12 B cells, macrophages, T-cells, 
dendritic cells 
Activates natural killer cells and promotes generation 
of Th1 CD4 T-cells 
IL-13 T-cells Shares characteristics of IL-4, but does not affect T-
cells; growth factor for human B cells 
GM-CSF T-cells, monocytes Promotes growth of granulocytes and macrophages; 
growth of dendritic cells in vitro 
IFN-γ Th1 cells Activates natural killer cells and macrophages; inhibits 
Th2 CD4 T-cells; induces expression of MHC class II on 
many cell types 
TNF-α Macrophages, mast cells Involved in inflammatory responses; activates 
endothelial cells and other cells of immune and 
nonimmune systems; induces fever and septic shock 
Abbreviations: IL, interleukin; GM-CSF, granulocyte-macrophage colony-stimulating factor; IFN, interferon; 


















1.9.4.1 Why study cytokines and painful HIV-DSP?  
A substantial amount of data exists on the association between cytokines and pain. The first 
indications that cytokines may play a role in hyperalgesia stemmed from research using 
cytokine injections in the rat (Ferreira et al., 1988, Cunha et al., 1992). The intraneural or 
intraplantar application of pro-inflammatory cytokines induces behavioural signs associated 
with pain and hyperalgesia. This can be effectively reduced by treatment with anti-
inflammatory cytokines. A pro-inflammatory cytokine profile has also been associated with 
pain in the setting of peripheral neuropathy in HIV-negative individuals, with higher blood 
messenger RNA (mRNA)levels of TNF-α and IL-2 levels in individuals with painful 
neuropathy compared to those with painless neuropathy (Uceyler et al., 2007). 
Small but significant increases in pro-inflammatory cytokine activity were detected in 
chronic pain patients. Both blood and intrathecal concentrations of sTNFR were significantly 
elevated, as were cerebrospinal fluid (CSF) concentrations of IL-1ß. On the other hand, IL-
10, which has anti-inflammatory properties, was reduced in both compartments in patients 
suffering with chronic pain (Backonja et al., 2008). 
Although pro-inflammatory cytokines have been associated with severe HIV-associated 
dementia (Sevigny et al., 2004, Wesselingh et al., 1994, Tagliati et al., 1999), few reports 
exist assessing the role of cytokines in HIV-associated painful DSP. In a cross-sectional 
cohort, largely on cART, markers of immune activation in the plasma and CSF were studied; 
only CSF macrophage colony-stimulating factor levels predicted time to developing 
symptomatic DSP (Schifitto et al., 2005). Individuals with HIV-associated DSP compared to 
those without were found to have persistently higher levels of chemokine ligand 5 (CCL5) 
during the first 48 weeks after cART (Chew et al., 2011). Increased TNF-α- and reduced IL-4 
mRNA levels were also found in peripheral nerve tissue from AIDS patients with DSP (Tyor 
et al., 1995). A study genotyping polymorphisms in several cytokine genes in individuals 
with or without symptomatic ATN, showed an association with the TNFA-locus. (Cherry et 
al., 2008).  
Upon starting cART, immune reconstitution is accompanied by a rise in CD4 T-cell count 
and partial restoration of pathogen-specific immunity (Wilkinson et al., 2009). However, 8-
43% of patients will experience pathological inflammatory responses that may cause clinical 

















2010, Meintjes et al., 2008). Typically IRIS occurs during the first 12 weeks of cART 
initiation (Meintjes et al., 2009) and has been shown to be associated with increased 
circulating pro-inflammatory cytokines IL-6, IFN-γ and TNF-α, albeit in the setting of HIV-
TB co-infection (Tadokera et al., 2011). The resultant inflammation not only causes 
symptoms of the subclinical infection to emerge, which can be severe, but also results in 
oxidative stress with subsequent cell damage. In this research project we hypothesize that an 
exaggerated cytokine response after cART initiation may contribute to the 
immunopathogenesis of early painful ATN via the indirect mechanism of axonal damage. 
As discussed in section 1.7.2, axonal damage with exposure of cryptic epitopes may result in 
a secondary autoimmune response directed at the peripheral nerves. Alternatively, immune 
restoration and activation as a result of cART initiation with the release of cytokines can 
increase peripheral nerve hyperexcitability and injury. Subsequent release of cytokines, free 
radicals, and lipid membrane derivatives, are all potentially neurotoxic (Schifitto et al., 2005) 
and may also be associated with „dying-back‟ degeneration of peripheral nerve fibres (Cherry 
et al., 2008, Pardo et al., 2001, Dalakas et al., 2001).  
One common aspect to the manifestation of IRIS is a low CD4 T-cell count prior to treatment 
followed by a significant and rapid increase in CD4 T-cells after initiation of cART (Badri et 
al., 2002, Douek et al., 2001, Lawn et al., 2008). However, the pathogenesis of this amplified 
inflammatory response may be more complex. Individuals who develop IRIS may have 
perturbations in their T-regulato y cell profile and regulatory immune responses due to 
cytokine imbalances that may contribute to the manifestation of this syndrome both before 
and after cART is commenced (French, 2012, Oliver et al., 2010). Multiple cytokines may be 
part of the pathogenesis of IRIS and as various cytokines may in turn regulate the production 
of other cytokines, their combined effect is often greater than the function of a single 
component. However, the remainder of this review will be focused on those cytokines that 
have been implicated in the pathogenesis of painful neuropathy. 
Tumour necrosis factor alpha 
TNF-α is a multipotent pro-inflammatory cytokine that induces a wide variety of cellular 
responses, which includes apoptosis in some cells and proliferation in others (Ashkenazi 
1999). Its main function appears to be the recruitment and activation of mononuclear cells 
and neutrophils to the site of inflammation (Schafers et al., 2003a, Schafers et al., 2003b, 

















TNF-α, T-cells can also produce TNF-α during inflammation (Woska and Magram, 2005). In 
the nervous system, microglia and astrocytes are believed to be the primary producers of 
TNF-α (Szelenyi, 2001, Hopkins and Rothwell, 1995) whereas in the peripheral nervous 
system, it is macrophages, Schwann cells, dorsal root ganglia and sensory neurons (Wagner 
and Myers, 1996, Schafers et al., 2002, Schafers et al., 2003b). 
Several studies have shown TNF-α to be involved in the generation of inflammatory pain, 
neuropathic pain and hyperalgesia through its actions in the periphery and in the central 
nervous system (Aloe et al., 1997, Empl et al., 2001, Schafers et al., 2003b, Sommer et al., 
1998, Wagner and Myers, 1996, Watkins et al., 1995). Injury-induced increases in TNF-α 
expression in the nerve microenvironment correlate with the development of allodynia and 
hyperalgesia in several neuropathic pain models (Schafers et al., 2003b). Endoneurial and 
intrathecal injection of TNF-α induces axonal degeneration, demyelination and thermal and 
mechanical hyperalgesia, and topical application evokes ectopic activity in nerve fibres 
(Sorkin et al., 1997, Reeve et al., 2000). In an animal model of chronic nerve constriction 
injury, inhibition of the synthesis and release, or functional neutralization of TNF-α results in 
reduced pain-associated behaviour (Schafers et al., 2001, Sommer et al., 2001, Sommer et al., 
1998). 
Soluble TNF-α receptors 
The ability of TNF-α to influence cellular signalling is dependent on the activation of TNF 
receptors. An alternative measure of TNF-α activity is TNF receptor levels (Zangerle et al., 
1994), which are relatively stable and therefore better indicators of inflammatory responses 
than TNF-α concentrations (de Beaux et al., 1996, Gardiner et al., 1995, Chikanza et al., 
1993, Aziz et al., 1999). The longer plasma half-life of sTNFR and rapid biological 
inactivation of detectable systemic TNF-α may be the reason for this observation. There are 
two distinct TNF receptors, 55 kD (type I TNF receptor-TNFRI) and 75 kD (type II TNF 
receptor-TNFRII). Both are expressed by primary afferent nociceptors (Sommer et al., 1998) 
and both exist in soluble and cell surface membrane-bound forms. Neuropathic pain seems to 
be largely dependent on TNFRI signalling (Sommer et al., 1998) whereas TNFRII appears to 
play plays an important role in neurodegeneration (Arnett et al., 2001). However, both 
receptors are upregulated following experimental nerve lesions or systemic inflammation 


















Interleukin-1 is a pleiotropic cytokine with diverse roles in immunity and inflammation, 
having both protective and pro-inflammatory effects. Biologically active IL-1 consists of two 
distinct forms called IL-1α and IL-1β, respectively. Principal functions of IL-1 include 
mediation of the host‟s inflammatory response to infections and other inflammatory stimuli, 
induction of acute-phase protein synthesis and proliferation of Th2 cells. It is produced by a 
large variety of cells including macrophages, fibroblasts, glial cells and neurons (Callard and 
Gearing, 1994), although activated monocytes and macrophages are the major source. Stimuli 
for IL-1 production include bacterial products such as lipopolysaccharides and other 
cytokines such as TNF-α. 
In addition to its immune functions, IL-1 is involved in nociceptive behaviour (Bianchi et al., 
1998) and appears to play a role in rat dorsal root ganglion neural regeneration after axotomy 
(Horie et al., 1997). In cultured dorsal root ganglion cells, IL-1β has been shown to induce 
the release of substance P (Morioka et al., 2002). This peptide induces vasodilation, increases 
vascular permeability (Lembeck and Holzer, 1979), activates bystander macrophages and 
evokes inflammatory responses resulting in hyperalgesia (Walsh et al., 1995). Whether 
administered centrally or peripherally, IL-1β has been found to induce hyperalgesia in several 
animal pain models (Bianchi et al., 1998). Subcutaneously, IL-1β is able to produce a dose-
dependent increase in the sensitivity of rat paws to mechanical and thermal stimulation with 
the activation of small diameter cutaneous nerves (Fukuoka et al., 1994). 
Interleukin-I receptors and antagonist 
The capacity of IL-1 to influence cellular functions depends on the expression of the 
appropriate receptor. There are two membrane receptors that have been identified for IL-1. 
The type I IL-1 receptor (IL-1RI) is the major receptor for IL-1-mediated biologic responses. 
The type II IL-1 receptor (IL-1RII) does not transmit any cell signal and its major function is 
to act as a decoy receptor that competitively inhibits IL-1 binding to the type I signalling 
receptor (Cunningham and De Souza, 1993). IL-1RI knockout mice do not respond to 
intraperitoneal or intracerebroventricular injected IL-1 (Touzani et al., 2002). In the same 
way, IL-1RI inhibition through neutralizing antibodies administered to the lateral ventricle 
abrogates the behavioural effects of intracerebroventricular applied IL-1β (Cremona et al., 
1998a). In contrast, inhibition of IL-1RII potentiates this effect (Cremona et al., 1998b). More 

















IL-1 receptor antagonist (IL-1RA), and neutralizing antibodies to IL-1RI reduce pain-
associated behaviour in mice after chronic constrictive injury (Sommer et al., 1999). 
Interleukin-6 
Interleukin-6 is a pro-inflammatory cytokine and a terminal differentiation factor for B cells. 
It also stimulates acute-phase protein production by hepatocytes, T-cell activation and IL-2 
production (Callard and Gearing, 1994). IL-6 is synthesized by a variety of cells including T-
cells, monocytes, macrophages, fibroblasts, endothelial cells and keratinocytes (Callard and 
Gearing, 1994).  
There is considerable evidence in animal models reporting roles for IL-6 in nociception and 
inflammatory hyperalgesia (Cunha et al., 1992, Oka et al., 1995). Intraplantar, intrathecal or 
intracerebroventricular injection of IL-6 induces allodynia or hyperalgesia in rats. Increased 
IL-6 mRNA transcripts are detected in the dorsal root ganglion after chronic constriction 
injury. In behavioural studies, IL-6 knockout mice showed reduced thermal hyperalgesia and 
mechanical allodynia (Ramer et al., 1998, Zhong et al., 1999) and less hyperalgesia after 
carrageenan inflammation or nerve constriction (Xu et al., 1997). Neutralizing endogenous 
IL-6 with antibodies inhibits lipopolysaccharide-induced hyperalgesia (Sommer, 2001, 
Ramer et al., 1998). 
IL-6 has been associated with non-HIV small fibre neuropathies. Uceyler et al. reported an 
increase of IL-6 mRNA transcripts in skin biopsies of individuals with length-dependent 
small fibre neuropathy (Uceyler et al., 2007). 
This concludes the background summary covering all aspects of this research. The research 


















1.10 Study Aims 
High prevalence and incidence rates in a population at risk, various diagnostic and clinical 
management issues, and limited data especially within the first 12 weeks after cART 
initiation makes HIV-associated DSP research a priority. A prospective approach starting 
prior to cART initiation would offer the opportunity to assess the impact of various risk 
factors and offer a description of the natural clinical evolution of the disease within the first 
24 weeks of starting treatment. 
Specific aim 1 
To determine the incidence of painful ATN following the initiatio  of antiretroviral 
therapy and to examine the impact of cART on pre-existing HIV-DSP. 
The purpose of this research was to focus on painful ATN and specifically that which occurs 
in the first 24 weeks of starting cART. The first aim was to determine the incidence of 
symptomatic ATN in a community based cohort by recruiting ambulatory individuals at the 
point of cART initiation, and studying them over the first 24 weeks when the incidence of 
symptomatic ATN is reportedly the highest. 
Specific aim 2 
To investigate the impact of ce tain risk factors (such as age and prior TB infection) 
previously identified in this population in a cross-sectional study, on the development of 
ATN.  
The second aim was to examine the impact of certain risk factors identified in a previous 
cross-sectional study in this population on the development of ATN, to understand the 
pathogenesis of ATN with the ultimate objective of identifying an intervention without 
compromising HIV control. 
 
There are two additional etiological aspects we wished to study in relationship to incident 
neuropathy a) an early “inflammatory” component and b) the independent risk of TB therapy. 
This work is particularly relevant in Africa, which carries a disproportionate burden of the 


















Specific aim 3  
To correlate selected markers of immune dysregulation, with a particular focus on 
candidate cytokines previously associated with painful neuropathies (TNF-α, IL-1, IL-2, 
IL-6) with incident painful ATN within the first twelve weeks of initiating cART. 
The third aim of this research included a nested case-control-study to assess the hypothesis 
that ATN could represent an IRIS phenomenon in which previously identified “pain-
associated” cytokines may be involved in this immune dysregulation. The objective was to 
investigate the impact of ART-initiation on immune dysregulation or reconstitution, and how 
this correlates with the development of painful symptoms within the first 12 weeks when the 
incidence of IRIS as well as ATN peaks. 
Specific aim 4  
To evaluate NAT2 status as a surrogate marker for INH-acetylation status and serum 
pyridoxine levels (at baseline and 12 weeks) with markers of inflammation, and how these 
measures correlate with incident painful ATN. 
A history of TB infection was associated with an increased risk for DSP in African cohorts 
and INH-associated painful neuropathy is preventable with adequate vitamin B6 
supplementation. In addition, the hyper-inflammatory state accompanying HIV-infection may 
contribute to a critically low vitamin B6 level in certain tissue compartments. Therefore, the 
fourth aim was to determine whether vitamin B6 deficiency and the NAT2 acetylation 










































2.1 Ethical approval 
The Research Ethics Committee of the University of Cape Town (UCT) approved the study 
with reference number REC REF 221/2008 (See Appendix A). 
 
2.2 Study design and study site 
The study design was a prospective analytical observational cohort with a baseline cross-
sectional component. The study was undertaken at Crossroads Community Health Centre in 
Crossroads, a township approximately 15 km within the city of Cape Town, South Africa, 
from May 2009 until December 2010. This institution runs a dedicated clinic for an estimated 
6000 HIV-infected individuals. In Crossroads Township, services are limited to shared water 
outlets and toilet facilities. Unemployment is high in the area and is estimated to be between 
25-50%. Most people living in the area are indigenous Africans. The primary language is 
isiXhosa (O'Connor et al., 2011). 
 
2.3 Recruitment 
Ambulatory individuals were recruited from the clinic by two clinicians (Drs JJ vd Watt and 
C Centner) and a trained field worker, fluent in English, isiXhosa and isiZulu, who would 
also act as an interpreter between study staff members and participants if necessary. 
HIV-infected individuals not on cART and scheduled to commence cART within seven days 
were referred from the clinic doctors. After being counselled, individuals received an 
information pamphlet (see Appendix C). Consent was given for study participation, blood 
sampling for biochemistry, vitamin B6, cytokine and DNA analysis and storage of samples. 
Clinic folders were reviewed hereafter to screen for any exclusion criteria. Individuals were 
enrolled into the study consecutively as they were found to be eligible to start cART within 
the following days to one week. Study appointment dates were coordinated with the clinic in 
order to perform baseline visits within one week prior to commencing cART. Participants 
were instructed to be nil per mouth for a minimum of eight hours prior to each study visit and 


















2.4 Eligibility and exclusion criteria 
Individuals were eligible if 18 years or older and met criteria for cART initiation in the South 
African government-sponsored HIV treatment programme, i.e. a CD4 T-cell count <350 
cells/mm
3
 and/or WHO stage IV AIDS-defining illness.  
Exclusion criteria included active opportunistic infection, systemic illness, known 
inflammatory conditions, current pulmonary TB on therapy for less than one month, severe 
diarrhoea (> six stools per day), co-morbid neurological disease that may confound the 
diagnosis of DSP, diabetes mellitus, exposure to glucocorticoids within the past six months, 
or pregnancy. 
 
2.5 Clinical study procedure and assessments 
Clinical examinations were performed at baseline (the visit prior to cART initiation), 2-, 4- 
12- and 24 weeks thereafter. Assessments at baseline, week 12 and week 24 were conducted 
at Groote Schuur Hospital and the 2- and 4 week assessments were performed at Crossroads 


















Table 2.1: Summary of study procedures at each visit 
 
2.5.1 Neurological assessment 
Two clinicians (Drs JJ vd Watt and C Centner) performed the neurological assessment. For 
peripheral neuropathy, a combination of the BPNS and mTNS methods was used. The 
International HIV dementia scale (IHDS) was used as a screening tool for HIV dementia. 
2.5.1.1 Neuropathic symptoms 
The BPNS consists of brief questions regarding symptoms of DSP: 1) pain, aching, or 
burning; 2) pins and needles sensation; and 3) numbness in the feet or legs. Individuals 
Procedure Baseline Week 2* Week 4* Week 12 Week 24
Informed consent x
Clinic Folder review
Medical and drug history x x x x
Laboratory data collection x x
Clinical assesssment
Neurological assessment
BPNS 1 x x x x x
mTNS x x x x
IHDS x x x x x
Anthropometry x x x
Blood pressure x x x
Blood collection
Metabolic paramaters  2 x x x
NAT2 genotype x
PLP and 4-PA x x
Albumin x
Inflammatory biomarkers
Cytokines x x x x
Soluble receptors x x x x
C-reactive protein x x x x
*  Only applies to individuals without DSP at baseline and not on TB therapy
1   Modified at Week 2: Only neuropathic symptoms assessed without neurological examination

















graded each of these symptoms bilaterally on a VAS (translated into isiXhosa) from 0 
(absent) to 10 (severe). The single highest score of the three modalities as determined by the 
VAS was defined as the Total Sensory Severity score (see Appendix A). This score was used 
to establish a sensory severity grade, called Total Sensory Grade, which was important in 
defining the natural progression of DSP: 
0 if the Total Sensory Severity score = 0 
1 if the Total Sensory Severity score was 1 – 3 
2 if the Total Sensory Severity score was 4 – 6 
3 if the Total Sensory Severity score was 7 or 8 
4 if the Total Sensory Severity score was 9 or 10 
In the mTNS, sensory symptoms in all modalities are assessed as a single entity and scores 
represent the level of anatomical involvement. A higher score is obtained for more proximal 
involvement (0 for no symptoms; 1 – soles/toes; 2 – extends up to ankle; 3 – extends up to 
knee; and 4 – more proximal involvement). 
Both clinical tools required symptoms and signs to be symmetrically present, and individuals 
with asymmetry were excluded from the analysis. In addition, if neuropathic symptoms were 
absent at baseline, individuals were asked if symptoms had been experienced in the past. 
2.5.1.2 Neuropathic signs 
The BPNS includes the examination of two neurological signs, namely vibration perception 
and deep tendon reflexes. Vibration perception was evaluated using a 128 Hz tuning fork 
(RAGG, England), opposing the two ends and applying it to the dorsum of the hallux 
interphalangeal joint of both feet, proximal to the nail bed. Vibration sense was defined as 
normal if vibration felt for at least 10 seconds (see Appendix A). If vibration sense was <10 
seconds on the feet, the procedure was repeated proximally at the level of the ankle joint, 
followed by the knee joint. 
Deep tendon reflexes were examined with the individual sitting on the side of the examining 
table, relaxing the lower limbs. A long-handed reflex hammer (Eschmann, England) was 
used. Ankle reflexes were compared to knee reflexes. The ankle reflex was elicited by 

















noting plantar flexion. Reflexes were defined as absent, normal, hypoactive or hyperactive 
with or without clonus. 
The mTNS examination includes the following four evaluations: (1) pinprick sensibility, (2) 
vibration perception, (3) tendon reflexes and (4) distal strength. Each of the four elements 
was graded from 0 (normal) to 4 (most abnormal). For elements (1) and (2), grades 
represented the level of anatomical involvement as described for sensory symptoms. Tendon 
reflexes (3) were simultaneously graded according to severity and level of involvement (0 for 
all normal; 1 for ankle reflexes reduced; 2 for ankle reflexes absent; 3 for ankle reflexes 
absent and others reduced; and 4 for all reflexes absent). Ankle- and toe plantar- and 
dorsiflexion (4) were graded according to the Medical Research Council muscle power 
grading (0 – 4). In addition to the BPNS and mTNS, proprioception at the big toe was 
assessed (normal, reduced or absent). Neuropathy findings were recorded on a neuropathy 
data form (see Appendix A). 
2.5.1.3 IHDS Cognitive function screening 
The IHDS was applied as a screening tool for HIV-associated cognitive involvement (shown 
in Appendix D). It has been validated as a sensitive screening test for HIV dementia and 
consists of three subtests: timed finger tapping (motor speed), timed alternating hand 
sequence test (psychomotor speed), and memory recall (Sacktor et al., 2005). A total score 
out of 12 was calculated for each individual, with each of the three subtests contributing 4 
points to the total score. The cut-off of <10 out of 12 was applied for defining HIV dementia. 
2.5.2 Other clinical measures 
Digital blood pressure (BP) readings were recorded in triplicate with the use of an Omron M6 
Comfort BP monitor (Omron Healthcare, Kyoto, Japan). Systolic and diastolic BP measures 
were obtained from seated individuals. Anthropometric data on weight, height and waist-to-
hip ratio were collected for all individuals. Field workers conducted interviews to complete a 
questionnaire regarding social and medical history. 
2.5.3 Blood collection and storage 
Fasting venous blood was collected between 08h00 and 09h00 to reduce variability (diurnal 
variations or food ingestion) (Geiss et al., 1997). Capillary blood was collected for fasting 

















system (Roche, Mannheim, Germany). Thereafter intravenous canulation was performed and 
venous blood was collected for: 
a) Metabolic parameters viz. glucose, insulin, lipid profile (baseline, 12- and 24 
weeks) 
b) DNA for NAT2 genotyping (baseline) 
c) PLP and 4-PA for vitamin B6 levels (baseline and 12 weeks) 
d) Albumin (baseline) 
e) High-sensitivity (hs)-CRP, cytokine and soluble receptor screen (baseline, 2-, 4- 
and 12 weeks) 
Venous samples were collected by venepuncture using the appropriate vacuum blood 
collection tubes (Greiner Bio-One, Kremsmunster, Germany). After blood collection, 
samples were immediately placed on ice until centrifuged. Samples were centrifuged at 3300 
g1 for ten minutes (min). The supernatant fraction of each tube aliquoted into 1.5 mL 
Eppendorf tubes labelled with the appropriate study identification number, date and visit 
number, and stored immediately in a -80°C freezer. (Laboratory materials and methods will 
be discussed further in Chapter 3). 
2.5.4 Clinic folder reviews 
Data on general medical history and laboratory risk factors were extracted from the clinic 
medical records. General medical history included the date of HIV diagnosis, WHO clinical 
stage, previous or current TB infection, current prescribed vitamin supplementation (vitamin 
B complex or vitamin B6) or any analgesia (all verified during history taking). Changes in 
cART regimens were recorded as well as any evidence of cART-related adverse effects. 
Data from routine blood testing performed at the clinic were collected from clinic folders 
(and confirmed on electronic records from the National Health Laboratory Services). These 
consisted of baseline measurements of mean corpuscular volume (MCV), haemoglobin (Hb), 
                                                 
1
 The relationship between Revolutions Per Minute and Relative Centrifugal Force (expressed in units of 




. Where g is the relative centrifugal force, R is the radius of the rotor 


















white cell count (WCC), creatinine and alanine aminotransferase (ALT), and baseline and 24-
week measurements of CD4 T-cell counts. Plasma HIV RNA viral load was used as a 
measure of virological control 24 weeks after commencing cART according to South African 
guidelines. All viral load levels <200 RNA copies/mL were considered undetectable. Data 
from clinic folder reviews were recorded on an examination form (see Appendix E). 
2.6 Study definitions and criteria for diagnosis 
2.6.1 Clinical definitions 
Clinical definitions used in defining neuropathy at baseline are summarized in Table 2.2. At 
baseline assessment, the diagnosis of DSP required at least two of four key components 
(sensory symptoms, vibration sense, pin sensibility, and tendon reflexes) to be abnormal:  
a) An individual was defined as having symptomatic DSP (SDSP) if sensory symptoms 
were present and at least one of the three remaining key components were abnormal. 
b) An individual was considered to have asymptomatic DSP (ADSP) if sensory 
symptoms were absent and at least two of three remaining key components were 
abnormal with a minimum mTNS score of 3. 
The primary baseline analysis compared individuals with DSP to those without DSP, and 
those with symptomatic DSP to those without DSP. 
Table 2.2: Baseline neuropathy definitions 
 
Follow-up DSP definitions are summarized in Table 2.3. Incident symptoms were defined as 
no sensory symptoms at baseline and the development of any sensory symptoms after 
Neuropathy status Sensory symptomsa Neuropathic signsb Neuropathy score
DSP
Symptomatic (SDSP) Any one Any one
Asymptomatic (ADSP) None At least two mTNS score ≥ 3
Symptoms only Any one None
a   Pain, numbness or paraesthesiae (according to the BPNS or mTNS score)
b   Abnormal pin sensibility, vibration sensibility, deep tendon jerks or muscle strength

















baseline. Incident symptomatic DSP was defined as no symptomatic DSP at baseline, with 
development of symptomatic DSP after baseline. For worsening or improving symptoms or 
signs in individuals with DSP pre-cART, we compared the number and severity of symptoms 
and signs in each individual between the initial and follow-up visits (see Table 2.3).  
The primary outcome measure for the longitudinal study was a diagnosis of ATN either at 2-, 
4-, 12- or 24 weeks after initiating cART. ATN was defined as individuals who developed 
any new neuropathic symptoms (with or without neuropathic signs), or worsened in existing 
symptomatic DSP. The follow-up analysis compared individuals with ATN to those who had 
been exposed to cART but had not developed ATN during the 24-week follow-up period. A 
caveat in the definition of ATN is that worsening of neuropathic symptoms may be part of the 
natural progression of HIV-DSP; the addition of cART as an additional neurotoxic insult 
does not necessarily imply that the worsening was due to cART. Furthermore, the population 
at risk for incident symptoms and that at risk for worsening symptoms (which would be 
individuals with symptomatic DSP at baseline) are mutually exclusive and with our definition 
of ATN, individuals with symptomatic DSP will be in both comparative groups. Therefore, 
an analysis was also performed looking at individuals who developed neuropathic symptoms, 
comparing them to individuals who never had or developed neuropathic symptoms, and 


















Table 2.3: Follow-up neuropathy definitions 
 
To investigate risk factors for the development of HIV-associated DSP overall, a comparison 
was performed between those who either had symptomatic DSP at baseline or developed 
ATN to those who remained symptom-free. This analysis was performed to investigate the 
hypothesis that symptomatic DSP at baseline and the development of ATN are part of a 
continuum of the same disease process. This group of individuals will be referred to as „HIV-
SN‟. 
Transition of DSP states over the 24-week follow-up period was examined by dividing 
individuals into four baseline DSP groups, namely no DSP, asymptomatic DSP, symptomatic 
DSP and symptoms only (neuropathic symptoms without any neuropathic signs). 
Category Definition
Incident symptoms No sensory symptoms at all prior study visits (including baseline); AND
Any one abnormal sensory symptom at specified follow-up study visit.
Incident SDSP No SDSP at all prior study visits (including baseline); AND
SDSP at specified follow-up study visit.
Worsened symptoms Increase in BPNS Total Sensory Grade at specified follow-up study visit
since baseline* compared to baseline.
Worsened signs Increase in the sum of mTNS scores relating to neuropathic signs at
since baseline* specified follow-up study visit compared to baseline.
Worsened SDSP SDSP at baseline; AND
since baseline* SDSP at specified follow-up study visit; AND
Worsened symptoms since baseline.
ATN Incident symptoms; OR
Worsened SDSP since any prior study visit.
Improved symptoms Decrease in BPNS Total Sensory Grade at specified follow-up study visit
since baseline* compared to baseline.
Improved signs Decrease in the sum of mTNS scores relating to neuropathic signs at
since baseline* specified follow-up study visit compared to baseline.
*   The definition compares the specified follow-up study visit to baseline.
     It can be applied at any specified follow-up study visit compared to any prior study visit,

















2.6.2 Vitamin B6 definitions 
Vitamin B6 deficiency was defined as a plasma PLP level <25 nmol/L. Individuals received 
pyridoxine supplementation in two forms: 
a) Vitamin B complex supplementation: Pyridoxine doses in vitamin B complex 
preparations may vary according to the manufacturer, but this currently equates to 
2-4 mg/day in South African government-sponsored programmes (Rossiter et al., 
2012). This will further be referred to as „vitamin Bco supplementation‟. 
b) Vitamin B6 supplementation: A dosage of 25 mg/day, further referred to as 
„vitamin B6 supplementation‟. 
2.6.3 Metabolic definitions 
Abnormal fasting serum triglyceride, high-density lipoprotein (HDL), low-density lipoprotein 
(LDL) and total cholesterol were defined in line with the National Cholesterol Education 
Program Adult Treatment Panel III guidelines and WHO definitions (Lorenzo et al., 2007, 
Grundy et al., 2005): 
a) Elevated triglycerides (≥1.7 mmol/L) 
b) Low HDL cholesterol levels (<1.15 mmol/L)  
c) Elevated LDL cholesterol (≥3.0 mmol/L) 
d) Elevated total cholesterol (≥5.0 mmol/L) 
Normal body mass index (BMI) was defined as 20.0-25.0 kg/m
2
. 
Abnormal waist-to-hip ratio was defined as >0.90. 
Metabolic Syndrome was defined if at least three of the following criteria from the National 
Cholesterol Education Program Adult Treatment Panel III were present (Grundy et al., 2005):  
a) Elevated mean arterial BP of at least 100 mmHg 
b) Elevated fasting triglycerides (≥1.7 mmol/L) 
c) Reduced HDL cholesterol (<1.15 mmol/L) 
d) Obesity with elevated BMI (>25 kg/m2) 
e) Elevated fasting plasma glucose (≥5.6 mmol/L) 


















2.7 Data capturing 
Data were captured by JJvdW via an electronic version of the examination form designed 
using Microsoft Excel 2007 (Microsoft Corporation, Redmond, Washington, USA) and 
stored in an Excel database. The electronic form was designed to perform the following 
functions: 
a) Allow the user to input the result of an examination. 
b) Validate the data as it is entered using validation rules that were customised for 
each field. 
c) Automatic calculation of results of all pre-defined scores and definitions and final 
calculations of the BPNS and mTNS scores. 
d) Convert the data to an Excel database. 
e) Look up results of a particular examination for a particular individual from the 
database and to view the data in the format that it was recorded as. 
All uploading of new data, data corrections and changes to the electronic form and database 
were documented in an audit trail in the relevant Excel workbooks. 
 
2.8 Statistical analysis 
Data management and statistical analysis were performed using STATA version 12.0 
(Statacorp, College Station, Texas, USA). All statistical analyses were performed by JJvdW 
and supervised by a statistician, Dr Henri Carrara, School of Public Health and Medicine, 
University of Cape Town. Descriptive statistics were used to describe the study sample and 


















2.8.1 Cross-sectional analysis 
2.8.1.1 Univariate analysis 
In the univariate analysis variables were evaluated for their association with DSP. All 
variables were investigated and will be presented and grouped in the following way in all 
relevant chapters: 
a) Clinical: Age, weight, height, BMI, waist-to-hip ratio, systolic and diastolic BP, 
TB history 
b) Immunological/Haematological: WHO HIV stage, CD4 T-cell count, white cell 
count, hs-CRP, haemoglobin and MCV 
c) Biochemical: Albumin, ALT and creatinine 
d) Metabolic: Fasting glucose, insulin, triglycerides, total cholesterol, HDL, LDL 
and lactate 
e) Pyridoxine: PLP and 4-PA 
All variables were tested for normality and log-transformed when necessary. Untransformed 
data are displayed in the tables and figures. For normally distributed data, t-tests were used to 
compare continuous variables, and Pearson‟s chi-squared (χ
2
) test was used to compare 
differences in categorical variables. A non-parametric statistical approach was used for data 
that remained non-normally distributed after transformation; Wilcoxon rank-sum test was 
used to compare continuous variables, and Fisher‟s exact test to compare differences in 
categorical variables. Differences were considered statistically significant at p-value ≤0.05. 
All reported p-values are two-tailed. The odds ratio (OR) was estimated by generalized linear 
models and were calculated to determine univariate risk factors associated with DSP status. 
Factors significantly associated in the primary analysis (parametric, non-parametric and 
proportional) were examined by individual logistic regression. All variables were explored 
for an association, but only variables showing significance level of p<0.25 in the primary 
analysis were included in the multivariate analysis, described in section 2.8.1.2. 
Spearman‟s correlation coefficients were used for bivariate correlation analyses. The strength 
of the relationship was defined by rho (ρ) as: 1) less than 0.3 – weak, 2) 0.3 to 0.5 – 
moderate, 3) 0.6 to 1.0 – strong. Categorizing continuous variables by biological meaningful 
cut-off values or by population medians were additionally used as a measure of variation in 

















analysis for the specific variable. Individuals who did not complete follow-up at 24 weeks 
were excluded from the 24-week analysis. 
To evaluate the association of vitamin B6 and hs-CRP with DSP status, we used two parallel 
strategies: 1) to test differences between individuals categorized as DSP and no DSP, 2) to 
test correlations between vitamin B6, hs-CRP and other variables, such as triglycerides or 
albumin, independent of DSP category. The association between NAT2 and DSP status was 
investigated using three different genetic models described in section 3.1.3.6. 
2.8.1.2 Multivariate analysis 
Using a stepwise backward approach to variable selection, we fitted a multivariate logistic-
regression model to study baseline continuous or categorical variables found to be 
significantly associated with DSP in the univariate analysis.  
Variables with a p-value ≤0.25 were included in the initial multivariate model. Variables not 
independently statistically significant (i.e. with a p-value >0.05) were excluded from the 
multivariate model by stepwise backward logistic regression. Therefore, the final model 
included only those variables independently associated with DSP status. All models included 
age and gender. Analyses included all individuals with blood samples available at the 
specified time of assessment. The model with the best fit was determined with the Hosmer-
Lemeshow test for goodness of fit. Adjusted odds ratios and 95% confidence intervals (CIs) 
were estimated from the final model. The coefficient of determination (R
2
) was used in the 
statistical models to describe the proportion of variability in the data set that was accounted 
for by the specific model. Explanatory variables were assessed for collinearity. 
Nonmonotonic continuous variables were dichotomized for the multiple logistic regression 
analysis. All reported p-values are two-sided. No correction was made for multiple 
comparisons in the cytokine analysis as specific biomarkers were selected in a pre-established 
hypothesis. 
It was decided not to use a forward logistic regression approach. The disadvantage of using 
forward logistic regression is the possible statistical removal of a mediating or confounding 
variable that could increase the magnitude of the relationship between the independent and 
dependent variable (Menard, 2001, MacKinnon et al., 2000). Although both forward and 

















likely to uncover associations since all variables are initially included in the model (Menard, 
2001). 
2.8.2 Longitudinal analysis 
Shift tables were used to describe DSP group transitions over time. As data were collected at 
four time points, it was only known that neuropathy occurred within a certain time interval. 
The data was therefore interval censored, therefore the assumption was made that neuropathy 
developed at a halfway point between two time points. The incidence rate of ATN was 
calculated as the ratio of the number of individuals who had developed ATN to the number of 
individuals at risk during a specific time interval. Only the first detected episode of ATN was 
considered for calculating the incidence rate. In order for the incidence rates to be accurately 
calculated, exposure for each time interval was dependent on whether or not the individual 
was examined at the end of that interval. For example, if the individual had a 12-week 
follow-up visit, but was not seen at week 2, the individual was not included in the 0-2 week 
interval exposure group. 
Different methods were used to assess the serial changes in the variables of interest over time. 
First the longitudinal trends in the variables were examined graphically. Additionally, as the 
data consisted of repeated observations on the same individuals taken at specific time points 
(cross-sectional time series analysis), repeated measures analysis with a random effects 
model was performed. The model describes the trend over time while taking account of the 
correlation that exists between serial measurements. It also describes the variation in the 
baseline measurement and in the rate of change over time. To analyze the longitudinal 
patterns of different laboratory measurements, we used time as a within-individual factor and 
group (DSP status) as the between-individual factor (Genser et al., 2007). Random slopes 
were included in the model to address heterogeneity in measurements over time by adding 
dummy variables for the three time points after baseline, and creating interactions between 
group and time dummies. Data were expressed as a regression coefficient and represents the 
rate of change of one variable as a function of changes in the other, compared to baseline. No 
adjustment was made for multiple comparisons.  
Cox proportional hazards regression, an aspect of time-to-event (survival) analysis, was used 
to assess the relationship between two or more continuous or categorical variables and ATN 

















creatinine were not routinely performed at the local clinic after 24 weeks on cART. 
Therefore, these measurements were not included in the week 24 random effects model. 
To determine the within-individual stability of the immunological data, Spearman‟s rank 
correlations were calculated between time points. The immunological data are presented as 
median and interquartile range (IQR) values, since their distribution was not normal. 
2.8.3 Sample size for symptomatic DSP 
We calculated sample size estimate using the proportions known to have developed 
symptomatic DSP from a cross-sectional study from a similar population (OpenEpi v2; 
http://www.openepi.com/SampleSize/SSPropor.htm). From a previous cross-sectional cohort 
(n=270) we expected 67% to have been eligible to enter the study i.e. would not have 
developed symptomatic neuropathy pre-cART. If Crossroads clinic services 6000 people who 
are HIV-infected (as per clinic manager) and about 3000 are already on cART. Every month 
approximately 30 individuals commence cART, therefore we estimate that the population 
size of 360 will be eligible for the study in one year of recruitment. 
The hypothesized frequency of developing symptomatic DSP on cART in this population 
would be 36% ±5% (with a 95% CI) based on a previous South African cross-sectional study 










































3.1 NAT2 genotyping 
3.1.1 DNA isolation 
Genomic DNA was prepared from 3-5 mL of peripheral whole blood collected from each 
individual, in separate ethylenediaminetetraacetic acid (EDTA)-containing vacutainer tubes. 
The buffy coat was prepared by centrifuging whole blood at 3300 g for 10 min at room 
temperature. The samples were divided into aliquots and stored at -80°C until analysed. 
Genomic DNA was isolated from the thawed samples using the QIAamp DNA Mini Kit 
(QIAGEN GmbH, Hilden, Germany). All extractions were performed according to the 
manufacturer's instructions (see Appendix F). 
3.1.2 Determination of DNA concentration and integrity 
The quantification of the purified nucleic acid solution was determined 
spectrophotometrically at 260 and 280 nm, by measuring the absorbance of a diluted sample 
aliquot placed in a beam of light with a 1 cm path length (NanoDrop 1000 software, 
NanoDrop Technologies, Wilmington, Delaware, USA) (Sambrook et al., 1989). Good 
quality high molecular weight genomic DNA was extracted. Stock solutions were diluted in 
sterile distilled water to a final working concentration of 50 ng/μL and stored at -20°C. The 
integrity of the DNA samples was ascertained by subjecting 150 ng of each sample with 5 μL 
loading buffer [40% sucrose, 0.25% bromophenol blue (Merck, Germany)] to agarose gel 
electrophoresis for 30 min at 120 V, on a 1% agarose low electroendosmosis gel (Roche 
Diagnostics, Indiana, USA) using Tris-Borate EDTA electrophoresis buffer (TBE)(891.8 mM 
Tris base; 889.4 mM boric acid; 19.9 mM EDTA, pH 8), and incorporating ethidium bromide 
(Sigma-Aldrich, Missouri, USA) (0.5 μg/mL) for visualization under ultraviolet light 
[UVIpro UVIGold Transiluminator (UVItec Limited, UK)]. 
3.1.3 Determination of NAT2 genotype 
NAT2 genotype was determined using a polymerase chain reaction (PCR)-restriction 


















3.1.3.1 Polymerase chain reaction (PCR) 
NAT2 was amplified by PCR using 150 ng of genomic DNA in a 100 μL reaction, each 
containing 0.04 μmol deoxyribonucleotide triphosphate (dNTP), 0.01 μmol MgCl2, 2.5 units 
Taq DNA polymerase I and 1μg of each primer 5‟GGCTATAAGAACTCTAGGAAC-3‟ 
(forward) and 5‟AAGGGTTTATTTTGTTCCTTATTCTAAAT-3‟ (reverse) (Integrated 
DNA Technologies, Coralville, Iowa, USA) in corresponding reaction buffer (Promega, 
Madison, Wisconsin, USA) and distilled water. The mixture was subjected to thermal cycling 
conditions described in Table 3.1. 
Table 3.1: Thermal cycling conditions for NAT2 PCR, allele-specific PCR and cycle sequencing 
 
Following the PCR, a 4 μL aliquot was mixed with 3 μL loading buffer, and electrophoresed 
on a 1% agarose gel in TBE buffer containing 0.5 μL/mL ethidium bromide for 30 min at 120 
V. To determine the molecular mass of the band observed, 500 ng of the Gene Ruler 100 bp 
DNA Ladder-Plus Molecular Weight Marker (Fermentas International Inc., Hanover, USA) 
was included as a size standard. DNA was visualized and photographed under ultraviolet 
light. The resulting 895 bp PCR-product was subjected to RFLP analysis as described below. 
3.1.3.2 Restriction fragment length polymorphism (RFLP) analysis 
The presence or absence of eight separate nucleotide substitutions (all except 341 T>C) was 
determined by RFLP analysis. Digestion of 20 μL of PCR product was done in a total volume 
of 40 μL using the appropriate buffers and restriction enzymes for each reaction obtained 
from Promega/Fermentas Laboratories. Digestions were performed in four separate reactions. 
The restriction enzymes use in each reaction, their recognition and cleavage sites as well as 
their incubation conditions are summarized in Table 3.2. 
Temperature Duration Temperature Duration Temperature Duration
1 x Pre-denaturation 94.0 ᵒC 5 min 94.0 ᵒC 5 min 98.0 ᵒC 5 min
Denaturation 94.0 ᵒC 1 min 94.0 ᵒC 1 min 96.0 ᵒC 30 sec
Annealing 55.0 ᵒC 1 min 57.5 ᵒC 30 sec 50.0 ᵒC 15 sec
Extension 72.0 ᵒC 1 min 72.0 ᵒC 1 min 60.0 ᵒC 4 min
1 x Final extension 72.0 ᵒC 5 min 72.0 ᵒC 5 min - -
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Table 3.2: Restriction enzymes used for determination of seven polymorphisms of NAT2, recognition 
and cleavage sites and incubation conditions 
 
Nucleotide substitutions 191 G>A, 434 A>C, and 481 C>T were detected by digesting PCR 
product with the restriction enzymes MspI (10 units) and KpnI (10 units). MspI cuts NAT2 at 
bases 189 and 96 and KpnI cuts at base 480 resulting in fragments of 415, 291, 96, and 93 bp 
(Figure 3.1). The 191 G>A substitution causes the loss of the MspI site, yielding a 384-bp 
fragment instead of 291- and 93-bp fragments. An additional MspI site is added by nucleotide 
substitution 434 A>C, yielding bands of 416, 244, 93, 66 and 47 bp. Nucleotide substitution 
481 C>T leads to the loss of the KpnI restriction site resulting in the replacement of the 415- 
and 291-bp fragments with a 706-bp fragment. 
 




Recognition site Temperature Duration
1 191 G>A Msp I 5'-C↓CGG-3' 37 ᵒC 3 hours
434 A>C Msp I 5'-C↓CGG-3' 37 ᵒC 3 hours
481 C>T Kpn I 5'-GGTAC↓C-3' 37 ᵒC 3 hours
2 590 G>A Taq I 5'-T↓CGA-3' 37 ᵒC 2 hours
857 G>A Bam HI 5'-G↓GATCC-3' 65 ᵒC 2 hours
3 282 C>T Fok I 5'-GGATG (N)9↓-3' 37 ᵒC 3 hours
845 A>C Dra III 5'-CACNNN↓GTG-3' 37 ᵒC 3 hours
4 803 A>G Dde I 5'-C↓TNAG-3' 37 ᵒC 3 hours
191 G>A 434 A>C 481 C>T

























Nucleotide substitutions 590 G>A and 857 G>A were detected by digesting the PCR product 
with restriction enzymes TaqI (10 units) and BamHI (10 units). The 590 G>A substitution 
causes a loss of one of the TaqI sites at base 588, resulting in a 396-bp fragment instead of 
the 226- and 170-bp fragments (Figure 3.2). Nucleotide substitution 857 G>A causes the loss 
of the BamHI restriction site resulting in a 137-bp fragment instead of the 98- and 39-bp 
fragments (Figure 3.2). 
 
Figure 3.2: Predicted cleavage of NAT2 by restriction enzymes TaqI and BamHI (Digest 2) 
The 282 C>T and 845 A>C substitutions were detected by digestion of the PCR product with 
the restriction enzymes FokI (10 units) and DraIII (10 units). Nucleotide substitution 282 
C>T causes the loss of one of the FokI sites resulting in a 697-bp fragment instead of the 268- 
and 429-bp fragments (Figure 3.3). A new DraIII site id added by the 845 A>C substitution, 
cutting the 198-bp fragment into 153- and 45-bp fragments (Figure 3.3). 
 



















































Nucleotide substitution 803 A>G was detected by digesting the 20 μL NAT2 PCR product 
with the restriction enzyme DdeI (10 units). The 803 A>G substitution results in an additional 
DdeI restriction site, cutting a 119 bp fragment to 96- and 23-bp fragments (Figure 3.4). 
 
Figure 3.4: Predicted cleavage of NAT2 by restriction enzyme DdeI (Digest 4) 
For better separation of similarly-sized bands, digested samples were loaded on a 2.5% 
agarose gel containing 0.5 μL/mL ethidium bromide, run at 80 V for 2 hours, and visualized 
and photographed under ultraviolet light. In the presence of any unclear bands, the agarose 
gel was submerged in 0.5 μL/mL ethidium bromide staining solution for 15 min. The gel was 
then resubmerged in distilled water for 30 min to remove background staining, and thereafter 
visualized and photographed under ultraviolet light. 
3.1.3.3 Allele-specific PCR amplification 
Nucleotide substitution 341 T>C was detected by using allele-specific PCR due to the lack of 
a known restriction site near base 341. In order to distinguish between a C or a T at 
nucleotide 341, genomic DNA was amplified using two sets of primers: one primer set was 
specific for NAT2 alleles with 341 T (5‟-CTCCTGCAGGTGACCAT-3‟ and 5‟-
GGAGACGTCTGCAGGTATG-3‟), whereas the other primer set was specific for NAT2 
alleles with 341 C (5‟-CTCCTGCAGGTGACCAC-3‟ and 5‟-
GGAGACGTCTGCAGGTATG-3‟). 
Amplification of NAT2 (100 ng DNA) was carried out by PCR in a 100 μL reaction, each 
containing 0.04 μmol deoxyribonucleotide triphosphate (dNTP), 0.01 μmol MgCl2, 2.5 units 
Taq DNA polymerase I and 1 μg of each primer in corresponding reaction buffer and distilled 
water. The optimal annealing temperature was determined with a temperature gradient 



































band) and showed the least amount of non-specific amplification (other bands). The mixture 
was then subjected to thermal cycling conditions as summarized in Table 3.1. PCR products 
were loaded onto a 1% agarose gel containing 0.5 μl/mL ethidium bromide, run at 100 V for 
40 min, and visualized and photographed under ultraviolet light. Only primer set T amplified 
NAT2 alleles homozygous for 341 T, NAT2 alleles homozygous for 341 C were amplified 
only by primer set C, and heterozygotes were amplified by both sets of primers.  
3.1.3.4 NAT2 sequencing 
Forty-four PCR products samples were randomly selected and sequenced to confirm the 
genotyping obtained by RFLP. NAT2 amplification was carried out by PCR using a forward 
primer (5´-GTCACACGAGGAAATCAAATGC-3`) and a reverse primer (5´-
GTTTTCTAGCATGAATCACTCTGC-3`) as described in section 3.1.3.1. Sequencing 
reactions were done using the ABI PRISM™ BigDye Terminator Cycle Sequencing Ready 
Reaction Kit version 3.1 (Applied Biosystems, Foster City, California, USA). Reaction 
volumes are listed in Table 3.3 and reactions were performed according to thermal cycling 
conditions in Table 3.1.  
Table 3.3: Reaction volumes for DNA sequencing 
 
Products of the cycle sequencing reaction were then purified by ethanol precipitation prior to 
resolution on the ABI PRISM 3100 Genetic Analyzer (Applied Biosystems) as recommended 
by the manufacturer. Results were collected using ABI PRISM Data Collection Software v1.1 
(Applied Biosystems). NAT2 sequence chromatograms were visually inspected and analysed 
using software programme Chromaspro version 1.5 and aligned with the NAT2 reference 
sequence (GenBank Accession number X14672.1) for SNP identification. Chromatograms 
were analysed for heterozygous changes and ambiguous sequence positions, and then aligned 

























Figure 3.5: Chromatogram examples demonstrating SNP 191 heterozygous (A) and homozygous (B) and 
SNP 481 heterozygous (C) and homozygous (D) 
Positions that differed from the reference sequence in both the forward and reverse sequences 
for a particular individual were investigated in the literature to determine their relevance to 
the structure and function of NAT2 and its protein product. With a novel variant, the NAT2 
haplotype was translated into its corresponding amino acid sequence. The web-based tools 
PolyPhen-2 and PANTHER were used to predict the effect of the polymorphism on protein 
activity by measuring the evolutionary constraint acting on the site where it appeared. 
3.1.3.5 Haplotype reconstruction 
PHASE v2.1.1, a statistical programme for haplotype reconstruction was used to clarify 
haplotype ambiguity. The programme predicts an individual‟s acetylation status using a 
default model for recombination rate variation (Stephens et al., 2001, Stephens and Donnelly, 
2003, Li and Stephens, 2003). 
The PHASE method from Agundez et al. was applied (Agundez et al., 2008). We performed 
20 independent runs with 1000 iterations, 500 burn-in iterations, and a thinning interval of 1. 
Of the 20 runs we selected one that showed the best consistency of results across all runs. The 
consistency of the results obtained was also investigated by applying the PHASE algorithm 
191 GA 191 GG

















repeatedly with default and varying values for the number of iterations, burn-in iterations and 
the thinning interval.  
3.1.3.6 Genotype classification and genetic models 
SNP frequencies were evaluated for Hardy-Weinberg equilibrium using the χ
2
 test for 
goodness of fit to detect differences between observed and predicted frequencies of 
homozygous and heterozygous SNPs. The Hardy-Weinberg law states that both allele and 
genotype frequencies of a large, randomly mating population remain constant from 
generation to generation provided migration, mutation, and selection do not take place 
(Lunetta, 2008). Therefore, Hardy-Weinberg equilibrium is the stable distribution of 
frequencies of the genotypes AA, AB, and BB in the proportions p
2
, 2pq, and q
2
, respectively 
(where p and q represent the frequencies of the alleles A and B) (Lunetta, 2008). The 
genotype of each individual was determined as per standard NAT2 nomenclature scheme 
(University of Louisville, 2011). 
Three exploratory genetic models were applied for testing association between NAT2 
genotype and DSP status. In the dominant model, dominance of one of the alleles is inferred 
by treating the heterozygote and one of the homozygote genotypes as a single category. This 
dichotomization of the SNP genotypes implies that heterozygotes have the same risk or mean 
phenotype as one of the homozygotes (Lewis, 2002). 
 
The general genetic model retains the three genotypes and makes no distinction about how 
the risk differs between heterozygotes or homozygotes. A single SNP with alleles A and B 
will generate six different genotypes (AA, AB and BB) between cases and controls (Lewis, 
2002). 
 
AA AB + BB
Cases a b + c
Controls d e + f
AA AB BB
Cases a b c

















In the additive model, the risk conferred by an allele is increased r-fold for heterozygotes and 
2r-fold for homozygotes, although it is acknowledged that genes do not generally act in a 
simple additive manner, but rather through complex networks involving gene to gene and 
gene to environment interactions (Colhoun et al., 2003). 
 
Additive model: r-fold increased risk for AB, 2r increased risk for BB 
3.1.3.7 NAT2 phenotype 
We inferred from NAT2 genotypes the distribution of rapid, intermediate and slow acetylation 
phenotypes. Individuals homozygous for slow bearing haplotypes were classified as slow 
acetylation phenotype. Individuals homozygous for rapid haplotypes were classified as rapid 
acetylation phenotype. Heterozygote individuals bearing a rapid and a slow haplotype were 
considered intermediate acetylators, because they present a mean intermediate NAT2 activity 
significantly different from that of rapid or slow homozygotes (Cascorbi et al., 1995).  
 
3.2 Cytokine and soluble cy okine receptor quantification 
3.2.1 Multiplex multiple analyte profiling 
Levels of plasma cytokine concentrations were quantified on a BioPlex Multiplex platform 
(Bio-Rad Laboratories, Hercules, California, USA) using MILLIPLEX xMAP High 
Sensitivity Human Cytokine kits (Millipore, Billerica, Massachusetts, USA). The Millipore 
Multiplex Multiple Analyte Profiling (MAP) system permits the simultaneous quantitative 
analysis of up to 100 different proteins and peptides in 12 µL or less of sample – thus the 
term "multiplexing". The system uses a liquid suspension array of 100 sets of 5.6 µm 
polystyrene microspheres (beads), each internally dyed with different ratios of two spectrally 
distinct fluorophores, red and infrared. This red/infrared mixture assigns it a unique spectral 
signature. 
Each set of beads is then conjugated with a different capture molecule (Figure 3.6). Capture 
molecules can include DNA, enzyme substrates, antigens, antibodies and receptors. The 
AA AB BB
Cases a b c

















conjugated beads are then mixed with a sample and incubated in a microplate-well to react 
with specific cytokines. To detect and quantitate each captured analyte, a fluorescently 
labelled reporter antibody that specifically binds the analyte is added. The reporter antibody 
is biotinylated, enabling a fluorescent protein, streptavidin phycoerithrin, to bind. 
 
Figure 3.6: Multiple analyte profiling assay principle 
Following incubation, the contents of each microplate well are drawn into the Bio-Plex array 
reader, and precision fluidics, based on the principle of flow cytometry, align the beads in 
single file through a flow cell. This allows the particles to be measured discretely. Here two 
lasers excite the beads individually. As the bead passes through the detection chamber, the 
red laser excites both the internal red and infrared dyes, allowing the proper classification of 
the bead (i.e. classification channel reading). The green laser excites any orange fluorescence 
associated with the binding of the analyte (i.e. reporter channel reading). Since both the 
classification and the reporter readings are made on each individual particle, the system is 
able to precisely determine multiplexed assay. High-speed digital signal processors and Bio-
Rad software record the fluorescent signals simultaneously for each bead, translating the 
signals into data for each assay. 
3.2.2 Method 
Assays were performed by JJvdW on plasma samples processed as previously described. As 
we anticipated low systemic cytokine levels, measuring picogram (pg) levels of cytokines 

















sensitivity assay. This assay simultaneously measures levels of the following human 
cytokines: Granulocyte-macrophage colony-stimulating factor (GM-CSF), IFN-γ, IL-1β, IL-
2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12(p70), IL-13 and TNF-α.  
Plasma cytokine receptor concentrations of soluble IL (sIL)-1 receptor I (sIL-1RI), sIL-1 
receptor II (sIL-1RII), sIL-2 receptor-α (sIL-2Rα), sIL-4 receptor (sIL-4R), sIL-6 receptor 
(sIL-6R), sTNF receptor I (sTNFRI) and sTNF receptor II (sTNFRII) were quantified using 
MILLIPLEX xMAP Human Soluble Cytokine Receptor Panel. IL-1RA was quantified by 
using a customised MILLIPLEX xMAP Human Cytokine/Chemokine Immunoassay. 
Milliplex kits were stored at 2-8°C until used for quantification. The assays were carried out 
according to the manufacturer‟s instructions. In brief, 25 μL pre-mixed antibody-conjugated 
beads were prepared and aliquoted into a 96-well pre-wetted filter plate before addition of 
either 50 μL of standard or control solution in the designated wells or 50 μL of undiluted 
plasma. For the soluble cytokine receptor and IL-1RA quantification, 25 μL antibody-
conjugated beads were added to a pre-wetted filter plate after addition of either 25 μL of 
standard or control in the designated wells or 25 μL of undiluted plasma. The fluorescent 
beads for this study were obtained from Millipore (Billerica, Massachusetts, USA). The filter 
plate was sealed with a plate sealer, covered with the lid and incubated with agitation on a 
plate shaker overnight (16-18 hours) at 4°C for maximum sensitivity. 
Samples were run in single wells only to allow all samples for each assay to be run on a 
single plate and thus avoid plate-to-plate variability. Two controls per plate and eight 
calibrated standards with known concentrations of the cytokines of interest (measured in 
duplicate) were added to aid in the in interpretation of results (Figure 3.7). Subsequent steps 
involved washes interspersed by the addition of 50 μL biotinylated detector antibody and 
later 50 μL streptavidin-phycoerythrin solution. Incubation with agitation on a plate shaker 
followed for 30 min at room temperature (20-25°C). For the soluble receptor and IL-1RA 
analysis, this step involved washes interspersed by the addition of 25 μL biotinylated detector 
antibodies with 25 μL streptavidin-phycoerythrin solution. Incubation with agitation on a 


















Figure 3.7: Well plate layout with calibrated standard- and control samples 
For analysis, the plate was placed on the XY platform of the Bio-Rad Luminex 100 Bio-Plex 
Liquid Array Multiplexing System (BioRad Laboratories Ltd, Missasauga, Ontario, Canada) 
after adding 100 μL sheath fluid to each well. STarStation v3.0 software was used for data 
acquisition and analysis. Standard curves were generated for each analyte, and the mean 
fluorescence intensity value of each analyte in each well was converted into a concentration 
using the linear portion of the standard for all detected values. Concentrations lower than the 
detection limit of the kit‟s sensitivity were extrapolated from the standard curve. 
Concentrations were plotted over time using Prism version 6 (GraphPad Software, Inc., La 
Jolla, California, USA). 
 
3.3 Vitamin B6 quantification 
Plasma vitamin B6 levels were quantified at the United States Centers for Disease Control 
and Prevention (CDC) under the direction of Dr Michael Rybak. A reversed-phase high-
performance liquid chromatography (HPLC) method with fluorometric detection was used 

















Fasting plasma samples were collected in EDTA tubes at baseline and 12-week visits. The 
samples were immediately placed on ice after collection to protect samples from exposure to 
direct ultraviolet-light. After blood collection, tubes were centrifuged at 3300 g for 10 min 
The supernatant fraction of each tube aliquoted into labelled 1.5 mL Eppendorf tubes and 
stored immediately in a -80°C freezer for long-term storage. Prepared samples were sealed in 
plastic containers and shipped to Atlanta (Georgia, USA) on dry ice prior to analysis. 
 
3.4 High-sensitivity CRP and albumin quantification 
Metropolis Pathology Laboratories (Cape Town, South Africa) performed serum hs-CRP and 
albumin quantification. Albumin levels were measured by an immunoturbidimetric assay 
(Roche Diagnostics, Mannheim, Germany). High-sensitivity CRP levels were measured by a 
particle-enhanced immunoturbidimetric assay (Roche Diagnostics). Prepared aliquoted serum 









































4.1 Baseline results 
4.1.1 Demographic characteristics 
The baseline study sample comprised of 184 participants. Initially, 190 individuals who were 
eligible to initiate cART and elected to participate were enrolled. Two individuals were 
excluded from the study, as they did not commence cART within two weeks of the baseline 
(pre-cART) assessment. Three individuals withdrew their consent to participation prior to the 
baseline assessment. One individual was excluded due to asymmetrical neuropathic signs on 
examination. 
The baseline (pre-cART) characteristics of the 184 remaining individuals are summarized in 
Table 4.1 for continuous variables and Table 4.2 for categorical variables. The baseline 
assessment was performed a median of 1 day prior to initiation of cART (IQR 1-5 days). The 
study population was predominantly female (70%), with an age range of 19-63 years and a 
median age of 33 years (IQR 26-39 years). 
Sixty-nine individuals (38%) had a history of previous or current treatment for TB (indicating 
INH exposure). Of these, 39 completed TB treatment before study entry and 30 started TB 
treatment before study entry, continuing with treatment during the study period. Eight 
developed TB after cART initiation and started TB treatment after the baseline assessment 
(six between week 4 and week 12, and two after week 12). Fifty-two individuals (29%) 


















Table 4.1: Baseline characteristics in individuals with and without DSP (continuous data) 
 
 
Total (N=184) DSP (N=41) No DSP (N=143)
Clinical
Age years 33 (26 - 39) 38 (29 - 43) 31 (26 - 37) 0.001
β
Weight kg 61 (54 - 71) 61 (53 - 71) 61 (55 - 71) 0.488
β
Height metre 1.61 (1.56 - 1.67) 1.62 (1.55 - 1.70) 1.61 (1.56 - 1.66) 0.348
β
Body Mass Index kg/m
2 20.0 - 25.0 23.2 (20.3 - 27.7) 22.9 (20.2 - 26.1) 23.2 (20.4 - 28.0) 0.430 ε
Waist : Hip ratio < 0.90 0.86 (0.81 - 0.90) 0.87 (0.83 - 0.93) 0.86 (0.81 - 0.89) 0.073
β
Systolic BP mmHg 120 - 140 110 (103 - 122) 110 (100 - 122) 111 (104 - 121) 0.431
β
Diastolic BP mmHg 80 - 90 72 (66 - 80) 71 (66 - 78) 73 (67 - 80) 0.215
ε
Haematological
CD4 T-cell count cells/mm
3 > 500 158 (114 - 196) 162 (105 - 199) 156 (114 - 196) 0.447 β
White cell count x10
9/L 4.0 - 11.0 5.3 (4.1 - 6.5) 5.2 (3.9 - 6.0) 5.4 (4.1 - 6.8) 0.455 β
C-reactive protein mg/L < 5.0 2.8 (0.9 - 6.6) 3.7 (1.2 - 11.9) 2.7 (0.9 - 5.9) 0.199
β
Haemoglobin g/dL 11.6 - 15.6 11.8 (10.4 - 12.6) 12.1 (9.6 - 12.9) 11.7 (10.6 - 12.6) 0.569
β
MCV fL 80.0 - 100.0 92.4 (88.5 - 96.1) 93.2 (89.8 - 96.9) 92.1 (87.9 - 95.9) 0.075
β
Biochemical
Albumin g/L 38 - 54 39 (35 - 43) 38 (34 - 43) 39 (35 - 43) 0.286
β
ALT IU/L 10 - 41 19 (15 - 26) 23 (18 - 29) 18 (14 - 26) 0.107
β
Creatinine µmol/L 53 - 115 64 (55 - 73) 65 (55 - 75) 64 (55 - 73) 0.908
β
Metabolic
Fasting glucose mmol/L 4.1 - 5.6 4.7 (4.4 - 4.9) 4.7 (4.5 - 4.9) 4.7 (4.4 - 4.9) 0.859
β
Fasting insulin µU/mL 0.2 - 9.4 5.2 (2.5 - 8.6) 4.3 (1.8 - 7.6) 5.5 (2.5 - 8.9) 0.155
β
Total cholesterol mmol/L 3.1 - 5.2 3.7 (3.2 - 4.3) 4.1 (3.0 - 4.4) 3.7 (3.2 - 4.2) 0.602
β
Triglycerides mmol/L 0.5 - 2.0 0.9 (0.7 - 1.2) 1.0 (0.7 - 1.4) 0.8 (0.7 - 1.1) 0.035
β
HDL mmol/L 1.15 - 1.68 0.94 (0.75 - 1.13) 0.94 (0.74 - 1.25) 0.95 (0.75 - 1.12) 0.659
β
LDL mmol/L 1.0 - 3.0 2.3 (1.9 - 2.9) 2.5 (1.8 - 2.9) 2.3 (1.9 - 2.9) 0.420
β
Lactate mmol/L < 2.0 2.4 (1.7 - 3.1) 2.1 (1.2 - 2.8) 2.5 (1.7 - 3.3) 0.099
β
Pyridoxine
PLP nmol/L > 25.0 23.8 (16.5 - 38.4) 25.5 (16.5 - 53.7) 23.8 (15.7 - 36.8) 0.392
β
4-PA nmol/L unknown 17.4 (11.9 - 23.3) 20.5 (12.1 - 28.6) 16.7 (11.6 - 22.4) 0.089
ε
β    Student's t -test






















Table 4.2: Baseline characteristics in individuals with and without DSP (grouped data) 
 
4.1.2 HIV staging and severity 
Seventy five per cent of individuals (n=138) were diagnosed with HIV after 2007. Nearly two 
thirds (n=115, 63%) were classified as either WHO stage 1 or 2 HIV infection, and only 4% 
(n=7) were classified as WHO stage 4. None of the individuals had any overt clinical 
Total (N=184) DSP (N=41) No DSP (N=143)
Female sex 129 (70%) 27 (66%) 102 (71%) 0.500
§
Age > 40 years 42 (23%) 16 (40%) 26 (18%) 0.004
§
Previous/Current TB 69 (38%) 22 (54%) 47 (33%) 0.015
§
Time of TB 0.128
¶
Currently 30 (16%) 11 (27%) 19 (13%)
< 1 year ago 13 (7%) 4 (10%) 9 (6%)
1 year ago 5 (3%) 2 (5%) 3 (2%)
2 years ago 5 (3%) 1 (2%) 4 (3%)
> 2 years ago 16 (9%) 4 (10%) 12 (8%)
Vit Bco supplement 179 (97%) 40 (98%) 139 (97%) 1.000
¶
Vit B6 supplement 15 (8%) 8 (20%) 7 (5%) 0.011
¶
WHO clinical stage 0.612
¶
Stage 1 57 (32%) 11 (28%) 46 (33%)
Stage 2 58 (32%) 11 (28%) 47 (34%)
Stage 3 58 (32%) 16 (40%) 42 (30%)
Stage 4 7 (4%) 2 (5%) 5 (4%)
CD4 T-cell count 0.929
§
< 100 cells/mm 3 30 (17%) 6 (15%) 24 (17%)
100 - 200 cells/mm 3 108 (60%) 24 (60%) 84 (60%)
> 200 cells/mm 3 42 (23%) 10 (25%) 32 (23%)
Metabolic syndrome 22 (12%) 4 (10%) 18 (13%) 0.622
§
Body Mass Index 0.901
§
< 20 kg/m 2 37 (21%) 9 (23%) 28 (20%)
20 - 25 kg/m 2 77 (43%) 16 (41%) 61 (44%)
25 - 30 kg/m 2 37 (21%) 9 (23%) 28 (20%)
> 30 kg/m 2 28 (16%) 5 (13%) 23 (16%)
Alcohol last year 52 (29%) 8 (20%) 44 (31%) 0.160
§
IHDS score < 10 33 (24%) 10 (45%) 23 (20%) 0.011
§
¶    Fisher's exact test



















opportunistic infections as such cases were excluded from participating in the study at 
enrolment (n=7). 
The CD4 T-cell count prior to cART initiation ranged from 4 to 448 cells/mm
3
, with a 
median of 158 cells/mm
3 
(IQR 114-196). The majority of individuals (60%) had a CD4 T-cell 
count between 100 and 200 cells/mm
3
 and only 17% had counts <100 cells/mm
3
. Baseline 
HIV viral loads were not routinely done at the local clinic. 
4.1.3 Nutritional and metabolic parameters 
The median BMI was 23.2 kg/m
2
 (IQR 20.3-27.7) and 77 (43%) had normal values. There 
were less individuals underweight (21%) compared to overweight or obese individuals (36%) 
(Table 4.2) The height of this cohort ranged from 1.43 to 1.84 m, with a median height of 
1.61 metres (IQR 1.56-1.67). Waist-to-hip ratios were used to assess body fat distribution. 
Forty-eight females (37%) had a waist-to-hip ratio greater than 0.85 and 19 males (35%) had 
a ratio greater than 0.90. 
Baseline levels of serum albumin were done in 151 consecutive individuals (82%). Serum 
albumin <38 g/L was found in 68 (45%). There was no correlation between BMI and serum 
albumin (ρ=0.10 p=0.22). Of those with albumin <38 g/L, 23 (35%) were eutrophic and 19 
(29%) overweight or obese. Of 83 (55%) with serum albumin ≥38 g/L, 40 (48%) were 
eutrophic and 32 (39%) were overweight. 
Anaemia has been widely reported to predict a poorer prognosis independent of the CD4 T-
cell count in HIV-infected individuals, both in terms of progression to AIDS and in survival 
(Chene et al., 1997, Apolonio et al., 1995, Hoover et al., 1995). At baseline, 40 (22%) had a 
haemoglobin <10 g/dL, 123 (69%) had a haemoglobin between 10 and 14 g/dL, and 15 (8%) 
>14g/dL. The majority of individuals (86%, n=153) had a normal MCV; 16 (9%) had an 
MCV >100 fL and four individuals (2%) had a microcytic anaemia (with an MCV <80 fL 
and haemoglobin <10 g/dL). 
Levels of plasma PLP and 4-PA as measures of vitamin B6 were investigated in 159 
consecutively selected individuals who were followed up for at least 12 weeks. Detailed 

















Eight individuals (5%) were prediabetic and had fasting serum glucose levels >5.5 mmol/L. 
Median serum fasting glucose was 4.7 mmol/L (IQR 4.4-4.49). Fasting serum insulin levels 
>15 μU/mL, as a measure for insulin resistance (McLaughlin et al., 2003), were present in 
seven individuals (4%). 
Overall, the baseline fasting median values and IQR for all metabolic blood biochemistry 
outlined in Table 4.1 were within normal ranges. The median triglyceride level was 0.87 
mmol/L, the median total cholesterol 3.74 mmol/L and the median HDL cholesterol 0.94 
mmol/L. Thirty (16%) of the individuals had low HDL cholesterol levels, eight (5%) had 
elevated triglycerides, 10 (6%) had elevated total cholesterol, and 30 (16%) had elevated 
LDL cholesterol. Twenty-two individuals (12%) were classified as having metabolic 
syndrome at baseline assessment as defined in section 2.6. Point-of-care lactate levels ranged 
from 0.8 to 6.1 mmol/L, with 89 individuals (61%) having elevated lactate levels (>2.0 
mmol/L). 
4.1.4 Supplements and concomitant drug administration 
Nearly all individuals (97%) were prescribed vitamin B complex supplements at the time of 
enrolment. It was not documented why five individuals did not receive vitamin B complex 
supplementation. Of 30 individuals on TB treatment at the time of enrolment, only 12 (40%) 
received additional vitamin B6 supplementation in a dosage of 25 mg/day. Cotrimoxazole 
was prescribed for 97% of individuals at baseline. 
Eight individuals (4%) reported using analgesia (paracetamol and/or topical methyl 
salicylate) for existing neuropathic pain. These agents did not provide any relief in symptoms 
to any of these individuals. None of the individuals received amitriptyline during the study 
period. 
4.1.5 Frequency and clinical characteristics of DSP at baseline (pre-cART) 
The frequency of DSP at baseline was 22% (n=41). Baseline DSP status was categorised as 
follows: 
 Symptomatic DSP, 31 (17%)  

















 No DSP, 143 (78%) – those individuals did not meet the criteria of symptomatic DSP 
or asymptomatic DSP and included seven (4%) with neuropathic symptoms in 
isolation. 
Data regarding symptom and sign frequency for individuals with DSP are presented in Table 
4.3. Paraesthesiae and burning or aching pain were prevalent symptoms associated with DSP, 
affecting 73% of individuals. Muscle cramps as a neuropathic symptom were more prevalent 
in individuals with DSP (63%), although reported by 38% of those without DSP. Although 
most individuals with DSP at baseline experienced moderate symptoms (VAS=4-6), six 
(15%) reported mild (grade 1) symptoms, and in 10 (24%) the symptoms were graded as 
moderately severe (grade 3 or 4; VAS=7-10). 
Table 4.3: Baseline neuropathic symptoms and signs 
 
The most common neuropathic sign in individuals with DSP was altered pinprick sensibility 
in a stocking distribution, affecting 76% of the group. Eighteen individuals (13%) without the 
clinical definition of DSP also had altered pinprick sensibility. Twenty-eight individuals with 
DSP (68%) had abnormal ankle reflexes whereas 37 without DSP (26%) had abnormal ankle 
reflexes in isolation. Of those with abnormal ankle reflexes, nearly half (41%) had absent 
ankle reflexes. Fifteen individuals (37%) had abnormal vibratory sensibility. Weakness of the 
extensors was only present in six individuals (3%) and was mild; those with weakness also 
Total (N=184) DSP (N=41) No DSP (N=143)
Neuropathic symptoms
Pain 30 (16%) 26 (63%) 4 (3%) <0.001 ¶
Paraesthesiae 29 (16%) 26 (63%) 3 (2%) <0.001 ¶
Numbness 22 (12%) 19 (46%) 3 (2%) <0.001 ¶
Cramps 80 (43%) 26 (63%) 54 (38%) 0.003 §
Positive Sensory* 35 (19%) 30 (73%) 5 (4%) <0.001 ¶
Neuropathic signs
Altered vibration sensibility 23 (13%) 15 (37%) 8 (6%) <0.001 ¶
Altered pin sensibility 49 (27%) 31 (76%) 18 (13%) <0.001 §
Altered proprioception 17 (9%) 9 (22%) 8 (6%) 0.001 ¶
Absent/reduced deep tendon reflexes 65 (35%) 28 (68%) 37 (26%) <0.001 §
Reduced muscle strength 6 (3%) 6 (15%) 0 (0%) <0.001 ¶
*    Pain and/or paraesthesiae
¶    Fisher's exact test



















had abnormal ankle reflexes, five had abnormal vibratory sensation and four had altered 
pinprick sensibility. Although 17 individuals (9%) had abnormal proprioception, this 
included eight individuals (6%) in whom the sign was isolated and therefore categorized as 
no DSP. The presence of at least one neuropathic sign in over 25% of individuals categorized 
as no DSP suggests a definition that is perhaps too stringent. 
4.1.6 Risk factor investigation 
4.1.6.1 DSP risk factors in cART naïve individuals at baseline 
A comparison of baseline characteristics between individuals with DSP pre-cART and 
individuals without DSP are illustrated in Table 4.1 page 89. The presence of DSP [either (i) 
two signs or (ii) one symptom and one sign] in this cART-naïve cohort was associated with 
the following: 
a) Age >40 years (p=0.004) 
b) As individuals on TB treatment receive vitamin B6 supplementation, current or 
previous TB treatment (p=0.015) and vitamin B6 supplementation (p=0.011) were 
both associated with DSP. 
c) Increased fasting triglycerides (p=0.035). Although individuals with DSP had higher 
fasting triglycerides compared to those without DSP, the 75th percentile values of 
both DSP and no-DSP groups were within normal fasting triglyceride ranges. Of eight 
individuals with raised fasting triglyceride levels, only two had DSP at baseline. 
d) Total IHDS score <10 (p=0.011) 
Clinical features including sex (p=0.50), weight (p=0.49), height (p=0.35), BMI (p=0.43), 
systolic BP (p=0.43) and diastolic BP (p=0.22) were not significant predictors of DSP at 
baseline. There was a trend towards higher waist-to-hip ratios in individuals with DSP 
compared to those without, however the 75
th
 percentile values of both groups were still 
within normal range. 
The presence of DSP was not associated with advanced HIV disease. While there was no 
difference between the two groups in terms of WHO HIV stage (p=0.61) or baseline CD4 T-
cell count (p=0.45), there was a trend towards higher hs-CRP levels in individuals with DSP 

















Apart from triglycerides, other fasting lipids and metabolic factors did not associate with DSP 
at baseline, including total cholesterol (p=0.60), glucose (p=0.86), lactate (p=0.10), and the 
metabolic syndrome (p=0.62). Haematological factors including white cell count (p=0.46), 
haemoglobin (p=0.57) and MCV (p=0.08) were not significant predictors of DSP at baseline. 
Biochemical factors including ALT (p=0.11), albumin (p=0.29) and creatinine (p=0.91) did 
not associate with DSP at baseline. No difference was detected in alcohol exposure between 
the two groups in general (p=0.30). 
Univariate odds ratios and prevalence ratios (with a 95% CI) were calculated to determine 
univariate risk factors associated with DSP. Factors significantly associated with DSP in the 
primary analysis (parametric, non-parametric and proportional) were examined by individual 
logistic regression. All variables were explored for an association with DSP, but only 
variables primarily showing a significance level of p<0.25 in the primary analysis were 
included in the multivariate analysis and are shown in Table G-1 (Appendix G).  
A multivariate logistic regression analysis was performed as described in section 2.8.1.2 to 
identify independent predictors of DSP at baseline. Results are reflected in Table 4.4. 
Variables included in the multivariate model were age, sex, waist-to-hip ratio, diastolic BP, 
previous/current TB, alcohol exposure, ALT, hs-CRP, MCV, fasting insulin and triglycerides, 
lactate and 4-PA. The IHDS score and vitamin B6 supplementation were not included due to 
the possibility of a high covariance with DSP and TB treatment respectively. The wide 
confidence intervals make interp etation of the model difficult and introduce a degree of 
uncertainty in associations found. Furthermore, other associations cannot be ruled out. 










DSP vs No DSP 0.31 <0.001
Age * 1.14 1.07 - 1.22 <0.001
Triglycerides > 0.9 mmol/L 4.97 1.39 - 17.81 0.010
C-reactive protein > 5 mg/L 4.55 1.36 - 15.18 0.010
Previous/Current TB 4.00 1.23 - 13.01 0.020

















4.1.6.2 Risk factors for symptomatic DSP in cART naïve individuals at baseline 
To investigate risk factors associated with symptomatic DSP at baseline, a comparison 
between individuals with symptomatic DSP to those without DSP was performed (Table 4.5 
for continuous variables and Table 4.6 for categorical variables). 
Univariate analysis revealed that variables associated with symptomatic DSP at baseline 
included:  
a) Age >40 years (p=0.009). 
b) Previous or current TB treatment (p=0.009).  
c) Higher waist-to-hip ratio (p=0.022), a factor that only showed a trend towards an 
association with DSP at baseline. 
d) As individuals on TB treatment receive vitamin B6 supplementation, current or 
previous TB treatment (p=0.009) and vitamin B6 supplementation (p=0.001) were 
both associated with symptomatic DSP. 
e) Increased fasting triglycerides (p=0.026). Although individuals with symptomatic 
DSP had higher fasting triglycerides compared to those without DSP, the interquartile 
ranges of both groups were within normal limits. 
Therefore, the factors associated with symptomatic DSP were similar to those shown to be 





















Total (N=174) SDSP (N=31) No DSP (N=143)
Clinical
Age years 33 (26 - 39) 37 (29 - 43) 31 (26 - 37) 0.008
β
Weight kg 61 (54 - 71) 60 (53 - 71) 61 (55 - 71) 0.618
ε
Height metre 1.61 (1.56 - 1.67) 1.62 (1.55 - 1.68) 1.61 (1.56 - 1.66) 0.565
β
Body Mass Index kg/m
2 20.0 - 25.0 23.2 (20.4 - 27.8) 23.2 (20.8 - 25.9) 23.2 (20.4 - 28.0) 0.602 ε
Waist : Hip ratio < 0.90 0.86 (0.81 - 0.90) 0.87 (0.83 - 0.93) 0.86 (0.81 - 0.89) 0.022
β
Systolic BP mmHg 120 - 140 110 (103 - 120) 109 (99 - 119) 111 (104 - 121) 0.198
β
Diastolic BP mmHg 80 - 90 72 (66 - 79) 70 (66 - 77) 73 (66 - 80) 0.175
β
Haematological
CD4 T-cell count cells/mm
3 > 500 156 (113 - 196) 157 (105 - 217) 156 (114 - 196) 0.455 β
White cell count x10
9/L 4.0 - 11.0 5.4 (4.1 - 6.5) 5.1 (3.9 - 6.0) 5.4 (4.1 - 6.8) 0.374 ε
C-reactive protein mg/L < 5.0 2.9 (0.9 - 6.6) 3.8 (1.3 - 9.7) 2.7 (0.9 - 5.9) 0.251
β
Haemoglobin g/dL 11.6 - 15.6 11.7 (10.3 - 12.6) 11.6 (9.3 - 12.4) 11.7 (10.6 - 12.6) 0.142
β
MCV fL 80.0 - 100.0 92.4 (88.1 - 96.1) 93.3 (89.0 - 96.9) 92.1 (87.9 - 95.9) 0.138
β
Biochemical
Albumin g/L 38 - 54 39 (35 - 43) 37 (33 - 41) 39 (35 - 43) 0.096
β
ALT IU/L 10 - 41 19 (15 - 26) 23 (18 - 28) 18 (14 - 26) 0.063
ε
Creatinine µmol/L 53 - 115 64 (56 - 73) 65 (57 - 73) 64 (55 - 73) 0.855
ε
Metabolic
Fasting glucose mmol/L 4.1 - 5.6 4.7 (4.4 - 4.9) 4.7 (4.5 - 4.9) 4.7 (4.4 - 4.9) 0.785
ε
Fasting insulin µU/mL 0.2 - 9.4 5.3 (2.5 - 8.6) 4.3 (2.5 - 7.6) 5.5 (2.5 - 8.9) 0.200
β
Total cholesterol mmol/L 3.1 - 5.2 3.7 (3.2 - 4.2) 3.9 (3.0 - 4.3) 3.7 (3.2 - 4.2) 0.323
β
Triglycerides mmol/L 0.5 - 2.0 0.9 (0.7 - 1.2) 1.0 (0.8 - 1.4) 0.8 (0.7 - 1.1) 0.026
β
HDL mmol/L 1.15 - 1.68 0.94 (0.75 - 1.12) 0.89 (0.74 - 1.13) 0.95 (0.75 - 1.12) 0.464
β
LDL mmol/L 1.0 - 3.0 2.3 (1.9 - 2.8) 2.2 (1.8 - 2.7) 2.3 (1.9 - 2.9) 0.103
β
Lactate mmol/L < 2.0 2.4 (1.7 - 3.1) 1.8 (1.2 - 2.6) 2.5 (1.7 - 3.3) 0.067
β
Pyridoxine
PLP nmol/L > 25.0 23.4 (16.2 - 38.4) 20.7 (16.2 - 53.7) 23.8 (15.7 - 36.8) 0.474
β
4-PA nmol/L unknown 17.3 (11.7 - 22.8) 20.7 (12.1 - 28.6) 16.7 (11.6 - 22.4) 0.169
ε
β    Student's t -test






















Table 4.6: Baseline characteristics in individuals with symptomatic DSP vs those without DSP (grouped 
data) 
 
Univariate odds ratios and prevalence ratios (with 95% CIs) were calculated to determine 
univariate risk factors associated with symptomatic DSP and are shown in Table G-2 
(Appendix G). In the stepwise backward multivariate logistic regression analysis, 
independent predictors of symptomatic DSP are reflected in Table 4.7. Variables included in 
Total (N=174) SDSP (N=31) No DSP (N=143)
Female sex 123 (71%) 21 (68%) 102 (71%) 0.691
§
Age > 40 years 38 (22%) 12 (40%) 26 (18%) 0.009
§
Previous/Current TB 65 (37%) 18 (58%) 47 (33%) 0.009
§
Time of TB 0.039
¶
Currently 29 (17%) 10 (32%) 19 (13%)
< 1 year ago 12 (7%) 3 (10%) 9 (6%)
1 year ago 5 (3%) 2 (6%) 3 (2%)
2 years ago 5 (3%) 1 (3%) 4 (3%)
> 2 years ago 14 (8%) 2 (6%) 12 (8%)
Vit Bco supplement 170 (98%) 31 (100%) 139 (97%) 1.000
¶
Vit B6 supplement 15 (9%) 8 (26%) 7 (5%) 0.001
¶
WHO clinical stage 0.340
¶
Stage 1 54 (32%) 8 (27%) 46 (33%)
Stage 2 54 (32%) 7 (23%) 47 (34%)
Stage 3 55 (32%) 13 (43%) 42 (30%)
Stage 4 7 (4%) 2 (7%) 5 (4%)
CD4 T-cell count 0.831
§
< 100 cells/mm 3 28 (16%) 4 (13%) 24 (17%)
100 - 200 cells/mm 3 102 (60%) 18 (60%) 84 (60%)
> 200 cells/mm 3 40 (24%) 8 (27%) 32 (23%)
Metabolic syndrome 21 (12%) 3 (10%) 18 (13%) 0.652
§
Body Mass Index 0.878
§
< 20 kg/m 2 35 (21%) 7 (24%) 28 (20%)
20 - 25 kg/m 2 72 (43%) 11 (38%) 61 (44%)
25 - 30 kg/m 2 35 (21%) 7 (24%) 28 (20%)
> 30 kg/m 2 27 (16%) 4 (14%) 23 (16%)
Alcohol last year 50 (29%) 6 (20%) 44 (31%) 0.213
§
IHDS score < 10 27 (21%) 4 (27%) 23 (20%) 0.549
§
¶    Fisher's exact test



















the initial model include: age, sex, waist-to-hip ratio, systolic and diastolic BP, 
previous/current TB, alcohol exposure, hs-CRP, haemoglobin, MCV, fasting insulin, LDL 
cholesterol and triglycerides, lactate, ALT, and 4-PA. Again, vitamin B6 supplementation 
was not included due to the possibility of covariance with previous or current TB therapy. 
Also, the wide confidence intervals make interpretation of the model difficult and introduce a 
degree of uncertainty in associations found. Further, other associations cannot be ruled out.  
Table 4.7: Multivariate analysis of baseline symptomatic DSP risk factors – SDSP vs no DSP 
 
Further statistical analysis comparing individuals with symptomatic DSP to those without 
symptomatic DSP were also performed. Such analysis revealed similar results regarding the 
risk factors in multivariate analysis and is summarized in Appendix H 
4.1.7 Cognitive screen at baseline 
IHDS scores were performed randomly on 137 individuals at baseline. The median total score 
was 11.0 (IQR 10.5-12.0). Thirty-three individuals (24%) had an IHDS score of less than the 
accepted normal of 10 (Table 4.1). Further analysis of the total IHDS score across DSP 
groups is shown in Table I-1 in Appendix I. Individuals with DSP at baseline had a 
significantly lower total IHDS score compared to their counterparts without DSP (mean 10.4 
vs 11.0; p=0.026). A poorer performance in all three subcategories of the IHDS score was 
observed in individuals with DSP, although only the psychomotor speed score reached 
significance (mean score 3.1 vs 3.8; p=0.035). 
Although total IHDS score was associated with DSP, individuals with symptomatic DSP at 










SDSP vs No DSP 0.38 <0.001
Age * 1.14 1.05 - 1.23 <0.001
ALT > 19 IU / L 12.99 2.40 - 70.31 <0.001
Previous/Current TB 8.02 1.84 - 34.94 0.010
C-reactive protein > 5 mg/L 5.07 1.21 - 21.27 0.030

















4.1.8 Comparison between asymptomatic and symptomatic DSP at baseline 
To determine whether any potential risk factors could distinguish between individuals with 
symptomatic DSP (n=31) and those with asymptomatic DSP (n=10), a baseline comparison 
was performed between these groups. The results are shown in Table 4.8 for continuous 
variables and Table 4.9 for categorical variables. 
Although fasting triglyceride levels were associated with symptomatic DSP at baseline, other 
lipid parameters associated with asymptomatic DSP at baseline; individuals with 
symptomatic DSP had significantly lower total cholesterol levels (p=0.010), mostly due to 
lower levels of HDL compared to those with asymptomatic DSP (p=0.023). Further, values of 
the 75
th
 percentile for HDL are lower than reported normal range. Lower haemoglobin levels 
were observed in individuals with symptomatic DSP at baseline (p=0.032) but not when 
compared to those without DSP.  
The IHDS scores were significantly lower in individuals with asymptomatic DSP compared 
to those with symptomatic DSP. The detailed analysis of total IHDS score across DSP groups 
is shown in Appendix I. Sixty per cent (n=6) of the individuals with asymptomatic DSP had 
an IHDS score less than 10 compared to 27% (n=4) with symptomatic DSP (p=0.020). 
Investigating the components of the IHDS, individuals with asymptomatic DSP performed 
significantly worse in the alternating hand sequence test adapted from the Luria sequencing 
test (psychomotor speed) (p=0.003) compared to the other two modalities where scores were 
similar between those individuals with symptomatic DSP and those with asymptomatic DSP 
(motor speed, p=0.31 and memory recall, p=0.21). 
Taking into account the relatively small number of this group (n=41), the relatively weak 
correlations and risk inherent with multiple testing, these results should be interpreted with 
caution. Due to the limited sample number for this analysis, a multivariate regression model 
with more than 3 independent variables would have less than the recommended cut-off of 10 


















Table 4.8: Baseline characteristics in individuals with symptomatic DSP vs those with asymptomatic 
DSP (continuous data) 
 
 
Total DSP (N=41) SDSP (N=31) ADSP (N=10)
Clinical
Age years 31 (26 - 37) 37 (29 - 43) 39 (30 - 51) 0.531
β
Weight kg 61 (55 - 71) 60 (53 - 71) 63 (59 - 70) 0.909
β
Height metre 1.61 (1.56 - 1.66) 1.62 (1.55 - 1.68) 1.65 (1.55 - 1.71) 0.646
β
Body Mass Index kg/m
2 20.0 - 25.0 23.2 (20.4 - 28) 23.2 (20.8 - 25.9) 22.0 (20.2 - 27.3) 0.797 ε
Waist : Hip ratio < 0.90 0.86 (0.81 - 0.89) 0.87 (0.83 - 0.93) 0.85 (0.80 - 0.92) 0.133
β
Systolic BP mmHg 120 - 140 111 (104 - 121) 109 (99 - 119) 111 (101 - 129) 0.287
β
Diastolic BP mmHg 80 - 90 73 (67 - 80) 70 (66 - 77) 74 (66 - 84) 0.310
ε
Haematological
CD4 T-cell count cells/mm
3 > 500 156 (114 - 196) 157 (105 - 217) 174 (117 - 193) 0.873 β
White cell count x10
9/L 4.0 - 11.0 5.4 (4.1 - 6.8) 5.1 (3.9 - 6.0) 5.2 (4.1 - 5.9) 0.721 β
C-reactive protein mg/L < 5.0 2.7 (0.9 - 5.9) 3.8 (1.3 - 9.7) 2.6 (1.0 - 18.8) 0.984
β
Haemoglobin g/dL 11.6 - 15.6 11.7 (10.6 - 12.6) 11.6 (9.3 - 12.4) 12.8 (11.5 - 14.0) 0.032
β
MCV fL 80.0 - 100.0 92.1 (87.9 - 95.9) 93.3 (89 - 96.9) 92.3 (90.8 - 96.9) 0.862
β
Biochemical
Albumin g/L 38 - 54 39 (35 - 43) 37 (33 - 41) 40 (39 - 43) 0.135
β
ALT IU/L 10 - 41 18 (14 - 26) 23 (18 - 28) 24 (15 - 33) 0.652
β
Creatinine µmol/L 53 - 115 64 (55 - 73) 65 (57 - 73) 69 (51 - 83) 0.570
β
Metabolic
Fasting glucose mmol/L 4.1 - 5.6 4.7 (4.4 - 4.9) 4.7 (4.5 - 4.9) 4.7 (4.4 - 5.4) 0.315
β
Fasting insulin µU/mL 0.2 - 9.4 5.5 (2.5 - 8.9) 4.3 (2.5 - 7.6) 4.6 (1.7 - 7.2) 0.993
β
Total cholesterol mmol/L 3.1 - 5.2 3.7 (3.2 - 4.2) 3.9 (3.0 - 4.3) 4.9 (4.2 - 5.3) 0.010
β
Triglycerides mmol/L 0.5 - 2.0 0.8 (0.7 - 1.1) 1.0 (0.8 - 1.4) 0.7 (0.6 - 1.5) 0.553
β
HDL mmol/L 1.15 - 1.68 0.95 (0.75 - 1.12) 0.89 (0.74 - 1.13) 1.38 (0.88 - 1.74) 0.023
β
LDL mmol/L 1.0 - 3.0 2.3 (1.9 - 2.9) 2.2 (1.8 - 2.7) 3.0 (2.6 - 3.2) 0.073
β
Lactate mmol/L < 2.0 2.5 (1.7 - 3.3) 1.8 (1.2 - 2.6) 2.4 (1.1 - 3.8) 0.499
β
Pyridoxine
PLP nmol/L > 25.0 23.8 (15.7 - 36.8) 20.7 (16.2 - 53.7) 27.5 (22.9 - 32.0) 0.931
β
4-PA nmol/L unknown 16.7 (11.6 - 22.4) 20.7 (12.1 - 28.6) 19.0 (15.2 - 30.8) 0.734
ε
β    Student's t -test






















Table 4.9: Baseline characteristics in individuals with symptomatic DSP vs those with asymptomatic 
DSP (grouped data) 
 
 
Total DSP (N=41) SDSP (N=31) ADSP (N=10)
Female sex 27 (66%) 21 (68%) 6 (60%) 0.712 ¶
Age > 40 years 16 (40%) 12 (40%) 4 (40%) 1.000 ¶
Previous/Current TB 22 (54%) 18 (58%) 4 (40%) 0.319 §
Time of TB 0.478 ¶
Currently 11 (27%) 10 (32%) 1 (10%)
< 1 year ago 4 (10%) 3 (10%) 1 (10%)
1 year ago 2 (5%) 2 (6%) 0 (0%)
2 years ago 1 (2%) 1 (3%) 0 (0%)
> 2 years ago 4 (10%) 2 (6%) 2 (20%)
Vit Bco supplement 40 (98%) 31 (100%) 9 (90%) 0.244 ¶
Vit B6 supplement 8 (20%) 8 (26%) 0 (0%) 0.164 ¶
WHO clinical stage 0.692 ¶
Stage 1 11 (28%) 8 (27%) 3 (30%)
Stage 2 11 (28%) 7 (23%) 4 (40%)
Stage 3 16 (40%) 13 (43%) 3 (30%)
Stage 4 2 (5%) 2 (7%) 0 (0%)
CD4 T-cell count 0.775 ¶
< 100 cells/mm 3 6 (15%) 4 (13%) 2 (20%)
100 - 200 cells/mm 3 24 (60%) 18 (60%) 6 (60%)
> 200 cells/mm 3 10 (25%) 8 (27%) 2 (20%)
Metabolic syndrome 4 (10%) 3 (10%) 1 (10%) 1.000 ¶
Body Mass Index 1.000 ¶
< 20 kg/m 2 9 (23%) 7 (24%) 2 (20%)
20 - 25 kg/m 2 16 (41%) 11 (38%) 5 (50%)
25 - 30 kg/m 2 9 (23%) 7 (24%) 2 (20%)
> 30 kg/m 2 5 (13%) 4 (14%) 1 (10%)
Alcohol last year 8 (20%) 6 (20%) 2 (20%) 1.000 ¶
IHDS score < 10 10 (45%) 4 (27%) 6 (86%) 0.020 ¶
¶    Fisher's exact test



















4.2 Follow-up results at week 24 
4.2.1 Retention and attrition 
Among the 184 individuals who were enrolled at baseline, 164 completed 12 weeks follow-
up, and 144 completed 24 weeks follow-up (attrition rate of 21% at 24 weeks). The reasons 
for not completing follow-up are summarized in Figure 4.1. All follow-up data are described 
for the cohort of 144 individuals. Only individuals who were symptom-free at the baseline 
assessment had 2-week (n=111) and 4-week (n=114) follow-up assessments. 
 
Figure 4.1: Flow chart of participant retention and attrition 
4.2.2 Comparison between excluded individuals and the 24-week study 
cohort 
A comparison of baseline characteristics was performed between those individuals who were 
excluded from the study and those who remained in the study until 24 weeks. This analysis 
was performed to establish any significant differences in the patient profile or risk factors 
investigated between these groups. Excluded individuals did not differ from the main study 
cohort. There were no statistically significant differences in terms of any of the potential risk 
factors investigated, including sex (p=0.25), age (p=0.44), WHO HIV stage (p=0.76), CD4 T-
cell count (p=0.86) or any factors that associated with DSP at baseline [previous/current TB 
190 cART naïve individuals screened 
184 individuals with complete 
baseline screening
164 individuals with complete
12-week screening
144 individuals with complete
24-week screening
6 did not enter the study
2 excluded for not starting cART
4 withdrew




10 (50%) lost to follow-up
20 with incomplete follow-up screen
2 (10%) pregnant
6 (30%) withdrew

















(p=0.27), triglycerides (p=0.76), hs-CRP (p=0.15)]. The results are summarized in Table J-1 
and Table J-2 in Appendix J. 
4.2.3 Initiation of cART 
Of the 144 individuals followed up for 24 weeks, 82 (57%) began cART with a stavudine-
containing regimen, 16 (11%) with zidovudine, and 46 (32%) with tenofovir. Over the 24-
week period, 9 individuals had within-class changes in cART therapy; five individuals 
changed from nevirapine (NVP) to efavirenz (EFV), two from stavudine to tenofovir, one 
from stavudine to zidovudine and one from efavirenz to nevirapine. One individual changed 
from nevirapine to zidovudine. No study participants underwent a class change from a non-
NRTI-based to a protease inhibitor-based regimen.  
All changes in cART were either secondary to commencing TB therapy or non-specific side 
effects, such as drug intolerance (excluding pain) or drug-induced skin rash. Two individuals 
who developed ATN during the 24-week follow-up period had a change in cART regimen 
from stavudine to tenofovir due to neuropathic symptoms. One of them experienced 
improvement in neurological symptoms after switching to tenofovir, the other had a change 
in regimen at week 24 and the symptoms had resolved at a 1-year follow-up. The seven final 
different drug combinations based on longest exposure time, on which further analysis was 
performed, are listed in Table 4.10.  
Table 4.10: Combination ART regimens at 24 weeks 
Drug combination N % 
Stavudine / Lamivudine / Nevirapine 49 34 
Stavudine / Lamivudine / Efavirenz 32 22 
Tenofovir / Lamivudine / Nevirapine 23 16 
Tenofovir / Lamivudine / Efavirenz 23 16 
Zidovudine / Lamivudine / Nevirapine 11 8 
Zidovudine / Lamivudine / Efavirenz 5 3 
Zidovudine / Lamivudine / Tenofovir 1 1 
 
Individuals with symptomatic DSP at baseline were more likely to have started on a 
stavudine-based regimen than those without symptomatic DSP. Seventy per cent of 
individuals (n=21) with symptomatic DSP at baseline were started on stavudine, compared to 

















At week 24, plasma HIV viral load was used as a measure of virological control, and CD4 T-
cell count as a measure of immunologic status. The cART treated cohort displayed viral 
control (i.e. viral load <200 copies/mL) in 68% of individuals seen at 24 weeks (n=87). CD4 
T-cell count was significantly higher after 24 weeks of cART with a median of 272 cells/mm
3
 
(IQR 204-368, p=0.007) (Table 4.21, page 121). 
4.2.4 Incidence of ATN and new neuropathic symptoms at 24 weeks 
The primary outcome measure for the longitudinal study was a diagnosis of ATN, defined as 
the development of any new neuropathic symptoms (with or without neuropathic signs) or 
worsening in existing symptomatic DSP, after cART initiation. The incidence rates of ATN 
are shown in Figure 4.2, calculated as the ratio of the number of individuals who had 
development of ATN to the number of individuals at risk during the specific time interval 
(see section 2.8.2). The peak incidence of ATN was seen between week 4 and 12 (14%). The 
overall estimated crude ATN incidence rate for the total population after 24 weeks was 34%. 
Eight individuals who developed ATN did not complete th  study period and were therefore 
























ATN r1 R1 
0 – 2 111 6 0.05 0.05 
2 – 4 107 11 0.10 0.15 
4 – 12 145 20 0.14 0.26 
12 – 24 115 11 0.10 0.34 
r1 is calculated as the ratio of the number of patients who had development 
of ATN to the number of patients at risk during the interval 
R1 is the cumulative rate of development of ATN by end of the interval 
Patients at risk are calculated as individuals at the specific study interval without ATN 
 
Figure 4.2: Incidence rates for ATN 
The development of new neuropathic symptoms (with or without signs) was also calculated, 
as it was the outcome measure used in the cytokine analysis (see Chapter 10). The greatest 
incidence in neuropathic symptoms was seen between week 4 and week 12 (14%) (Figure 































































0 – 2 109 6 0.06 0.06 
2 – 4 104 10 0.10 0.15 
4 – 12 114 16 0.14 0.27 
12 – 24 91 4 0.04 0.30 
r1 is calculated as the ratio of the number of patients who had incident 
symptoms to the number of patients at risk during the interval 
R1 is the cumulative rate of incident symptoms by end of the interval 
Patients at risk are calculated as individuals at the specific study interval 
who had not yet developed symptoms 
 
Figure 4.3: Incidence rates for neuropathic symptoms 
Overall incidence rates of DSP (as defined in section 2.6.1) for each time interval between 
study assessments were determined to compare incidence rates with other studies. Results are 
shown in Figure K-1 in Appendix K. The incidence rates of asymptomatic DSP are shown in 
Figure K-3 in Appendix K. In contrast to the incidence of ATN and new neuropathic 
symptoms, the incidence of asymptomatic DSP increased steadily over time with the highest 
incidence rate seen between week 12 and 24 (6%). The overall estimated crude asymptomatic 


















































4.2.5 Characteristics of incident neuropathic symptoms and signs 
Of all individuals with incident symptoms, 89% presented with positive sensory symptoms 
(pain and/or paraesthesiae). Paraesthesiae was marginally more frequent (69%) than 
numbness (64%). Pain was the presenting neuropathic symptom in 53% of individuals (Table 
4.11). 
Table 4.11: Incident neuropathic symptoms 
 
The mean symptom severity score for incident symptoms did not differ between the different 
time points at which symptoms developed and ranged from 3.2 to 6.8, expressed as the mean 
VAS score (Table 4.12). 
Table 4.12: Mean symptom severity for incident neuropathic symptoms at each specific visit 
 
Report of distal pain or paraesthesiae was strongly associated with objective findings of DSP. 
Twenty-eight individuals (78%) who developed new neuropathic symptoms during the 24-







Positive Sensory* 32 (89%)







Week 2* 5.7 3.6
Week 4 3.2 2.8 0.146 β
Week 12 5.0 2.8 0.646 β
Week 24 6.8 2.8 0.623 β
*    Reference category


















neuropathic sign occurring together with neuropathic symptoms. Of these 28 individuals, the 
most frequent neuropathic signs were altered pinprick sensibility and abnormal deep tendon 
reflexes, both occurring in 50% of individuals (Table 4.13). Vibration sensibility was altered 
in only 18% of individuals. None of the individuals with incident neuropathic symptoms 
developed distal muscle weakness after commencing cART. 
Table 4.13: Frequency of neuropathic signs for individuals with incident SDSP 
 
4.2.6 Transition in DSP Status from baseline to 24 weeks 
Transition within the tetratomic DSP states (asymptomatic DSP, symptomatic DSP, 
symptoms only and no DSP) is illustrated in a transition matrix (Table 4.14). It should be 
noted that only individuals who were symptom-free at the baseline assessment had 2- and 4-
week follow-up assessments (as outlined in section 2.5). Individuals who did not attend a 
specific follow-up visit are included in Table 4.14 as the „missing‟ group. For the purposes of 
this analysis, data will be described for 4-, 12-, and 24-week follow-up visits, and expressed 
as a percentage of individuals s en at the specific visit. 
To summarize Table 4.14, of those with no DSP at baseline, the number of individuals with 
incident symptomatic DSP doubled from baseline to 12 weeks, but decreased after 24 weeks, 
with only a few individuals experiencing new neuropathic symptoms in isolation (five at 
week 12 and two at week 24). Further, the number of individuals with asymptomatic DSP 
steadily increased over the 24-week period. 
Of 10 with asymptomatic DSP at baseline, nine were followed up to 24 weeks. Five had 
improvement in neurological signs and reverted to not having DSP, the other four remained 
stable. Of 31 individuals with symptomatic DSP at baseline examination, 24 were followed to 
48 weeks. Three individuals had complete resolution in neuropathic symptoms at week 12, 
and therefore classified as asymptomatic DSP. Only one of these three continued to have 
Neuropathic sign No. (%)
Altered vibration sensibility 5 (18%)
Altered pin sensibility 14 (50%)
Altered proprioception 2 (7%)

















asymptomatic DSP at 24 weeks. By week 24, four individuals who had symptomatic DSP at 
baseline improved to having no DSP. The rest remained stable. 
Five of seven individuals who had symptoms in isolation at baseline were followed up until 
24 weeks; one progressed to symptomatic DSP while the symptoms in four individuals 
completely resolved. Therefore, although limited by a small sample size, these analyses 
suggest that neither asymptomatic DSP nor the presence of neuropathic symptoms in 
isolation are risk factors for developing symptomatic DSP after initiating cART within the 
first 24 weeks of cART (p=0.36 and p=0.19, respectively). 
The transition between the DSP states at baseline and that at week 24 was further analysed to 
examine the transitions in-between these two examinations. For example, of 61 individuals 
with DSP at baseline who completed every examination visit, 84% remained DSP-free. The 
remaining 16% had brief transitions to one or more of the DSP states in-between the baseline 
and week 24 examinations. The transition rates for selected DSP states for interim visits are 
shown in Table L-1 in Appendix L (with individuals group d according to their baseline and 


















Table 4.14: Transition between four DSP states (No DSP, ADSP, SDSP and symptoms in isolation) across specific time points since baseline (left) and since the prior visit (right) 
Baseline count 136 10 31 7 136 10 31 7
No DSP ADSP SDSP Symptoms Total No DSP ADSP SDSP Symptoms Total
No DSP 86 (76%) 3 (3%) 2 (2%) 0 (0%) 91 (81%) 86 (76%) 3 (3%) 2 (2%) 0 (0%) 91 (81%)
ADSP 4 (4%) 5 (4%) 0 (0%) 0 (0%) 9 (8%) 4 (4%) 5 (4%) 0 (0%) 0 (0%) 9 (8%)
SDSP 7 (6%) 0 (0%) 0 (0%) 1 (1%) 8 (7%) 7 (6%) 0 (0%) 0 (0%) 1 (1%) 8 (7%)
Symptoms 5 (4%) 0 (0%) 0 (0%) 0 (0%) 5 (4%) 5 (4%) 0 (0%) 0 (0%) 0 (0%) 5 (4%)
Total 102 (90%) 8 (7%) 2 (2%) 1 (1%) 113 (100%) 102 (90%) 8 (7%) 2 (2%) 1 (1%) 113 (100%)
Missing 34 2 29 6 71 34 2 29 6 71
No DSP ADSP SDSP Symptoms Total No DSP ADSP SDSP Symptoms Total
No DSP 90 (55%) 6 (4%) 4 (2%) 2 (1%) 102 (63%) 65 (61%) 5 (5%) 1 (1%) 3 (3%) 74 (70%)
ADSP 8 (5%) 3 (2%) 3 (2%) 0 (0%) 14 (9%) 10 (9%) 2 (2%) 0 (0%) 0 (0%) 12 (11%)
SDSP 19 (12%) 0 (0%) 19 (12%) 1 (1%) 39 (24%) 6 (6%) 2 (2%) 6 (6%) 1 (1%) 15 (14%)
Symptoms 5 (3%) 0 (0%) 0 (0%) 3 (2%) 8 (5%) 4 (4%) 0 (0%) 1 (1%) 0 (0%) 5 (5%)
Total 122 (75%) 9 (6%) 26 (16%) 6 (4%) 163 (100%) 85 (80%) 9 (8%) 8 (8%) 4 (4%) 106 (100%)
Missing 16 1 5 1 23 6 0 0 1 7
No DSP ADSP SDSP Symptoms Total No DSP ADSP SDSP Symptoms Total
No DSP 76 (53%) 5 (3%) 4 (3%) 4 (3%) 89 (62%) 72 (51%) 4 (3%) 7 (5%) 3 (2%) 86 (61%)
ADSP 18 (13%) 4 (3%) 1 (1%) 0 (0%) 23 (16%) 11 (8%) 7 (5%) 5 (4%) 0 (0%) 23 (16%)
SDSP 10 (7%) 0 (0%) 19 (13%) 1 (1%) 30 (21%) 5 (4%) 3 (2%) 21 (15%) 1 (1%) 30 (21%)
Symptoms 2 (1%) 0 (0%) 0 (0%) 0 (0%) 2 (1%) 0 (0%) 0 (0%) 0 (0%) 2 (1%) 2 (1%)
Total 106 (74%) 9 (6%) 24 (17%) 5 (3%) 144 (100%) 88 (62%) 14 (10%) 33 (23%) 6 (4%) 141 (100%)
Missing 30 1 7 2 40 12 0 6 2 20








































4.2.7 Trends in neuropathic symptoms and signs over time 
The progression of symptoms and signs over the 24 weeks after cART initiation was 
investigated (Figure 4.4). Overall, the proportion of individuals experiencing neuropathic 
symptoms peaked at week 12 and then decreased again by week 24 (Figure 4.4 A). This 
observation was driven by the increase in incident symptoms (Figure 4.4 C); in those with 
symptomatic DSP at baseline (Figure 4.4 B), symptoms generally improved over the 24-week 
period, more notably in the first 12 weeks. By week 12, 29% of individuals had experienced 
complete resolution of symptoms. 
Paraesthesiae remained the most frequent reported incident neuropathic symptom up to 12 
weeks after cART (46%) (Figure 4.4 C). Burning or aching pain remained least frequently 
reported until week 12, at which time it became more frequent (peaking just below 
paraesthesiae at week 12). The symptom profile in those with incident symptoms irrespective 
of signs (Figure 4.4 C) did not differ compared to the group of individuals with incident 


















Figure 4.4: Trends in proportions of neuropathic symptoms over time for (A) all individuals, (B) 
individuals with SDSP at baseline, (C) individuals with incident symptoms and (D) individuals with 
incident SDSP 
A repeated measures analysis was performed to assess change in symptom severity for 
individuals with symptomatic DSP at baseline, within 24 weeks after cART initiation (Table 
4.15). Data are presented as a regression coefficient (with 95% CI), representing the rate of 
change in neuropathic symptoms as a function of time on cART. The mean VAS score 
decreased significantly over the 24-week follow-up period from 5.8 at baseline to 4.4 at week 
24 (p=0.003). The greatest decrease in symptoms severity was observed within the first 12 
weeks after initiation of cART (coefficient -1.80; p<0.001). 
A.      Proportion of patients with symptoms B .      Proportion of patients with symptoms
(All patients)  (SDSP at baseline group)
C .     Proportion of patients with incident symptoms D.      Proportion of patients with incident SDSP
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Table 4.15: Neuropathic symptom severity score over time for individuals with SDSP at baseline 
 
Figure 4.5 summarizes the frequency of neuropathic signs experienced over the follow-up 
period grouped according to DSP status (all individuals, symptomatic DSP, incident 
symptoms and incident symptomatic DSP). Both small and large fibre sensory modalities 
were affected. The upward trend over time in the proportion of individuals with neuropathic 
signs is similar to the upward trend seen in proportions of individuals experiencing 
neuropathic symptoms. However, overall there is not a distinct peak in the proportion of 
individuals with neuropathic signs at week 12 (Figure 4.5 A). Instead, there appears to be a 
steady increase in the proportion of individuals with neuropathic signs (including small and 
large fibre signs) over the 24-week follow-up period. Abnormal pinprick sensation remained 
the most frequent neuropathic sign overall during the 24 week follow-up period (Figure 4.5 
A) and was the most frequent neuropa hic sign in those individuals with incident symptoms 
and incident symptomatic DSP (Figure 4.5 C and D).  
The overall upward trend in neuropathic signs appears to be influenced by the increased 
frequency of new neuropathic signs (Figure 4.5 D and E). There was no distinct trend in signs 
over time among those with symptomatic DSP at baseline (Figure 4.5 B), and signs generally 
improved in those with asymptomatic DSP at baseline (Figure 4.5 F). Abnormal pinprick 
sensation appeared to show the fastest recovery within the first 12 weeks after cART in those 












Week 12 3.9 -1.80 (-2.69 ; -0.91) <0.001
Week 24 4.4 -1.39 (-2.30 ; -0.48) 0.003


















Figure 4.5: Trends in proportions of neuropathic signs over time for (A) all individuals, (B) individuals 
with SDSP at baseline, (C) individuals with incident symptoms, (D) individuals with incident SDSP, (E) 
individuals with incident ADSP and (F) individuals with ADSP at baseline 
A.      Proportion with abnormal signs B.      Proportion with abnormal signs
  (All patients)  (SDSP at baseline group)
C.      Proportion with abnormal signs (and incident symptoms) D.      Proportion with abnormal signs (and incident SDSP)
   (No DSP at baseline group) (No DSP at baseline group)
E.      Proportion with abnormal signs (and incident ADSP) F.      Proportion with abnormal signs
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4.2.8 A longitudinal analysis of the relationship between neuropathic 
symptoms and signs 
A longitudinal analysis was performed to investigate the relationship between neuropathic 
symptoms and signs, and whether individuals who experience worsening in symptoms also 
have worsening in signs. Twenty-four individuals with symptomatic DSP and 24 individuals 
with incident symptoms completed 24 weeks of follow-up. 
4.2.8.1 Symptomatic DSP at Baseline 
The correlations between changes in neuropathic symptoms and signs for individuals with 
symptomatic DSP at baseline are depicted in Table 4.16. The categories of improving, 
worsening and unchanged symptoms or signs were defined according to the criteria outlined 
in section 2.6. By week 12, just over half (n=13) improved in neuropathic symptoms whereas 
11 worsened or remained unchanged (four worsened, seven unchanged). Within the first 12 
weeks of cART, the improvement in symptoms correlated significantly with improvement in 
signs (p=0.005). None of those whose symptoms worsened showed and improvement in 
signs; in 50% the signs worsened and in the rest it remained unchanged. However, the 
correlation between symptoms and signs was not evident between 12 and 24 weeks (p=0.62). 
Small sample size precluded multivariate analyses to determine the effect of other variables, 
such as CD4 T-cell count or cART regimen on worsening or improving of symptoms and 
signs. 
Table 4.16: Comparison between changes in neuropathic symptoms and changes in neuropathic signs for 





Week 12 vs Baseline
Symptoms Improved 9 4 0.005 ¶
Symptoms Worsened/Unchanged 1 10
Week 24 vs Week 12
Symptoms Improved 3 2 0.615 ¶
Symptoms Worsened/Unchanged 7 12
¶    Fisher's exact test
Change in signs

















4.2.8.2 Incident neuropathic symptoms 
The correlation between changes in neuropathic symptoms versus changes in neuropathic 
signs for individuals with incident neuropathic symptoms after cART, over the 24-week 
follow-up period are summarised in a transition matrix in Table 4.17. 
Table 4.17: Comparison between changes in neuropathic symptoms and changes in neuropathic signs for 
the group of individuals with incident neuropathic symptoms at any point within the 24-week period 
 
The three most important findings are: 
a) Six individuals who experienced new symptoms, also had at least one new 
neuropathic sign. Eleven individuals with new symptoms had worsening of existing 
neuropathic signs. 
b) Of all individuals who had experienced improvement in neuropathic symptoms within 
the first 12 weeks after cART, none had an improvement in signs. 
Improved Unchanged Worsened New signs
Week 2 vs Baseline
Symptoms Improved - - - -
Symptoms Unchanged 5 12 - -
Symptoms Worsened - - - -
New symptoms 6 - - -
Week 4 vs Week 2
Symptoms Improved - - 3 -
Symptoms Unchanged - 5 3 3
Symptoms Worsened - - 1 -
New symptoms - 4 3 3
Week 12 vs Week 4
Symptoms Improved - 1 2 1
Symptoms Unchanged 1 2 4 2
Symptoms Worsened - 2 1 -
New symptoms - 8 6 2
Week 24 vs Week 12
Symptoms Improved 4 6 5 -
Symptoms Unchanged 1 4 1 -
Symptoms Worsened 1 2 - -



















c) After 12 weeks of study participation, general improvement in symptoms was not 
accompanied by improvement in signs. Whilst the proportion of individuals with 
neuropathic symptoms decrease after 12 weeks on cART, the proportion with 
neuropathic signs continues to increase, albeit at a lower rate than the first 12 weeks 
following cART. 
d) By week 24, symptoms had resolved in 22, whereas the remainder had persistent or 
worsening symptoms. 
From this data it appears that neuropathic signs may persist even after neuropathic symptoms 
have improved or resolved. 
4.2.9 Comparison between symptoms at baseline and newly developed 
symptoms 
To determine whether neuropathic symptoms that existed prior to cART initiation differ from 
symptoms that developed early after starting cART, a comparison was performed between 
individuals who had symptomatic DSP at baseline and individuals who developed 
neuropathic symptoms after cART (Table 4.18). 
Table 4.18: Comparison of neuropathic symptoms – SDSP at baseline vs Incident Symptoms 
 
While burning, aching pain and paraesthesiae were more frequent amongst individuals with 
symptomatic DSP pre-cART, paraesthesiae and numbness were more frequent amongst 
individuals with incident neuropathic symptoms. These differences were significant for the 





Pain 26 (84%) 19 (53%) 0.005 §
Paraesthesiae 26 (84%) 25 (69%) 0.163 ¶
Numbness 19 (61%) 23 (64%) 0.941 §
Positive Sensory* 30 (97%) 32 (89%) 0.209 ¶
*    Pain and/or paraesthesiae
¶     Fisher's exact test




















that paraesthesiae and numbness are earlier symptoms of painful neuropathy and that 
neuropathic pain is not the predominant feature of early ATN. 
A comparison of neuropathic signs between individuals who had symptomatic DSP at 
baseline visit and individuals with incident symptoms with signs (i.e. incident symptomatic 
DSP) after cART initiation is presented in Table 4.19. The only difference in signs between 
the two groups was the significantly greater proportion of abnormal pinprick sensation in the 
group with symptomatic DSP at baseline (81% vs 50%, p=0.004), although it was also the 
most frequent sign together with abnormal deep tendon reflexes in individuals with incident 
symptomatic DSP. 
Table 4.19: Comparison of neuropathic signs – SDSP at baseline vs Incident SDSP 
 
4.2.10 Risk factors for the development of ATN 
4.2.10.1 Cross-sectional analysis at 24 weeks 
A comparison of baseline and 24-week factors between individuals who developed ATN and 
those without ATN are summarized in Table 4.20 and Table 4.21 for continuous data, and 





Altered vibration sensibility 11 (35%) 5 (18%) 0.146 ¶
Altered pin sensibility 25 (81%) 14 (50%) 0.004 §
Altered proprioception 5 (16%) 2 (7%) 0.425 ¶
Absent/reduced deep tendon reflexes 18 (58%) 14 (50%) 0.309 §
¶    Fisher's exact test
























Total (N=144) ATN (N=40) No ATN (N=104)
Clinical
Age years 33 (27 - 39) 35 (28 - 43) 32 (26 - 39) 0.165 β
Weight kg 62 (55 - 71) 61 (54 - 70.5) 63 (56 - 71) 0.842 β
Height metre 1.61 (1.56 - 1.68) 1.62 (1.58 - 1.67) 1.61 (1.56 - 1.69) 0.852 β
Body Mass Index kg/m2 20.0 - 25.0 23.4 (20.3 - 28.0) 23.1 (20.1 - 28.5) 23.5 (20.3 - 27.8) 0.784
ε
Waist : Hip ratio < 0.90 0.86 (0.82 - 0.91) 0.87 (0.82 - 0.91) 0.86 (0.82 - 0.90) 0.488 β
Systolic BP mmHg 120 - 140 111 (103 - 122) 109 (100 - 118) 111 (104 - 122) 0.542 β
Diastolic BP mmHg 80 - 90 72 (66 - 79) 71 (65 - 78) 73 (66 - 80) 0.453 ε
Haematological
CD4 T-cell count cells/mm3 > 500 159 (121 - 193) 157 (116 - 212) 160 (123 - 191) 0.515
β
White cell count x109/L 4.0 - 11.0 5.1 (4.0 - 6.5) 5.0 (4.0 - 6.5) 5.1 (4.0 - 6.5) 0.867
ε
C-reactive protein mg/L < 5.0 3.0 (1.0 - 7.1) 2.8 (0.9 - 6.4) 3.2 (1.0 - 7.5) 0.708 β
Haemoglobin g/dL 11.6 - 15.6 11.8 (10.5 - 12.8) 11.8 (10.6 - 12.6) 11.8 (10.4 - 12.8) 0.862 β
MCV fL 80.0 - 100.0 92.4 (88.5 - 96.0) 92.7 (88.6 - 97.0) 92.2 (88.5 - 95.8) 0.862 β
Biochemical
Albumin g/L 38 - 54 39 (35 - 42) 39 (35 - 43) 39 (35 - 42) 0.992 β
ALT IU/L 10 - 41 19 (14 - 27) 18 (13 - 24) 21 (15 - 28) 0.056 β
Creatinine µmol/L 53 - 115 64 (56 - 73) 64 (57 - 74) 64 (55 - 73) 0.665 ε
Metabolic
Fasting glucose mmol/L 4.1 - 5.6 4.7 (4.4 - 4.9) 4.7 (4.4 - 5.0) 4.6 (4.4 - 4.9) 0.459 ε
Fasting insulin µU/mL 0.2 - 9.4 5.2 (2.5 - 8.6) 4.7 (2.0 - 8.6) 5.5 (2.7 - 8.6) 0.313 β
Total cholesterol mmol/L 3.1 - 5.2 3.7 (3.2 - 4.2) 3.5 (3.0 - 4.2) 3.7 (3.3 - 4.3) 0.372 β
Triglycerides mmol/L 0.5 - 2.0 0.9 (0.6 - 1.2) 0.8 (0.6 - 1.3) 0.9 (0.7 - 1.2) 0.449 β
HDL mmol/L 1.15 - 1.68 0.94 (0.75 - 1.12) 0.93 (0.75 - 1.08) 0.97 (0.74 - 1.13) 0.251 β
LDL mmol/L 1.0 - 3.0 2.3 (2.0 - 2.9) 2.3 (1.9 - 2.8) 2.4 (2.0 - 2.9) 0.561 β
Lactate mmol/L < 2.0 2.4 (1.7 - 3.1) 2.4 (1.4 - 3.3) 2.3 (1.7 - 3.0) 0.861 β
Pyridoxine
PLP nmol/L > 25.0 24.3 (17.1 - 38.4) 23.3 (18.2 - 46.8) 24.7 (16.6 - 36.6) 0.493 β
4-PA nmol/L unknown 17.6 (11.8 - 24.5) 17.1 (11.7 - 22.8) 17.9 (12.0 - 25.5) 0.805 ε
β    Student's t -test






















Table 4.21: Week 24 characteristics for individuals with and without ATN (continuous data) 
 
Total (N=144) ATN (N=40) No ATN (N=104)
Clinical
Weight kg 66 (57 - 75) 66 (55 - 74) 66 (58 - 75) 0.725 β
Height metre 1.61 (1.57 - 1.68) 1.62 (1.57 - 1.66) 1.61 (1.57 - 1.69) 0.947 β
Body Mass Index kg/m2 20.0 - 25.0 24.4 (21.0 - 29.2) 24.7 (20.8 - 29.1) 24.3 (21.5 - 29.3) 0.574 ε
Waist : Hip ratio < 0.90 0.85 (0.80 - 0.89) 0.83 (0.79 - 0.91) 0.85 (0.80 - 0.89) 0.801 ε
Systolic BP mmHg 120 - 140 115 (109 - 124) 117 (109 - 125) 115 (107 - 122) 0.932 β
Diastolic BP mmHg 80 - 90 74 (69 - 80) 75 (71 - 80) 73 (68 - 80) 0.557 β
Haematological
CD4 T-cell count cells/mm3 > 500 272 (204 - 368) 344 (223 - 457) 260 (186 - 337) 0.007 β
C-reactive protein* mg/L < 5.0 4.5 (1.3 - 9.7) 3.8 (1.5 - 8.3) 4.8 (1.0 - 10.7) 0.795 ε
Virological
HIV viral load copies/mL 20 (20 - 56) 20 (20 - 55) 20 (20 - 57) 0.875 ε
Metabolic
Fasting glucose mmol/L 4.1 - 5.6 4.9 (4.7 - 5.2) 4.9 (4.7 - 5.2) 4.9 (4.7 - 5.2) 0.971 ε
Fasting insulin µU/mL 0.2 - 9.4 5.5 (2.5 - 8.5) 4.9 (2.8 - 7.9) 5.8 (2.5 - 8.7) 0.384 ε
Total cholesterol mmol/L 3.1 - 5.2 4.4 (3.9 - 5.1) 4.2 (3.7 - 5.1) 4.5 (3.9 - 5.1) 0.306 β
Triglycerides mmol/L 0.5 - 2.0 0.8 (0.7 - 1.1) 0.8 (0.7 - 1.1) 0.8 (0.7 - 1.0) 0.402 ε
HDL mmol/L 1.15 - 1.68 1.41 (1.12 - 1.64) 1.37 (1.05 - 1.56) 1.45 (1.20 - 1.82) 0.027 β
LDL mmol/L 1.0 - 3.0 2.5 (2.0 - 2.9) 2.6 (2.1 - 2.9) 2.5 (2.0 - 2.9) 0.962 β
Pyridoxine
PLP* nmol/L > 25.0 20.9 (13.3 - 34.7) 26.7 (13.1 - 35.1) 20.1 (13.4 - 33.5) 0.984 β
4-PA* nmol/L unknown 19.2 (12.5 - 27.7) 18.6 (13.7 - 23.3) 19.2 (12.2 - 30.3) 0.829 ε
*   Week 12 blood samples
β    Student's t -test






















Table 4.22: Baseline and 24-week characteristics for individuals with and without ATN (grouped data) 
 
Total (N=144) ATN (N=40) No ATN (N=104)
Female sex 97 (67%) 27 (68%) 70 (67%) 0.982 §
Age > 40 years 35 (24%) 13 (33%) 22 (21%) 0.155 §
Previous/Current TB 57 (40%) 13 (33%) 44 (42%) 0.281 §
Time of TB 0.045 ¶
Currently 11 (8%) 0 (0%) 11 (11%)
< 1 year ago 26 (18%) 5 (13%) 21 (20%)
1 year ago 4 (3%) 3 (8%) 1 (1%)
2 years ago 3 (2%) 1 (3%) 2 (2%)
> 2 years ago 12 (8%) 4 (10%) 8 (8%)
Vit Bco supplement 143 (99%) 40 (100%) 103 (99%) 1.000 ¶
Vit B6 supplement 6 (4%) 2 (5%) 4 (4%) 0.875 ¶
WHO clinical stage 0.317 ¶
Stage 1 47 (33%) 11 (28%) 36 (35%)
Stage 2 43 (30%) 16 (40%) 27 (26%)
Stage 3 48 (34%) 11 (28%) 37 (36%)
Stage 4 5 (4%) 2 (5%) 3 (3%)
Baseline variables
CD4 T-cell count 0.402 §
< 100 cells/mm 3 22 (15%) 6 (15%) 16 (16%)
100 - 200 cells/mm 3 88 (62%) 22 (55%) 66 (65%)
> 200 cells/mm 3 32 (23%) 12 (30%) 20 (20%)
Metabolic syndrome 17 (12%) 6 (15%) 11 (11%) 0.565 ¶
Body Mass Index 0.847 §
< 20 kg/m 2 31 (22%) 10 (25%) 21 (21%)
20 - 25 kg/m 2 57 (40%) 14 (35%) 43 (42%)
25 - 30 kg/m 2 29 (20%) 8 (20%) 21 (21%)
> 30 kg/m 2 25 (18%) 8 (20%) 17 (17%)
Alcohol last year 42 (30%) 11 (28%) 31 (30%) 0.734 §
IHDS score < 10 14 (10%) 7 (18%) 7 (7%) 0.062 ¶
Week 24 variables
CD4 T-cell count 0.418 ¶
< 100 cells/mm 3 5 (4%) 0 (0%) 5 (5%)
100 - 200 cells/mm 3 27 (21%) 7 (18%) 20 (22%)
> 200 cells/mm 3 98 (75%) 31 (82%) 67 (73%)
HIV viral load 0.731 §
< 200 copies/mL 87 (68%) 25 (66%) 62 (69%)
> 200 copies/mL 41 (32%) 13 (34%) 28 (31%)
Antiretroviral drugs
Stavudine 81 (56%) 24 (60%) 57 (55%) 0.574 §
Zidovudine 17 (12%) 3 (8%) 14 (13%) 0.399 ¶
Lamivudine 144 (100%) 40 (100%) 104 (100%) N/A
Efavirenz 60 (42%) 15 (38%) 45 (43%) 0.529 §
Nevirapine 83 (58%) 25 (63%) 58 (56%) 0.464 §
Tenofovir 47 (33%) 13 (33%) 34 (33%) 0.982 §
Drug combination 0.614 ¶
3TC / NVP / TDF 23 (16%) 7 (18%) 16 (15%)
3TC / EFV / TDF 23 (16%) 6 (15%) 17 (16%)
AZT / 3TC / TDF 1 (1%) 0 (0%) 1 (1%)
AZT / 3TC / NVP 11 (8%) 1 (3%) 10 (10%)
AZT / 3TC / EFV 5 (3%) 2 (5%) 3 (3%)
D4T / 3TC / NVP 49 (34%) 17 (43%) 32 (31%)
D4T / 3TC / EFV 32 (22%) 7 (18%) 25 (24%)
¶    Fisher's exact test



















The development of ATN was not associated with any of the baseline variables. Risk factors 
that were associated with symptomatic DSP at baseline in the univariate analysis, viz. age, 
waist-to-hip ratio, triglycerides and previous/current TB, were not significant predictors of 
the development of ATN (p=0.17; p=0.49; p=0.45 and p=0.28, respectively). Clinical features 
including sex (p=0.98), weight (p=0.84), height (p=0.85), BMI (p=0.78), systolic BP 
(p=0.54), and diastolic BP (p=0.45) were not predictors of the development of ATN. Also, 
there was no association with baseline HIV severity as measured by WHO HIV stage 
(p=0.32), baseline CD4 T-cell count (p=0.52) or hs-CRP (p=0.71). 
Baseline fasting lipids and metabolic factors did not associate with the development of ATN 
including fasting total cholesterol (p=0.37), HDL (p=0.25), glucose (p=0.46), lactate 
(p=0.86), and the metabolic syndrome (p=0.57). 
Baseline haematological factors including white cell count (p=0.87), haemoglobin (p=0.86) 
or MCV (p=0.86) were not significant predictors of ATN. Baseline biochemical factors 
including albumin (p=0.99) and creatinine (p=0.67) did not associate with the development of 
ATN. There was a trend towards lower ALT levels in individuals who developed ATN 
compared to those who did not (18.0 vs 21.0 IU/L, p=0.06). However, the interquartile range 
for ALT was still within normal range for both groups. Again, no difference was detected in 
alcohol exposure between the two groups in general (p=0.73). ATN was not associated with 
vitamin B6 indicators at baseline [PLP (p=0.49) and 4-PA (p=0.81)]. 
Of the 24-week factors, the development of ATN was associated with: 
a) Higher CD4 T-cell count at week 24 (p=0.007). Individuals who developed ATN had 
a median CD4 T-cell count of 344 cells/mm
3
 (IQR 223-457), compared to 260 
cells/mm
3
 (IQR 186-337) for the group who did not develop ATN. Although 
individuals with ATN showed greater CD4 T-cell reconstitution after 24 weeks 
compared with the ATN-free group, HIV viral loads at 24 weeks did not differ 
between the two groups (p=0.88). 
b) Lower HDL levels at week 24 (p=0.03). Median HDL cholesterol levels for 
individuals who developed ATN was 1.37 mmol/L (IQR 1.05-1.56) compared to 1.45 
mmol/L (IQR 1.20-1.82) for individuals who did not develop ATN. The HDL 

















Apart from lower HDL levels at 24 weeks on cART, none of the other metabolic factors 
investigated at 24 weeks showed any associations with the development of ATN. 
There was no significant difference in initial NRTI backbone between individuals who 
developed ATN compared to those who remained without ATN (p=0.61). Notably, only 30% 
of individuals who received stavudine developed ATN. Specifically, of individuals with 
ATN, 24 (60%) received stavudine, while in those who did not develop ATN, 57 (55%) 
received stavudine (p=0.57) (Table 4.22). 
The presence of asymptomatic DSP at baseline was not associated with the development of 
ATN (p=0.21). Of note, on retrospective recall, only one of the 10 individuals with 
asymptomatic DSP at baseline reported having neuropathic symptoms in the past. These 
symptoms resolved spontaneously. 
Univariate hazard ratios (with 95% CIs) were calculated to determine longitudinal risk factors 
associated with ATN within 24 weeks (Table M-7 in Appendix M). Individuals who were 
lost during follow-up were censored after the last known visit. Baseline factors significantly 
associated with ATN in the primary analysis (parametric, non-parametric and proportional) 
were examined by individual Cox regression. All baseline variables were explored for an 
association with ATN, but only variables showing significance level of p<0.25 in the primary 
analysis were included in in the multivariate analysis. In the multivariate Cox regression 



















Table 4.23: Multivariate Cox regression analysis of baseline risk factors for ATN 
 
As discussed in section 2.6.1, a caveat in our definition of ATN is that worsening of 
neuropathic symptoms may be part of the natural history of DSP; the addition of cART as an 
additional neurotoxic insult does not necessarily imply that the worsening was due to cART. 
Furthermore, those individuals with symptomatic DSP at baseline formed part of the ATN-
free comparative group. Therefore, to exclude this confounding effect, an analysis was 
performed looking at individuals who developed neuropathic symptoms, comparing them to 
individuals who never had neuropathic symptoms and the results are summarized in 
Appendix M. Individuals with incident symptoms showed a trend towards greater CD4 T-cell 
counts at 24 weeks (p=0.11, Table M-2 in Appendix M). Development of incident 
neuropathic symptoms was associated with lower ALT levels at baseline (p=0.003) and lower 
HDL levels at week 24 (p=0.038) (Table M-8 in Appendix M). In the multivariate Cox 
regression analysis, an ALT >19 IU/L was associated with a decreased risk of developing 
ATN (p=0.026) (Table 4.24). 
Clinical variable
Hazard Ratio in 
multivariate analysis
Hazard Ratio 95% 
Confidence Interval
p-value
Female sex 1.10 0.47 - 2.59 0.822
Age > 40 years 2.13 0.82 - 5.55 0.120
Previous/Current TB 2.22 0.70 - 7.00 0.175
WHO clinical stage
Stage 1* 1.00
Stage 2 1.75 0.73 - 4.18 0.207
Stage 3 0.32 0.09 - 1.20 0.091
Stage 4 0.60 0.07 - 5.39 0.652
IHDS score < 10 0.48 0.17 - 1.33 0.158
Alcohol last year 0.88 0.40 - 1.94 0.743
ALT > 19 IU/L 0.40 0.17 - 0.93 0.034


















Table 4.24: Multivariate Cox regression analysis of baseline risk factors for incident symptoms 
 
4.2.10.2 Longitudinal patterns of clinical and laboratory variables over 24 weeks in 
risk of developing ATN 
In addition to an analysis of baseline factors, we performed repeated measures analysis to 
assess longitudinal patterns over the 24-week follow-up period. To determine the effect of 
cART initiation on risk factors investigated, as well as the difference in change in factors 
between individuals who developed ATN and those who remained without ATN, a cross-
sectional time series analysis was performed (random effects model). Data is presented as a 
regression coefficient (with 95% CI), representing the rate of change in the variable (relative 
to baseline) between the two groups. Time on cART was used as within-individual factor and 
group (ATN vs no ATN) as the between-individual factor Table 4.25). 
Clinical variable
Hazard Ratio in 
multivariate analysis
Hazard Ratio 95% 
Confidence Interval
p-value
Female sex 1.09 0.47 - 2.55 0.840
Age > 40 years 1.92 0.74 - 4.98 0.176
Previous/Current TB 2.62 0.81 - 8.49 0.109
WHO clinical stage
Stage 1* 1.00
Stage 2 1.84 0.78 - 4.35 0.163
Stage 3 0.30 0.08 - 1.14 0.077
Stage 4 0.48 0.05 - 4.47 0.521
IHDS score < 10 0.52 0.19 - 1.44 0.211
Alcohol last year 0.98 0.44 - 2.18 0.964
ALT > 19 IU/L 0.37 0.16 - 0.89 0.026
































Baseline 159 157 160 0.515 β
Week 24 272 140.59 (121.06 ; 160.13) <0.001 344 260 64.07 (22.40 ; 105.75) 0.003
Fasting glucose
Baseline 4.7 4.7 4.6 0.459 ε
Week 12 4.9 0.24 (0.15 ; 0.34) <0.001 4.9 4.8 0.10 (-0.11 ; 0.31) 0.339
Week 24 4.9 0.25 (0.16 ; 0.34) <0.001 4.9 4.9 -0.07 (-0.28 ; 0.14) 0.510
Fasting insulin
Baseline 5.2 4.7 5.5 0.313 β
Week 12 5.3 0.46 (-0.48 ; 1.40) 0.336 5.7 5.3 1.23 (-0.85 ; 3.32) 0.245
Week 24 5.5 0.53 (-0.41 ; 1.46) 0.271 4.9 5.8 -0.18 (-2.28 ; 1.92) 0.869
Total cholesterol
Baseline 3.7 3.5 3.7 0.372 β
Week 12 4.2 0.53 (0.41 ; 0.64) <0.001 4 4.2 -0.09 (-0.34 ; 0.17) 0.505
Week 24 4.4 0.68 (0.57 ; 0.80) <0.001 4.2 4.5 -0.02 (-0.28 ; 0.24) 0.908
Triglycerides
Baseline 0.9 0.8 0.9 0.449 β
Week 12 0.8 0.01 (-0.12 ; 0.15) 0.862 0.8 0.8 0.21 (-0.09 ; 0.51) 0.170
Week 24 0.8 -0.04 (-0.17 ; 0.10) 0.581 0.8 0.8 0.08 (-0.22 ; 0.38) 0.599
HDL
Baseline 0.94 0.93 0.97 0.251 β
Week 12 1.3 0.36 (0.30 ; 0.42) <0.001 1.19 1.33 -0.05 (-0.19 ; 0.08) 0.447
Week 24 1.41 0.51 (0.45 ; 0.57) <0.001 1.37 1.45 -0.12 (-0.25 ; 0.02) 0.096
LDL
Baseline 2.3 2.3 2.4 0.561 β
Week 12 2.4 0.13 (0.03 ; 0.23) 0.011 2.4 2.4 -0.07 (-0.29 ; 0.14) 0.506
Week 24 2.5 0.16 (0.06 ; 0.25) 0.002 2.6 2.5 0.11 (-0.11 ; 0.33) 0.336
Systolic BP
Baseline 111 109 111 0.542 β
Week 12 115 3.72 (1.61 ; 5.84) 0.001 118 115 5.70 (1.10 ; 10.30) 0.015
Week 24 115 3.49 (1.39 ; 5.58) 0.001 117 115 1.68 (-2.96 ; 6.31) 0.479
Diastolic BP
Baseline 72 71 73 0.453 ε
Week 12 73 1.17 (-0.39 ; 2.74) 0.143 73 73 1.92 (-1.52 ; 5.36) 0.274
Week 24 74 1.37 (-0.19 ; 2.93) 0.084 75 73 2.48 (-0.98 ; 5.95) 0.160
Weight
Baseline 62 61 63 0.842 β
Week 12 64 1.70 (1.05 ; 2.36) <0.001 62 65 0.47 (-0.97 ; 1.91) 0.520
Week 24 66 3.03 (2.38 ; 3.67) <0.001 66 66 0.70 (-0.74 ; 2.14) 0.339
Body Mass Index
Baseline 23.4 23.1 23.5 0.784 ε
Week 12 24.5 0.78 (0.48 ; 1.07) <0.001 25 24.1 0.24 (-0.40 ; 0.89) 0.458
Week 24 24.4 1.15 (0.86 ; 1.44) <0.001 24.7 24.3 0.10 (-0.55 ; 0.75) 0.763
Waist : Hip Ratio
Baseline 0.86 0.87 0.86 0.488 β
Week 12 0.85 -0.01 (-0.03 ; 0.02) 0.670 0.83 0.85 -0.01 (-0.07 ; 0.04) 0.668
Week 24 0.85 0.00 (-0.02 ; 0.02) 0.996 0.83 0.85 -0.03 (-0.08 ; 0.03) 0.312
C-reactive protein
Baseline 2.9 2.8 3.2 0.708 β
Week 12 4.4 5.36 (-0.13 ; 10.85) 0.056 3.8 4.8 1.47 (-11.02 ; 13.97) 0.817
PLP
Baseline 24.3 23.3 24.7 0.493 β
Week 12 20.9 -2.01 (-6.88 ; 2.85) 0.417 26.7 20.1 -5.01 (-15.82 ; 5.80) 0.363
4PA
Baseline 17.6 17.1 17.9 0.805 ε
Week 12 19.2 3.85 (-0.71 ; 8.40) 0.098 18.6 19.2 4.07 (-6.07 ; 14.20) 0.432
a    Time effect is the effect of cART on mean concentrations for the entire cohort β    Student's t -test





















Overall, CD4 T-cell count recovered significantly after 24 weeks on cART. The initiation of 
cART also had a significant effect on nutritional and metabolic factors. Metabolic 
parameters, including total cholesterol, HDL, LDL and fasting glucose rose significantly after 
cART treatment with the greatest increase occurring by week 24. Similarly clinical factors 
including, weight (p<0.001), BMI (p<0.001) and systolic BP (p<0.001) were significantly 
higher at 24 weeks compared to baseline concentrations. Diastolic BP, waist-to-hip ratio, 
fasting insulin, triglycerides, PLP and 4-PA remained unchanged during the course of follow-
up. 
A greater increase in CD4 T-cell count at 24 weeks was associated with development of ATN 
(p=0.003). Individuals who developed ATN had a greater increase in systolic BP at week 12 
compared to those without ATN. Despite the general increase in most measures after cART 
initiation, there was no significant difference in magnitude of response between the 
individuals who developed ATN compared to those who did not develop ATN (“group 
effect”) and included the following: 
a) Clinical factors: Weight, BMI, waist-to-hip ratio and diastolic BP 
b) Metabolic factors: Triglycerides, HDL, LDL, total cholesterol, glucose and insulin 
c) Inflammatory markers: hs-CRP 
d) Vitamin B6 indicators: PLP and 4-PA 
The random effects model for individuals with incident symptoms compared to individuals 
without new symptoms is shown in Table N-1 in Appendix N. No significant associations 
with any risk factors were found. 
4.2.11 Comparison between individuals with symptomatic DSP at baseline and 
individuals who developed symptomatic DSP 
An analysis was performed comparing the group with symptomatic DSP at baseline to the 
group developing symptomatic DSP during 24 weeks follow-up to examine any significant 
differences between the two groups (refer to Table 4.26, Table 4.27 and Table 4.28). Only 






















SDSP at baseline (N=24) Incident SDSP (N=24)
Clinical
Age years 38 (29 - 44) 33 (26 - 41) 0.090 β
Weight kg 61 (55 - 73) 61 (55 - 66) 0.712 β
Height metre 1.63 (1.56 - 1.68) 1.62 (1.58 - 1.66) 0.841 β
Body Mass Index kg/m2 20.0 - 25.0 24.1 (20.9 - 26.0) 21.8 (19.9 - 26.1) 0.793 β
Waist : Hip ratio < 0.90 0.88 (0.85 - 0.93) 0.84 (0.79 - 0.90) 0.034 β
Systolic BP mmHg 120 - 140 111 (100 - 121) 109 (100 - 117) 0.944 β
Diastolic BP mmHg 80 - 90 70 (67 - 78) 71 (65 - 74) 0.626 β
Haematological
CD4 T-cell count cells/mm3 > 500 167 (126 - 223) 141 (118 - 201) 0.496 ε
White cell count x109/L 4.0 - 11.0 4.7 (3.8 - 6.0) 5.7 (4.8 - 7.1) 0.256 β
C-reactive protein mg/L < 5.0 3.8 (2.2 - 11.9) 2.9 (0.9 - 7.1) 0.601 β
Haemoglobin g/dL 11.6 - 15.6 11.9 (9.6 - 12.8) 11.9 (10.7 - 13.1) 0.422 β
MCV fL 80.0 - 100.0 93.3 (89.3 - 95.6) 92.3 (87.9 - 97.0) 0.646 β
Biochemical
Albumin g/L 38 - 54 38 (34 - 42) 41 (35 - 44) 0.210 β
ALT IU/L 10 - 41 24 (18 - 29) 17 (13 - 20) 0.009 β
Creatinine µmol/L 53 - 115 66 (58 - 74) 64 (58 - 76) 0.517 β
Metabolic
Fasting glucose mmol/L 4.1 - 5.6 4.7 (4.6 - 4.9) 4.7 (4.4 - 5.2) 0.622 β
Fasting insulin µU/mL 0.2 - 9.4 4.6 (2.7 - 9.0) 5.6 (3.6 - 9.3) 0.429 β
Total cholesterol mmol/L 3.1 - 5.2 4.0 (3.1 - 4.3) 3.7 (3.2 - 4.2) 0.988 β
Triglycerides mmol/L 0.5 - 2.0 1.0 (0.8 - 1.4) 0.7 (0.6 - 1.0) 0.009 β
HDL mmol/L 1.15 - 1.68 0.94 (0.79 - 1.16) 0.90 (0.71 - 1.07) 0.309 β
LDL mmol/L 1.0 - 3.0 2.5 (1.8 - 2.8) 2.6 (2.0 - 3.0) 0.189 β
Lactate mmol/L < 2.0 2.1 (1.2 - 2.6) 2.4 (1.7 - 3.3) 0.302 β
Pyridoxine
PLP nmol/L > 25.0 20.7 (16.4 - 53.7) 21.4 (18.2 - 32.3) 0.807 β
4-PA nmol/L unknown 20.2 (12.0 - 26.2) 16.8 (11.7 - 21.6) 0.567 β
β    Student's t -test






















Table 4.27: Week 24 characteristics of individuals with SDSP at baseline vs those with incident SDSP 
(continuous data) 
 
SDSP at baseline (N=24) Incident SDSP (N=24)
Clinical
Weight kg 66 (58 - 74) 66 (55 - 69) 0.496 β
Height metre 1.61 (1.57 - 1.69) 1.62 (1.58 - 1.66) 0.900 β
Body Mass Index kg/m2 24.3 (21.6 - 27.1) 24.7 (20.1 - 26.7) 0.548 β
Waist : Hip ratio 0.85 (0.83 - 0.92) 0.83 (0.78 - 0.88) 0.084 ε
Systolic BP mmHg 115 (109 - 130) 117 (109 - 124) 0.574 β
Diastolic BP mmHg 73 (68 - 83) 75 (70 - 78) 0.687 β
Haematological
CD4 T-cell count cells/mm3 260 (255 - 395) 344 (212 - 457) 0.848 β
Viral Load copies/ml 20 (20 - 34) 20 (20 - 769) 0.102 ε
C-reactive protein* mg/L 4.8 (1.3 - 11.4) 3.8 (1.7 - 16.5) 0.272 ε
Metabolic
Fasting glucose mmol/L 4.9 (4.8 - 5.2) 4.9 (4.6 - 5.3) 0.556 β
Fasting insulin µU/mL 5.8 (2.9 - 8.3) 4.9 (2.9 - 7.4) 0.460 ε
Total cholesterol mmol/L 4.5 (4.0 - 5.1) 4.2 (3.8 - 5.2) 0.877 β
Triglycerides mmol/L 0.8 (0.7 - 1.0) 0.8 (0.7 - 1.3) 0.890 β
HDL mmol/L 1.45 (1.11 - 1.65) 1.37 (1.06 - 1.51) 0.115 β
LDL mmol/L 2.5 (2.1 - 2.8) 2.6 (2.1 - 3.3) 0.394 β
Pyridoxine
PLP* nmol/L 20.1 (11.9 - 33.1) 26.7 (10.4 - 33.2) 0.536 β
4-PA* nmol/L 19.2 (12.6 - 27.0) 18.6 (12.4 - 23.1) 0.560 ε
*   Week 12 blood samples
β    Student's t -test
ε    Wilcoxon rank-sum test



















Table 4.28: Baseline and 24-week characteristics for individuals with SDSP at baseline vs those with 
incident SDSP (grouped data) 
 
 
SDSP at baseline (N=24) Incident SDSP (N=24)
Female sex 15 (63%) 16 (67%) 1.000 ¶
Age > 40 years 11 (46%) 6 (25%) 0.227 ¶
Previous/Current TB 14 (58%) 7 (29%) 0.042 §
Time of TB 0.015 ¶
Currently 7 (29%) 0 (0%)
< 1 year ago 3 (13%) 4 (17%)
1 year ago 2 (8%) 0 (0%)
2 years ago 1 (4%) 1 (4%)
> 2 years ago 1 (4%) 2 (8%)
Vit Bco supplement 24 (100%) 24 (100%)
Vit B6 supplement 6 (25%) 1 (4%) 0.048 ¶
WHO clinical stage 0.038 ¶
Stage 1 8 (33%) 6 (25%)
Stage 2 4 (17%) 12 (50%)
Stage 3 11 (46%) 4 (17%)
Stage 4 1 (4%) 2 (8%)
Baseline variables
CD4 T-cell count 0.901 ¶
< 100 cells/mm 3 2 (8%) 2 (8%)
100 - 200 cells/mm 3 14 (58%) 16 (67%)
> 200 cells/mm 3 8 (33%) 6 (25%)
Metabolic syndrome 1 (4%) 2 (8%) 1.000 ¶
Body Mass Index 0.749 ¶
< 20 kg/m 2 5 (21%) 7 (29%)
20 - 25 kg/m 2 9 (38%) 11 (46%)
25 - 30 kg/m 2 6 (25%) 4 (17%)
> 30 kg/m 2 4 (17%) 2 (8%)
Alcohol last year 6 (25%) 6 (25%) 1.000 ¶
IHDS score < 10 3 (30%) 3 (13%) 0.328 ¶
24 week variables
CD4 T-cell count 0.666 ¶
100 - 200 cells/mm 3 4 (17%) 2 (10%)
> 200 cells/mm 3 19 (83%) 19 (90%)
Viral Load < 200 copies/ml 16 (70%) 11 (52%) 0.354 ¶
¶    Fisher's exact test



















There were a few differences at baseline. Fifty per cent of individuals with symptomatic DSP 
at baseline were HIV stage 3 or 4 compared to only 25% of individuals with incident 
symptomatic DSP (p=0.038). In those with incident symptomatic DSP, waist-to-hip ratios 
were lower (p=0.034), although height and weight were similar. The ALT and fasting 
triglyceride levels were lower in those with incident symptomatic DSP (p=0.009 and 
p=0.009, respectively). Interestingly, there was no difference in CD4 T-cell count, hs-CRP or 
fasting glucose levels between the two groups. After 24 weeks, all these longitudinal 
parameters were similar, although follow-up ALT levels were not performed as standard of 
care. Again, there was no difference in CD4 T-cell count or hs-CRP level (see further 
discussion in Chapter 10). However, grouping specific variables of interest showed that 
symptomatic DSP at baseline was significantly associated with previous or current TB 
therapy (p=0.042). Taking into account the relatively small number of this analysis (n=48), 









































5.1 The frequency of HIV-DSP at baseline and influence of the 
clinical tool used 
HIV-DSP was present in 22% of a well-characterized cohort of individuals prior to 
commencing cART by using the case definitions of 1) at least two neuropathic signs 
(asymptomatic DSP) or 2) one or more neuropathic signs together with one or more 
neuropathic symptoms (symptomatic DSP). Previously, the „two signs‟ definition was 
considered too stringent with loss of sensitivity (Simpson et al., 2006). However, it was 
decided a priori that this was necessary to enable accurate assessment for risk factors in this 
group, as asymptomatic DSP was purely a clinical diagnosis. 
Other prospective studies in which the prevalence of HIV-DSP was reported prior to cART 
initiation are summarized in Table 5.1. Prevalence estimates vary substantially depending on 
the criteria employed to define DSP. In order to compare DSP prevalence from our study 
with those listed in Table 5.1, the respective definitions from these studies were applied to 
our data. By only using the BPNS, and applying a case definition of at least one sign 
(abnormal reflexes or vibration sensation), the prevalence of DSP in this cohort was 42% at 
baseline. In comparison, a North American study found the prevalence of DSP to be 
considerably lower (23%) using the same definition (Evans et al., 2011). 
The inclusion of pin sensibility, which reflects small unmyelinated nerve fibre function, 
increased the sensitivity of the screening exam, given that vibration sensibility and tendon 
reflexes reflect large myelinated fibre function. The prevalence increased from 42% to 59% 
when abnormal pinprick sensibility from the mTNS was included as a neuropathic sign in 
defining DSP. Using the same definition as used herein, another African study also reported a 
high DSP prevalence of 43% prior to initiating cART, twofold more than observed in HIV-

















Table 5.1: Comparative frequencies of DSP prior to cART initiation 
 
The overall frequency of symptomatic DSP at baseline (pre-cART) in this cohort was 17%. 
Using only the BPNS (i.e. without pinprick sensibility), the frequency of symptomatic DSP 
was 12%. This is comparable to another African study, which reported a frequency of 11% 
(Mehta et al., 2011), but threefold higher than the frequency of 4% from a large North 
American cohort (Evans et al., 2011). Forna et al. also reported longitudinal data from an 
African cohort, but used a less stringent case definition of ≥1 neuropathic symptom or sign 
(Forna et al., 2007). Using this definition, our frequency was considerably higher than that 
described in their cohort. However, their study investigated safety and tolerability of NRTI 
therapy and not primarily the frequency of DSP. Also, study participants were evaluated by 
field officers and not clinicians. Previous work has demonstrated that the BPNS tool did not 
perform well in the hands of nurses trained in the administration of this tool when compared 
with clinicians or neurologists (Cettomai et al., 2010, Simpson et al., 2006). 
Overall, after correcting for varying diagnostic criteria, our frequency figures for both DSP 
and symptomatic DSP are generally higher than those from developed countries. The 
increased frequency may reflect a higher prevalence of comorbidities, notably TB infection, 
that contribute to DSP in our study population. More advanced HIV disease as demonstrated 
by lower median CD4 T-cell counts in our study compared to that of Evans et al., may also 
affect DSP prevalence [158 vs 206 cells/mm
3
 (Evans et al., 2011)]. Differences in execution 
Study cohort Forna Sacktor Mehta Evans










Symptoms and ≥ 1 sign, BPNS b 12% 11% 4%
Other
Symptoms or ≥ 1 sign
c 63% 13%
a   Either (i) ≥ 2 signs or (i i) symptoms and ≥ 1 sign
b   BPNS refers to assessment of deep tendon reflexes and vibration sensibility only
c   Assessment of signs: pin sensibility, deep tendon reflexes and vibration sensibility



















of neurological assessment and interpretation of signs may have contributed to the discrepant 
results. Sample sizes influence credibility of the frequency estimates, and ranged from 150 
individuals (Mehta et al., 2011) to over a thousand (Evans et al., 2011). 
 
5.2 Pain is a common clinical characteristics of HIV-DSP 
HIV-DSP was characterized by a high frequency of positive sensory symptoms (73% with 
pain and/or paraesthesiae). Pain was the most prevalent symptom at baseline, affecting nearly 
two thirds of all individuals with DSP. Of those, 77% experienced their pain as at least 
moderately severe (VAS ≥4/10). This was similar to previous findings in a comparable 
population from this region (Maritz et al., 2010) Although numbness has previously been 
reported to be the most common symptom of HIV-DSP, it was the least frequent symptom in 
our cohort affecting only 46% of those with DSP at baseline (Harrison and Smith, 2011). 
Decreased pinprick sensation was the most common neuropathic sign (76%), followed by 
abnormal ankle reflexes (68%). Distal mild toe extensor weakness occurred in only 15% and 
never as an isolated sign. The relatively high frequency of decreased pinprick sensation may 
be an important consideration when using the BPNS as a screening tool since this modality is 
not included in the BPNS. This could decrease the sensitivity of detecting DSP (see Table 
5.1). In nearly a third (29%) of individuals with symptomatic DSP at baseline, decreased 
pinprick sensation was the only neuropathic sign and these individuals would therefore not 
have been included in the diagnosis of symptomatic DSP, had only the BPNS been used. 
Furthermore, the absence of investigating pinprick sensation would have excluded six of 10 
individuals with asymptomatic DSP at baseline. These findings suggest that the use of the 
mTNS would be the preferred clinical tool for determining DSP status as the BPNS lacks 
sensitivity in the assessment of HIV-DSP. 
Eliciting neuropathic symptoms may be clinically important in resource-limited settings 
where clinicians or special investigations are not always readily available. We found that the 
distal symptoms of pain, paraesthesiae or numbness was strongly associated with objective 
findings of HIV-DSP, with only 4% of individuals presenting with symptoms in isolation 
(Table 5.1), consistent with the findings of another group (Robinson-Papp et al., 2010). 

















neuropathy screen (SQNS) may prove useful in busy primary health care settings as 
suggested by Cettomai et al. (Cettomai et al., 2010). 
 
5.3 Risk factors for DSP prior to cART initiation 
Possible risk factors for HIV-DSP were investigated. This study supports the view that HIV-
DSP is a multifactorial process and that insults to the peripheral nervous system are 
cumulative. Furthermore, risk factors found with this study are theoretically related to an 
increased susceptibility to mitochondrial damage (see section 1.8.3). 
Age: Relatively few risk factors were independently associated with the presence of either 
DSP or symptomatic DSP, prior to initiating cART. Advancing age, which has proven to be 
an important risk factor for HIV-associated DSP in several studies (Tagliati et al., 1999, 
Morgello et al., 2004, Maritz et al., 2010, Evans et al., 2011, Lichtenstein et al., 2005) was 
associated with both DSP and symptomatic DSP at baseline. While ageing has an effect on 
the integrity of mtDNA resulting in oxidative stress (see section 1.8.3.2), it also influences 
the peripheral nervous system in other ways. Morphologic studies have reported loss of 
myelinated and unmyelinated nerve fibres in elderly individuals (Jacobs and Love, 1985, 
Bouche et al., 1993). Axonal atrophy occurs due to a reduction in the expression and axonal 
transport of cytoskeletal proteins in peripheral nerves (Stromska and Ochs, 1982). Delayed 
nerve regeneration after injury due to changes in neuronal, axonal, Schwann cell and 
macrophage responses, has also been described (Komiyama and Suzuki, 1992). Changes in 
innate and adaptive immune function associated with ageing may augment HIV immune 
dysfunction and also increase susceptibility to opportunistic infections or malignancies 
(Giunta et al., 2008, Robinson-Papp et al., 2012). Furthermore, due to age-associated 
comorbidities such as liver disease, vascular disease, renal disease or cumulative toxicities of 
substance abuse, ageing HIV-infected individuals have an increased risk of other toxicities 
and drug-drug interactions (Goulet, Fultz et al. 2007). 
High-sensitivity CRP: Increased hs-CRP levels were independently associated with both 
DSP and symptomatic DSP at the baseline visit. This has not been previously reported and 
likely reflects a higher set point of HIV-induced systemic inflammation in these individuals. 
The higher hs-CRP levels in individuals with DSP suggest a greater degree of immune 

















damage. As discussed in section 1.7.2, HIV immune dysregulation may indirectly contribute 
to peripheral nerve injury and dysfunction by promoting macrophage infiltration in peripheral 
nerves and the dorsal root ganglia with release of cytokines and ROS production. The time of 
DSP onset was not available for the individuals with pre-existing DSP at baseline. The left 
censored data meant that conclusions about possible causality could not be made. However, 
the association with hs-CRP levels strengthens the study hypothesis of underlying immune 
dysregulation contributing to DSP. 
Triglycerides: Fasting metabolic factors such as glucose and lipids were assessed at the point 
of cART initiation. Several associations emerged; both DSP and symptomatic DSP were 
associated with higher fasting triglyceride levels at baseline. However, 75
th
 percentile values 
of both groups were still within normal range unlike a previous cohort from the developed 
world (Ances et al., 2009). An association with elevated triglyceride levels was reported by 
Ances et al. in which elevated fasting triglyceride levels (>1.70 mmol/L) conferred a 30% 
greater risk of having HIV-DSP, albeit in a mixed group of cART-naïve and cART exposed 
individuals (Ances et al., 2009). Similarly, Banerjee et al. showed that elevated but non-
fasting triglyceride levels independently increased the risk for HIV-DSP (Banerjee et al., 
2011). The association with higher triglyceride levels in our study, albeit still within normal 
range, suggests that triglycerides may be a surrogate for another unmeasured factor that 
serves as the causal link to DSP, such as mitochondrial dysfunction. 
Several metabolic pathways are affected by mitochondrial respiratory chain dysfunction. 
Firstly, when ATP can no longer be synthesized efficiently through oxidative 
phosphorylation there is increased dependence on glycolysis. Secondly, the block of NADH 
utilization in the respiratory chain increases the intracellular NADH/NAD+ ratio. This 
alteration of the redox status promotes the conversion of pyruvate to lactate, inhibiting key 
enzymes involved in the mitochondrial β-oxidation of fatty acids, and consequently resulting 
in the accumulation of triglycerides (Fromenty and Pessayre, 1995). Individuals with elevated 
triglyceride levels may also be at higher risk of mitochondrial dysfunction through its effect 
on mitochondrial energy metabolism and membrane permeability (see section 1.8.3.4). 
Furthermore, in an animal model, plasma triglyceride levels positively correlated with small 
dense LDL (Griffin et al., 1994), a component of LDL vulnerable to oxidation (Isomaa et al., 
2001). Mice fed high-fat diets had increased triglyceride-containing oxidized small dense 

















conduction velocities and sensory function (Vincent et al., 2009). Small dense LDL particles 
were not measured in our study. 
While triglyceride levels may be a marker of mitochondrial dysfunction, another possibility is 
that it may be a surrogate for early dyslipidaemia. Triglyceride levels correlated significantly 
with waist-to-hip ratio in our subjects, which in turn has been shown to be associated with 
dyslipidaemia (Jeong et al., 2005). Dyslipidaemia, a component of the metabolic syndrome, 
has been associated with a systemic low-grade inflammatory state and increased production 
of cytokines in several studies (Tamakoshi et al., 2003, Ridker et al., 2003, Han et al., 2002). 
It is worth noting that waist-to-hip ratio also significantly associated with DSP in a univariate 
analysis. Although other metabolic factors and markers of macronutritional status such as 
weight and BMI were not associated with DSP, waist-to-hip ratio rather than BMI has been 
suggested to be a more reliable indicator of early dyslipidaemia (Jeong et al., 2005). 
Therefore, the association between DSP and waist-to-hip ratio may be linked to early 
dyslipidaemia. 
There remains some controversy regarding the accuracy of fasting triglycerides as an 
independent predictor of metabolic risk, because adjustment for other covariates in particular 
HDL, markedly decreases both the magnitude and significance of observed epidemiologic 
effects (Sarwar et al., 2007). However, in a multivariate model correcting for HDL and LDL, 
the raised triglyceride levels remained independently associated with DSP. Statin use has also 
been shown to increase risk for HIV-DSP, potentially mediating an association between 
triglycerides and DSP (Evans et al., 2012). However, none of the individuals in our cohort 
received statin drugs during the study period. 
HIV/TB co-infection: Although we found current TB infection and/or its therapy to be 
independently associated with DSP and symptomatic DSP at baseline, a history of TB 
infection was not associated. This is in contrast to a previous cross-sectional study from a 
South African population, although it should be noted that their association was in cART-
exposed individuals only (Maritz et al., 2010). Both the inflammation associated with TB 
infection as well as the metabolites of INH therapy may produce ROS, leading to 
mitochondrial damage (see section 1.9.1). The mitochondrial toxicity of stavudine together 
with the mitochondrial damage associated with TB and INH therapy may cumulatively lead 
to redox imbalance with subsequent oxidative stress and nerve damage. None of the 

















The frequency of previous TB infections in the study population was 22%. This is 
considerably lower than that reported previously from other HIV-infected cohorts from this 
region (47% to 52%) and could have limited the power to evaluate the impact of previous TB 
on HIV-associated DSP (Lawn et al., 2006, Maritz et al., 2010). The lower proportion of 
individuals with a history of previous TB may be attributed to a change in the government-
sponsored programme with earlier initiation of cART at higher CD4 T-cell counts (350 vs 
200 cells/mm
3
) (Badri et al., 2002). 
While it is possible that oxidative stress as a result of TB infection may lead to the 
manifestation of subclinical HIV-DSP (section 1.9.1.1), INH-associated painful neuropathy is 
a well known entity and is related to a deficiency in biologically active vitamin B6 (Van der 
Watt et al., 2011) and may have represented our association found with current TB treatment. 
Vitamin B6 and its association with DSP and NAT2 will be discussed in further detail in 
Chapter 9. 
Alanine aminotransferase (ALT): The measurement of ALT was a routine part of the cART 
initiation workup performed by the clinic at baseline. The association between DSP and 
higher, albeit normal ALT levels, was therefore an unexpected finding. ALT levels above the 
normal limit were present in only 10% of individuals at baseline. The cause of this 
association, as well as its clinical significance, is unclear and this makes the interpretation 
difficult, particularly as liver function tests have high intra-individual variability (Kovari et 
al., 2010). Hepatitis C co-infection is known to affect ALT levels and cause peripheral 
neuropathy, and although concerns of possible synergistic effects of co-infection on the 
peripheral nervous system have been raised (Brew, 2003, Cornblath and Hoke, 2006, 
Estanislao et al., 2005), hepatitis C co-infection has not been shown to be a risk factor for 
HIV-DSP (Cherry et al., 2010, Evans et al., 2011). The background prevalence of hepatitis C 
infection is low in South Africa, although it varies between different population groups: in 
our community-based setting (Cape Town), the prevalence ranges from below 0.1% in blood 
donors to 1.6% amongst HIV-infected Caucasian men who have sex with men (Tucker et al., 
1997, Amin et al., 2004). Our study cohort was predominantly female, as generally found in 
South African HIV-infected cohorts, and hepatitis C/HIV co-infection is expected to be rare. 
Asymptomatic hepatic steatosis is common in HIV-infected individuals with metabolic 
abnormalities (Ingiliz et al., 2009). It has been shown that ALT, as a surrogate marker for 

















lipodystrophy, dyslipidaemia, insulin resistance, or with alcohol consumption (Oh et al., 
2006). Insulin resistance, increased pro-inflammatory cytokine production, oxidative stress 
and mitochondrial dysfunction leading to hepatocyte damage have all been posed as 
important pathophysiological mechanisms for raised ALT levels in hepatic steatosis 
(Schindhelm et al., 2006). 
In our population, ALT correlated significantly with waist-to-hip ratio (p<0.001 ρ=0.26) and 
fasting triglycerides (p=0.004, ρ=0.22), but was not associated with raised BMI, impaired 
glucose metabolism, hs-CRP or alcohol consumption. Alcohol abuse is a known cause of 
neuropathy, but has not been shown to increase the risk for HIV-DSP in this cohort. 
However, it is possible that the lack of association between alcohol use, DSP and/or ALT 
may be due to the insensitivity of the measurement tool used to assess alcohol abuse. For 
example, an overly inclusive definition of alcohol use can potentially underestimate its 
impact on ALT or DSP. 
Although an ALT level >19 IU/L was a strong predictor of DSP at baseline according to the 
multivariate model, the overall effect of other variables on DSP may have been 
underestimated due to the presence of mediating factors. For example, there was a significant 
correlation between ALT, fasting triglycerides and waist-to-hip ratio, but the latter two 
variables showed no independent association with symptomatic DSP after adjustment in a 
multivariate model. It would be incorrect to interpret that these variables are not associated 
with symptomatic DSP. Due to the observational nature of this study as well as the potential 
interactions between variables, the best multivariate model is not necessarily the most 
accurate description of what is influencing risk for symptomatic DSP. Furthermore, the 
dichotomization of ALT levels may have led to an inevitable loss of information and power, 
increasing the probability of false positive results. An ALT level of 19 IU/L was chosen to 
dichotomize the cohort as only eight individuals had ALT levels above normal limits. These 
results should therefore be interpreted with caution. 
Stage of HIV disease: Data from pre-cART era cohorts indicate that DSP is more frequent in 
individuals with advanced immunosuppression and high viral load (Tagliati et al., 1999, 
Simpson et al., 2002, Childs et al., 1999). In this study, DSP with or without symptoms did 
not associate with lower baseline CD4 T-cell count or greater WHO stage of disease. Entry 
criteria limited enrolment to individuals about to commence cART with a CD4 T-cell count 
<350 cells/mm
3
 and only 17% had counts <100 cells/mm
3

















individuals at lower risk for having DSP, possibly blunting the influence of CD4 T-cell count 
on the observed frequency of DSP at baseline. 
Due to left censoring of data and risk factors at the baseline visit, it was not possible to 
account for all possible neurological insults. It is possible that confounding conditions not 
dependent on immunologic or virologic status, such as micronutrient deficiencies, previous 
infections, other medication or substance use may be important in the pathogenesis of DSP. 
 
5.4 A comparison between symptomatic and asymptomatic HIV-
DSP at baseline (pre-cART) 
Many reports have tried to address the issue of whether asymptomatic DSP is a different 
entity from symptomatic DSP. Although only 10 individuals had asymptomatic DSP at 
baseline, they were more likely to have abnormal tendon reflexes compared to those with 
symptomatic DSP (100% vs 58%) and less likely to have reduced pin sensibility (60% vs 
81%). Individuals with asymptomatic DSP at baseline performed significantly poorer in the 
IHDS score, particularly in the psychomotor speed performance compared to the other 
domains. 
Individuals with symptomatic DSP at baseline had significantly lower fasting total 
cholesterol compared to those with asymptomatic DSP. The lower total cholesterol in 
symptomatic individuals was mostly driven by low HDL cholesterol, with the 75
th
 percentile 
below normal range in this group. In vitro data have shown that HDL has anti-inflammatory 
properties and decreases oxidation (Hessler et al., 1979), possibly contributing to the redox 
imbalance leading to oxidative stress and ultimately to the development of painful DSP. 
Although haemoglobin levels were significantly higher in individuals with asymptomatic 
compared to symptomatic DSP, a low haemoglobin level was not a predictor of symptomatic 
DSP (when compared to individuals without DSP). It remains possible though that anaemia 
may be a marker for other risk factors such as micronutrient deficiencies unmeasured in this 
study. Other risk factors for symptomatic DSP such as increasing age, previous or current TB 



















5.5 The incidence rate of ATN peaked within 12 weeks after 
starting cART 
Incidence estimates of symptomatic neuropathy after starting cART vary substantially 
depending on the population studied, the time period under investigation and the definition 
employed to determine neuropathy status. Using a definition of ATN, which included the 
development of new symptoms or worsening of symptomatic DSP at baseline, the cumulative 
incidence rate in this community clinic-based population was 34% after 24 weeks. 
The peak period of developing neuropathic symptoms was between 2-4 weeks (10%) and 4-
12 weeks (16%), with a decrease in incidence after 12 weeks. This is similar to a report from 
Europe/Australia showing a peak incidence within 90 days after commencing cART (Arenas-
Pinto et al., 2008), However, in those who did not develop symptoms, but only accumulated 
signs, there was a steady increase over the 24-week follow-up period with the highest 
incidence of 6% evidently between 12 and 24 weeks. These findings suggest, to some degree, 
a separate pathogenetic mechanism for asymptomatic DSP. Further follow-up after this 
period will be useful in determining whether the incidence rate plateaus or continues to rise.  
Other studies have not reported neuropathy incidence rates for the first 12 weeks after cART 
initiation, and as the incidence rate with this study was not constant over different periods of 
time, incidence density rates (per person time incidence rate) would be superficially inflated 
when expressed over longer time intervals. For this reason, cumulative incidence rates of 
other studies commenci g cART, were compared to ours, applying the respective definitions 
of the comparative studies.  
The cumulative incidence rate of 30% for new neuropathic symptoms within 6 months was 
similar to 38% reported by a Ugandan study (Sacktor et al., 2009). Using only the BPNS, the 
cumulative incidence of 21% was higher than that from a Kenyan study of 11% within one 
year after starting cART (Mehta et al., 2011). The incidences of both African studies were 
higher than that of the DELTA trial from Europe and Australia, reporting a cumulative 
incidence of 6% for neuropathic symptoms within three years after commencing cART 

















Table 5.2: Reported cumulative incidence rates of ATN 
 
The different studies cannot be compared directly as the periods of observation as well as the 
observation points differ. However, after correcting for varying diagnostic criteria, the 
cumulative incidence for symptomatic neuropathy in this study appears generally higher. This 
observation may be as a result of detecting the peak incidence of symptomatic neuropathy by 
assessing individuals between short time intervals within 12 weeks after commencing cART. 
We directly estimated the incidence of symptomatic neuropathy over a specific exposure 
period for individuals at risk. It is possible that the comparative studies did not take into 
account substantial changes in incidence that may have occurred over a short time period 
early on in cART exposure or only calculated incidence proportions for the population 
initially at risk. Furthermore, differences in the execution and interpretation of neuropathic 
signs by non-clinicians have been documented (Simpson et al., 2006). In the study by Forna 
et al., study participants were evaluated by trained field officers and again, this may have 
contributed to the discrepant results. The increased incidence in this cohort might reflect a 
higher prevalence of comorbidities, notably TB infection, which could contribute to the 
pathogenesis of symptomatic DSP. The prevalence of previous TB in our study population 
was eight times higher than that documented in the Kenyan population (Mehta et al., 2011). 
Study cohort Forna Arenas-Pinto Sacktor Mehta
2012 2007 2008 2009 2011
(24 weeks) (3 years) (3 years) (24 weeks) (1 year)
ATN










Symptoms 30% 6% 38%
Symptoms and ≥ 1 sign, BPNS
c 21% 11%
Symptoms or ≥ 1 sign
d 78% 36%
a   Incident symptoms or worsening of SDSP
b   Either (i) ≥ 2 signs or (i i) symptoms and ≥ 1 sign
c   BPNS refers to assessment of deep tendon reflexes and vibration sensibility only
d   Assessment of signs: pin sensibility, deep tendon reflexes and vibration sensibility





















5.6 The progression of HIV-DSP after starting cART 
More than half of the cohort was initiated on stavudine-containing cART regimen before the 
government-sponsored programme was changed and stavudine replaced with tenofovir. 
Although a preliminary study has suggested that cART may improve thermal and heat pain 
thresholds in HIV-infected individuals with pre-existing symptoms (Martin et al., 2000), the 
clinical effect of cART initiation on existing symptomatic or asymptomatic DSP has only 
been documented in an anecdotal report (Pialoux et al., 1997) and a small prospective study 
of three patients (Markus and Brew, 1998). We found that within the first 12 weeks of cART 
more than half of individuals (54%) with symptomatic DSP at baseline experienced 
improvement of neuropathic symptoms, of whom half had complete resolution of symptoms. 
However, one third experienced worsening of symptoms usually after 12 weeks of 
observation. A few individuals (n=7) reported symptoms without any neuropathic signs at 
baseline. Prospective evaluation of these individuals revealed that only two went on to 
develop neuropathic signs. Therefore, it is unlikely that this phenotype represents a 
transitional state of developing clinically evident neuropathy. 
An important consideration in the treatment of HIV infection is whether the presence of 
asymptomatic DSP at baseline increases the risk to developing symptomatic ATN on cART, 
as it may preclude the use of potentially neurotoxic drugs in resource constrained settings. 
Based on our prospective clinical evaluations, asymptomatic DSP at baseline did not predict 
progression to symptomatic ATN. Of the 10 individuals with asymptomatic DSP at baseline, 
none developed ATN and half had complete resolution in neuropathic signs by 24 weeks on 
cART. However, there were few individuals with asymptomatic DSP at baseline and the 
sample size might have been too small to delineate the relationships between asymptomatic 
DSP and the progression to symptomatic DSP, or to accurately assess risk factors associated 
with asymptomatic DSP. In addition, whether progressive improvement in baseline DSP, be 
it symptomatic or asymptomatic DSP, occurred because of improvement in general condition 
or immunological status, a specific cART regimen, or because it simply reflected the 


















Overall, the positive effect of cART on the cognitive performance screening tool was evident 
at 24 weeks; 10% had mild cognitive impairment as defined by an IHDS score <10, 
compared to 24% at baseline. The results are comparable to that from Sacktor et al., showing 
similar frequencies (13% at 24 weeks vs 33% at baseline) (Sacktor et al., 2009). 
To summarize, over the first 24 weeks on cART, there was improvement in asymptomatic 
DSP as well as in cognitive performance. Those with painful symptoms at onset frequently 
improved on cART. However, approximately one third of individuals with no symptoms pre-
cART developed new symptoms, usually within the first 12 weeks. 
 
5.7 Clinical evolution of symptoms and signs over the first 24 
weeks of cART 
The most frequent incident neuropathic symptom after cART initiation was paraesthesiae, 
followed by numbness, and least frequently burning aching neuropathic pain. The latter was 
the most frequent symptom in the pre-cART group. This contrasts with previous work 
reporting that pain is an early feature and more intense, compared to HIV-DSP (pre-cART), 
although these cohorts had either more advanced HIV disease or longer duration of cART 
exposure (Berger et al., 1993, Moyle and Sadler, 1998, Maritz et al., 2010). 
This study shows that neuropathic pain in individuals who had existing symptomatic DSP 
pre-cART appeared to be more severe compared with new positive sensory symptoms that 
developed after cART. It is likely that pre-cART symptoms may have been present for a 
longer period. Further follow-up would determine whether symptoms worsen over time in the 
ATN cohort. 
The distribution of neuropathic signs did not differ significantly between the individuals who 
had symptomatic DSP at baseline, compared to those with ATN. Although more individuals 
with symptomatic DSP at baseline had abnormal pinprick sensation compared to individuals 
with ATN, it remained the most frequent neuropathic sign in both groups. This again 
emphasizes the poor sensitivity of the BPNS when used alone. 
Several observations can be made from studying the natural progression of neuropathic signs 

















weeks after cART, improvement in signs correlated significantly with improvement in 
symptoms in individuals with symptomatic DSP pre-cART. This correlation did not continue 
after 12 weeks. Secondly, in contrast to the peak incidence of symptomatic ATN seen 
between 4 and 12 weeks, the incidence of asymptomatic DSP continued to increase after each 
study visit until 24 weeks. Therefore, neuropathic signs appear to take longer to resolve and 
may persist even after the resolution of symptoms. Neuropathic signs also develop later than 
symptoms after cART initiation. 
 
5.8 Risk factors for the development of ATN 
After 24 weeks on cART, those developing ATN showed a significantly greater CD4 T-cell 
count recovery compared to those without ATN. This concurs with our hypothesis that an 
immune-mediated inflammatory response may be associated with nerve damage contributing 
to the development of ATN. The impact of cART-initiation on immune dysregulation or 
reconstitution, and how it may correlate with the development of ATN within the first 12 
weeks of starting cART was investigated further and is discussed in Chapter 10. 
Although advancing age, previous or current TB, increased baseline triglyceride levels, hs-
CRP and waist-to-hip ratio showed an association with the presence of DSP at baseline, none 
of these factors correlated with development of ATN within 24 weeks of cART initiation. It 
is possible that the study period of 24 weeks may have been too short for a sizeable effect of 
cART on some covariates. Fasting triglyceride and HDL levels as well as the waist-to-hip 
ratios, all covariates that associated with symptomatic DSP at baseline, showed no significant 
change over the follow-up period after the addition of cART. These risk factors can therefore 
not be excluded as contributing to cumulative nerve injury over time and contributing to the 
development of ATN, although there was no effect noted within the first 24 weeks of cART. 
Also, a 24-week follow-up period is not sufficient to expose age-related associations. 
Increasingly, accelerated senescence is thought to be an important complication of HIV 
infection (Effros et al., 2008). As NRTIs inhibit the function of polymerase-γ, it is possible 
that these drugs contribute to accelerated ageing through mtDNA damage. An increasingly 
ageing cART-treated population may also accumulate metabolic risk factors (Letendre et al., 
2009) leading to further mitochondrial damage. Also, due to age-associated comorbidities, 

















interactions (Goulet et al., 2007).  
The national government-sponsored cART protocol changed during the study period (section 
1.9.2). Prior to May 2010, the first-line cART regimen NRTI backbone was either stavudine 
or zidovudine; in May 2010 the national guidelines replaced stavudine with tenofovir as the 
preferred first-line NRTI backbone agent. The effect was that 56% of our cohort received 
stavudine during the 24-week follow-up period. This offered the opportunity to assess, albeit 
unparalleled, the early effects of stavudine versus no stavudine on neuropathy status within 
the first 24 weeks. The use of d-drug cART was not associated with the development of 
ATN, with 30% of individuals on stavudine developing ATN compared to 27% on non-d-
drug cART. Although some cART studies indicated that d-drugs might not only cause DSP, 
but exacerbate existing DSP (Moore et al., 2000, Berger et al., 1993), other trials have 
suggested that d-drug cART did not add further risk to the occurrence of HIV-associated DSP 
(Simpson et al., 2002, Schifitto et al., 2005, Morgello et al., 2004, Lichtenstein et al., 2005). 
In some studies, the use of d-drug containing cART was found to be protective for DSP after 
the first year of therapy (Lichtenstein et al., 2005, Hung et al., 2008, Ellis et al., 2010). In a 
study by Lichtenstein et al., although the use of d-drugs was associated with incident DSP in 
the first year of their use, increasing duration of d-drug exposure was associated with a 
decreased incidence of DSP (Lichtenstein et al., 2005). These observations are important for 
resource-limited settings where more affordable drugs may be life saving. However, the long-
term effects of d-drugs on mtDNA remain unknown. 
Alternatively, the seemingly neuroprotective effect of d-drug NRTI previously described 
could be due to survival bias: individuals with early development of neurotoxic neuropathy 
may be more likely to discontinue d-drugs and be “weeded out” from subsequent cohort 
studies, thereby rendering paradoxical results (Simpson et al., 2010, Simpson et al., 2006). 
During the first 24 weeks after cART, this was not the case in our cohort. With this 
prospective analysis, albeit in a relatively small cohort, we found that only two individuals 
had changed in cART therapy from stavudine to tenofovir due to the development of 
neuropathic symptoms. It is possible that this low number of regimen changes is due to the 


















Some have hypothesized that the risk-to-benefit ratio of NRTIs in terms of virological control 
versus neuropathic symptoms differs between cohorts based on the age of individuals, stage 
of disease, the level of immunosuppression or malnutrition, therefore giving neuroprotection 
to some individuals (as a result of recovery of immune and neurological function or better 
virological control). However, in others there is increasing risk of developing ATN due to the 
additional insult as part of the cumulative damage to mitochondria. This then manifests as a 
worsening in neuropathic symptoms in for example those individuals with pre-existing HIV-
DSP. 
It should be noted that data on adherence to antiviral regimens were retrieved from clinic 
folder reviews. Therefore, it is possible that individuals taking these drugs differed in terms 
of dose exposure and consequently in their risk for developing ATN. With compliance based 
on viral control, 68% of the overall cohort had an undetectable viral load after 24 weeks on 
cART. Seventy nine per cent had a viral load <400 copies/mL, which is higher than that 
observed in other resource-poor settings, as well as reports from developed countries (Ivers et 
al., 2005, Staszewski et al., 2001, Staszewski et al., 1999, Walmsley et al., 2002). Although 
HIV viral load was not associated with the development of ATN at 24 weeks, pre-cART 
levels were not available. It remains possible that an association with the viral set point and 
damage to the peripheral nervous system may have occurred at an earlier period associated 
with a higher viral load.  
Other factors were also investigated but showed no association with the development of 
ATN. Similar to a North American study, we did not find impaired glucose metabolism to be 
associated with ATN (Evans et al., 2011). While they found an association with history of 
diabetes, these individuals were excluded from our analysis to minimise the possible 
confounding effect of diabetes. By including these individuals, the North American study 
however demonstrated that non-insulin diabetic therapy reduced the odds of converting from 
asymptomatic to symptomatic DSP (Evans et al., 2012). They concluded that apart from 
better glucose control, the prevention of oxidative stress neuronal injury may be another 
possible mechanism that explains the association. In dyslipidaemic individuals, metformin 
decreased serum levels of IL-6 and TNF-α, probably due to a reduction in the activity of 
nuclear factor kappa B (Gomez-Garcia et al., 2007, Li et al., 2005). Interestingly, in 
individuals with hepatic steatosis, metformin led to normalization of raised ALT levels, and a 

















(Bugianesi et al., 2005). However, we did not find an association between impaired glucose 
metabolism and ALT levels. 
Although one prospective cohort found that women were almost 10 times more likely than 
men to develop symptomatic DSP in the first year of cART (Mehta et al., 2011), we found no 
gender differences in the distribution of ATN within the first 24 weeks of cART. The 
relationship between taller stature and HIV-associated DSP remains unclear. Height was not 
found to be associated with either HIV-DSP or ATN in this cohort, nor from a previous 
report from this population (Maritz et al., 2010). In contrast, increased height has been 
described as a risk factor for DSP in cART exposed individuals from Australia, South-East 
Asia and North America (Cherry et al., 2009, Evans et al., 2011), although it did not predict 
the transformation of asymptomatic to symptomatic DSP after long-term cART (Evans et al., 
2012). Nevertheless, gender bias may have confounded the association between height and 
DSP as our population consisted mostly of females (70%) with a median height of 1.61 m 
(IQR 1.56-1.67). The narrow height range and the relatively low median height of our cohort 
may have limited the power to detect differences in height between those with DSP and those 
without. 
Although cART had a significant effect on macronutritional status over the 24-week study 
period, with significant increases in body weight and BMI, we found no association between 
these and the development of ATN. Reports from the pre-cART era found nutritional indices 
such as decreased albumin, anaemia and weight loss to be associated with DSP in AIDS 
patients (Tagliati et al., 1999, So et al., 1988, Snider et al., 1983). However, the impact of 
nutritional status, including micronutrients on the development of ATN in the cART era has 
not been studied prospectively. 
To summarize, these results illustrate the pathogenetic complexity of HIV-associated DSP in 
its broader sense in which not only HIV infection, but also its treatment, is a major 
contributor. HIV-DSP and ATN may therefore possibly be part of a continuum, being the 



















5.9 Study limitations 
Our study has several limitations. A major limitation in any study of DSP is the absence of a 
gold standard for diagnosing DSP especially in epidemiological field studies such as ours. 
Different research groups also use different tools and definitions. Our diagnosis was based on 
clinical measures, albeit using two different validated tools, without electrophysiological or 
histological confirmation of the diagnosis.  
The comparator group, no-DSP, was defined as individuals not meeting the criteria for DSP 
and may therefore have included individuals with isolated neuropathic symptoms or one sign. 
The decision to define the main outcome as DSP versus no DSP and symptomatic DSP 
versus no DSP was based on the low proportion of individuals who were entirely free of any 
neuropathic symptoms and/or signs at baseline (only 40%). This is a fi ding not unique to 
this study. Wadley et al. documented a prevalence of 25% for individuals with isolated 
neuropathic symptoms or signs (Wadley et al., 2011). 
The definition of worsening symptomatic DSP has not been uniformly defined. A change in 
the TNS score has been utilized in some studies (Simpson et al., 2006, Cavaletti et al., 2007), 
but the exact point-change associating with a clinically meaningful difference is not known. 
Further, worsening of one modality may be balanced out by an „improvement‟ in another. As 
the primary objective of this study was to focus on painful neuropathy (section 1.10), it was 
decided a priori to define worsening symptomatic DSP as worsening in neuropathic 
symptoms. This definition was extrapolated from previous work where a 2-point 
improvement in pain (on an 11-point VAS) was validated against a standard patient global 
impression of change score (Farrar et al., 2001). Worsening in pain was not assessed and this 
definition may therefore not have construct validity. Furthermore, the population at risk for 
incident symptoms and those at risk for worsening symptoms (which would be individuals 
with symptomatic DSP at baseline) are mutually exclusive and with our definition of ATN, 
individuals with symptomatic DSP will be in both comparative groups. It was therefore 
decided to also perform longitudinal analyses on individuals only developing new 
neuropathic symptoms compared to individuals who remained symptom-free (Appendix M). 
The study was undertaken at a local community clinic in Cape Town. Ascertainment bias 
through exclusion criteria such as known diabetes or individuals on TB therapy for less than 
one month hinders the extrapolation of these figures to the overall HIV population. There is a 

















return for follow-up visits. Also, the results from a relatively small cohort may not be as 
robust as those from larger multicentre studies. Due to the small sample size, some effect 
estimates, although not significant, cannot rule out potential associations.  
Individuals with symptomatic HIV-DSP at baseline were not examined at 2 and 4 weeks. It 
would be informative to investigate whether those who improved on cART at 12 weeks, 
experienced a transient period of worsening in symptoms prior to improvement, possibly due 
to the initial „insult‟ of NRTI therapy. Interestingly, all three individuals who improved at 24 
weeks initially worsened in symptoms at 12 weeks after cART initiation. 
 
5.10 Study strengths 
Both the BPNS and the mTNS were used to assess neuropathy status as each had its strength; 
the former allowed quantitative assessment of symptoms and the latter a more qualitative 
measure of neuropathy severity with the focus on small-fibre functioning, and thus increasing 
the specificity for the diagnosis of HIV-associated DSP. Individuals were assessed within 
days prior to commencing cART and 2-, 4-, 12- and 24-weeks thereafter. The incidence and 
evolution of ATN has not previously been studied within the first 4 weeks of commencing 
cART. These clinical outcomes can now be evaluated against biomarkers that we have 
hypothesized are important as contributing to the pathogenesis of ATN – the following 
chapters will discuss these further. 
As the study included individuals with HIV-DSP at baseline, this allowed for a cross-
sectional analysis of a „clean‟ cART-naïve cohort as well as the effect of cART on 
progression of DSP. In contrast to cross-sectional analyses in which the temporal sequence of 
exposure and outcome is often not ascertained, the longitudinal observational design of this 
study allowed for a more precise determination of predictors. Loss to follow-up was random 
and occurred as a result of many factors (see section 4.2.1). More than half of individuals lost 
to follow-up defaulted cART at the local clinic and were therefore excluded (n=22). 
However, 78% of individuals completed follow-up assessments, and therefore provided 
unbiased estimates in the follow-up analyses. 
An additional strength was having only two clinicians performing the clinical examination. 

















reliability in some studies where nurses were used (Simpson et al., 2006). In this study, the 
clinical assessments were performed by two clinicians trained and supervised by a 
neurologist and stringent criteria of ≥2 signs were used for the definition of asymptomatic 
DSP. Finally, due to the observational nature of the study, observed associations may not be 
causal. Furthermore, the author had direct involvement with all aspects of the study, which 










































With the NAT2 substudy we firstly investigated the variability of the NAT2 gene in a sub-
Saharan African Xhosa population. Secondly, the relationship between NAT2 INH acetylation 
status and vitamin B6 levels was investigated; the hypothesis being that slow acetylation-
phenotype would have an increased requirement for vitamin B6 and thus be at increased risk 
of deficiency, and potentially developing HIV-associated DSP. 
 
6.2 NAT2 genotyping 
NAT2 genotyping was performed on 165 consecutively selected individuals at baseline. Two 
of these individuals were excluded from the analyses related to DSP, as they did not 
commence cART within two weeks of the baseline (pre-cART) assessment. 
Genomic DNA concentrations were satisfactory for further analysis and varied between 45 
ng/μL and 231 ng/μL. PCR amplification of genomic DNA resulted in the amplification of an 
895 bp fragment containing NAT2. As discussed in section 3.1.3.7, for NAT2 polymorphism 
identification using RFLP, the wild-type sequences (NAT2*4) were discriminated from 
homozygous and heterozygous variations based on the pattern of restriction enzyme digestion 
of the amplified PCR products. 
The variation in a single nucleotide at a particular position abolished specific restriction 
enzyme sites (MspI for 191 G>A and 434 A>C, FokI for 282 C>T, KpnI for 481 C>T, TaqI 
for 590 G>A, DdeI for 803 A>G, DraIII for 845 A>C and BamHI for 857 G>A) so that 
alleles were defined based on the availability of a specific endonuclease recognition 
sequence. Unique RFLP patterns were observed after restriction digestion of PCR products 
(see section 3.1.3.2). These distinct patterns were used to determine the presence or absence 
of certain SNPs. Figure 6.1 and Figure 6.2 represent images obtained from the PCR 
digestions after gel electrophoresis. Due to the lack of a known restriction enzyme site near 
base 341, the 341 T>C substitution was detected by using allele-specific PCR described in 
section 3.1.3.7. We identified seven variant SNPs that have all been previously reported (Doll 


















Figure 6.1: NAT2 RFLP digests - MspI & KpnI (left) and TaqI & BamHI (right) 
 
Figure 6.2: NAT2 RFLP digests - FokI & DraIII (left) and DdeI (right) 
6.2.1 Allelic frequencies 
The seven identified SNPs were polymorphic and in Hardy-Weinberg equilibrium (p<0.05). 
The genotypic and allelic frequencies are presented in Table 6.1. NAT2*12 was the most 














































NAT2*18 (845 A>C) were not present in this cohort. 
Table 6.1: NAT2 allelic frequencies 
 
Although the frequencies of 341 T>C and 481 C>T were similar (25% vs 23%), the 
occurrence of 481 C>T was not as strongly linked to the occurrence of 341 C>T, as 
previously described in Caucasian populations (Sabbagh and Darlu, 2005). Of 83 alleles with 
Genotype frequency Allele frequency
n (%) n (%)




























a    Standard NAT2  allele nomenclature

















341 T>C substitutions, only 65 (78%) were also shown to have 481 C>T whereas the 
remaining 18 alleles (22%) showed the wild-type sequence for nucleotide 481, namely 481 C. 
This finding reflects a significant level of decay of linkage disequilibrium between these two 
SNPs and has also been observed in other African populations (Sabbagh et al., 2008). 
6.2.2 Novel and uncommon NAT2 polymorphisms 
To confirm polymorphisms detected by RFLP and to identify any novel polymorphisms not 
detected by RFLP, the NAT2 gene of 44 randomly selected individuals from the study 
population was subsequently sequenced. The bidirectional sequencing method is described in 
section 3.1.3.4. A novel 589 C>T polymorphism was found in one individual (allelic 
frequency 0.01) as well as three uncommon polymorphisms. Two of these uncommon 
polymorphisms, 403 C>G (allelic frequency 0.01) and 766 A>G (allelic frequency 0.01), 
were previously described in a central African population (Patin et al., 2006) and one, 345 
C>T, was previously described in a North African population (allelic frequency 0.01) 
(Sabbagh et al., 2008).  
The 589 C>T variant results in the arginine amino acid changing to a TGA stop codon. The 
403 C>G polymorphism results in an amino acid change from cysteine to glycine and 766 
A>G in a change from lysine to glutamic acid. The 345 C>T polymorphism is synonymous 
and does not change the amino acid sequence. The impact of these variants on NAT2 
function will be discussed in section 6.3.1. 
6.2.3 Distribution of NAT2 SNPs and haplotypes 
Sixteen distinct haplotypes were inferred by the PHASE programme (the results of which are 
shown in Table 6.2). The most frequent haplotypes were NAT2*12A (22%) and NAT2*6A 
(22%). Wild type NAT2*4 was present in 6% of haplotypes. A unique haplotype, not 
compatible with standard NAT2 nomenclature include the haplotype GCCTAAG with base 

















Table 6.2: PHASE-predicted NAT2 haplotype frequencies 
 
The synonymous base changes 481 C>T, 803 A>G and 282 C>T, encoding for NAT2*11, 
NAT2*12 and NAT2*13 respectively, do not result in functional change of the NAT2 enzyme 
and has previously been classified as NAT2*4 (Bakayev et al., 2004, Dandara et al., 2003). 
We therefore grouped the abovementioned three alleles together with the ancestral reference 
genotype, NAT2*4. Using this classification, NAT2*4 was the most common genotype (44%) 
while NAT2*7 was the least common (0.3%). NAT2*5 and NAT2*6 were both present in 





















a    Haplotype with seven positions: 191, 282, 
      341, 481, 590, 803 and 857

















Table 6.3: PHASE-predicted NAT2 haplotype frequencies (alternative classification) 
 
A large number of different diplotype patterns of similar frequencies occurred in our cohort. 
Table 6.4 shows different combinations of the seven SNPs, which defined 49 distinct 
diplotype combinations. Diplotype frequencies ranged from 1% to 11%. Twenty-two 
diplotypes (45%) occurred with a frequency greater than 2%. PHASE v2.1.1 was used to 
generate genotypes for each diplotype configuration. The most frequent genotype was 
NAT2*6A/12A. 
Computational genotypes from the PHASE programme were compared to actual genotypes 
obtained by means of allele-specific haplotype mapping and sequencing (Agundez et al., 
2008). In most cases, genotype reconstruction fully corresponded to actual genotypes (Table 
6.4). However, in some cases, the most probable predicted genotypes did not correspond to 
the actual genotype described by Agundez et al. (Agundez et al., 2008), viz. diplotypes 
number 5, 18, 42 and 44 noted in Table 6.4. This discrepancy may be as a result of 
















a    Haplotype with seven positions: 191, 282, 
      341, 481, 590, 803 and 857






















191 282 341 481 590 803 857 PHASE reconstruction (probability) Actual genotypes PHASE reconstruction (probability)
1 GG CC TT CC GG AG GG 2% *4/*12A (1.00) *4/*12A *4/*12A (1.00)
2 GG CC TT CC GG GG GG 2% *12A/*12A (1.00)
3 GG CC TT CC GA AG GG 1% *6B/*12A (0.98) *6B/*12A *6B/*12A (1.00)
4 GG CC TT CC AA AA GG 1% *6B/*6B (1.00)
5 GG CC TT CT GG AG GG 1% *11A/*12A (0.67) *4/*12C *4/*12C (1.00)
6 GG CC TT CT GG GG GG 1% *12A/*12C (1.00)
7 GG CC TC CC GG AG GG 1% *4/*5C (0.75) *4/*5C *4/*5C (0.97) *5D/*12A (0.03)
8 GG CC TC CC GG GG GG 5% *5C/*12A (1.00)
9 GG CC TC CT GG AA GG 2% *4/*5A (0.88) *4/*5A *4/*5A (1.00)
10 GG CC TC CT GG AG GG 2% *4/*5B (0.63) *4/*5B *4/*5B (1.00)
11 GG CC TC CT GG GG GG 6% *5B/*12A (0.95) *5B/*12A *5B/*12A (1.00)
12 GG CC TC CT GA AG GG 1% *5B/*6B (0.69) *5B/*6B *5B/*6B (1.00)
13 GG CC TC CT GA GG GG 1% *5B/*6F (0.55)
14 GG CC TC CT AA AA GG 1% *6B/? (0.95)ς
15 GG CC TC TT GG GG GG 2% *5B/*12C (1.00) *5B/*12C *5B/*12C (1.00)
16 GG CC TC TT GA AG GG 1% *12C/? (0.61)ς
17 GG CC CC CT GG GG GG 2% *5B/*5C (1.00) *5B/*5C *5B/*5C (1.00)
18 GG CC CC CT GA AG GG 1% *5C/? (0.67)ς *5B/*5E *5B/*5E (0.97)
19 GG CC CC TT GG AG GG 1% *5A/*5B (1.00) *5A/*5B *5A/*5B (1.00)
20 GG CC CC TT GG GG GG 1% *5B/*5B (1.00) *5B/*5B *5B/*5B (1.00)
21 GG CT TT CC GG AA GG 1% *4/*13 (1.00)
22 GG CT TT CC GG AG GG 6% *12A/*13 (0.87) *12A/*13 (n = 1) *4/*12B (n = 1) *12A/*13 (0.70) *4/*12B (0.30)
23 GG CT TT CC GG AG GA 1% *7B/*12A (0.44) *7B/*12A *7B/*12A (1.00)
24 GG CT TT CC GG GG GG 1% *12A/*12B (1.00)
25 GG CT TT CC GA AA GG 4% *4/*6A (0.79) *4/*6A *4/*6A (1.00)
26 GG CT TT CC GA AG GG 11% *6A/*12A (0.96) *6A/*12A *6A/*12A (0.96) *4/*6C (0.04)
27 GG CT TT CC AA AA GG 1% *6A/*6B (1.00) *6A/*6B *6A/*6B (1.00)
28 GG CT TT CT GG AA GG 1% *11A/*13 (0.98)
29 GG CT TT CT GA AA GG 2% *6A/*11A (0.93)
30 GG CT TT CT GA AG GG 1% *6A/*12C (0.95) *6A/*12C *6A/*12C (1.00)
31 GG CT TC CC GG AG GG 1% *5C/*13 (0.94)
32 GG CT TC CC GA AG GG 2% *5C/*6A (0.99) *5C/*6A *5C/*6A (1.00)
33 GG CT TC CT GG AG GG 3% *5B/*13 (0.93) *5B/*13 *5B/*13 (0.98) *4/*5G (0.02)
34 GG CT TC CT GG GG GG 2% *5B/*12B (0.97)
35 GG CT TC CT GA AA GG 1% *5A/*6A (0.80) *5A/*6A *5A/*6A (1.00)
36 GG CT TC CT GA AG GG 10% *5B/*6A (0.98) *5B/*6A *5B/*6A (1.00)
37 GG TT TT CC GG AA GG 1% *13/*13 (1.00)
38 GG TT TT CC GA AA GG 4% *6A/*13 (1.00) *6A/*13 *6A/*13 (1.00)
39 GG TT TT CC GA AG GG 2% *6A/*12B (0.97)
40 GG TT TT CC AA AA GG 1% *6A/*6A (1.00) *6A/*6A *6A/*6A (1.00)
41 GA CC TT CC GG AA GG 1% *4/*14A (1.00) *4/*14A *4/*14A (1.00)
42 GA CC TT CC GG AG GG 3% *12A/*14A (0.98) *4/*14E *12A/*14A (0.97) *4/*14E (0.03)
43 GA CT TT CC GG AA GG 1% *4/*14B (0.52)
44 GA CT TT CC GG AG GG 1% *12A/*14B (0.86) *4/*14G *4/*14G (1.00)
45 GA CT TT CC GA AA GG 1% *6A/*14A (0.76) *6A/*14A (n = 3) *4/*14D (n = 1) *6A/*14A (0.60) *4/*14D (0.40)
46 GA CT TC CC GG AA GG 1% *5D/*14B (0.94)
47 GA CT TC CC GG AG GG 1% *5C/*14B (0.98)
48 GA CT TC CT GG AG GG 2% *5B/*14B (0.98)
49 GA TT TT CC GA AA GG 3% *6A/*14B (0.99)





















6.3 NAT2 phenotypes 
From the NAT2 genotypes we inferred the distribution of rapid, intermediate and slow 
acetylation phenotypes in our cohort. The distribution of NAT2 phenotypes were assessed 
using three pre-specified classifications: 
A) Classification 1: Rapid acetylators compared to individuals with at least one slow 
allele. 
B) Classification 2: Comparing rapid, slow and intermediate acetylators. 
Heterozygote individuals bearing a rapid and a slow haplotype were considered 
intermediate acetylators (Cascorbi et al., 1995). 
C) Classification 3: Comparing rapid, slow, intermediate and ambiguous NAT2 
genotypes grouped as slow/intermediate. Slow/intermediate acetylation included 
individuals with two or more SNPs associated with slow acetylation occurring 
with a rapid allele. Assuming the slow SNPs occur on the same chromosome 
would make the individual an intermediate acetylator. If they occur on different 
chromosomes, the individual would be a slow acetylator. 
 
 
Figure 6.3: NAT2 acetylation phenotype distribution using three different classifications 
Figure 6.3 illustrates the distribution of rapid, intermediate and slow acetylation phenotypes 
according to the three different classifications. One slow allele was present in 135 individuals 
(83%) (Figure 6.3 A), 17% were rapid acetylators, 8% slow and 54% were intermediate 

















NAT2 phenotype and was classified as slow/intermediate (Figure 6.3 C). Computational 
PHASE analysis predicted a slow phenotype in all 35 ambiguous genotypes. 
6.3.1 Predicted functional effect of novel and rare polymorphisms on NAT2 
activity 
To determine the effects of the SNPs on NAT2 enzyme activity, we theoretically translated 
each NAT2 haplotype into its corresponding amino acid sequences. The aim was to assess the 
unknown functional impact of two SNPs (345 C>T and 589 C>T). Two rare SNPs previously 
reported to have no effect on NAT2 activity (403 C>G and 766 A>G) were also investigated. 
We also used the web-based tools PolyPhen-2 and PANTHER to predict the effect of the 
variant on protein activity by measuring the evolutionary constraint acting on the site where it 
appeared. In order to test the reliability of PolyPhen-2 and PANTHER, the SNPs resulting in 
amino acid change where the impact on NAT2 activity is well known, were included as 
controls. The SNPs 191 G>A, 341 T>C, 590 G>A, 857 G>A are known to alter NAT2 
activity while 803 A>G does not alter NAT2 activity. Our analysis predicted that 403 C>G, 
345 C>T and 766 A>G do not alter NAT2 functional activity, while 589 C>T resulting in a 
stop codon, likely does. 
 
6.4 The association between NAT2 and HIV-DSP 
6.4.1 NAT2 and DSP at baseline 
The allele distribution between the group with symptomatic DSP at baseline and the group 
without DSP at baseline are presented in Table 6.5. Data were analysed using three pre-
specified genetic models (described in section 3.1.3.6). None of the SNPs linked to slow 
acetylation showed a significant association with symptomatic DSP at baseline for any of the 
three genetic models, with relatively equal distributions of these SNPs between both groups.  
The allele distribution between the individuals with DSP at baseline and those without were 
also investigated and are presented in Table O-5 in Appendix O. DSP was not associated with 
any of the alleles investigated using any of the three models. Although a greater proportion of 
individuals with DSP at baseline had the 341 T>C SNP compared to those without DSP (57% 

















effect of a history of previous TB therapy, the association was significantly strengthened 
(p=0.032), suggesting a possible augmenting interaction between NAT2 and previous TB 
therapy. The DSP odds ratios for allelic groups after correcting for previous TB therapy are 

















Table 6.5: Allele distribution between SDSP and No DSP shown in three genetic models 
 
SNP SDSP No DSP Total SNP SDSP No DSP Total SNP SDSP No DSP Total







GG 28 (93%) 107 (86%) 135 (88%) GG 28 (93%) 107 (86%) 135 (88%) G 58 (97%) 231 (93%) 289 (94%)
GA 2 (7%) 17 (14%) 19 (12%) GA+AA 2 (7%) 17 (14%) 19 (12%) A 2 (3%) 17 (7%) 19 (6%)







CC 11 (37%) 46 (37%) 57 (37%) GG 11 (37%) 46 (37%) 57 (37%) G 37 (62%) 156 (63%) 193 (63%)
CT 15 (50%) 64 (52%) 79 (51%) GA+AA 19 (63%) 78 (63%) 97 (63%) A 23 (38%) 92 (37%) 115 (37%)
TT 4 (13%) 14 (11%) 18 (12%)
341 T>C 0.313 ¶ 341 T>C 0.169 § 341 T>C 0.319 §
TT 13 (43%) 71 (57%) 84 (55%) GG 13 (43%) 71 (57%) 84 (55%) G 42 (70%) 189 (76%) 231 (75%)
TC 16 (53%) 47 (38%) 63 (41%) GA+AA 17 (57%) 53 (43%) 70 (45%) A 18 (30%) 59 (24%) 77 (25%)
CC 1 (3%) 6 (5%) 7 (5%)
481 C>T 1.000 ¶ 481 C>T 0.974 § 481 C>T 0.879 §
CC 18 (60%) 74 (60%) 92 (60%) GG 18 (60%) 74 (60%) 92 (60%) G 47 (78%) 192 (77%) 239 (78%)
CT 11 (37%) 44 (35%) 55 (36%) GA+AA 12 (40%) 50 (40%) 62 (40%) A 13 (22%) 56 (23%) 69 (22%)







GG 14 (47%) 67 (54%) 81 (53%) GG 14 (47%) 67 (54%) 81 (53%) G 43 (72%) 186 (75%) 229 (74%)
GA 15 (50%) 52 (42%) 67 (44%) GA+AA 16 (53%) 57 (46%) 73 (47%) A 17 (28%) 62 (25%) 79 (26%)
AA 1 (3%) 5 (4%) 6 (4%)
803 A>G 0.607 § 803 A>G 0.339 § 803 A>G 0.358 §
AA 9 (30%) 27 (22%) 36 (23%) GG 9 (30%) 27 (22%) 36 (23%) G 33 (55%) 120 (48%) 153 (50%)
AG 15 (50%) 66 (53%) 81 (53%) GA+AA 21 (70%) 97 (78%) 118 (77%) A 27 (45%) 128 (52%) 155 (50%)
GG 6 (20%) 31 (25%) 37 (24%)
857 G>A 1.000 ¶ 857 G>A 1.000 ¶ 857 G>A 1.000 ¶
GG 30 (100%) 123 (99%) 153 (99%) GG 30 (100%) 123 (99%) 153 (99%) G 60 (100%) 247 (100%) 307 (100%)
GA 0 (0%) 1 (1%) 1 (1%) GA+AA 0 (0%) 1 (1%) 1 (1%) A 0 (0%) 1 (0%) 1 (0%)
AA 0 (0%) 0 (0%) 0 (0%)
¶    Fisher's exact test
§    χ2 test


















The distribution of slow, intermediate and rapid acetylators between the individuals with 
symptomatic DSP at baseline and those without DSP is presented in Table 6.6. There was no 
significant difference in distribution of NAT2 acetylation phenotypes between the 
symptomatic DSP group and those individuals without DSP. 
Table 6.6: NAT2 acetylation phenotype distribution between baseline SDSP and No DSP 
 
The distribution of slow, intermediate and rapid acetylators between individuals with DSP 
and those without DSP are presented in Table O-1 in Appendix O. No significant difference 
in distribution in the NAT2 acetylation phenotype was found. 
6.4.2 NAT2 and ATN 
No single SNP significantly associated with the development of ATN within 12 weeks of 
cART using the dominant, recessive and additive models. The allele distribution between the 
ATN and the ATN-free group are presented in Table O-7 in Appendix O. The distribution of 
slow, intermediate and rapid acetylator phenotypes between the ATN and the ATN-free 
groups are presented in Table 6.7. The data demonstrated a tendency of ATN to be associated 
with slow acetylator phenotype (although not statistically significant) with 91% of the ATN 
cohort having at least one slow allele compared to 81% without ATN (p = 0.17). In the Cox 
Total (N=163) SDSP (N=30) No DSP (N=124)
Acetylation Classification 1 0.943 §
Rapid 25 (16%) 5 (17%) 20 (16%)
Slow 129 (84%) 25 (83%) 104 (84%)
Acetylation Classification 2 1.000 ¶
Rapid 25 (16%) 5 (17%) 20 (16%)
Intermediate 116 (75%) 23 (77%) 93 (75%)
Slow 13 (8%) 2 (7%) 11 (9%)
Acetylation Classification 3 0.552 ¶
Rapid 25 (16%) 5 (17%) 20 (16%)
Intermediate 84 (55%) 14 (47%) 70 (56%)
Slow/Intermediate 32 (21%) 9 (30%) 23 (19%)
Slow 13 (8%) 2 (7%) 11 (9%)
¶
    Fisher's  exact test




















regression analysis, there was a trend for individuals with at least one slow allele to develop 
ATN (OR 3.13; 95% CI 0.75-13.11; p=0.12). 
Table 6.7: NAT2 acetylation phenotype distribution between individuals with and without ATN 
 
The proportion of individuals developing new neuropathic symptoms was significantly 
associated with the presence of at least one slow allele (Table 6.8). In the Cox regression 
analysis, there was only a trend for individuals with at least one slow allele to develop new 
neuropathic symptoms (OR 3.22; 95% CI 0.77-13.49; p=0.11) and the trend remained after 
adjusting for a history of previous INH TB therapy (p=0.069, Table P-7 in Appendix P). 
 
Total (N=157) ATN (N=33) No ATN (N=124)
Acetylation Classification 1 0.165 §
Rapid 27 (17%) 3 (9%) 24 (19%)
Slow 130 (83%) 30 (91%) 100 (81%)
Acetylation Classification 2 0.188 ¶
Rapid 27 (17%) 3 (9%) 24 (19%)
Intermediate 117 (75%) 29 (88%) 88 (71%)
Slow 13 (8%) 1 (3%) 12 (10%)
Acetylation Classification 3 0.312 ¶
Rapid 27 (17%) 3 (9%) 24 (19%)
Intermediate 84 (54%) 21 (64%) 63 (51%)
Slow/Intermediate 33 (21%) 8 (24%) 25 (20%)
Slow 13 (8%) 1 (3%) 12 (10%)
¶    Fisher's  exact test
§































Acetylation Classification 1 0.036 §
Rapid 22 (17%) 1 (4%) 21 (20%)
Slow 110 (83%) 27 (96%) 83 (80%)
Acetylation Classification 2 0.041 ¶
Rapid 22 (17%) 1 (4%) 21 (20%)
Intermediate 99 (75%) 26 (93%) 73 (70%)
Slow 11 (8%) 1 (4%) 10 (10%)
Acetylation Classification 3 0.086 ¶
Rapid 22 (17%) 1 (4%) 21 (20%)
Intermediate 73 (55%) 20 (71%) 53 (51%)
Slow/Intermediate 26 (20%) 6 (21%) 20 (19%)
Slow 11 (8%) 1 (4%) 10 (10%)
¶    Fisher's  exact test
§    χ2 test












































The study demonstrated the diversity of the NAT2 gene in a sub-Saharan African Xhosa 
population by genotyping 330 chromosomes. Individual NAT2 SNP frequencies in this 
indigenous African population were similar to those reported elsewhere from the Western 
Cape and other African populations (Adams et al., 2003, Parkin et al., 1997, Sabbagh et al., 
2008). However, some differences were also observed. Comparative allele frequencies of the 
seven common NAT2 SNPs in African populations are shown in Figure 7.1. (Sabbagh et al., 
2008). 
 
Figure 7.1: SNP frequencies in 8 different African populations. (1) Study population (Xhosa); (2) 
Tswana; (3) Ateke Bantus; (4) Bakola Pygmies; (5) Baka Pygmies; (6) Mandenka; (7) Dogons and (8) 
Somali (Functional SNPs 341 T>C, 191 G>A, 590 G>A) (Adapted from Sabbagh et al., 2008) 
The base change 803 A>G, which defines the NAT2*12 allelic group, is the one that occurred 
with the highest frequency in our population (51%), consistent with other African 
populations. The two most frequent allelic groups associated with a slow acetylation 
phenotype were NAT2*5 (341 T>C) and NAT2*6 (590 G>A), both occurring with a 
frequency of 25%. Intraracial variability has been reported for 341 T>C with frequencies in 
other African populations ranging from 5% to 42%. Compared to our population, 590 G>A 
has previously been found at lower frequencies among Tswana, Tanzanian, Venda and 
Zimbabwean populations (Dandara et al., 2003), although higher in Northern African (e.g. 
Somali) populations. The NAT2*14 allelic group (191 G>A) has functional implications, and 
is regarded as an ancestral African-specific group, rarely occurring in Caucasian and Asian 
populations. Although 191 G>A occurred at a frequency of 6%, it is similar to other African 
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functional 857 G>A variant is primarily found in Asia and Central America and as expected, 
had a very low frequency in our population (<1%). In addition, we found a novel 589 C>T 
polymorphism in one individual and three uncommon polymorphisms previously described in 
African populations, viz. 403 C>G, 766 A>G and 345 C>T (Sabbagh et al., 2008, Patin et al., 
2006). 
A marked degree of linkage disequilibrium exists in Caucasian populations between SNP 
positions 341 and 481, where 341 T>C rarely occurs without 481 C>T (Lin et al., 1993). In 
our cohort, similar to that reported for other African populations (Bakayev et al., 2004, 
Sabbagh et al., 2008), the linkage disequilibrium was less pronounced: of 83 alleles with 341 
T>C substitutions, only 78% were also shown to have 481 C>T. In addition, we found a high 
occurrence of nucleotide changes 803 A>G and 282 C>T in isolation (defining alleles 
NAT2*12A and NAT2*13 respectively). In contrast, these nucleotide changes are almost 
always tightly linked to other polymorphisms in European populations (Cascorbi and Roots, 
1999). 
A common problem in NAT2 genotyping is that the allelic effect of variations in cis or trans 
is not apparent and may influence the phenotype. Rather than indicating actual genotypes, the 
results of most genotyping methods indicate the predicted sum of two haplotypes 
(diplotypes), and many such diplotypes can represent different allelic combinations with 
different functional consequences (Sabbagh et al., 2008, Agundez et al., 2008). Forty-nine 
different diplotypes with similar frequencies occurred in our study population (Table 6.4). 
Ambiguous genotypes, where two or more enzyme-inactivating SNPs may be located either 
in cis or trans were demonstrated in 35 individuals (21%). These individuals may therefore 
be intermediate acetylators (cis) or slow acetylators (trans). To overcome this ambiguity, 
PHASE computational haplotype reconstruction was performed, which predicted a slow 
acetylation phenotype in all 35 individuals with ambiguous genotypes. 
To date, no comparisons between actual haplotypes and reconstructed haplotypes have been 
performed in a study group large enough to include rare variant alleles in African individuals. 
Actual NAT2 genotypes cannot be fully determined by haplotype prediction techniques. In 
Caucasian populations the ambiguity of the haplotype reconstruction with PHASE v2.1.1 
ranged from 0.1% to 1.2% in previous studies (Golka et al., 2008, Agundez et al., 2008). 
However, an error rate of approximately 3% has been reported in an African population 

















with ambiguous multilocus genotypes, creating difficulty in the statistical inference of 
haplotypes. For this reason, in addition to performing PHASE reconstruction, we compared 
the PHASE predicted genotypes to a reference set which converted diplotypes to actual 
genotypes based on molecular haplotype mapping (Agundez et al., 2008). In our dataset, 6% 
of the PHASE predicted genotypes did not correspond to the actual genotype described by 
Agundez et al. (Agundez et al., 2008). It is possible that this discrepancy reflects the 
difference between the two populations in the comparison (African vs Spanish). In addition, 
over half of the diplotypes from our cohort occurred with a frequency <2%, and as 
demonstrated by Stephens et al., lower-frequency variants are less easily estimated 
statistically, leading to possible PHASE reconstruction error (Stephens et al., 2001). 
Consequently, due to the possibility that rare haplotypes may be important for disease risk or 
for predicting drug response, molecular haplotyping may be necessary to unambiguously 
determine linkage phase in African populations (Sabbagh and Darlu, 2005). 
To determine the distribution of NAT2 acetylation phenotypes in this population, we inferred 
the distribution of rapid, intermediate and slow acetylation phenotypes from the NAT2 
genotypes as described in section 3.1.3.7. Consistent with previous African populations, the 
distribution of NAT2 phenotypes in this cohort was skewed toward the slow phenotype, with 
83% having at least one slow allele. In most European populations, the proportions of slow 
and rapid acetylators are equal, whereas in Alaskan Inuits the majority are rapid acetylators 
(95%) and Saudi Arabians are generally slow acetylators (95%) (Matar et al., 2004). 
NAT2 determines acetylation and influences the risk for INH-associated neuropathy. 
Furthermore, symptomatic DSP is independently associated with previous TB and thus 
possibly with INH exposure. We therefore investigated whether NAT2 genotype and the 
deduced acetylation phenotype was a risk factor for HIV-associated symptomatic DSP. 
Overall, none of the SNPs associated with symptomatic DSP at baseline and neither did the 
NAT2 acetylation phenotypes. At 24 weeks, although none of the SNPs associated with the 
development of ATN, there was a trend for slow acetylation to predict the development of 
ATN. Furthermore, the development of new neuropathic symptoms over 24 weeks was 
significantly associated with the slow acetylation phenotype (Table 6.8).  
Despite the association found between slow acetylation and new neuropathic symptoms, 
previous or current TB therapy was not associated with the development of new neuropathic 

















acetylation and incident symptoms after cART, regardless of a history of previous TB, 
suggests the possibility that slow acetylation may be an independent risk factor for the 
development of neuropathic symptoms on cART. This relationship may be the result of slow 
acetylation increasing vulnerability to mechanisms such as oxidative stress that may be 
attributed to TB/HIV co-infection, cART initiation, or concomitant cotrimoxazole treatment 
(see later). 
It is important to note that the slow acetylation phenotype is not homogeneous and is 
dependent upon an individual's specific NAT2 haplotype or allelic profile. With 49 different 
NAT2 diplotypes observed in this cohort, a wide variation in NAT2 enzyme activity between 
different individuals is to be expected. With this relatively small sample size and wide 
confidence intervals, important associations between acetylation phenotype and HIV-
associated DSP may not be accurately represented. 
This study, as with most other NAT2 studies, used phenotypes inferred from genotyping 
results and thus the validity of the derived conclusions may be compromised by NAT2 
genotype-phenotype discrepancies (Walraven et al., 2008). In healthy individuals, there is a 
high correlation between NAT2 genotype and phenotype activity. Previously, discrepancies 
between genotype and phenotype occurred in only 7% where rapid genotypes showed slow 
acetylation phenotypes (Cascorbi et al., 1995). Similar low rates of discordance are reported 
by other studies, some of which employed test substrates other than caffeine (Mrozikiewicz et 
al., 1994, Graf et al., 1992, Blum et al., 1991). However, in the context of chronic 
inflammatory disease, the relationship between genotype and phenotype is not clear. For 
example, acetylation phenotype/genotype discordance has been reported in 17% of HIV-
infected individuals (O'Neil et al., 2000) and 35% in patients with AIDS (Wolkenstein et al., 
2000). In both these studies, enzyme activity was quantified using caffeine as probe. 
The reasons for the discordance between measured and predicted phenotype may be due to 
the method used to determine NAT2 phenotype. For example, the genotype/phenotype 
discordance rate is higher when caffeine rather than dapsone is used as a probe in HIV-
positive patients (O'Neil et al., 2000). The determination of acetylation phenotype using 
dapsone is dependent upon determination of only a primary metabolite, monoacetyl dapsone 
(Zuidema et al., 1986). However, when using caffeine as a probe, the substrate for the NAT2 
enzyme is not caffeine itself but rather a secondary metabolite (5-acetylamino-6-

















(CYP1A2) enzyme system (Grant et al., 1984). There is considerable variation in CYP1A2 
metabolic activity due to genetic factors, environmental factors, and drug-drug interactions. 
The NAT2 acetylation phenotype determination using caffeine as probe is thus potentially 
highly variable. 
The discrepancy between phenotype and genotype may also be due to undetected rare 
nucleotide changes in NAT2 when using conventional PCR-RFLP genotyping methods 
(Kaufmann et al., 1996, O'Neil et al., 2000, O'Neil et al., 1997). By sequencing only a third of 
our cohort, we found a novel non-synonymous 589 C>T variant with a predicted effect on 
protein structure and functional activity. Three rare variants, only previously described in 
African populations (Patin et al., 2006), were also found although these are unlikely to 
translate into any functional effect. Our results suggest that DNA sequencing for the entire 
intron-exon organization of the NAT2 gene may provide more detailed information about 
genetic diversity that potentially affect NAT2 activity in this population. 
Apart from these difficulties in accurately determining NAT2 acetylation phenotype, other 
factors such as environmental, genetic or epigenetic factors may influence an individual‟s 
capacity to acetylate a substrate. Concomitant medication is potentially one such candidate in 
HIV-infected populations exposed to polypharmacy, although there are no known inhibitors 
or inducers of the NAT2 enzyme. Furthermore, gene-gene interactions may have confounded 
our results. McKeown-Eyssen et al. associated NAT2 and CYP2D6 gene-gene interaction 
with multiple chemical sensitivities (McKeown-Eyssen et al., 2004). Their results suggest 
that individuals with the rapid-metabolizing forms of both enzymes were 18 times more 
likely to have chemical hypersensitivity to drugs such as sulfamethoxazole than individuals 
with normal metabolizing forms of these enzymes. Gene-gene interactions between CYP2D6 
and another P450 enzyme, CYP3A4, have also been found to influence the metabolism of 
commonly used pharmaceutical agents (Le Corre et al., 2004). Co-administration of NAT2 
substrates such as sulfamethoxazole, a component of cotrimoxazole, may have affected 
acetylation phenotype. Sulfamethoxazole is metabolized by the NAT2 and cytochrome P450 
enzymes (Alfirevic et al., 2003). Given that most of our cohort (97%) received cotrimoxazole 
during the study period, this may have influenced our results. Slow acetylation would be 
expected to result in shunting of this drug to an alternative oxidative pathway, resulting in 
toxic metabolites, hydroxyl amine and nitroso compounds (Alfirevic et al., 2003). These toxic 

















antioxidants (Cribb and Spielberg, 1992). As discussed in section 1.8.3.6, HIV-infected 
individuals have low concentrations of glutathione (Buhl et al., 1989) leading to the 
accumulation of toxic metabolites that may bind to macromolecules, causing protein damage 
and cellular injury.  
Malnutrition may also affect NAT2 acetylation. HIV-associated wasting is characterized by a 
hypermetabolic state that includes disruption of carbohydrate and lipid metabolism 
(Hellerstein et al., 1990). This disruption could lead to diminished pools of NAT2 cofactors, 
such as acetyl coenzyme A, with a concomitant loss of NAT2 activity. 
Finally, as acetylation occurs in the liver and the acetylation products are excreted by the 
kidneys, both hepatic and renal dysfunction influence acetylation phenotype. Hepatic disease 
has emerged as the most common non-AIDS–related cause of death among HIV-infected 
patients, accounting for 14%–18% of all deaths (Price and Thio, 2010, Palella et al., 2006). 
Furthermore, renal impairment, based on a single creatinine clearance measurement, was very 
common among African HIV-infected adults with clinically non-advanced HIV disease: 19% 
had moderate and 2% severe renal impairment (Struik et al., 2011). 
To conclude, this research adds to the knowledge base for NAT2 genetic variation and 
acetylation phenotypes in this South African population. A considerable prevalence of 
genotype-deduced slow acetylators was demonstrated. Although we were only able to show a 
significant association between a NAT2 acetylation phenotype and the development of new 
neuropathic symptoms, further studies investigating the interaction between cART and/or 
sulfamethoxazole and anti-TB therapy in the development of HIV-associated DSP is 
warranted. The growing practice of relying solely on genotype determination to assess the 
potential role of metabolic differences as a contributor to disease or drug-induced toxicity 
may need to be reconsidered, at least for NAT2 substrates in HIV/TB co-infection. To this 
end, acetylation of INH as a substrate in HIV/TB co-infected individuals and their NAT2 
acetylation phenotype should be correlated, and may be helpful to determine vitamin B6 









































8.1 Demographic Characteristics 
The nested cohort for the vitamin B6 study consisted of 159 consecutively enrolled 
individuals who had neurological data available at baseline and at week 12. The individuals 
were genotyped for NAT2 and also had vitamin B6 concentrations measured. These results 
are summarized in Table 8.1 and Table 8.2. The demographic and clinical features for this 
nested cohort were similar to the total longitudinal cohort described in Chapter 4 (see Table 
4.1 and Table 4.2, page 89). 
Table 8.1: Vitamin B6 cohort baseline characteristics (continuous data) 
 
Total (N=159) SDSP (N=31) No SDSP (N=128)
Clinical
Age years 33 (26 - 39) 37 (29 - 43) 32 (26 - 38) 0.019 β
Weight kg 61 (55 - 71) 60 (53 - 68) 62 (55 - 71) 0.555 ε
Height metre 1.61 (1.56 - 1.67) 1.62 (1.55 - 1.68) 1.61 (1.56 - 1.67) 0.698 β
Body Mass Index kg/m2 20.0 - 25.0 23.2 (20.3 - 28.0) 23.6 (20.8 - 25.9) 23.2 (20.3 - 28.0) 0.691 ε
Waist : Hip ratio < 0.90 0.86 (0.81 - 0.90) 0.87 (0.83 - 0.92) 0.86 (0.81 - 0.90) 0.066 β
Systolic BP mmHg 120 - 140 111 (103 - 122) 109 (98 - 119) 111 (104 - 122) 0.067 β
Diastolic BP mmHg 80 - 90 71 (66 - 79) 70 (66 - 77) 72 (66 - 80) 0.170 β
Haematological
CD4 T-cell count cells/mm3 > 500 156 (113 - 193) 167 (121 - 217) 151 (112 - 191) 0.271
ε
White cell count x109/L 4.0 - 11.0 5.4 (4.1 - 6.5) 4.7 (3.9 - 5.9) 5.4 (4.3 - 6.7) 0.310 ε
C-reactive protein mg/L < 5.0 2.9 (0.9 - 6.6) 3.8 (1.4 - 11.9) 2.6 (0.9 - 6.3) 0.169 β
Haemoglobin g/dL 11.6 - 15.6 11.7 (10.3 - 12.8) 11.8 (9.4 - 12.6) 11.7 (10.3 - 12.8) 0.406 β
MCV fL 80.0 - 100.0 92.1 (88.0 - 96.1) 93.5 (89.8 - 96.9) 91.7 (87.9 - 96.1) 0.134 β
Biochemical
Albumin g/L 38 - 54 39 (35 - 43) 38 (34 - 42) 40 (35 - 43) 0.114 β
ALT IU/L 10 - 41 20 (15 - 27) 24 (18 - 29) 19 (14 - 26) 0.171 β
Creatinine µmol/L 53 - 115 64 (55 - 74) 66 (57 - 73) 64 (55 - 74) 0.700 ε
Metabolic
Fasting glucose mmol/L 4.1 - 5.6 4.7 (4.4 - 4.9) 4.7 (4.5 - 4.9) 4.6 (4.4 - 4.9) 0.813 ε
Fasting insulin µU/mL 0.2 - 9.4 5.1 (2.5 - 8.6) 4.3 (2.5 - 7.6) 5.4 (2.5 - 8.6) 0.286 β
Total cholesterol mmol/L 3.1 - 5.2 3.7 (3.2 - 4.3) 3.9 (3.1 - 4.3) 3.7 (3.2 - 4.3) 0.532 β
Triglycerides mmol/L 0.5 - 2.0 0.9 (0.7 - 1.3) 1.0 (0.8 - 1.4) 0.8 (0.6 - 1.2) 0.045 β
HDL mmol/L 1.15 - 1.68 0.94 (0.74 - 1.13) 0.89 (0.77 - 1.13) 0.94 (0.73 - 1.13) 0.592 β
LDL mmol/L 1.0 - 3.0 2.4 (1.9 - 2.9) 2.3 (1.8 - 2.7) 2.4 (1.9 - 2.9) 0.185 β
Lactate mmol/L < 2.0 2.4 (1.7 - 3.1) 2.0 (1.2 - 2.6) 2.4 (1.7 - 3.1) 0.277 β
Pyridoxine
PLP nmol/L > 25.0 23.8 (16.5 - 38.4) 20.7 (16.2 - 53.7) 24.1 (17.4 - 36.8) 0.512 β
4-PA nmol/L unknown 17.4 (11.9 - 23.3) 20.7 (12.1 - 28.6) 17.0 (11.7 - 22.8) 0.212 ε
β    Student's t -test























Table 8.2: Vitamin B6 cohort baseline characteristics (grouped data) 
 
The majority of the nested cohort was female (69%) with ages ranging between 19 and 63 
years [median age of 33 (IQR 26-39)]. Overall, 59 individuals (37%) had a history of TB 
therapy (current or previous INH exposure). Of these, 35 completed TB treatment before 
study entry and 24 started before study entry and continued treatment during the study period. 
Eight individuals developed TB infection after the baseline assessment (six started treatment 
between 4 and 12 weeks, and two after 12 weeks). 
Total (N=159) SDSP (N=31) No SDSP (N=128)
Female sex 110 (69%) 17 (65%) 93 (70%) 0.647 §
Age > 40 years 39 (25%) 11 (42%) 28 (21%) 0.023 §
Previous/Current TB 59 (37%) 16 (62%) 43 (32%) 0.005 §
Time of TB 0.020 ¶
Currently 24 (15%) 8 (31%) 16 (12%)
< 1 year ago 11 (7%) 3 (12%) 8 (6%)
1 year ago 5 (3%) 2 (8%) 3 (2%)
2 years ago 4 (3%) 1 (4%) 3 (2%)
> 2 years ago 15 (9%) 2 (8%) 13 (10%)
Vit Bco supplement 155 (97%) 26 (100%) 129 (97%) 1.000 ¶
Vit B6 supplement 12 (8%) 7 (27%) 5 (4%) 0.001 ¶
WHO clinical stage 0.285 ¶
Stage 1 51 (33%) 8 (31%) 43 (33%)
Stage 2 49 (31%) 5 (19%) 44 (34%)
Stage 3 50 (32%) 12 (46%) 38 (29%)
Stage 4 6 (4%) 1 (4%) 5 (4%)
CD4 T-cell count 0.264 §
< 100 cells/mm 3 26 (17%) 2 (8%) 24 (18%)
100 - 200 cells/mm 3 96 (62%) 16 (62%) 80 (62%)
> 200 cells/mm 3 34 (22%) 8 (31%) 26 (20%)
Body Mass Index 0.939 §
< 20 kg/m 2 34 (22%) 6 (23%) 28 (22%)
20 - 25 kg/m 2 65 (42%) 10 (38%) 55 (42%)
25 - 30 kg/m 2 30 (19%) 6 (23%) 24 (18%)
> 30 kg/m 2 27 (17%) 4 (15%) 23 (18%)
Alcohol last year 44 (28%) 6 (23%) 38 (29%) 0.524 §
IHDS score < 10 29 (25%) 3 (30%) 26 (25%) 0.716 §
Neuropathy status
DSP 35 (22%)
Symptomatic DSP 26 (16%)
Asymptomatic DSP 9 (6%)
Symptoms only 6 (4%)
¶
    Fi sher's  exact test



















Nearly two thirds (n=100, 64%) were classified as HIV WHO stage 1 or 2, with only six 
individuals (4%) in stage 4. The baseline median CD4 T-cell count was 156 cells/mm
3
 (IQR 
113-193) with 79% having counts <200 cells/mm
3
 and 17% <100 cells/mm
3
. 
The BMI ranged from 16.5 to 39.5 kg/m
2
, with a median of 23.2 kg/m
2
. Median fasting lipid 
values were within normal ranges. Serum albumin, done on 145 of the 159 individuals (91%), 
did not correlate with BMI at baseline (ρ=0.12, p=0.14). Serum albumin <38 g/L was found 
in 65 (45%) and of these, 34% were eutrophic and 34% underweight. Of the 55% with 
normal serum albumin levels, 49% were eutrophic and 13% were underweight. Thirty-seven 
individuals (23%) had a haemoglobin level <10 g/dL. 
Nearly all individuals (97%) were prescribed two tablets of vitamin B complex supplements 
at the time of enrolment
2
. Twelve individuals (8%) were prescribed additional 25 mg/day 
vitamin B6 supplementation. 
During the follow-up period, 10 of 24 individuals (42%) on TB therapy received additional 
vitamin B6 supplementation, i.e. 25 mg/day (six of whom had symptomatic DSP at baseline). 
Two individuals completed TB therapy less than six months prior to enrolment, and were still 
prescribed additional vitamin B6 supplementation at the time of the baseline assessment. 
In this nested cohort, the distribution of DSP status was comparable to that of the total cohort 
and was categorised as follows: 
 No DSP, 124 (78%) – individuals not meeting criteria of symptomatic DSP or 
asymptomatic DSP including six individuals (4%) with neuropathic symptoms in 
isolation. 
 Asymptomatic DSP, 9 (6%) 
 Symptomatic DSP, 26 (16%) 
 
                                                 
2 Pyridoxine doses in vitamin B complex preparations may vary according to the manufacturer, but this 

















8.2 Pyridoxine concentrations in a South African community-
based HIV-infected cohort before and after cART  
8.2.1 Plasma PLP and 4-PA concentrations at baseline (before cART) 
At the baseline assessment, PLP concentrations ranged from 5.8 to 128.0 nmol/L with a 
median of 23.8 nmol/L. Over half of the cohort (53%) was vitamin B6 deficient at baseline 
(PLP <25 nmol/L). Figure 8.1 illustrates the positively skewed distribution of baseline 
plasma PLP and 4-PA concentrations overall. Baseline plasma 4-PA concentrations ranged 
from 4.9 to 197.0 nmol/L with a median of 17.4 nmol/L, not indicative of any ongoing or 
recent vitamin B6 supplementation (Bates et al., 1999, Bor et al., 2003). 
 
Figure 8.1: Baseline concentrations of PLP (left) and 4-PA (right) 
8.2.2 Factors influencing plasma PLP concentrations at baseline 
To investigate the relationship between PLP and NAT2 acetylation phenotype, as well as 
previously identified factors associated with symptomatic DSP, immunity and metabolic 
status, Spearman correlation coefficients were calculated (Table 8.3). There was a significant 
albeit moderate positive correlation between PLP and 4-PA (ρ=0.57; p<0.001) as well as 
between PLP and albumin levels (ρ=0.29; p<0.001) and a weak correlation between PLP and 
haemoglobin levels at baseline (ρ=0.19; p=0.018). Therefore, poor micronutritional status 
reflected by low albumin and haemoglobin levels correlated with suboptimal PLP levels. 
There was an inverse correlation between PLP and hs-CRP, i.e. higher hs-CRP levels 
correlated with lower PLP concentrations (ρ=-0.25; p=0.002). Of the risk factors associated 
with symptomatic DSP at baseline (see section 4.1.6.2), PLP levels showed a significant 

















PLP and other variables investigated appear in Table 8.3. Baseline PLP concentration did not 
correlate with any other clinical factors related to macronutritional status, including weight, 
BMI and waist-to-hip ratio, nor with any of the metabolic factors, such as total cholesterol, 
HDL, LDL, triglycerides or fasting glucose. 
Table 8.3: Spearman correlations between baseline PLP levels and baseline factors possibly related to 
nutritional status or symptomatic DSP 
 
 





Body Mass Index 0.06 0.440
Waist : Hip ratio 0.14 0.081
Systolic BP 0.05 0.544
Diastolic BP -0.10 0.219
Haematological
CD4 T-cell count 0.01 0.941
White cell count -0.02 0.826








Fasting glucose 0.01 0.860
Fasting insulin 0.08 0.345























To determine whether there is a significant difference in PLP concentrations between the 
group variables of interest, PLP median values between groups were compared (Table 8.4). 
Although no significant correlations were detected, there was a trend for men to have higher 
median PLP levels compared to women (29.0 vs 22.8 nmol/L, p=0.10). As a measure of HIV 
severity, individuals were grouped using two arbitrary CD4 T-cell count cut-offs, viz. 100 
and 200 cells/mm
3
. In both these groups, no significant relationship was found between lower 
CD4 T-cell count and low PLP concentrations; those with a CD4 T-cell count <100 
cells/mm
3
 had a median PLP of 24.8 nmol/L compared to the level of 23.8 nmol/L in the 
group with a higher CD4 T-cell count (p=0.23). Vitamin B6 supplementation by prescription, 
either as vitamin B complex or as 25 mg vitamin B6 had no significant effect on PLP 
concentrations overall (p=0.52). 
The effect of prior TB therapy on PLP concentrations was investigated. Table 8.4 shows that 
there was no difference in median PLP concentrations between the 35 individuals who were 
previously exposed to INH therapy, compared to INH-naïve individuals (p=0.99). Twenty-
four individuals started TB therapy before study entry and continued on INH during the study 
period. While there was a trend towards higher PLP concentrations in these individuals 
compared to INH-naïve individuals, the differences observed were modest (27.4 vs 23.1 
nmol/L, p=0.15). 
To establish whether individuals with a slow NAT2 acetylation phenotype had lower vitamin 
B6 concentrations compared to those with a rapid acetylation phenotype, plasma PLP and 4-
PA concentrations were compared between different NAT2 acetylation phenotypes deduced 
from NAT2 genotypes (Table 8.4). PLP concentrations were not significantly different 
between rapid, intermediate and slow acetylators (p=0.69), with median PLP concentrations 
of 23.8, 23.4 and 26.7 nmol/L respectively. Comparing individuals homozygous for rapid 
acetylator genotype to individuals bearing at least one slow allele (acetylation phenotype 1, 

















Table 8.4: Comparison of PLP medians between different categories possibly related to nutritional 
status or symptomatic DSP 
Variable Median (IQR)
Sex 0.102 β
Female 22.8 (16.2 - 34.5)
Male 29.0 (19.7 - 46.8)
Age groups 0.901 β
> 40 years 24.4 (16.6 - 46.8)
< 40 years 23.8 (16.5 - 38.4)
Previous/Current TB 0.421 β
Yes 23.8 (14.7 - 49.2)
No 23.9 (17.5 - 36.6)
Current TB 0.148 β
Yes 27.4 (17.1 - 60.1)
No 23.1 (16.5 - 36.8)
Previous TB 0.988 β
Yes 22.4 (13.9 - 40.8)
No 23.9 (17.5 - 36.6)
Vit B6 supplement 0.520 β
Yes 28.4 (15.6 - 54.9)
No 23.7 (16.6 - 36.8)
Acetylation-phenotype 1 0.410 β
Rapid 23.8 (12.8 - 34.0)
Slow 23.7 (17.4 - 38.5)
Acetylation-phenotype 2 0.689 φ
Rapid 23.8 (12.8 - 34.0)
Intermediate 23.4 (17.5 - 39.4)
Slow 26.7 (13.0 - 32.3)
WHO Stage 0.798 β
Stage 1 or 2 24.8 (18.0 - 36.6)
Stage 3 or 4 22.5 (13.3 - 48.0)
CD4 T-cell count 0.227 β
< 100 cells/mm 3 24.8 (14.7 - 33.6)
> 100 cells/mm 3 23.8 (17.4 - 43.7)
Alcohol last year 0.434 β
Yes 23.1 (17.3 - 33.8)
No 24.8 (16.6 - 43.4)
IHDS score 0.240 β
< 10 27.8 (22.9 - 36.8)
≥ 10 23.4 (14.5 - 36.8)
β    Student's t -test


















Not all individuals on INH therapy were prescribed 25 mg/day additional vitamin B6 
supplementation and this may have had an effect on PLP concentrations. To understand the 
possible effect of the additional vitamin B6 supplementation (25mg/day) on PLP and 4-PA 
concentrations among individuals on INH therapy during the study period, the group with 
25mg/day vitamin B6 supplementation was compared to those without (Table 8.5). In both 
these groups all individuals were prescribed Vitamin B complex. PLP and 4-PA 
concentrations were not significantly different between individuals who were prescribed 25 
mg/day of vitamin B6 supplementation and those who were not (p=0.22 and p=0.42, 
respectively). 
Table 8.5: PLP and 4-PA levels for individuals currently on TB treatment grouped by vitamin B6 
supplementation (25 mg/day) 
 
Univariate odds ratios and prevalence ratios (with a 95% CI) were calculated to determine 
factors associated with vitamin B6 deficiency (PLP <25 nmol/L). All variables were explored 
for an association, but only variables showing a significance level of p<0.25 in the primary 
analysis were included in the multivariate analysis and are shown in Table Q-15 in Appendix 
Q. A multivariate logistic regression analysis identified factors independently associated with 
vitamin B6 deficiency at baseline. The results are summarized in Table 8.6. Higher levels of 
fasting triglycerides (>0.9 mmol/L) and ALT (>19 IU/L) remained significantly associated 
with PLP concentrations <25 nmol/L while higher albumin levels (>38 g/L) was associated 
with PLP concentration ≥25 nmol/L. Pyridoxic acid (4-PA) was not included into the model 




No additional vitamin 
B6 supplement*
(N=14)
PLP nmol/L > 25.0 23.6 (12.5 - 38.2) 28.1 (18.0 - 76.5) 0.218 β
4-PA nmol/L unknown 22.4 (15.7 - 33.2) 33.0 (18.2 - 46.2) 0.418 β
*    All  patients received vitamin Bco containing up to 4mg vitamin B6; Additional vitamin B6 refers to 25 mg/day
β    Student's t -test
Median (IQR)

















Table 8.6: Multivariate analysis of risk factors for PLP deficiency at baseline 
 
Grouping PLP and 4-PA levels into quartiles did not provide any additional insights into the 
relationship between vitamin B6 levels and the various aforementioned factors (See Table 
Q-3 to Table Q-14 in Appendix Q). 
8.2.3 Low plasma pyridoxine concentrations as a risk factor for HIV-DSP at 
baseline 
The association of vitamin B6 levels with DSP status was investigated. At baseline, 
individuals with DSP were compared to those without. None of the DSP types (DSP, 
symptomatic DSP or asymptomatic DSP) were associated with lower baseline measures of 
circulating plasma vitamin B6 concentrations (PLP and 4-PA) (Table 8.7). 
Model Odds Ratio







PLP > 25 nmol/L vs PLP < 25 nmol/L 0.15 <0.001
Albumin > 38 g/L 3.86 1.59 - 9.35 0.003
Triglycerides > 0.9 mmol/L 0.39 0.17 - 0.92 0.031

















Table 8.7: Baseline and week 12 vitamin B6 levels categorized by baseline DSP status 
 
Comparison of proportions of individuals with DSP, symptomatic DSP or asymptomatic DSP 
at baseline across the vitamin B6 quartiles and halves (PLP and 4-PA) were assessed. No 
significant differences were found between the different groups and these results are 
summarized in Table Q-16 – Table Q-19 in Appendix Q. 
To assess the impact of previous TB therapy on current vitamin B6 status, we stratified the 
cohort by TB history and investigated the association of low vitamin B6 concentrations with 
symptomatic DSP in only those individuals with a history of previous or current TB therapy 
(n=59). Symptomatic DSP at baseline was significantly associated with PLP deficiency 
(p=0.029) (Table 8.8). 
Baseline DSP status N
Median (IQR) Median (IQR)
DSP 35 25.5 (16.5 - 53.7) 0.392 ε 20.0 (11.2 - 35.1) 0.562 ε 0.108 λ
No DSP 124 23.8 (15.7 - 36.8) 21.2 (14.2 - 33.4)
SDSP 26 20.7 (16.2 - 53.7) 0.474 ε 19.2 (11.2 - 31.1) 0.597 ε 0.166 λ
No DSP 124 23.8 (15.7 - 36.8) 21.2 (14.2 - 33.4)
ADSP 9 27.5 (22.9 - 32.0) 0.563 ε 29.2 (11.6 - 37.6) 0.766 ε 0.515 λ
No DSP 124 23.8 (15.7 - 36.8) 21.2 (14.2 - 33.4)
Median (IQR) Median (IQR)
DSP 35 20.5 (12.1 - 28.6) 0.089 ε 20.3 (12.2 - 28.2) 0.983 ε 0.810 λ
No DSP 124 16.7 (11.6 - 22.4) 19.1 (12.5 - 26.9)
SDSP 26 20.7 (12.1 - 28.6) 0.169 ε 18.9 (12.2 - 25.7) 0.782 ε 0.660 λ
No DSP 124 16.7 (11.6 - 22.4) 19.1 (12.5 - 26.9)
ADSP 9 19.0 (15.2 - 30.8) 0.235 ε 21.4 (16.4 - 31.0) 0.585 ε 0.785 λ
No DSP 124 16.7 (11.6 - 22.4) 19.1 (12.5 - 26.9)
ε    Wilcoxon rank-sum test for difference in median vitamin B6 level between DSP groups at a specific time point




























Table 8.8: Vitamin B6 levels in individuals with previous TB: comparing SDSP to No DSP 
 
The median plasma PLP concentrations in symptomatic DSP and DSP-free individuals with 
different NAT2 genotypes are summarized in Table Q-1 in Appendix Q. There is no 
indication that the plasma PLP values were lower amongst the symptomatic slow acetylators 
on enrolment. 
8.2.4 Plasma PLP and 4-PA concentrations after 12 weeks on cART 
Figure 8.2 illustrates the positively skewed distribution of PLP and 4-PA concentrations after 
12 weeks of cART when 55% of individuals had vitamin B6 deficiency (PLP <25 nmol/L). 
The median plasma PLP level was 21.0 nmol/L and 4-PA had a median of 19.2 nmol/L. 
 
Figure 8.2: Week 12 concentrations of PLP (left) and 4-PA (right) 
8.2.5 Changes in vitamin B6 status between different DSP groups after 12 
weeks of cART 
For the cohort overall, plasma PLP concentrations after 12 weeks did not change significantly 
from baseline concentrations (23.8 to 21.0 nmol/L; p=0.27). An insignificant increase in 
Total (N=59) SDSP (N=16) No DSP (N=43)
PLP
Below 25 nmol/L 30 (51%) 12 (75%) 18 (42%) 4.17 (1.15 ; 15.04) 0.029
Above 25 nmol/L 29 (49%) 4 (25%) 25 (58%)
4-PA
Below median (17.4 nmol/L) 28 (48%) 8 (50%) 20 (47%) 1.15 (0.36 ; 3.63) 0.812























median 4-PA concentration was observed during the first 12 weeks on cART (17.4 to 19.2 
nmol/L; p=0.11). 
Table 8.7 (page 186) illustrates the median plasma PLP and 4-PA concentrations at baseline 
and 12 weeks after cART grouped according to baseline DSP status. Compared to baseline, 
median PLP concentrations at week 12 were lower in all comparative groups except for the 
nine individuals who had asymptomatic DSP, in whom the median PLP concentration was 
higher. However, a random effects model showed no significant differences in the mean 
vitamin B6 levels in any DSP groups between baseline and week 12 (Table 8.7). 
8.2.6 Factors influencing plasma PLP concentrations after 12 weeks of cART 
To determine whether any factors had an effect on PLP levels over the 12-week period, or 
any factors predispose an individual to a greater decrease in PLP after commencing cART, 
the longitudinal relationship between PLP and the various factors were investigated (Table 
8.9). Factors of interest included those associated with symptomatic DSP such as stavudine, 
nutritional factors, immune-related factors and NAT2 acetylation phenotype. 
At week 12, 59% were receiving cART with a stavudine-containing cART regimen, 28% 
with tenofovir, and 12% with zidovudine. Plasma PLP differed significantly according to the 
use of individual antiretroviral agents. The PLP levels at week 12 were significantly higher in 
the group of individuals on stavudine (d4T) compared to the other individuals (Table 8.9). 
The regression coefficient showed that the average increase in PLP over 12 weeks is 9.96 
nmol/L higher in the group of individuals prescribed stavudine compared to the rest 
(p=0.032). To investigate this further, an association between stavudine use and 25 mg/day 
vitamin B6 supplementation was explored but none was found (p=1.00). 
The baseline BMI <20 kg/m
2
 was associated with lower PLP concentrations after 12 weeks 
(p=0.043). There was a trend towards lower PLP concentrations in individuals with an IHDS 
score <10, which may be a marker of advancing HIV disease. However, this was not 
supported by associations with CD4 T-cell count and WHO HIV stage. None of the factors 
that showed a correlation with PLP at baseline affected PLP concentrations over 12 weeks on 
cART. These included 4-PA, hs-CRP, albumin and ALT. Prescriptions of vitamin B6 
supplementation (25 mg/day) were also not associated with PLP levels after 12 weeks of 
cART (p=0.24). Factors associated with symptomatic DSP at baseline did not affect PLP 

















other factors investigated are summarized in Table 8.9. 







Female sex -0.27 (-10.05 ; 9.52) 0.957
Age > 40 years -2.81 (-13.35 ; 7.73) 0.601
WHO clinical stage 3 or 4 -2.95 (-12.27 ; 6.36) 0.534
IHDS score < 10 -10.71 (-21.80 ; 0.37) 0.058
Previous / Current TB -2.28 (-11.58 ; 7.01) 0.631
Current TB 0.47 (-12.93 ; 13.88) 0.945
Previous TB -3.31 (-12.65 ; 6.04) 0.488
Stavudine Exposure 9.96 (0.83 ; 19.09) 0.032
Vitamin B6 supplementation (25mg) 9.41 (-6.14 ; 24.96) 0.236
Alcohol last year 6.89 (-3.27 ; 17.06) 0.184
Weight > 61 kg 4.47 (-4.66 ; 13.60) 0.337
Height > 1.61 metre -3.18 (-12.36 ; 6.00) 0.497
Body Mass Index < 20 kg/m2 -11.17 (-0.33 ; -22.00) 0.043
Body Mass Index > 25 kg/m2 2.36 (-7.12 ; 11.84) 0.625
Waist : Hip ratio > 0.9 -7.35 (-18.23 ; 3.54) 0.186
Haematological
CD4 T-cell count < 200 cells/mm3 1.28 (-10.17 ; 12.72) 0.827
CD4 T-cell count < 100 cells/mm3 11.33 (-0.94 ; 23.60) 0.070
White cell count > 5.4 x109/L 3.96 (-5.41 ; 13.33) 0.407
C-reactive protein > 5 mg/L 1.01 (-8.75 ; 10.77) 0.840
Haemoglobin > 11.7 g/dL -0.35 (-9.53 ; 8.82) 0.940
MCV > 92 fL -1.29 (-10.52 ; 7.95) 0.785
Biochemical
Albumin < 37 g/L 2.52 (-7.22 ; 12.27) 0.612
ALT > 19 IU/L 2.39 (-6.82 ; 11.60) 0.611
Creatinine > 64 µmol/L -1.63 (-10.79 ; 7.53) 0.727
Metabolic
Fasting glucose > 5.6 mmol/L 0.29 (-20.42 ; 20.99) 0.978
Fasting insulin > 5.1 µU/mL -2.75 (-12.07 ; 6.58) 0.564
Total cholesterol > 3.7 mmol/L 2.75 (-6.60 ; 12.10) 0.564
Triglycerides > 0.9 mmol/L -4.21 (-13.55 ; 5.12) 0.376
HDL < 1.41 mmol/L -6.03 (-15.92 ; 3.86) 0.232
LDL > 2.4 mmol/L -6.32 (-15.60 ; 2.96) 0.182
Lactate > 2 mmol/L -1.97 (-11.79 ; 7.86) 0.695
NAT2 Acetylation
Slow acetylation 5.80 (-13.38 ; 24.99) 0.553
Intermediate acetylation -1.85 (-14.04 ; 10.34) 0.767

















8.2.7 Low plasma vitamin B6 concentrations as a risk factor for ATN 
The development of ATN, incident symptomatic DSP or incident neuropathic symptoms 
were not associated with lower measures of circulating plasma pyridoxine concentrations at 
baseline (PLP and 4-PA) (Table 8.10). At 12 weeks, despite the decrease in PLP levels after 
cART initiation overall, there was no significant difference in magnitude of response between 
the individuals who developed ATN compared to those who did not (p=0.41) or between 
individuals with incident symptoms and those without (p=0.53). 
Both groups showed slight increases in 4-PA concentration over time, although this increase 
was not statistically significant and the mean increase was not significantly different between 
the ATN group and their ATN-free counterparts (p=0.68) or between individuals with 
incident symptoms and those without (p=1.00). 
Table 8.10: Baseline and week 12 vitamin B6 concentrations categorized by week 12 DSP status 
 
Week 12 DSP status N
Median (IQR) Median (IQR)
ATN 33 24.4 (18.0 - 36.8) 0.930 ε 23.7 (13.1 - 32.3) 0.850 ε 0.407 λ
No ATN 122 23.8 (16.2 - 38.5) 20.1 (13.4 - 34.2)
Incident SDSP 20 20.1 (18.1 - 34.6) 0.626 ε 24.1 (15.5 - 32.8) 0.918 ε 0.610 λ
No SDSP 109 24.4 (16.7 - 36.8) 21.0 (13.4 - 34.2)
Incident symptoms 28 21.4 (16.4 - 34.7) 0.486 ε 24.1 (13.0 - 31.1) 0.901 ε 0.525 λ
No symptoms 101 24.4 (17.4 - 38.4) 20.2 (14.2 - 34.5)
Median (IQR) Median (IQR)
ATN 33 16.6 (11.7 - 22.7) 0.579 ε 17.0 (12.5 - 22.1) 0.474 ε 0.676 λ
No ATN 122 17.9 (12.1 - 24.2) 19.3 (12.5 - 28.8)
Incident SDSP 20 16.1 (12.1 - 20.6) 0.580 ε 18.7 (12.4 - 23.2) 0.569 ε 0.899 λ
No SDSP 109 17.5 (12.0 - 24.8) 19.1 (12.6 - 28.8)
Incident symptoms 28 16.8 (12.1 - 22.4) 0.793 ε 18.7 (13.0 - 23.2) 0.805 ε 0.998 λ
No symptoms 101 17.5 (12.0 - 24.2) 19.1 (12.5 - 28.8)
ε    Wilcoxon rank-sum test for difference in median vitamin B6 level between DSP groups at a specific time point




























Two groups were formed using a 50 nmol/L cut-off level to test it as a possible critical level 
for the presence HIV-associated DSP. The level was chosen by visual inspection of the 
follow-up data upon noticing a higher frequency of ATN among those with PLP <50 nmol/L 
at baseline. This level was also consistent with PLP levels from healthy cohorts ranging 
between 40 and 60 nmol/L (Bailey et al., 1999, Shen et al., 2010, Ye et al., 2010). The 
proportions of individuals in these groups for various DSP categories are shown in Table 8.11 
and Table 8.12. 
Table 8.11: Distribution of DSP status per PLP group below and above 50 nmol/L  
 
In the group of individuals with baseline PLP levels >50 nmol/L, the frequency of 
symptomatic DSP at baseline was higher than for the group with lower PLP levels (p=0.011). 
When correcting for vitamin B6 supplementation, this association was no longer evident (OR 
0.37; 95% CI 0.13-1.05; p=0.06). Therefore, individuals with symptomatic DSP may have 
higher PLP concentrations at baseline due to additional vitamin B6 supplementation and this 
may be the result of the clinician‟s response to symptoms (Table 8.2). However, these results 
should be interpreted with caution due to the relatively small number of people in the group 
with PLP >50nmol/L. 
Although not statistically significant, lower baseline PLP levels were seen in those who 
developed ATN. By comparing individuals with incident symptoms to individuals without, 
and excluding those with symptomatic DSP at baseline, there is a trend towards lower 







(N = 135) (N = 24)
DSP 25 (19%) 10 (42%) 0.012 §
SDSP 18 (13%) 8 (33%) 0.011 §
ADSP 7 (5%) 2 (8%) 0.626 ¶
§    χ2 test
¶   Fisher's exact test

















Table 8.12: Distribution of 12-week DSP status per baseline PLP group below and above 50 nmol/L 
 
ATN was significantly associated with a 12-week PLP level <50 nmol/L (p=0.032) (Table 
8.13). Excluding individuals with symptomatic DSP at baseline from the analysis (to remove 
the effect of the association found between symptomatic DSP and PLP >50nmol/L) showed 
that the development of new neuropathic symptoms was significantly associated with a PLP 
<50 nmol/L (p=0.043). These results may not be credible due to the relatively small number 
of people in the group with 12-week PLP >50nmol/L. 
Table 8.13: Distribution of 12-week DSP status per week 12 PLP group below and above 50 nmol/L 
 
Taken together, vitamin B6 levels were low overall and appear to co-segregate with other 
markers of micronutritional deficiency such as low haemoglobin and albumin. At 12 weeks 
there was a tendency for PLP levels to decrease further. Those individuals with higher PLP 





(N = 131) (N = 24)
ATN 30 (23%) 3 (13%) 0.253 §
Incident symptoms 28 (21%) 1 (4%) 0.096 §
Incident SDSP 19 (15%) 1 (4%) 0.274 §
§    χ2 test
Week 12 DSP status p-value
(n = 142) (n = 15)
ATN 34 (24%) 0 (0%) 0.032 §
(n = 118) (n = 13)
Incident symptoms 29 (25%) 0 (0%) 0.043 §
Incident SDSP 20 (17%) 0 (0%) 0.107 §
¶    Fisher's exact test
§    χ2 test













































This study demonstrates the high prevalence of suboptimal circulating vitamin B6 in a South 
African HIV-infected cohort. Vitamin B6 deficiency was present in 53% of this cohort prior 
to commencing cART with a median PLP concentration of 24 nmol/L. Plasma vitamin B6 
levels remained low despite vitamin B complex supplementation which forms part of the 
government‟s HIV standard of care treatment programme. A previous South African study, 
albeit in a group of HIV/TB co-infected children prior to initiating TB therapy, found that 
50% of vitamin B6 levels were suboptimal, with a median PLP concentration of 34 nmol/L 
(Cilliers et al., 2010). 
A summary of studies investigating vitamin B6 deficiency is included in Table 9.1. In North 
American HIV-infected cohorts deficient vitamin B6 levels were reported in 11% to 34% of 
cART naïve individuals with WHO Stage I HIV infection (Baum et al., 1991, Tang et al., 
1997a) and in 53% of individuals with more advanced HIV infection (Beach et al., 1992). 
However, others did not find higher prevalence of vitamin B6 deficiency in HIV-infected 
individuals compared with the general population (Skurnick et al., 1996, Look et al., 2001). 
For example, in a small study of 17 individuals on protease inhibitors, a modest increase in 
vitamin B6 concentrations was shown three months after cART initiation (48.2 to 63.5 
nmol/L), despite not receiving vitamin supplementation (Look et al., 2001). These levels are 
nearly 2-fold higher than those shown in our cohort. In the same study, mean PLP 
concentrations were similar to HIV-negative individuals.  
The reported differences in vitamin B6 levels may be attributed to a number of confounders 
including age of study participants, stage of HIV disease, comorbid conditions, or the method 
used to determine vitamin B6 levels. Compared to the static (direct) method used in our study 
(performed by Dr M Rybak, CDC, Atlanta, GA, USA), the functional (indirect) method used 
in earlier reports has been shown to be less accurate (Krishnamurthy et al., 1967, Lumeng et 

















Table 9.1: Summary of studies performed investigating vitamin B6 deficiency in HIV-infected cohorts and in general populations 
 
Group Study population Cohort size
PLP deficiency definition
(nmol/L)
% deficient Mean PLP (nmol/L)
HIV-infected cohorts
Baum et al. 1991 HIV-infected men who have sex with men (WHO Stage I)(20-50 years), USA 112 Not specified 34%
† Not specified
Beach et al. 1992 HIV-infected men who have sex with men, USA 100 Not specified 53%
† Not specified
Skurnick et al. 1996 HIV-infected adults, USA 64 179.0
‡ 2% 389.0
HIV negative adults, USA 33 179.0
‡ None 317.0
Tang et al. 1997 HIV-infected men who have sex with men (WHO Stage I), USA 310 88.0¶ 11% 223.0
Look et al. 2001 HIV-infected individuals starting protease inhibitor cART regimen (25-65 years), Germany 17 Not specified¶ § None 48.1
HIV-infected individuals 100 days after cART initiation (25-65 years), Germany 17 Not specified¶ § None 63.5a
Healthy control individuals (24-82 years), Germany 42 Not specified¶ § None 58.3
Cilliers et al. 2010 HIV-infected children <13 years on TB treatment, South Africa 19 24.3* 52% 33.6
HIV negative children <13 years on TB treatment, South Africa 33 24.3* 18% 45.6
General cohorts
Bailey et al. 1999 Volunteers from local authority schools, local health centres & general practitioners, UK 51 (adolescent 13-14 yr) 34.4¶ 50% 36.4 (males), 43.5 (females)
131 (adult 20-64 yr) 34.4¶ 38% 39.2 (males), 40.0 (females)
68 (elderly 68-73 yr) 34.4¶ 48% 34.8 (males), 35.3 (females)
44 (old >73 yr) 34.4¶ 27% 57.8 (males), 49.0 (females)
Friso et al. 2001 Population-based Framingham Heart Study cohort, CRP<6 mg/L, USA 834 Not specified¶ Not specified 55.8
Population-based Framingham Heart Study cohort, CRP>6 mg/L, USA 57 Not specified¶ Not specified 36.5
Friso et al. 2004 Individuals with severe multivessel Coronary Artery Disease, USA 475 36.3 (median)¶ 50% 33.9
Individuals free from Coronary Artery Disease, USA 267 36.3 (median)¶ 50% 31.2
Rybak et al. 2004 Nonrepresentative population subset, USA 303 Not specified¶ Not specified 42.4b
Visser et al. 2004 Ambulatory patients on TB treatment, South Africa 19 24.3* 89% 16.0c
Woolf et al. 2008  Population-based females with/without rheumatoid arhtritis (55-82 years), USA 18 (Healthy) 20.0¶ 15% 46.0
33 (Rheumatoid) 20.0¶ 56% 20.0
Matarese et al. 2009 Intestinal transplant patients, USA 29 13.4¶ 1% 13.4
Shen et al. 2010 Population-based Puerto Rican adults, USA 1205 Not specified* Not specified 42.4d
Ye et al. 2010 Population-based Puerto Rican adults (45-75 years), USA 1236 30.0* 29% 44.3
†   Erythrocyte transaminase assay, activity coefficient >1.85 for deficiency
a   100 days after cART initiation
‡   Microbioogical assay
b   Geometric mean
¶   High performance liquid chromatography
c   Graphic interpretation - median
§   Cystathionine level used as surrogate
d   Median

















Differences in the amount of vitamin B6 supplementation, which is not always well 
documented, may have affected the results. Vitamin B complex supplementation containing 
up to 4 mg vitamin B6, was virtually universal within our cohort, as per standard of care. 
However, the pattern of plasma vitamin B6 levels did not reflect ongoing or recent 
supplementation as neither of the two static measurements of vitamin B6 significantly 
improved within the 12 weeks for the overall cohort. It was previously reported that after a 
30-day period of daily vitamin B6 supplementation (40 mg/day), PLP levels increased more 
than tenfold and 4-PA levels by fiftyfold in a cohort with a median baseline PLP below 25 
nmol/L (Bor et al., 2003). In addition, in individuals on INH TB therapy but without HIV 
infection, a dose of 6 mg/day of vitamin B6 increased the mean B6 concentration more than 
threefold after 12 weeks (31 to 161 nmol/L) (Krishnamurthy et al., 1967). As mentioned 
above, one group from the developed world found that cART initiation was associated with 
an increase in vitamin B6 levels without supplementation. From our study it appears that 
daily vitamin B complex supplement (containing up to 4 mg vitamin B6) is not sufficient to 
maintain adequate vitamin B6 levels for HIV-infected individuals, with or without 
concomitant TB prior to commencing cART. This level of supplementation also seems 
insufficient to maintain adequate vitamin B6 levels after cART initiation. However, data on 
prescription of vitamin B6 supplementation were retrieved from clinic folder reviews and it is 
possible that individuals differed in terms of compliance and therefore dose exposure. This 
may have affected the plasma levels measured. 
The study data also imply that health facilities are not prescribing vitamin B6 at dosages of 
25 mg/day to individuals on TB therapy, who are at higher risk of developing DSP. Of those 
on INH TB therapy at the time of the study, only 42% were prescribed 25 mg vitamin B6 
daily. The underuse of vitamin B6 supplementation may be attributed to the variability in the 
recommendations regarding vitamin B6 supplementation in the context of HIV/TB co-
infection (Van der Watt et al., 2011). South African guidelines for example, do not 
recommend additional vitamin B6 supplementation above standard of care vitamin B 
complex for individuals on TB therapy without evidence of risk factors such as alcohol 
abuse, pregnancy, diabetes or epilepsy (South African Department of Health, 2004). In 
contrast to international guidelines, HIV is not mentioned as a high risk group (WHO, 2009, 
South African Department of Health, 2004). Other possible reasons why additional vitamin 
B6 supplementation remains underprescribed include underestimation of the risk for and 

















Given that a history of TB therapy was associated with increased risk for DSP in previous 
African cohorts (Maritz et al., 2010, Forna et al., 2007) and that INH-associated painful 
neuropathy is preventable with adequate vitamin B6 supplementation (Biehl and Sklavem, 
1953), another study objective was to investigate the association between vitamin B6 
deficiency and existing DSP (including symptomatic DSP) or the development of ATN after 
cART initiation. 
For the cohort overall, we found no association between vitamin B6 deficiency (defined as 
PLP <25 nmol/L) and DSP, with or without symptoms, pre-cART. It is possible that an 
association between vitamin B6 deficiency and DSP was concealed by the positively skewed 
distribution of vitamin B6 concentrations, which limited the power to detect any differences 
in concentrations between groups. Another possible confounder was additional vitamin B6 
supplementation, as it was shown that the prescription of 25 mg/day vitamin B6 
supplementation was associated with symptomatic DSP at baseline as well as significantly 
higher 4-PA concentrations (Table Q-6 in Appendix Q). This may be the result of clinic staff 
prescribing additional vitamin B6 in response to the recognition of neuropathic symptoms. 
Exact vitamin intake is unknown as data on supplementation were retrieved from clinic folder 
reviews. However, the higher 4-PA levels suggest recent intake in those individuals 
prescribed additional vitamin B6. 
By investigating the association between DSP and vitamin B6 levels only in individuals with 
a history of TB therapy, PLP levels were significantly lower in those with symptomatic DSP 
at baseline (Table 8.8). This is in line with other findings suggesting that vitamin B6 
deficiency contributes to the risk of symptomatic DSP in INH-exposed HIV-infected 
individuals; a randomized control trial showed that multivitamin supplementation which 
included 25 mg pyridoxine daily reduced the risk for symptomatic DSP in HIV/TB co-
infected individuals (Villamor et al., 2008). 
After 12 weeks of cART, although not associated with vitamin B6 deficiency at baseline or 
12 weeks, ATN was significantly associated with a 12-week PLP level <50 nmol/L 
(p=0.032). Excluding individuals with symptomatic DSP at baseline from the analysis (to 
remove the effect of the association found between symptomatic DSP and PLP ≥50 nmol/L), 
the development of new neuropathic symptoms remained significantly associated with a PLP 
level <50 nmol/L (p=0.043) compared to individuals who never had any neuropathic 

















beneficial in reducing the risk of developing neuropathic symptoms after cART. The cut-off 
level of 50 nmol/L was chosen by visual inspection of the data and was also guided by PLP 
levels from healthy cohorts ranging between 40 and 60 nmol/L (Bailey et al., 1999, Shen et 
al., 2010, Ye et al., 2010). Due to the subjective cut-off level, the association found may be 
specific to this cohort. The small number of individuals with PLP levels ≥50 nmol/L 
compared to those with PLP <50 nmol/L may also have influenced the results. 
The variation in the literature regarding the laboratory definition of vitamin B6 deficiency 
contributed to the difficulties in interpreting the data. There is no consensus on the 
biochemical cut-off point that defines „deficiency‟ and the lower end of PLP reference ranges 
may vary from 20 nmol/L to 30 nmol/L (Leklem, 1990, Lui et al., 1985) (Table 9.1). At the 
other extreme, another study defined vitamin B6 deficiency as plasma PLP <88 nmol/L (Tang 
et al., 1997a). Furthermore, dichotomization of a continuous variable leads to an inevitable 
loss of information and power and may increase the probability of false positive results. We 
based our definition of 25 nmol/L on the South African definition for PLP deficiency (Visser 
et al., 2004, Cilliers et al., 2010). However, irrespective of the definition of vitamin B6 
deficiency, HPLC measured plasma PLP levels from North American cohorts are 
substantially higher than this African population.  
Another reason why a clear association between vitamin B6 deficiency and HIV-associated 
DSP could not be shown, may be that the mechanism for nerve injury in HIV-infected 
individuals is multifactorial and not entirely related to nutrition (see section 1.7). One such 
mechanism, which may contribute to vitamin B6 deficiency, is inflammation. Previous 
studies have shown that low plasma PLP concentrations are characteristic of individuals with 
inflammatory conditions such as rheumatoid arthritis or inflammatory bowel disease (Chiang 
et al., 2005a, Roubenoff et al., 1995, Saibeni et al., 2003). Furthermore, inverse relationships 
have been reported between vitamin B6 levels and markers of inflammation in the general 
population (Kelly et al., 2004, Gori et al., 2006, Friso et al., 2001) and animal models 
(Chiang et al., 2005b). We examined the association of hs-CRP and serum albumin with PLP. 
In this cohort, plasma PLP levels inversely associated with albumin and hs-CRP levels but 
the association with hs-CRP was no longer evident after correcting for serum albumin in a 
multivariate model. Serum albumin is a major confounder of plasma PLP concentration and 
in this ambulant group of individuals, nearly half had hypoalbuminaemia. The level of 

















therefore difficult to ascertain whether the relationship between PLP and albumin level is 
caused by an association between malnutrition and inflammation or an association between 
two markers of malnutrition. The observation that albumin levels are inversely related to hs-
CRP and the relationship between them was partly attenuated by adjustment for PLP and 4-
PA, is consistent with the possibility that both inflammation and malnutrition may be 
contributory to the association between PLP and albumin. 
In HIV-infected individuals, other factors may contribute to vitamin B6 deficiency, thereby 
weakening the association between vitamin B6 and inflammation. These factors include 
insufficient dietary intake (as a result of anorexia, dysphagia, odynophagia), malabsorption 
and diarrhoea, malignancies, HIV-related enteropathy, impaired storage and altered 
metabolism due to hepatic or renal impairment (Keusch and Farthing, 1990, Tang and Smit, 
1998). This malnutrition may lead to further immunosuppression, opportunistic infections 
and mucosal damage with failure of normal intestinal mucosal turnover and healing, all of 
which could exacerbate the vitamin B6 deficiency. 
There was an inverse correlation between PLP and triglycerides but not with any other lipid 
markers. While vitamin B6 supplementation has been reported to be an effective strategy to 
ameliorate plasma triglycerides and total cholesterol levels, the biological mechanism 
remains unknown (de Gomez Dumm et al., 2003). However, as the interquartile ranges of 
triglyceride levels were within normal limits, it is likely that triglyceride levels are serving as 
a surrogate marker for another process related to vitamin B6 deficiency. For example, 
excessive alcohol usage is known to cause vitamin B6 deficiency and higher triglycerides. No 
such association was found in this study but this may theoretically be the result of an 
inadequate measure used to assess alcohol abuse. In addition, as discussed in Chapter 5, 
mitochondrial dysfunction leads to the accumulation of triglycerides. If the mitochondrial 
dysfunction is related to increased ROS as a result of inflammation (see section 1.8), vitamin 
B6 may be utilized at an increased rate and result in reduced concentrations in the plasma. 
Since the liver is known to play a central role in vitamin B6 metabolism, hepatic impairment 
may lead to PLP deficiency (Lumeng et al., 1974, Labadarios et al., 1977). Plasma PLP levels 
correlated inversely with serum ALT, although only 10% of ALT concentrations were raised. 
Therefore, the role of hepatic impairment is unlikely to have been a significant contributory 
factor to the low serum PLP levels in these individuals. As with triglycerides, it is likely that 

















This study was unable to demonstrate any correlation between vitamin B6 status and CD4 T-
cell count or WHO disease stage, although all individuals had a CD4 T-cell count of less than 
≤350 cells/mm
3
, possibly blunting the influence of CD4 T-cell count on vitamin B6 levels. 
Among cART-naïve individuals, previous observational studies have shown low or deficient 
serum concentrations of several micronutrients, including thiamine, selenium, zinc, and 
vitamins A, -B3, -B6, -B12, -C, -D, and -E to be associated with either low CD4 T-cell 
counts or HIV disease progression (Visser et al., 2004, Tang et al., 1997b, Tang et al., 1993, 
Haug et al., 1998, Baum et al., 1995, Abrams et al., 1993). 
The relationship between NAT2 acetylation phenotype and vitamin B6 levels were 
investigated, the hypothesis being that a slow acetylation phenotype would increase vitamin 
B6 requirements and thus the risk for deficiency. An association between low circulating 
vitamin B6 levels (plasma PLP and 4-PA) and slow NAT2 acetylation phenotype could not 
be demonstrated, even after adjusting for a history of previous TB therapy. Possible 
explanations for this finding could be the relatively small sample size with overrepresentation 
of slow acetylation phenotype in this cohort, or the positively skewed distribution of both 
PLP and 4-PA levels. Discordance between genotype-deduced phenotype and true phenotype 
cannot be ruled out and may have affected associations observed (as discussed in Chapter 7). 
The question remains: What constitutes sufficient vitamin B6 supplementation? Unpublished 
research from our group in a cohort of hospitalized HIV/TB co-infected individuals suggest 
that 25 mg/day of observed vitamin B6 supplementation is probably sufficient to prevent or 
reverse vitamin B6 deficiency, and that administering more than 25 mg/day may be 
unnecessary (Centner, 2012). Mean PLP levels were four times higher than that of our cohort. 
However, as these individuals were non-fasting and plasma samples were obtained within a 
median of six hours after a pyridoxine dose, the observed elevated PLP levels could be 
explained by the pharmacokinetic peak after supplementation (Ubbink et al., 1987). 
Saturation levels for ambulant HIV-infected populations remain undetermined. Others have 
demonstrated that 50 mg/day of vitamin B6 might be the saturation level for critically ill 
hospitalized patients and between 40 and 100 mg/day in healthy HIV-negative individuals, 
with patients being unable to efficiently utilize vitamin B6 doses higher than these levels 
(Cheng et al., 2006, Ubbink et al., 1987, Bor et al., 2003). A recent randomized controlled 
trial involving individuals initiating cART in Tanzania demonstrated that “high-dose” 

















neuropathy compared with standard-dose supplementation (1.3 mg vitamin B6 daily) 
(Isanaka et al., 2012). However, they found that overall “high-dose” multivitamin 
supplementation (including thiamine, riboflavin, niacin, folic acid, vitamin B12, -C and -E) 
was associated with increased ALT levels. The exact mechanism of action for high-dose 
multivitamins to cause ALT elevation in the context of cART remains unknown although 
increased mortality after cART initiation has been observed among patients with low BMI in 
several analyses from sub-Saharan Africa (Johannessen et al., 2008, Stringer et al., 2006, 
Zachariah et al., 2006). Overly aggressive multivitamin regimens coinciding with cART 
initiation may propagate metabolic disturbances and contribute to poor clinical outcomes 
among patients who are severely malnourished. Compared to our cohort, individuals from the 
Tanzanian study had more advanced HIV infection with CD4 T-cell counts <100 cells/mm
3
 
in 40% and 7% with a BMI <16 kg/m
2
. For these reasons, it is difficult to extrapolate their 
ALT findings to our population. 
Based on the above findings and our study results, 4 mg vitamin B6 daily is not sufficient to 
correct vitamin B6 deficiency in an HIV-infected population about to commence cART who 
does not have evidence of overt malnutrition, a median CD4 T-cell count of 156 cells/mm
3
 
and a high prevalence of TB co-infection. Furthermore, in those prescribed 25 mg/day, it did 
not significantly affect PLP concentrations. Although poor compliance may have affected our 
findings, we recommend that higher dosage of vitamin B6 supplementation (at least greater 
than 4 mg/day) should be considered standard of care in all HIV-infected patients, 
irrespective of TB therapy. 
In summary, the current longitudinal observational study is novel in the investigation of 
fasting plasma PLP and 4-PA concentrations in an African HIV-infected population about to 
commence cART, and evaluating the effect of the first 12 weeks of cART on vitamin B6 
status. We have shown a high prevalence of suboptimal circulating plasma PLP levels in this 
African cohort. Half of the population was vitamin B6 deficient at baseline and after 12 
weeks on cART, despite vitamin B complex supplementation. The low vitamin B6 status 
correlated with low albumin levels and could be a reflection of a general state of 
micronutrient deficiency. The results from our study support previous findings in which the 
protective effect of 25 mg vitamin B6 supplementation on peripheral neuropathy was 
demonstrated, not only in individuals with INH treated TB infection but also in individuals 

















high TB co-infection rate and both these infections may impact on nutrition and consequently 
vitamin B6 status. A concerted effort to educate health professionals and patients regarding 
optimal nutrition is necessary. This study suggests that adequate vitamin B6 replacement is 
an area that requires attention and that guidelines should be altered particularly in areas where 
HIV/TB co-infection is common. We suggest that public health care policies should 
implement the recommendations of the developed world regarding vitamin B6 
supplementation (10-25 mg) (JTC, 1998, CDC, 2003, WHO, 2009, Chan and Iseman, 2002), 










































We investigated the association between incident painful neuropathy and the concentrations 
of markers previously shown to be associated with painful neuropathies and/or immune 
reconstitution within 12 weeks after cART-initiation. These included hs-CRP, CD4 T-cell 
count, specific cytokines TNF-α, IL-2, IL-4, IL-6 and their soluble receptors. 
 
10.2 Cohort characteristics 
As part of the prospective cohort followed up for 24 weeks (n=144), 32 individuals (27%) 
developed neuropathic symptoms within the first 12 weeks (see section 4.2.4). Two 
individuals had detectable viral loads at week 24, and as the substudy was examining 
inflammation, these individuals were excluded; the remaining 30 comprised the incident 
symptom-group. 
A nested-control group was selected and consisted of 30 individuals who remained symptom-
free for 24 weeks. The groups were paired using risk factors previously described in the 
literature such as age (difference ≤3 years), gender, previous isoniazid exposure, baseline 
CD4 T-cell count (difference ≤25 cells/mm
3
) and dNRTI containing regimen (Lichtenstein et 
al., 2005, Maritz et al., 2010, Morgello et al., 2004) (Table 10.1 and Table 10.2). Of note, 
factors such as height, weight, white cell count and hs-CRP, which were not paired, showed 
similar distributions between the two groups. Even though median CD4 T-cell counts were 
similar, the groups were stratified for counts <100 cells/mm
3
, 100-200 and >200 cell/mm
3
. 
Again, the distribution between cases and controls remained similar (p=0.86). Baseline HIV 



























Age years 33 (26 - 37) 32 (26 - 35) 34 (26 - 41) 0.215 β
Weight kg 58.5 (53.0 - 68.0) 58.0 (52.5 - 68.5) 59.5 (54.0 - 64.0) 0.866 β
Height metre 1.61 (1.55 - 1.64) 1.58 (1.55 - 1.64) 1.62 (1.57 - 1.65) 0.235 β
Body Mass Index kg/m2 20.0 - 25.0 22.6 (19.8 - 28.0) 22.7 (20.1 - 28.0) 22.6 (19.8 - 25.3) 0.598 β
Waist : Hip ratio < 0.90 0.85 (0.81 - 0.88) 0.86 (0.82 - 0.90) 0.85 (0.81 - 0.87) 0.516 β
Systolic BP mmHg 120 - 140 110 (103 - 123) 110 (106 - 123) 110 (101 - 123) 0.925 β
Diastolic BP mmHg 80 - 90 73 (65 - 80) 73 (65 - 81) 73 (69 - 80) 0.797 β
Haematological
CD4 T-cell count cells/mm3 > 500 141 (110 - 189) 145 (109 - 181) 138 (110 - 194) 0.753 β
White cell count x109/L 4.0 - 11.0 5.7 (4.3 - 7.1) 5.7 (3.9 - 6.4) 5.7 (4.4 - 7.9) 0.270 β
C-reactive protein mg/L < 5.0 2.7 (0.9 - 6.7) 2.6 (0.9 - 5.4) 2.9 (0.9 - 6.7) 0.693 β
Haemoglobin g/dL 11.6 - 15.6 11.7 (10.1 - 13.1) 12.3 (10.5 - 13.3) 11.4 (9.7 - 12.6) 0.118 β
MCV fL 80.0 - 100.0 91.4 (87.6 - 95.6) 90.9 (87.5 - 94.5) 91.5 (87.6 - 97.0) 0.599 β
Biochemical
Albumin g/L 38 - 54 39 (35 - 43) 40 (36 - 43) 39 (35 - 43) 0.426 β
ALT IU/L 10 - 41 17 (14 - 25) 18 (15 - 28) 16 (13 - 20) 0.070 β
Creatinine µmol/L 53 - 115 65 (57 - 73) 66 (56 - 72) 64 (57 - 74) 0.782 β
Metabolic
Fasting glucose mmol/L 4.1 - 5.6 4.7 (4.4 - 4.8) 4.6 (4.4 - 5.0) 4.7 (4.4 - 4.8) 0.633 ε
Fasting insulin µU/mL 0.2 - 9.4 5.0 (3.0 - 7.9) 5.2 (3.8 - 8.9) 4.9 (2.2 - 7.3) 0.343 β
Total cholesterol mmol/L 3.1 - 5.2 3.7 (3.0 - 4.3) 3.9 (3.2 - 4.4) 3.5 (3.0 - 4.2) 0.298 β
Triglycerides mmol/L 0.5 - 2.0 0.9 (0.7 - 1.1) 0.9 (0.7 - 1.0) 0.8 (0.6 - 1.2) 0.736 β
HDL mmol/L 1.15 - 1.68 0.88 (0.71 - 1.09) 0.92 (0.73 - 1.14) 0.86 (0.67 - 1.04) 0.354 β
LDL mmol/L 1.0 - 3.0 2.3 (1.9 - 3.0) 2.4 (1.9 - 3.1) 2.3 (1.8 - 2.8) 0.180 β
Lactate mmol/L < 2.0 2.5 (1.7 - 3.3) 2.5 (1.8 - 3.3) 2.4 (1.7 - 3.3) 0.597 β
Pyridoxine
PLP nmol/L > 25.0 23.2 (14.7 - 36.8) 24.4 (16.7 - 40.3) 20.2 (14.7 - 34.5) 0.642 β
4-PA nmol/L unknown 16.3 (11.3 - 22.1) 15.8 (11.2 - 21.1) 16.6 (11.7 - 22.1) 0.616 β
β    Student's t -test






















Table 10.2: Demographic characteristics for the cytokine cohort (grouped data) 
 
Nineteen individuals (33%) had elevated hs-CRP levels >5mg/L (IQR 5.2-161 mg/L) of 
which 11 were >10 mg/L. One had an hs-CRP >100 mg/L for which no obvious reason was 
found on baseline examination or careful folder review; there was no record of any acute 
infection or inflammatory condition in the clinic folder, and the white cell count was 9.98 
x10
9
/L. Only one individual had an elevated white cell count (16.5x10
9
/L), but without cause; 
the hs-CRP was 1.8 mg/L. 
Of those who developed neuropathic symptoms, the peak incidence was between weeks 4 and 
12 (14%). The overall estimated crude incidence rate after 24 weeks was 30% (see Figure 
4.3, section 4.2.4). In this substudy, the most frequent symptom was paraesthesiae (25/30), 
followed by numbness (21/30) and pain (15/30). At initial presentation median 







Female sex 44 (73%) 22 (73%) 22 (73%) 1.000 ¶
Age > 40 years 12 (20%) 9 (30%) 3 (10%) 0.104 ¶
Previous/Current TB 14 (23%) 7 (23%) 7 (23%) 1.000 ¶
Time of TB 1.000 ¶
Currently 0 (0%) 0 (0%) 0 (0%)
< 1 year ago 6 (10%) 3 (10%) 3 (10%)
1 year ago 0 (0%) 0 (0%) 0 (0%)
2 years ago 1 (2%) 0 (0%) 1 (3%)
> 2 years ago 7 (12%) 4 (13%) 3 (10%)
Vit Bco supplement 58 (97%) 29 (97%) 29 (97%) 1.000 ¶
Vit B6 supplement 0 (0%) 0 (0%) 0 (0%) 1.000 ¶
WHO clinical stage 0.172 ¶
Stage 1 18 (30%) 6 (20%) 12 (40%)
Stage 2 28 (47%) 18 (60%) 10 (33%)
Stage 3 12 (20%) 5 (17%) 7 (23%)
Stage 4 2 (3%) 1 (3%) 1 (3%)
CD4 T-cell count 0.864 ¶
< 100 cells/mm 3 11 (18%) 5 (17%) 6 (20%)
100 - 200 cells/mm 3 39 (65%) 19 (63%) 20 (67%)
> 200 cells/mm 3 10 (17%) 6 (20%) 4 (13%)
Body Mass Index 16 (28%) 9 (30%) 7 (25%) 0.981 ¶
< 20 kg/m 2 16 (28%) 9 (30%) 7 (25%)
20 - 25 kg/m 2 23 (40%) 12 (40%) 11 (39%)
25 - 30 kg/m 2 11 (19%) 5 (17%) 6 (21%)
> 30 kg/m 2 8 (14%) 4 (13%) 4 (14%)
Alcohol last year 17 (29%) 8 (27%) 9 (32%) 0.775 ¶
IHDS score < 10 5 (11%) 3 (12%) 2 (9%) 1.000 ¶



















resolved in 18, whereas the remainder had persistent or worsening symptoms. Of the 30 with 
incident symptoms, 15 (50%) developed ≥1 new/worsening neuropathic sign(s). 
 
10.3 Cytokine analysis 
10.3.1 Baseline cytokine concentrations 
The baseline cytokine concentrations at the pre-cART visit are tabulated in Table 10.3. 
Median concentrations of IL-4, IL-12(p70) and IL-13 were below the minimum detectable 
level at baseline. Levels of IL-4 were undetectable in 97% of individuals. 
Table 10.3: Baseline cytokine concentrations, minimum detectable concentrations and the percentage of 
undetectable levels for each cytokine in the overall cytokine cohort. 
 
10.3.2 Trends in cytokine concentrations over the 12 week follow-up 
The initiation of cART significantly affected both pro- and anti-inflammatory cytokine 
concentrations, irrespective of the development of neuropathic symptoms (see heat map 
Figure 10.1 and Figure R-1 to Figure R-4 in Appendix R). Almost all the cytokines measured, 
whether pro- or anti-inflammatory, demonstrated significantly higher concentrations at week 
2 and -4 returning to baseline levels by week 12; these included IL-1β, IL-2, IL-4, IL-5, IL-6, 
IL-7, IL-10, IL-12p(70), IL-13, IFN-γ, GM-CSF and TNF-α [Table 10.4 and Table R-1 in 










Interleukin-1β 0.12 (0.01 ; 0.36) 0.06 17 (29%)
Interleukin-2 0.99 (0.14 ; 2.38) 0.16 16 (27%)
Interleukin-4 0.12 (0.12 ; 0.12) 0.13 58 (97%)
Interleukin-5 0.56 (0.32 ; 1.11) 0.01 1 (2%)
Interleukin-6 2.84 (1.92 ; 5.11) 0.10 1 (2%)
Interleukin-7 2.06 (0.67 ; 3.68) 0.12 4 (7%)
Interleukin-8 3.77 (2.46 ; 5.25) 0.11 0 (0%)
Interleukin-10 14.91 (7.03 ; 29.35) 0.15 0 (0%)
Interleukin-12 0.01 (0.01 ; 1.02) 0.11 37 (62%)
Interleukin-13 0.47 (0.47 ; 7.26) 0.48 34 (57%)
IFN-γ 1.20 (0.01 ; 3.23) 0.29 22 (37%)
GM-CSF 0.73 (0.17 ; 1.51) 0.46 23 (38%)

















2 onwards compared to those at baseline. Irrespective of symptom-status, TNF-α increased 
from pre-cART levels, peaked between weeks 2 and -4, but then decreased at week 12 to a 
lower level compared with baseline (p=0.008). At week 12, IL-6 remained higher than 
baseline levels (p=0.033). 
















Baseline 0.12 0.11 0.16 0.608 ε
Week 2 1.71 1.52 (1.24 ; 1.79) <0.001 1.20 2.23 -0.57 (-1.10 ; -0.03) 0.038
Week 4 1.31 1.15 (0.87 ; 1.43) <0.001 1.11 1.65 -0.19 (-0.73 ; 0.35) 0.486
Week 12 0.26 0.26 (0.00 ; 0.53) 0.054 0.29 0.24 0.18 (-0.34 ; 0.70) 0.497
Interleukin-2
Baseline 0.99 1.01 0.95 0.796 ε
Week 2 10.73 10.99 (8.97 ; 13.00) <0.001 8.54 14.44 -3.94 (-7.90 ; 0.01) 0.051
Week 4 9.90 9.01 (6.98 ; 11.05) <0.001 7.94 10.29 -0.99 (-4.99 ; 3.02) 0.629
Week 12 1.69 1.92 (-0.03 ; 3.87) 0.054 1.80 1.34 0.54 (-3.29 ; 4.37) 0.782
Interleukin-4
Baseline 0.12 0.12 0.12 0.147 ε
Week 2 1.21 4.11 (1.11 ; 7.11) 0.007 0.12 2.79 -0.69 (-6.64 ; 5.26) 0.820
Week 4 0.12 2.22 (-0.81 ; 5.25) 0.151 0.13 0.12 -1.37 (-7.38 ; 4.65) 0.656
Week 12 0.12 1.60 (-1.31 ; 4.51) 0.282 0.12 0.12 2.74 (-3.05 ; 8.53) 0.354
Interleukin-6
Baseline 2.84 2.84 2.97 0.693 ε
Week 2 8.71 8.18 (5.37 ; 10.99) <0.001 6.79 9.15 1.39 (-4.18 ; 6.97) 0.624
Week 4 8.71 6.76 (3.91 ; 9.61) <0.001 7.62 8.79 0.35 (-5.29 ; 6.00) 0.903
Week 12 4.09 2.95 (0.24 ; 5.66) 0.033 3.37 4.21 4.53 (-0.84 ; 9.91) 0.098
Interleukin-10
Baseline 14.91 14.31 16.25 0.720 ε
Week 2 36.28 25.52 (9.47 ; 41.57) 0.002 36.68 35.68 12.36 (-19.56 ; 44.27) 0.448
Week 4 31.82 19.53 (3.27 ; 35.80) 0.019 30.94 33.99 -10.80 (-43.13 ; 21.54) 0.513
Week 12 10.68 7.93 (-7.53 ; 23.39) 0.315 13.99 9.89 -3.99 (-34.71 ; 26.74) 0.799
TNF-α
Baseline 6.64 7.36 6.53 0.820 ε
Week 2 14.19 6.55 (4.59 ; 8.50) <0.001 12.47 15.98 -1.22 (-5.09 ; 2.66) 0.539
Week 4 14.52 6.79 (4.81 ; 8.77) <0.001 13.94 14.76 -1.90 (-5.82 ; 2.02) 0.343
Week 12 5.52 -2.56 (-4.44 ; -0.67) 0.008 5.71 5.20 1.50 (-2.24 ; 5.24) 0.432
a    Time effect is the effect of cART on mean cytokine concentration for the entire cohort
b    Group effect is the difference in mean cytokine concentration between groups compared to baseline























Figure 10.1: Heat map of cytokine concentrations for all individuals at four different time points 
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A = Interleukin-1        B = Interleukin-2        C = Interleukin-4        D = Interleukin-5        E = Interleukin-6        F = Interleukin-7        G = Interleukin-8
H = Interleukin-10        I = Interleukin-12        J = Interleukin-13        K = IFN-γ         L = GMCSF         M = TNF-α



























The pro-inflammatory Th1 cytokines showed the greatest increases from baseline 
concentrations; IL-12p(70) (≈700-fold), IL-2 (≈300-fold) and IFN-γ (≈200-fold). Although 
TNF-α concentrations only increased 3-fold, these were at higher baseline levels. Compared 
with baseline, the Th2 cytokine levels also responded to cART initiation; IL-13 increased 59-
fold and IL-4 36-fold at 2 weeks. IL-5 and IL-10 increased by comparatively modest amounts 
(4- to 5-fold). 
10.3.3 Within-individual stability across time 
To assess the impact of random variability and fluctuations within an individual‟s cytokine 
peak measurements over time, rank correlation analysis was performed. Through this 
analysis, we gained insight into the predictability of the trend observed in concentration for a 
particular cytokine. For the interval of 12 weeks, cytokine levels showed within-individual 
stability and predictability by correlating at two different time points for 11 cytokines, and at 
three time points for three of these (IL-5, IL-10 and IFN-γ) (Table 10.5). 
 
Table 10.5: Spearman rank correlation coefficients between baseline and 3 follow-up visits 
 
10.3.4 Comparison of cytokines between cases and controls 
To determine whether an elevated cytokine concentration at baseline is a predictor of 
development of neuropathic symptoms over the 24 weeks of follow-up, a cross-sectional 
comparison of cytokine levels was performed. The baseline pre-cART cytokine 
concentrations between the symptomatic and symptom-free groups were similar (Table 10.4). 
Cytokine Week 2 Week 4 Week 12
Interleukin-1β 0.22 0.52** 0.22
Interleukin-2 0.15 0.44* 0.29
Interleukin-4 0.22 0.14 0.29
Interleukin-5 0.40* 0.69** 0.56**
Interleukin-6 0.50** 0.57** 0.19
Interleukin-7 0.28 0.41* 0.41*
Interleukin-8 0.26 0.14 0.19
Interleukin-10 0.49** 0.71** 0.54**
Interleukin-12 0.30 0.52** 0.28
Interleukin-13 0.20 0.43* 0.35
IFN-γ 0.43* 0.68** 0.39*
GM-CSF 0.23 0.50** 0.47**
TNF-α 0.33 0.63** 0.47**
  * p < 0.05

















To determine the effect of cART initiation on cytokine production, as well as the difference 
in cytokine production between individuals with incident neuropathic symptoms and those 
who remained symptom-free, a cross-sectional time series analysis was performed (Table 
10.4). Despite the general increase in cytokine concentrations, there was a tendency for lower 
peaks in the symptomatic- compared to the symptom-free group. The marginally lower 
cytokine production in the symptomatic group compared to the individuals who remained 
symptom-free was only statistically significant for IL-1β and IL-13 at week 2 (p=0.038 and 
p=0.029, respectively), and a trend towards significance for IL-2 and GM-CSF (p=0.051 and 
p=0.072, respectively). 
 
10.4 Soluble receptors and IL-1 receptor antagonists 
Accumulating evidence indicates that biologic effects and regulation of cytokines in vivo may 
be modulated not only by cytokine secretion or the activity of one cytokine by other 
cytokines, but also by their respective soluble receptors and receptor antagonists. As the half-
lives of soluble cytokine receptors are longer than the respective cytokines they may be more 
informative of chronic cytokine activity (Arend et al., 1998, Chikanza et al., 1993). 
Therefore, we investigated the association f plasma concentrations of cytokine receptors 
sIL-1RI, sIL-1RII, sIL-2Rα, sIL-4R, sIL-6R, sTNFRI, sTNFRII, and IL-1RA and the 

















Table 10.6: Cross-sectional time series analysis for soluble receptors over 12 weeks after starting cART 
 
In the group who developed symptoms compared to those remaining symptom-free, median 
IL-1RA concentrations were significantly higher pre-cART (10.2 vs 1.9 pg/mL, p=0.030), 
and remained higher throughout the study period. However, 26 of 60 individuals (six 
















Baseline 29.6 33.3 25.5 0.159 ε
Week 2 34.0 4.7 (-0.4 ; 9.8) 0.073 36.9 33.6 -0.7 (-10.8 ; 9.4) 0.893
Week 4 37.6 4.0 (-1.2 ; 9.1) 0.132 37.5 38.7 -6.2 (-16.4 ; 4.1) 0.237
Week 12 28.2 1.4 (-3.6 ; 6.3) 0.585 34.5 25.2 1.3 (-8.5 ; 11.1) 0.789
sIL1RII
Baseline 4571.9 4160.6 4922.8 0.413 ε
Week 2 4885.7 -94.4 (-1249.1 ; 1060.4) 0.873 4744.4 4905.8 -294.9 (-2600.0 ; 2010.3) 0.802
Week 4 5116.7 781.2 (-388.7 ; 1951.1) 0.191 5115.7 5751.6 -626.6 (-2960.5 ; 1707.3) 0.599
Week 12 5806.5 941.3 (-178.8 ; 2061.5) 0.100 5604.6 6152.1 433.5 (-1802.0 ; 2669.0) 0.704
sIL2rα
Baseline 1102.3 1068.2 1210.3 0.554 ε
Week 2 1049.2 -238.1 (-647.9 ; 171.7) 0.255 1188.4 866.1 870.5 (63.8 ; 1677.1) 0.034
Week 4 881.2 -573.8 (-988.7 ; -158.9) 0.007 745.5 1032.1 695.8 (-121.3 ; 1512.8) 0.095
Week 12 733.3 -840.6 (-1236.0 ; -445.2) <0.001 647.1 823.8 396.5 (-381.9 ; 1174.9) 0.318
sIL6R
Baseline 9379.3 9379.3 9545.9 0.575 ε
Week 2 9480.6 -210.6 (-1457.6 ; 1036.4) 0.741 10038.4 9183.6 2064.7 (-387.2 ; 4516.6) 0.099
Week 4 11538.0 170.5 (-1093.0 ; 1434.1) 0.791 11248.9 11940.5 702.1 (-1781.4 ; 3185.6) 0.580
Week 12 8123.9 -1366.0 (-2568.2 ; -163.9) 0.026 8250.4 7518.7 2598.0 (234.6 ; 4961.5) 0.031
sTNFRI
Baseline 536.2 551.4 489.4 0.693 ε
Week 2 560.9 13.4 (-69.8 ; 96.6) 0.752 647.5 516.4 81.9 (-83.9 ; 247.7) 0.333
Week 4 606.9 77.2 (-7.1 ; 161.5) 0.072 646.0 571.0 4.6 (-163.5 ; 172.7) 0.957
Week 12 455.1 -50.7 (-130.9 ; 29.5) 0.215 532.9 415.2 53.3 (-106.5 ; 213.1) 0.513
sTNFRII
Baseline 5441.7 5441.7 5582.4 0.638 ε
Week 2 5104.3 -979.0 (-1695.3 ; -262.7) 0.007 5680.6 4236.9 1517.7 (116.3 ; 2919.2) 0.034
Week 4 4757.1 -1343.6 (-2069.2 ; -618.0) <0.001 4307.4 5766.0 -352.0 (-1771.9 ; 1068.0) 0.627
Week 12 4564.9 -1421.8 (-2112.7 ; -730.9) <0.001 4485.4 4579.4 -92.1 (-1443.5 ; 1259.3) 0.894
 IL1ra
Baseline 4.4 10.2 1.9 0.030 ε
Week 2 3.4 2.5 (-13.5 ; 18.5) 0.760 11.3 0.4 5.5 (-26.2 ; 37.1) 0.734
Week 4 5.4 0.4 (-15.7 ; 16.4) 0.965 5.7 2.1 -7.3 (-39.1 ; 24.6) 0.654
Week 12 3.4 9.7 (-5.8 ; 25.2) 0.219 5.1 0.0 19.3 (-11.4 ; 50.0) 0.219
a    Time effect is the effect of cART on mean cytokine concentration for the entire cohort
b    Group effect is the difference in mean cytokine concentration between groups compared to baseline





















After starting cART, the overall concentrations of sIL-2Rα and sTNFRII declined 
significantly from pre-cART/baseline levels to those at 12 weeks irrespective of symptom 
status (p<0.001). However, a repeated measures analysis for both sTNFRII and sIL-2Rα 
showed significant differences in the median levels between symptomatic and symptom-free 
groups at week 2 (sTNFRII, p=0.034; sIL-2Rα, p=0.034). 
Soluble IL-6R levels showed an overall upward trend over the first four weeks before 
declining, although concentrations in the symptomatic group were still higher at week 12 
(p=0.031). Soluble receptors IL-1RI, sIL-1RII and sTNFRI remained stable throughout the 
observation period without any differences between the two groups. 
It has been suggested that the biological cytokine activity may depend on the balance 
between the cytokine concentration and that of its soluble receptor. Therefore, the 
cytokine:soluble receptor ratios may provide an estimate of plasma biological activity (Arend 
et al., 1998, Cox et al., 2006, Dodoo et al., 2002, Hagiwara et al., 1996). Concentrations of all 
the soluble receptors tested were considerably higher than their respective cytokines. There 
was no significant difference in either the TNF-α/sTNFRI or TNF-α/sTNFRII ratios between 
individuals who developed neuropathic symptoms compared to control individuals. The 
ratios between IL-1β and its receptors sIL-RI and sIL-RII, IL-6 and its receptor sIL-6R and 
IL-2 and sIL-2Rα were also investigated (Table R-2 in Appendix R). At week 2 after cART, 
individuals with incident symptoms compared with symptom-free individuals showed lower 
ratios of IL-1β/sIL-1RI (p=0.004), IL-1 β/IL-1RA (p=0.006) and IL-2/sIL-2Rα (p=0.014). At 
the same time, “pain-associated” cytokines of a priori interest showed higher ratios in the 
symptomatic-group for TNF-α/IL-4 (p=0.022) and a trend for IL-6/IL-4 (p=0.054) and IFN-
γ/IL-4 (p=0.061). At week 12 the symptom-group still had a higher IFN-γ/IL-10 ratio 
(p=0.044). 
10.4.1 Possible factors affecting cytokine concentrations 
Increased cytokine production has been associated with low CD4 T-cell counts (Bebell et al., 
2008, Stylianou et al., 1999). A comparison of cytokine concentrations stratified by CD4 T-
cell count (below and above 100 cells/mm
3
) is shown in Table 10.7. Apart from significantly 
higher IL-6 and IL-10 concentrations in individuals with a CD4 T-cell count <100 cells/mm
3 
(p=0.006 and p=0.013 respectively), other cytokine concentrations did not differ significantly 

















Table 10.7: Comparison of baseline cytokine concentrations across CD4 T-cell groups 
 
Stratifying individuals by dNRTI exposure, previous TB history or vitamin B6 deficiency, 
did not show an association with cytokine concentrations at any sampling point (see Table 
R-3 – Table R-6 in Appendix R). However, the small sample size may limit the power to 
detect differences between stratified groups. 
10.4.1.1 Symptom duration and severity 
Cytokine concentrations of individuals with transient neuropathic symptoms (18/30) were 
compared to those individuals whose symptoms persisted after week 12 (12/30). The IL-6 
peak at week 2 was significantly higher for individuals with persistent symptoms compared 
to those with transient symptoms (p=0.023) (Table 10.8). To evaluate whether the pattern of 
cytokine release was related to severity of symptoms, individuals were stratified according to 
symptom severity grade. No statistical difference was found between individuals with a 
symptom grade ≥2 (representing VAS ≥6/10) compared to individuals with a symptom 
grading <2 (Table 10.8 and Table R-7 in Appendix R). 
Cytokine
CD4 < 100 cells/mm3
(n = 11)
CD4 > 100 cells/mm3
(n = 49)
Interleukin-1β 0.1 (0.0 - 0.3) 0.1 (0.0 - 0.4) 0.555 β
Interleukin-2 0.4 (0.0 - 1.7) 1.0 (0.1 - 2.5) 0.482 β
Interleukin-4 0.1 (0.1 - 0.1) 0.1 (0.1 - 0.1) 0.499 ε
Interleukin-5 0.6 (0.3 - 1.6) 0.5 (0.3 - 1.0) 0.653 β
Interleukin-6 4.6 (2.6 - 14.0) 2.8 (1.6 - 4.5) 0.006 ε
Interleukin-7 2.2 (1.2 - 9.1) 2.0 (0.7 - 3.6) 0.338 β
Interleukin-8 3.8 (2.7 - 7.4) 3.8 (2.4 - 4.8) 0.897 β
Interleukin-10 27.4 (20.4 - 41.0) 13.1 (6.9 - 25.4) 0.011 β
Interleukin-12 0.0 (0.0 - 0.2) 0.0 (0.0 - 1.1) 0.301 ε
Interleukin-13 0.5 (0.5 - 10.3) 0.5 (0.5 - 7.2) 0.622 ε
IFN-γ 2.5 (1.0 - 4.9) 0.9 (0.0 - 2.8) 0.085 β
GMCSF 0.7 (0.1 - 1.3) 0.7 (0.2 - 1.5) 0.847 β
TNF-α 9.2 (6.0 - 11.4) 6.2 (4.3 - 10.9) 0.168 β
β    Student's t -test






















10.5 CD4 T-cell reconstitution and hs-CRP analysis 
After 24 weeks individuals with incident symptoms showed greater CD4 T-cell reconstitution 
compared with the symptom-free group (335 vs 237 cells/mm
3
, p=0.008). Overall, and 
compared to pre-cART, hs-CRP levels peaked at 2 weeks (p=0.001) although without 









Week 2 -0.39 (-1.31 ; 0.52) 0.402 -0.15 (-0.97 ; 0.68) 0.724
Week 4 0.02 (-0.91 ; 0.94) 0.975 0.24 (-0.58 ; 1.07) 0.565
Week 12 0.08 (-0.85 ; 1.01) 0.868 0.28 (-0.52 ; 1.09) 0.491
Interleukin-2
Week 2 -2.89 (-9.48 ; 3.71) 0.391 -1.97 (-7.93 ; 4.00) 0.518
Week 4 1.05 (-5.60 ; 7.69) 0.758 2.67 (-3.29 ; 8.64) 0.380
Week 12 -1.51 (-8.23 ; 5.21) 0.661 0.44 (-5.35 ; 6.24) 0.880
Interleukin-4
Week 2 -3.00 (-15.49 ; 9.50) 0.638 1.56 (-9.69 ; 12.80) 0.786
Week 4 -2.17 (-14.75 ; 10.42) 0.736 -0.90 (-12.15 ; 10.34) 0.875
Week 12 10.13 (-2.57 ; 22.83) 0.118 9.77 (-1.17 ; 20.72) 0.080
Interleukin-6
Week 2 -11.50 (-21.43 ; -1.56) 0.023 7.92 (-1.37 ; 17.21) 0.095
Week 4 -3.66 (-13.69 ; 6.37) 0.474 6.61 (-2.68 ; 15.89) 0.163
Week 12 -7.90 (-18.05 ; 2.25) 0.127 5.75 (-3.20 ; 14.70) 0.208
Interleukin-10
Week 2 -6.48 (-42.28 ; 29.32) 0.723 -1.79 (-34.73 ; 31.15) 0.915
Week 4 -9.07 (-45.18 ; 27.05) 0.623 -7.71 (-40.65 ; 25.23) 0.646
Week 12 24.18 (-12.35 ; 60.71) 0.195 -22.73 (-54.54 ; 9.07) 0.161
TNF-α
Week 2 -3.02 (-8.81 ; 2.78) 0.307 -4.89 (-10.22 ; 0.44) 0.072
Week 4 -1.18 (-7.02 ; 4.67) 0.693 -1.22 (-6.55 ; 4.10) 0.652
Week 12 -1.00 (-6.91 ; 4.91) 0.741 -2.04 (-7.19 ; 3.10) 0.436
a    Difference in mean cytokine concentration between resolved symptoms and unresolved symptoms compared to baseline
b    Difference in mean cytokine concentration between grade ≥ 2  severity and grade 1 severity compared to baseline


















Table 10.9: CD4 T-cell count and hs-CRP before cART initiation and longitudinally over 12 weeks 












Baseline 141 (110 ; 189) 145 (109 ; 181) 138 (110 ; 194) 0.920 ε
24-week 272 (204 ; 368) <0.001 335 (210 ; 403) 237 (185 ; 260) 0.008
   
C-reactive protein
Baseline 2.7 (0.9 ; 6.7) 2.9 (0.9 ; 6.7) 2.6 (0.9 ; 5.4) 0.693 ε
Week 2 6.7 (2.1 ; 18.5) 0.001 8.4 (3.4 ; 17.0) 5.3 (1.8 ; 19.3) 0.606
Week 4 6.5 (3.3 ; 26.5) 0.137 8.4 (3.5 ; 30.6) 4.2 (3.3 ; 15.0) 0.930
Week 12 4.0 (1.5 ; 7.2) 0.651 3.8 (1.5 ; 8.3) 4.2 (1.0 ; 6.7) 0.216
ε    Wilcoxon rank-sum test
a    Difference between follow-up visit and baseline
b    Difference between groups compared to baseline
Variable










































We demonstrate a transient but significant burst in both pro- and anti-inflammatory plasma 
cytokine concentrations, as well as hs-CRP levels, within 2-4 weeks after starting cART in all 
individuals, irrespective of neuropathic symptom status. Twelve of the 13 cytokines analysed 
increased significantly within 4 weeks of starting cART; some such as IL-2, IL-12(p70) and 
IFN-γ, increased by more than 200-times relative to pre-cART/baseline concentrations before 
returning to these levels at 12 weeks. Although Padilla et al. measured inflammatory markers 
(IL-6 and hs-CRP) longitudinally starting four weeks after cART initiation/re-initiation, the 
2-week sampling visit proved informative in our study (Padilla et al., 2011). 
Comparing plasma cytokine concentrations in those developing neuropathic symptoms with 
those remaining symptom-free at 24 weeks, the symptomatic group demonstrated a trend 
towards lower peak cytokine concentrations between 2 and 4 weeks post-cART initiation. 
This was evident for both pro- and anti-inflammatory cytokines. However, only IL-1β and 
IL-13 concentrations at week 2 were significantly lower in the symptomatic-group. 
Soluble cytokine receptors were studied as an indicator of a more chronic systemic 
inflammatory response (Arend et al., 1998, Chikanza et al., 1993). Interestingly, the IL-1RA 
concentrations were 5-times higher in the symptomatic group preceding cART initiation. 
Two weeks after starting cART, the sIL-2rα and sTNFRII showed higher peak concentrations 
in the symptomatic- compared with the symptom-free group. At week 24, the symptomatic-
group showed greater reconstitution of CD4 T-cell count. In those with symptoms, higher IL-
6 levels associated with symptoms lasting up to 24 weeks compared to the levels in those 
with transient symptoms. Importantly, two individuals with detectable viral loads at week 24 
were excluded to minimize the confounding effect of uncontrolled HIV infection. Vitamin B6 
concentrations did not correlate with the change in cytokine concentrations. However, other 
antioxidants such as vitamin E and selenium levels were not accounted for in this analysis 
and may have also affected cytokine production. Taken together these results suggest that 
within the first 12-24 weeks there is evidence to support enhanced subclinical inflammation 
and immune reconstitution in the systemic compartment in individuals developing 
neuropathic symptoms compared with those remaining symptom-free. Individuals susceptible 
to developing neuropathic symptoms possibly have insults driving chronic subclinical 

















Previously, higher levels of systemic TNF-α- and IL-2-mRNA were reported in HIV-negative 
painful neuropathies when compared with painless neuropathies (Uceyler et al., 2007). 
Although in our study plasma IL-2 and TNF-α concentrations did not mirror the soluble 
receptor levels or segregate by symptom status, the systemic cytokine concentrations of both 
were substantially lower than the concentrations of their respective soluble receptors (sIL-
2rα, sTNFRI and sTNFRII). A possible explanation is that IL-2 and TNF-α, secreted by Th1 
cells, act locally in an autocrine or a paracrine manner and are neutralized systemically by 
their soluble receptors as an immune regulatory mechanism (Mosmann and Coffman, 1989). 
Furthermore, the longer plasma half-life of these soluble receptors and their rapid biological 
inactivation of systemic cytokines suggest that the elevated levels detected in the 
symptomatic group may indicate a relatively higher level of inflammation or injury, even 
prior to cART initiation (Barnes, 1998, Chikanza et al., 1993). 
In order to further explore a profile of immune dysregulation we assessed the ratios between 
key cytokines previously implicated in neuropathic pain (Tyor et al., 1995, Uceyler et al., 
2007). The group with symptoms had significantly higher ratios of TNF-α/IL-4 and IL-6/IL-4 
2 weeks after cART initiation, and IFN-γ/IL-10 at 12 weeks. This suggests that in individuals 
developing neuropathic symptoms, there is an imbalance between pro- and anti-inflammatory 
cytokines in which Th1 subsets and their cyt kine products including IL-6, IFN-γ and TNF-α, 
dominate over an immunoregulatory Th2 subset and their cytokines, IL-4 and IL-10. This 
imbalance may be due to either HIV-associated immune dysregulation, greater imbalance 
between ROS and antioxidants, or predisposing genetic factors inducing reduced or enhanced 
cytokine gene transcription upon any pathology. 
Although peak cytokine concentrations in this cohort overall were lower than those 
associated with hospitalized TB-IRIS patients (Conesa-Botella et al., 2012, Tadokera et al., 
2011), this study population comprised ambulatory individuals attending a community-based 
clinic. Parasitic and non-parasitic infections, as well as nutritional deficiencies could 
contribute to the degree of observed immune activation once the HIV-induced functional 
inhibition is reversed by cART. However, all individuals were well and by selection had 
achieved viral control by 24 weeks. 
We suggest that the lower cytokine peak in the symptomatic group may be the consequence 
of systemic neutralization by the concomitant and significantly higher concentration of IL-

















circulating inflammatory mediators, and also synthesized by locally activated monocytes to 
reduce the systemic responses to localized IL-1β production (Dinarello, 1996, Nicklin et al., 
2000). High levels of circulating IL-1RA have been reported in many inflammatory settings 
including target-organ autoimmune diseases such as rheumatoid arthritis; in the latter, 
systemic and local synovial production of IL-1RA is thought to be inadequate to dampen the 
IL-1 mediated synovial damage (Arend et al., 1998). The finding of high plasma levels of IL-
1RA prior to cART initiation in individuals who developed symptoms suggests that IL-1RA 
may be part of the host‟s homeostatic mechanism aimed at downregulating a pre-existing 
inflammatory challenge.  
Importantly, the symptom-free group at baseline had a similar IL-1β/IL-1RA ratio to a 
previous and comparable cohort of asymptomatic African women with reasonably preserved 
CD4 T-cell counts not on cART (Thea et al., 1996). By comparison, our symptomatic group 
showed a markedly altered IL-1β/IL-1RA ratio at baseline/pre-cART due to the significantly 
higher IL-1RA levels (Table 10.6). We propose that this higher plasma IL-1RA level in the 
group predicted to develop symptoms reflects the cytokine imbalance at the dorsal root 
ganglion particularly when the blood-nerve barrier is impaired (Thea et al., 1996). 
The dorsal root ganglion plays a pivotal role in the pathogenesis of HIV-associated 
neuropathy, which likely involves both indirect cytokine- and direct viral protein-mediated 
neurotoxicity (Jones et al., 2005). Neuronal toxicity in the dorsal root ganglion is associated 
with upregulated IL-1β and TNF-α expression (Acharjee et al., 2011, Jones et al., 2005). 
Subclinical levels of inflammation such as local IL-1β production, may prime proteinase-
activated receptors (PAR)2 on small dorsal root ganglion neurons and their afferent axons 
(Vergnolle et al., 2001). A “second hit” such as the cART-associated subclinical “cytokine 
burst” herein described, may facilitate further PAR2 activation with augmentation of 
nociceptive signalling via central pathways (Alier et al., 2008, Vergnolle et al., 2001). 
An alternative explanation for the lower cytokine peaks seen in individuals with symptoms 
may be that these individuals had already reached a threshold of mitochondrial damage 
preceding cART initiation. Mitochondrial damage leads to oxidative stress (Lewis et al., 
2003) and this in turn impacts on several T-cell functions including lymphocyte 
responsiveness and cytokine release (Grisham, 2004). The impairment of T-lymphocyte 
function by oxidative stress has been shown to be relevant in several models and conditions 

















Stefanova et al., 1996). Although it may be argued that oxidative stress and impairment in T-
lymphocyte functioning may impact on cytokine release after cART initiation, the timing of 
increased levels of several soluble receptors that coincides with the rising incident peak of 
ATN and neuropathic symptoms, negates this.  
As the principal downstream mediator of the acute-phase response, hs-CRP may account for 
the integrated effects of certain cytokines, including TNF-α and IL-6 (Liu et al., 2007). 
Similar to the trend shown in the cytokine concentrations, an overall increase in hs-CRP 
concentrations were observed between 2 and 4 weeks after starting cART. However, no 
significant differences were observed in hs-CRP concentrations during the 24-week follow 
period between individuals who developed neuropathic symptoms and individuals who 
remained symptom-free.  
The substudy has several limitations. Firstly, plasma levels may not reliably reflect local 
activation due to the local perineural action of cytokines at low concentrations. Therefore, 
systemic cytokine levels might not accurately demonstrate the extent of neural inflammation 
in symptomatic individuals. A more definitive measure of local inflammatory reactions at 
nerve level would be nerve biopsy; however this is impractical for community-based studies 
at fortnightly intervals. Secondly, our conclusions are based on a small sample reducing our 
statistical power to detect weaker associations. Fluctuation in cytokine levels may have 
affected results although rank correlation analyses demonstrated good within-individual 
stability and predictability for the majority of cytokines. A random effects model was used to 
limit the effect of variability and fluctuations on the longitudinal analysis of cytokine levels. 
Exclusion criteria such as known diabetes or individuals on TB therapy limit the 
generalizability of our findings. In addition, although individuals with detectable viral loads 
at 24 weeks were excluded from this study, a degree of undetectable viral replication may 
have confounded the interpretation of the cytokine results. Methodologic limitations also 
need to be taken into account. The analysis was hindered in part by the low plasma levels of 
some of the examined cytokines, such that, for instance, IL-4 and IL-12 were not detectable 
in several samples even by using ultrasensitive Multiplex kits. Furthermore, measurement 
error may influence results, which is a limitation in any study. 
Cytokine:receptor ratios for all groups were not normally distributed and showed a large 
variability with significant skewing. Ratios should therefore be confirmed in a larger study 

















of one pro-inflammatory cytokine to another anti-inflammatory cytokine may not be an 
accurate reflection of trends in cytokine responses. 
Strengths of this study include the examination of individuals (by clinicians) a few days prior 
to starting cART, in addition to four intervening clinical and sampling visits spanning the 
first 24 weeks after cART initiation. The prospective design of our study allowed us to assess 
the variation in the inflammatory biomarkers over the early stages of exposure to cART. 
Variation in inflammatory markers may be as a result of natural antagonists in the plasma and 
their effect on cytokine levels may be better observed in longitudinal data compared to a 
cross-sectional analysis. We were also able to demonstrate significant differences in trends 
between soluble receptors and cytokine concentrations. 
In conclusion, we present longitudinal plasma cytokine levels in a community-based, 
otherwise asymptomatic cohort starting cART. Overall, cART resulted in a significant 
increase in cytokine production from pre-treatment levels within the first 2-4 weeks after 
initiating therapy, possibly contributing to the general susceptibility to manifesting 
pathological IRIS in this window period. We show that individuals developing neuropathic 
symptoms within the following 12 weeks already have higher levels of IL-1RA pre-cART. 
We propose that this represents a homeostatic response to chronic higher levels of 
background inflammatory signals such as IL-1β. An additional “insult” such as initiating 
cART with the observed cytokine burst, altered and higher ratios of pain- associated 
cytokines (TNF-α/IL-4, IL-6/IL-4 and IFN-γ/IL-10), and concomitant increases in soluble 
cytokine receptors (sIL-2Rα and sTNFRII), on a background of HIV-associated immune 
dysregulation and/or susceptible genetic factors may give rise to neuropathic symptoms via 
complex direct and indirect signalling mechanisms. 
(Beadles et al., 2009, Cherry et al., 2006, Friso et al., 2004, Matarese et al., 2009, Nakamoto 
et al., 2010, Sithinamsuwan et al., 2008, van Oosterhout et al., 2005, Woolf and Manore, 










































The purpose of this community-based longitudinal observational study was firstly to 
investigate the characteristics and prevalence of HIV-associated DSP, with and without 
symptoms, prior to the introduction of cART. Secondly, we sought to investigate the 
progression in clinical characteristics of HIV-associated DSP within the first 24 weeks of 
cART initiation. 
This study provides novel data on the clinical evolution of HIV-associated DSP status within 
the first 24 weeks of starting cART to the extent that all individuals were examined days 
before cART initiation and followed up at four subsequent assessments. We found that HIV-
DSP remains a clinically relevant problem in this population with 22% of individuals having 
HIV-DSP prior to commencing cART, of whom 77% were symptomatic. Interestingly, 54% 
of the symptomatic individuals experienced improvement of neuropathic symptoms within 12 
weeks of starting cART. Half of the group with symptom improvement experienced complete 
resolution of symptoms on cART. In addition, 50% of those with asymptomatic DSP at the 
time of cART initiation (2 neuropathic signs by definition) showed complete resolution of 
both signs within 24 weeks; the neuropathic sign that resolved most frequently was distal pin 
loss. These results suggest that there are early beneficial effects associated with cART on the 
peripheral sensory pathways, either via virological control or immune recovery, which 
become evident within 12 weeks. The small sample size of this latter group precluded 
multivariate analyses. As a result, we were unable to investigate any differences in nutritional 
state, CD4 T-cell counts or viral loads at baseline in individuals who improve after cART. 
An important research aim was to determine the incidence and characteristics of symptomatic 
ATN as a clinically relevant outcome in the first 24 weeks of starting cART. The incidence of 
painful ATN was 34%, occurring most frequently between 4 and 12 weeks, after which the 
incidence rate decreased. The development of neuropathic signs on the other hand, increased 
steadily over the 24-week period. Although the sample was small and further longitudinal 
observations are necessary to assess the long-term trend in this cohort, it does suggest either a 
separate pathogenesis of asymptomatic DSP compared to symptomatic DSP, or a distinct 
mechanism related to the development of early painful ATN. Continued follow-up of this 
well-characterized cohort will be useful in determining whether there remains a difference in 

















a small sample, that the presence of asymptomatic DSP pre-cART is not a risk factor to the 
development of ATN within the first 24 weeks.  
The longitudinal association of candidate risk factors based on previous reports, notably age, 
d-drug history and previous TB infection with the development of ATN, were examined. 
Interestingly, there was no significant difference in NRTI backbone (d-drug vs no d-drug) 
between individuals who developed ATN compared to those who remained ATN-free. 
Although advancing age, relatively higher triglycerides (although still normal) and hs-CRP 
levels, as well as current INH TB therapy were all independent predictors of HIV-DSP at 
baseline/pre-cART, these factors did not associate with the development of ATN. This may 
be due to the short follow-up interval or due to the limitation of sample size. 
As symptomatic ATN appears early after cART and the timing coincides with the 
manifestations of IRIS, we hypothesized that incident painful ATN may represent an immune 
reconstitution manifestation. As such, after 24 weeks on cART the development of ATN was 
significantly associated with a greater CD4 T-cell count r covery. We observed a transient 
but significant burst in both pro- and anti-inflammatory plasma cytokine concentrations, as 
well as hs-CRP levels, within 2-4 weeks after starting cART in all individuals, irrespective of 
neuropathic symptom status. However, the symptomatic group showed higher sIL-2rα and 
sTNFRII peak concentrations at week 2, and significantly higher pro-inflammatory/anti-
inflammatory ratios for TNFα/IL-4 and IFNγ/IL-10 compared to the symptom-free group. 
Half of the symptomatic individuals only had transient symptoms despite remaining on the 
same cART regimen throughout the study period. Those individuals who had symptoms 
lasting up to 24 weeks had significantly higher IL-6 levels than those with transient 
symptoms. These results show that in individuals with early symptomatic ATN there is 
evidence of systemic dysregulation of cytokines previously implicated in painful 
neuropathies. Importantly, in the symptomatic group the IL-1RA concentrations, which may 
represent an acute phase protein response, were 5-times higher even before cART was 
initiated. Taken together, these results suggest that those who develop ATN already had a 
higher set point of the pro-inflammatory signalling cascade, albeit measured systemically, 
prior to initiating cART. 
Based on associations between a history of TB infection and HIV-associated DSP previously 
described in African populations where there is a high co-infection rate, we investigated 

















acetylation phenotype thus predisposing them to HIV-associated DSP. In contrast to 
European populations, the overall distribution of NAT2 acetylation phenotypes in this 
African cohort was skewed toward the slow phenotype. The slow acetylation phenotype was 
overrepresented in individuals developing ATN within 12 weeks of starting cART. This 
association that was strengthened by taking into account a history of INH exposure, 
suggesting a possible augmenting effect between slow NAT2 acetylation phenotype and 
previous TB therapy on the development of ATN. 
Overall, NAT2 acetylation phenotypes showed no association with vitamin B6 levels. 
However, the absence of a statistical association may be a result of the overall low vitamin 
B6 levels in this cohort; vitamin B6 deficiency was present in 53% of individuals at baseline. 
Plasma vitamin B6 levels remained low at week 12, despite “standard of care” vitamin B 
complex supplementation (containing ≤4mg pyridoxine). Although not statistically 
significant, there was a weak correlation between low plasma PLP and the development of 
ATN, suggesting a contributory role in the pathogenesis of ATN. 
 
12.2 Proposed multifactorial model of HIV-associated DSP 
pathogenesis 
Notwithstanding the possible differences in the incidence of symptomatic and asymptomatic 
DSP in relation to cART initiation, we propose that oxidative stress may represent a 
mechanistic pathway through which HIV-associated chronic immune dysregulation in 
association with low vitamin B6, slow NAT2 acetylation phenotype, previous opportunistic 
infections such as TB, dysglycaemia, dyslipidaemia, increasing age and NRTI-associated 
neurotoxicity and/or immune reconstitution, may contribute to HIV-associated DSP. These 
factors probably contribute to DSP largely in combination, although not in equal magnitude 
and may differ among individuals. A synergistic, dynamic multifactorial model for the 
development of DSP is outlined in Figure 12.1 where HIV-DSP and ATN represent a 


















Figure 12.1: Cumulative effect of HIV-infection, vitamin deficiency, opportunistic infections and NRTIs 
on mtDNA damage eventually leading to disruption in redox homeostasis, impaired mitochondrial 
function with oxidative stress and mtDNA damage. 
Multiple insults may affect the redox homeostasis by either directly increasing ROS or 
decreasing antioxidants, eventually contributing to oxidative stress and impairment of 
mitochondrial function. Once a critical threshold of mitochondrial dysfunction is surpassed, it 
would compromise cellular redox homeostasis, driving oxidative stress and further mtDNA 
damage. Antiretroviral therapy, particularly NRTI-containing regimens, in predisposed 
individuals such as those with increasing age, inadequately nourished individuals, advanced 
HIV disease, comorbid infections or genetic predisposition such as slow NAT2 acetylation or 
certain mitochondrial haplogroups, thus provide the context for multiple insults 
compromising the redox balance, eventually leading to peripheral nerve injury or 
dysfunction. 
Depending on factors such as the extent of nerve dysfunction or injury, susceptibility of nerve 
fibres and whether the exposure to the insult is acute or chronic, this process may lead to pain 
via complex direct and indirect signalling mechanisms. The timing and duration of symptoms 
will depend on the individual‟s susceptibility to oxidative stress, which in turn may be 
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comorbid conditions, metabolic disturbances, underlying subclinical nerve inflammation or 
nerve injury, inflammatory response related to HIV infection and/or cART initiation, T-cell 
function and nerve injury repair mechanisms. Although antiretroviral therapy is seen as an 
insult in our proposed model, these previously mentioned factors might all influence the 
potential neurotoxicity of NRTIs in a particular individual. For that reason, some individuals 
may benefit from NRTI therapy as a result of recovery of immune function and/or better 
virological control, thereby counterbalancing its potential neurotoxic effect. 
Although the model outlined in Figure 12.1 attempts to unify different pathogenetic 
mechanisms involving oxidative stress as a central component in the development of HIV-
associated DSP, some individuals develop a symptomatic neuropathy and others an 
asymptomatic neuropathy. The interplay between these two clinical manifestations is not 
clear. Of interest however, was the observation, albeit in a highly selected nested-case-control 
cohort, that individuals who developed neuropathic symptoms soon after cART initiation 
showed higher peak concentrations of sIL-2rα and sTNFRII and a significant imbalance 
between pro-and anti-inflammatory cytokines compared to a symptom-free control group. 
Furthermore, the symptomatic individuals showed a markedly altered IL-1β/IL-1RA ratio at 
baseline/pre-cART due to significantly higher IL-1RA levels. These results suggest an 
inflammatory process associated with cytokine imbalance at a higher set point even before 
cART initiation. Regions where the blood-nerve barrier may be less effective or impaired, 
such as the dorsal root ganglion and distal axons, may be particularly vulnerable to this 
altered cytokine milieu predisposing these individuals to the development of painful ATN. 
The dorsal root ganglion plays a pivotal role in the pathogenesis of HIV-associated 
neuropathy, which likely involves both indirect cytokine- and direct viral protein-mediated 
neurotoxicity, as previously discussed. Neuronal toxicity in the dorsal root ganglion has been 
associated with upregulated IL-1β and TNF-α expression (Acharjee et al., 2011, Jones et al., 
2005). HIV-associated immune dysregulation with subclinical levels of local IL-1β 
production may prime proteinase-activated receptor-2 (PAR2) on small dorsal root ganglion 
neurons and their afferent axons (Vergnolle et al., 2001). The cytokine burst triggered by the 
introduction of cART may facilitate further PAR2 activation with augmentation of 
nociceptive signalling via complex central pathways (Alier et al., 2008, Vergnolle et al., 
2001). Theoretically, the increase in cytokine and ROS production may also change axonal 

















mitogen activated protein kinase (MAPK) and nuclear factor kappa B (NF-κB), both shown 
to play a major role in neural inflammatory pain (Kamata et al., 2005, Takada et al., 2003). 
The observed cytokine burst on a background of HIV-associated immune dysregulation, 
underlying nerve inflammation and/or susceptible genetic and environmental factors may also 
provide the final push over a critical threshold of mitochondrial dysfunction, resulting in 
oxidative stress and pain. That is to say these individuals may have reached their threshold of 
mitochondrial damage prior to cART initiation. Given that oxidative stress may also result in 
impaired T-lymphocyte functioning, which may impact on cytokine release after cART 
initiation, the timing of increased levels of several soluble receptors in symptomatic 
individuals which coincides with the rising incident peak of ATN and neuropathic symptoms, 
contradicts this as a theory for painful ATN soon after cART initiation. Rather, surpassing the 
critical threshold of mitochondrial dysfunction with its effect on mtDNA may result in more 
latent consequences. 
The study period of 24 weeks may have been too short for the effect of cART to be 
significant on some covariates and to determine the natural progression of HIV-associated 
DSP after cART initiation. We suggest further follow-up for a longer period to determine its 
natural progression and the effect of metabolic and biochemical factors, such as waist-to-hip 
ratio, triglycerides and ALT levels on the development of HIV-associated DSP. In addition, 
not all neurological or mitochondrial insults could be accounted for with this study. Due to 
left censoring of the baseline DSP group, it was not possible to accurately assess all possible 
risk factors or the progression of symptoms and signs prior to cART for the group of patients 
who already had DSP at baseline assessment. There is also uncertainty about the relative 
contribution of the virus itself and the initial associated inflammatory response related to 
seroconversion. 
 
12.3 Clinical implications of the study findings 
Neuropathic pain is distressing and disabling and DSP remains undertreated. For clinicians 
treating HIV-infected individuals, there is a need for greater sensitivity in diagnosis and 
closer monitoring of DSP in primary health care clinics. It is possible that early diagnosis 
with intervention may lead to better outcomes. It has been suggested that a screening tool 

















However, a tuning fork and reflex hammer are necessary and such equipment is not readily 
available in resource-limited clinic settings. Another caution is that agreement between ankle 
reflexes performed by non-clinician healthcare workers, such as nurses, and by clinicians has 
been shown to be poor (Cettomai et al., 2010, Simpson et al., 2006). Our results show that the 
most common neuropathic sign associated with DSP was impaired pin sensibility, suggesting 
this as the preferred examination modality, but it is not tested in the BPNS. Assessment of pin 
sensibility can be rapidly performed and for non-clinicians it may be easier to perform than 
eliciting reflexes since it requires only a sharp object. However, distal neuropathic symptoms 
were strongly associated with objective findings of DSP. Therefore, symptom-based 
screening for DSP with a tool such as the single-question neuropathy screen (SQNS) may 
prove useful in busy primary health care settings. It is important that individuals should be 
routinely questioned about their experience of pain. 
This research expands our understanding of the pathophysiology of HIV-associated DSP. The 
results have implications not only on individuals who develop painful HIV-associated DSP 
and the early effects of commencing cART. The cART-associated cytokine burst is an 
important finding in all individuals commencing cART. It illustrates the susceptibility to 
pathology related to immune reconstitution and hypercytokinemia in all individuals 
commencing cART, which may result in oxidative stress and tissue damage as part of a 
multifactorial process in predisposed individuals. Whether the cytokine burst early after 
cART initiation may contribute to an increased susceptibility towards mitochondrial damage 
with possible long-term effects on mitochondrial function in an increasingly ageing HIV-
treated population remains unknown.  
Our nested case-control cohort focussing on the cytokine response early after cART initiation 
consisted of a relatively small sample size. Therefore, the possibility of using IL-1RA as a 
biomarker for the prediction of ATN development may need to be explored in a larger sample 
size. However, its use as a biomarker for the prediction of ATN development is unlikely due 
to the high cost of the assay and the often transient characteristics of early ATN symptoms. 
Although we are as yet unable to predict what drives the higher inflammatory set point in 
individuals predicted to develop early incident painful neuropathy, preventative strategies 
should be directed at multiple levels to maintain adequate redox homeostasis. Careful 
attention to micronutritional status and concomitant drugs in all individuals prior to starting 

















inflammation, thereby preventing nerve injury. Micronutrient supplementation may be 
particularly critical in areas with high rates of HIV/TB co-infection, such as Southern Africa 
(Allard et al., 1998, Israel et al., 1992).  
During the first weeks of starting cART, the production of free radicals may be greater than 
their normal clearance. The host‟s endogenous antioxidant system would play a major role to 
prevent or limit the deleterious effects of free radicals and maintain immune function, 
especially during the first 24 weeks in all individuals commencing cART (Jones et al., 2006, 
Tang et al., 2000). We demonstrated that vitamin B6 deficiency is frequent in this cohort, and 
although not classified as an antioxidant compound, vitamin B6 has been shown to have 
highly effective antioxidant properties (Matxain et al., 2006, Stocker et al., 2003). There is 
also evidence to suggest that vitamin B6 deficiency can accelerate mitochondrial decay and 
thus contribute to senescence and neurodegeneration (Ames, 2004, Atamna et al., 2002). In a 
recent randomized controlled trial, the use of high-dose vitamin supplementation which 
included 25 mg vitamin B6 daily, reduced the risk of neuropathy in individuals commencing 
cART (Isanaka et al., 2012). Apart from vitamin B6 deficiency, numerous other vitamin 
and/or mineral deficiencies that were not measured in our study may be present, likely due to 
increased utilization of antioxidant micronutrients because of increased oxidative stress. 
Vitamin B6 and other micronutrient deficiencies may also contribute to immunosuppression 
with reduced T-lymphocyte effector function (Baum et al., 1991, Rall and Meydani, 1993, 
Willis-Carr and St Pierre, 1978). Theoretically, this may result in a reduced capacity of 
lymphocytes to respond to relevant stimuli affecting repair mechanisms to local damage. 
Optimizing the redox homeostasis and host repair mechanisms against the various insults 
described earlier by improving antioxidant status prior to initiating cART may prove to be the 
best measure to prevent the development of HIV-associated DSP. Vitamin supplementation 
should not be withheld in this population, and an emphasis should be placed on compliance. 
Vitamin B complex is widely administered in HIV infection, but was not sufficient to prevent 
vitamin B6 deficiency. An argument can therefore be made for instituting higher doses of 
vitamin B6 supplementation to all HIV-infected individuals. Public health care policies 
should implement the recommendations of the developed world regarding pyridoxine 
supplementation (10-25 mg per day). Our results also suggest that there is a need to 
commence vitamin supplementation prior to cART in all individuals which may then reduce 

















commencement. Combination ART has led to a substantial reduction in TB incidence (Badri 
et al., 2002) and earlier cART initiation may therefore have a critical role in addressing the 
HIV/TB co-epidemic in South Africa and other African countries although this has cost 
implications in a high disease burden setting.  
Plasma and serum samples are available for all participants. To explore the oxidative stress 
model further, markers of oxidative stress and mitochondrial dysfunction are avenues for 
investigation. However, the demonstration of mitochondrial dysfunction and oxidative stress 
is complex and relies on a combination of pathological, biochemical and molecular genetic 
studies. 
Theoretically the presence of oxidative stress may be tested in one of three ways: (1) direct 
measurement of ROS; (2) downstream markers of oxidative damage to biomolecules/tissue; 
and (3) the detection of antioxidant levels. Most ROS are highly reactive and short lived and 
therefore difficult to measure directly. Markers to measure damaged proteins, lipids, DNA, 
RNA or other biomolecules are more stable and therefore provide a more reliable method. 
Increased systemic levels of lipid peroxidation products were shown in NRTI-treated 
individuals with symptomatic hyperlactatemia, lactic acidosis, or lipoatrophy (McComsey 
and Morrow, 2003), but not with DSP (Hulgan et al., 2006). It is possible that measuring the 
oxidative degradation of lipids may relate poorly to a disease process related to axonal injury. 
Furthermore, the oxidative stress related to nerve damage or dysfunction may be localized 
and therefore not of sufficient magnitude to alter systemic lipid or protein peroxidation 
profiles. Local measures of oxidative stress, or even inflammatory reactions at nerve level 
might be more informative, but challenging. Hahn et al. investigated markers of oxidative 
stress on post mortem sciatic nerve biopsies of AIDS patients, but failed to demonstrate 
increased levels of protein oxidation in those with clinical signs of neuropathy (Hahn et al., 
2008). Performing sural nerve biopsies on cART treated individuals may prove to be 
challenging in resource-limited settings, and it would be unethical to perform biopsies on 
DSP-free individuals as a control group. Furthermore, this strategy would investigate the 
distal aspect of the sensory neural pathway and not the more proximal elements such as the 
dorsal root ganglion. 
As the measurement of oxidative stress particularly in the context of the nervous system has 
been challenging, another approach might be to measure the “mopping-up defences” such as 

















generated in cells. Assays are available to measure the activity of specific antioxidants, such 
as glutathione, catalase and superoxide dismutase but access to nervous tissue is again a 
limitation. 
An additional avenue that might be explored would be to investigate markers of 
inflammatory pain such as guanosine triphosphate cyclohydrolase (GCH1). GCH1 is the rate-
limiting enzyme for tetrahydrobiopterin (BH4) synthesis, an essential cofactor for 
catecholamine, serotonin and nitric oxide production (Tegeder et al., 2006). GCH1 was 
identified as a modulator of neuropathic inflammatory pain in an animal model, and a 
functional polymorphic haplotype of the GCH1 gene showed an association with reduced 
levels of non-HIV neuropathic pain (Tegeder et al., 2006). Systemic levels of GCH1 may be 
interesting to explore for an association with painful neuropathy in HIV-infected individuals 
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SA BRIEF PERIPHERAL NEUROPATHY SCREENING/EXAM (UCT REC 221/2008) 
 
Patient Number:  _______________  Date of Visit (DD/MM/YYYY)  ____/____/20____   
 
We are going to ask you a few questions about sensation in your legs.  We will also briefly examine the nerves in your 
arms and legs.  We may advise the clinic doctor on treatment.  
 
BPNS : INSTRUCTIONS FOR RECORDING SYMPTOMS: Ask subject to rate the severity of each symptom in 1a to 
1c on a scale of 0 (absent) to 10 (most severe) for right and left feet, legs- worst in last week.  Enter the score for each 
symptom in the block marked Severity.  Enter extent of symptoms eg Soles of feet/ toes (TNS=1); up to ankle 
(TNS=2); up to knee (TNS= 3) or above (TNS=4) on the TNS score overleaf. 
    
1a. Pain, aching, burning in feet or legs. Ingaba iinyawo zakho zibuhlungu, ziyaqagamba, ziyatshisa 
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1b. “Pins-and-Needles" in feet or legs. Ingaba iinhawo zakho zineenaliti  
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Andinantlungu!  →                      →                           →                              Ndineentlungu ezigqithisileyo! 
            






















Andiva nto   
0 1 2 3 4 5 6 7 8 9 10 
            
  
             
TOTAL SENSORY PRESENCE/SEVERITY SCORE: Obtain the single highest severity score from 1-10 in 1(a - c) 
above:  0  =  Grade 0   1-3 = Grade 1 
  4- 6 = Grade 2   7-8 = Grade 3 
  9-10= Grade 4   Total sensory severity GRADE   ____/4 nn4 
 
1d. If a symptom was present in the past, but not now i.e “Currently Absent” Yes (1)  N/A (0)  nn5 
 
1e. Do you have any other unpleasant symptoms in you legs such as cramps? Yes (1)  No (0)  nn6 
 
1f. Has anything helped for the pain (medicine or other) ? ____________ Yes (1)  No (0)  nn7
  
1g. Do you think the ARV treatment helped your symptoms? Yes (1)  No (0)  Unknwn (2) nn8 
               
1h. Did the sensory symptoms in your feet start or get worse within 2-4 months of starting ARV Rx?    
Yes (1)  No (0)  Unknwn (2) nn9 
1i.   Did the sensory symptoms in your feet start or get worse within 2-4 months of changing the dose of ARV Rx?  
        Yes (1)  No (0)  Unknwn (2) nn10 
  
 
2. INSTRUCTIONS FOR EVALUATING PERCEPTION OF VIBRATION: 
Press the 2 ends together of a 128 Hz tuning fork, and release suddenly; place the vibrating tuning fork on the 
subject’s clavicle; can they recognise the vibration or “buzzing” (ngcungcazela) of the tuning fork? Repeat and 
immediately place the vibrating tuning fork firmly on the interphalangeal bone (not nail) of one great toe and begin 
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Revised V2 January 2010 (F:\longitudinal\BPNS1 
Vibration Perception     0- Vibration felt for >10 seconds (normal) 
(Take highest score but both R & L must be abnormal) 1- Vibration felt for 6-10 seconds (mild loss) 
      2- Vibration felt for 5 seconds or less (moderate loss) 
      3- No feeling of vibration (severe loss) 
      
 
Right   Left   
Great toe interphalangeal bone  ____                 ____  (2) use highest value______/3 nn11
  
3. INSTRUCTIONS FOR EVALUATING DEEP TENDON REFLEXES: 
With the subject seated, the examiner uses one hand to press upward on the ball of the foot, dorsiflexing the subject’s 
ankle to 90 degrees. Using a reflex hammer (long-handled), the examiner strikes the Achilles tendon.  
 Reflexes 4- Absent 
  3- Reduced (difficult to elicit)  
  2- Normal deep tendon reflexes   
1- Hyperactive deep tendon reflexes   
0- Clonus 
 
Right  Left   
 Ankle Reflexes:   _____  _____   (3) use highest value____/4 nn12 
(Take highest score but both R & L must be abnormal) 
 
Final score for BPNS (1+2+3) ____/11  nn13 
Reduced TNS score: tick in the box : 
 0 
 
1 2 3 4  
a. Sensory symptoms 
from 1a,b,c:  Pain, 




Only in toes or 
soles of feet 
 
Symptoms extend to 
ankle or wrist 
 
Symptoms extend to 
knee or elbow 
Symptoms knee or 









Reduced in fingers 
/toes 
Reduced up to wrist/ 
ankles 






c. Vibration sensibility 
(use normal as for BPNS) 
 
normal Reduced in fingers 
/toes 
Reduced up to wrist/ 
ankles 
  















Ankle reflexes absent Ankle reflexes absent, 
other reduced 





e. Strength- ankle and 
toes plantar & dorsi-
flexion 














Neuropathy classification according to TNS: 
 
Symptomatic DSP= a ≥1 and b≥1 or c≥1 or d≥1 or significant touch-evoked pain  yes/ no ________ n20
  
Asymptomatic DSP= TNS ≥3         yes/ no ________ nn21 
 
Indeterminate DSP= a ≥1 only        yes/ no ________ nn22 
 
Punch Biopsy performed         yes/ no ________ nn23 
 
Examination shows another form of peripheral neuropathy (not symmetric distal sensory) yes/no_____   nn24 
refer for further evaluation to neuromuscular HIV clinic at GSH (1st wed am of every month; 404-3209) 
 

















Appendix C Patient information sheet 
 
PATIENT INFORMATION SHEET – The study of inflammation and the development 
of neuropathy in HIV patients in the first 3 months of ARV treatment  (McHAART 
substudy) 
You have already been told about the McHAART study. Painful feet may develop in some 
patients with HIV infection. It is thought that this may be the result of the virus having an 
effect on the nerves of the feet or that some people are very sensitive to some of the 
antiretroviral treatments (ARVs). We are trying to understand this problem better so that we 
can change the treatment in people who may be at risk of developing these problems.  We are 
asking you to consider taking part in this study because you do not have painful feet. We are 
not expecting you to develop painful feet but we do know that some patients in your position 
may develop painful feet within the first three months of starting ARVs. We also want to see 
whether there is a change in the speed with which your brain allows you to do certain 
movements of the fingers and hands. We do not expect the speed of movement to change but 
we want to see whether these do change if you also perhaps develop symptoms in your feet. 
You may not directly benefit from this study but we are hoping that the information from this 
study will benefit people like you in the future. 
You do not have to take part in the substudy- please feel free to ask questions or to 
say no. This study is part of the main McHAART study, but if you want to only take part in 
the main study, you may do so. In the main study Dr van der Watt will ask you about 
symptoms in your feet and examine the nerves in your legs (10 minutes). He will also do 3 
brain function tests such as checking your memory by asking you to remember four words 
and test how fast you can perform certain movement of your fingers and hands (5 minutes).   
For the substudy you will only need to fill in a sheet of questions about possible 
symptoms in your feet at 2 of your regular Crossroads clinic visits; the visit at 14 days after 
starting ARV‟s, and the visit after 1 month. At the one-month visit Dr van der Watt will again 
examine your feet briefly and ask you to do the movements of your fingers and hands to 
check how fast you can do it- both these will be repeated again at three months.  At both 
these 2 visits (14 days and 1 month) Dr van der Watt will also take blood from you for 
special tests at the university laboratory to study the way your blood cells are reacting to the 

















may be taken at the 1 month visit to monitor for side effects.  We will only need 10 mL 
(about 2 teaspoons) of blood for these tests.  To compensate you for your time (filling in the 
questions and for the blood sample) and help with your transport we will give you R50 for 
the two-week visit and R50 for the 1 month visit. 
 If you do want to take part in this substudy the following will happen; 
 First visit – McHAART study visit at Groote Schuur Hospital. We will organise and pay 
for your transport to Groote Schuur Hospital and back; we will give you R150, as you 
will spend the morning with study related activities. 
 Two weeks later at your regular clinic visit at Crossroads we will do a questionnaire to 
ask about your feet and take 10 mL (2 teaspoons) of blood (Dr Van der Watt). 
 The one-month visit at Crossroads – we will do the same procedure as in the two-week 
visit. We will ask you to answer a few questions about your feet and we will take 10 mL 
(2 teaspoons) of blood but we will also spend 15 minutes examining your feet and 
movement in hands. 
 The three-month visit will be the regular longer visit of the McHAART study at Groote 
Schuur Hospital where you will have an examination and blood tests. You will be given 
R150 for transport at this visit. 
Trained people speaking both English and Xhosa will help with all these questions. Your 
participation in all these visits is very important as we wish to study how your body reacts to 
the ARVs at each visit. If you want to re-schedule a visit please contact Dr van der Watt at 
084 954 3305   
 
______________________   ______________________   ______________________ 
Name               Signature             Date  
______________________   ______________________   ______________________ 


















Appendix D International HIV Dementia Scale (IHDS) 
  
INTERNATIONAL HIV DEMENTIA SCALE (IHDS) 
 
Patient Number: _________________  Date of Visit (DD/MM/YYYY): ___/___/20__ 
 
Visit:   _________________ 
 
Total International HIV Dementia Scale Score: This is the sum of the scores on items 1-3. The maximum 




Memory-Registration – Give four words to recall (dog, hat, carrot, red) – 1 second to say each. Then ask 
the patient all four words after you have said them. Repeat words if the patient does not recall them all 
immediately. Tell the patient you will ask for recall of the words again a bit later. 
 
1. Motor Speed: Tap the first two fingers of the non-dominant hand as widely and as quickly as possible. 
 
4 =  15  in 5 seconds 
3 =  11-14  in 5 seconds 
2 =  7-10  in 5 seconds 
1 =  3-6  in 5 seconds 
0 =  0-2  in 5 seconds 
           ___/4 nn25 
 
2. Psychomotor Speed: Perform the following movements with the non-dominant hand as quickly as 
possible: 
 
1) Clench hand in fist on flat surface.  
2) Put hand flat on surface with palm down.  
3) Put hand perpendicular to flat surface on the side of the 5th digit. Demonstrate and have patient 
perform twice for practice. 
 
4 =  4 sequences in 10 seconds 
3 =  3 sequences in 10 seconds 
2 =  2 sequences in 10 seconds 
1 =  1 sequence in 10 seconds 
0 =  unable to perform 
`           ___/4 nn26 
 
3. Memory-Recall: Ask the patient to recall the four words. For words not recalled, prompt with a 
semantic clue as follows: animal (dog); piece of clothing (hat); vegetable (carrot); color (red). 
 
Give 1 point for each word spontaneously recalled. 
Give 0.5 points for each correct answer after prompting 
Maximum – 4 points. 
 
           ___/4 nn27 
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Appendix F DNA extraction procedure 
 
Step 1: Lyse 
 Pipet 20 μL QIAGEN Protease (or Proteinase K) into the bottom of a 1.5 mL 
microcentrifuge tube. 
 Add 200 μL buffy coat sample to the microcentrifuge tube. 
 Add 200 μL Buffer AL to the sample. Mix by pulse-vortexing for 15 seconds. 
 Incubate at 56°C for 10 min. 
 
Step 2: Lyse 
 Add 200 μL ethanol (96–100%) to the sample, and mix again by pulse-vortexing for 
15 seconds.  
 Apply mixture to the spin column (in a 2 mL collection tube) without wetting the rim, 
close the cap, and centrifuge at 6000 g for 1 min.  
 Place the spin column in a clean 2 mL collection tube, and discard the tube containing 
the filtrate. 
 
Step 3: Wash (Buffer AW1) 
 Open the spin column and add 500 μL Buffer AW1 without wetting the rim.  
 Close the cap and centrifuge at 6000 g for 1 min.  
 Place the spin column in a clean 2 mL collection tube, and discard the collection tube 
containing the filtrate. 
 
Step 4: Wash (Buffer AW2) 
 Open the spin column and add 500 μL Buffer AW2 without wetting the rim.  
 Close the cap and centrifuge at full speed (20 000 g for 3 min). 
 
Step 5: Elute 
 Place the spin column in a clean 1.5 mL microcentrifuge tube, and discard the 
collection tube containing the filtrate. Open the spin column and add 200 μL Buffer 
AE or distilled water. 


















Appendix G Odds ratios in univariate analysis 
 




Odds Ratio in 
univariate analysis
Odds Ratio 95% 
Confidence Interval
Prevalence Ratio in 
univariate analysis




Female sex 0.78 0.37 - 1.61 0.82 0.47 - 1.45 0.503
Age > 40 years 0.34 1.39 - 6.37 0.45 1.31 - 3.78 0.006
IHDS score < 10 3.33 1.28 - 8.67 2.01 0.71 - 5.64 0.016
Previous/Current TB 1.98 0.85 - 4.66 1.71 0.89 - 3.26 0.122
Current TB 2.39 1.03 - 5.56 1.88 1.07 - 3.33 0.048
Previous TB 1.98 0.85 - 4.66 1.71 0.89 - 3.26 0.122
Time of TB 0.227
Never* 1.00 1.00
Currently 2.93 1.20 - 7.13 2.22 1.19 - 4.14
< 1 year ago 2.25 0.63 - 8.05 1.86 0.75 - 4.64
1 year ago 3.37 0.53 - 21.54 2.42 0.77 - 7.64
2 years ago 1.26 0.13 - 11.94 1.21 0.20 - 7.33
> 2 years ago 1.68 0.49 - 5.78 1.51 0.59 - 3.88
Vitamin B6 supplementation 4.83 1.63 - 14.33 2.79 1.58 - 4.93 0.019
Alcohol last year 0.55 0.23 - 1.28 0.62 0.30 - 1.24 0.149
Waist : Hip ratio > 0.9 2.20 1.01 - 4.77 1.80 1.03 - 3.14 0.046
Diastolic BP > 80 mmHg 0.62 0.13 - 2.91 0.68 0.18 - 2.49 0.542
Haematological
C-reactive protein > 5 mg/L 1.58 0.71 - 3.52 1.42 0.77 - 2.61 0.264
MCV > 92 fL 1.86 0.84 - 4.13 1.64 0.86 - 3.15 0.125
Biochemical
ALT > 19 IU/L 2.56 1.21 - 5.39 2.09 1.15 - 3.80 0.014
Metabolic
Fasting insulin > 5.1 µU/mL N/A N/A
Triglycerides > 0.9 mmol/L 1.69 0.80 - 3.59 1.52 0.84 - 2.76 0.169
Lactate > 2 mmol/L 0.60 0.27 - 1.34 0.67 0.36 - 1.25 0.210
Pyridoxine























Odds Ratio in 
univariate analysis
Odds Ratio 95% 
confidence interval
Prevalence Ratio in 
univariate analysis




Female sex 0.85 0.37 - 1.96 0.87 0.44 - 1.72 0.693
Age > 40 years 2.97 1.28 - 6.93 2.35 1.25 - 4.44 0.014
IHDS score < 10 1.45 0.42 - 4.99 1.39 0.48 - 4.02 0.560
Previous/Current TB 2.83 1.28 - 6.26 2.32 1.22 - 4.42 0.010
Current TB 3.11 1.27 - 7.60 2.38 1.26 - 4.51 0.016
Previous TB 2.11 0.79 - 5.60 1.86 0.84 - 4.13 0.143
Time of TB 0.097
Never* 1.00 1.00
Currently 3.89 1.49 - 10.15 2.89 1.41 - 5.91
< 1 year ago 2.46 0.59 - 10.28 2.10 0.69 - 6.33
1 year ago 4.92 0.75 - 32.28 3.35 1.02 - 11.01
2 years ago 1.85 0.19 - 17.81 1.68 0.27 - 10.41
> 2 years ago 1.23 0.25 - 6.13 1.20 0.30 - 4.76
Vitamin B6 supplementation 7.13 2.34 - 21.72 3.86 2.08 - 7.16 0.003
Alcohol last year 0.55 0.21 - 1.43 0.60 0.26 - 1.38 0.199
Waist : Hip ratio > 0.9 2.40 1.02 - 5.66 2.01 1.04 - 3.88 0.045
Systolic BP > 120 mmHg 0.66 0.08 - 5.53 0.70 0.11 - 4.50 0.698
Diastolic BP > 80 mmHg 0.84 0.18 - 3.99 0.86 0.23 - 3.22 0.824
Haematological
C-reactive protein > 5 mg/L 1.46 0.58 - 3.64 1.36 0.65 - 2.88 0.420
Haemoglobin < 11.7 g/dL 1.28 0.58 - 2.83 1.23 0.64 - 2.35 0.536
MCV > 92 fL 1.55 0.69 - 3.48 1.43 0.73 - 2.81 0.293
Biochemical
Albumin < 37 g/L 0.34 0.14 - 0.85 0.41 0.19 - 0.89 0.021
ALT > 19 IU/L 2.43 1.05 - 5.60 2.09 1.03 - 4.22 0.037
Metabolic
Fasting insulin > 5.1 µU/mL N/A N/A
Triglycerides > 0.9 mmol/L 2.16 0.92 - 5.07 1.90 0.93 - 3.90 0.076
LDL > 2.4 mmol/L 0.78 0.34 - 1.78 0.81 0.40 - 1.62 0.551
Lactate > 2 mmol/L 0.48 0.20 - 1.16 0.54 0.26 - 1.12 0.101
Pyridoxine
4-PA > 17.4 nmol/L 1.55 0.66 - 3.65 1.44 0.71 - 2.92 0.313





















Odds Ratio in 
univariate analysis
Odds Ratio 95% 
Confidence Interval
Prevalence Ratio in 
univariate analysis




Female sex 0.88 0.38 - 2.00 0.89 0.45 - 1.79 0.754
Age > 40 years 2.71 1.18 - 6.23 2.22 1.17 - 4.23 0.022
Previous/Current TB 2.77 1.26 - 6.09 2.31 1.21 - 4.41 0.011
Current TB 3.17 1.30 - 7.69 2.44 1.28 - 4.65 0.014
Previous TB 2.02 0.77 - 5.33 1.81 0.81 - 4.05 0.163
Time of TB 0.084
Never* 1.00 1.00
Currently 3.92 1.51 - 10.18 2.95 1.44 - 6.06
< 1 year ago 2.35 0.57 - 9.67 2.04 0.67 - 6.24
1 year ago 5.23 0.80 - 34.28 3.54 1.08 - 11.62
2 years ago 1.96 0.20 - 18.91 1.77 0.28 - 10.99
> 2 years ago 1.12 0.23 - 5.50 1.11 0.27 - 4.46
Vitamin B6 supplementation 7.67 2.52 - 23.36 4.11 2.22 - 7.64 0.002
Alcohol last year 0.57 0.22 - 1.48 0.62 0.27 - 1.42 0.226
Waist : Hip ratio > 0.9 2.31 0.99 - 5.39 1.96 1.01 - 3.82 0.053
Systolic BP > 120 mmHg 0.54 0.07 - 4.43 0.59 0.09 - 3.88 0.566
Diastolic BP > 80 mmHg 0.90 0.19 - 4.30 0.92 0.25 - 3.43 0.898
Haematological
C-reactive protein > 5 mg/L 1.38 0.56 - 3.43 1.31 0.62 - 2.79 0.482
Haemoglobin < 11.7 g/dL 1.34 0.61 - 2.95 1.28 0.66 - 2.46 0.461
MCV > 92 fL 1.58 0.70 - 3.54 1.47 0.74 - 2.89 0.267
Biochemical
Albumin < 37 g/L 0.32 0.13 - 0.80 0.39 0.18 - 0.84 0.014
Metabolic
Fasting insulin > 5.1 µU/mL N/A N/A
Triglycerides > 0.9 mmol/L 2.19 0.94 - 5.12 1.94 0.94 - 3.98 0.070
LDL > 2.4 mmol/L 0.71 0.31 - 1.63 0.75 0.38 - 1.51 0.426
Lactate > 2 mmol/L 0.47 0.19 - 1.13 0.53 0.26 - 1.10 0.091
Pyridoxine


















Appendix H Baseline comparison - SDSP vs No SDSP group 




Total (N=184) SDSP (N=31) No SDSP (N=153)
Clinical
Age years 33 (26 - 39) 37 (29 - 43) 32 (26 - 37) 0.019 β
Weight kg 61 (54 - 71) 60 (53 - 71) 62 (55 - 71) 0.608 β
Height metre 1.61 (1.56 - 1.67) 1.62 (1.55 - 1.70) 1.61 (1.56 - 1.66) 0.617 β
Body Mass Index kg/m2 20.0 - 25.0 23.2 (20.3 - 27.7) 23.2 (20.2 - 26.1) 23.2 (20.4 - 28.0) 0.647 ε
Waist : Hip ratio < 0.90 0.86 (0.81 - 0.90) 0.87 (0.83 - 0.93) 0.86 (0.81 - 0.89) 0.019 β
Systolic BP mmHg 120 - 140 110 (103 - 122) 109 (100 - 122) 111 (104 - 121) 0.178 β
Diastolic BP mmHg 80 - 90 72 (66 - 80) 70 (66 - 78) 73 (67 - 80) 0.113 ε
Haematological
CD4 T-cell count cells/mm3 > 500 158 (114 - 196) 157 (105 - 199) 158 (114 - 196) 0.465 β
White cell count x109/L 4.0 - 11.0 5.3 (4.1 - 6.5) 5.1 (3.9 - 6.0) 5.3 (4.1 - 6.8) 0.388 β
C-reactive protein mg/L < 5.0 2.8 (0.9 - 6.6) 3.8 (1.2 - 11.9) 2.6 (0.9 - 5.9) 0.285 β
Haemoglobin g/dL 11.6 - 15.6 11.8 (10.4 - 12.6) 11.6 (9.6 - 12.9) 11.8 (10.6 - 12.6) 0.100 β
MCV fL 80.0 - 100.0 92.4 (88.5 - 96.1) 93.3 (89.8 - 96.9) 92.1 (87.9 - 95.9) 0.165 β
Biochemical
Albumin g/L 38 - 54 39 (35 - 43) 37 (34 - 43) 40 (35 - 43) 0.077 β
ALT IU/L 10 - 41 19 (15 - 26) 23 (18 - 29) 19 (14 - 26) 0.262 β
Creatinine µmol/L 53 - 115 64 (55 - 73) 65 (55 - 75) 64 (55 - 73) 0.732 β
Metabolic
Fasting glucose mmol/L 4.1 - 5.6 4.7 (4.4 - 4.9) 4.7 (4.5 - 4.9) 4.7 (4.4 - 4.9) 0.776 β
Fasting insulin µU/mL 0.2 - 9.4 5.2 (2.5 - 8.6) 4.3 (1.8 - 7.6) 5.5 (2.5 - 8.9) 0.224 β
Total cholesterol mmol/L 3.1 - 5.2 3.7 (3.2 - 4.3) 3.9 (3.0 - 4.4) 3.7 (3.2 - 4.2) 0.263 β
Triglycerides mmol/L 0.5 - 2.0 0.9 (0.7 - 1.2) 1.0 (0.7 - 1.4) 0.8 (0.7 - 1.1) 0.034 β
HDL mmol/L 1.15 - 1.68 0.94 (0.75 - 1.13) 0.89 (0.74 - 1.25) 0.97 (0.75 - 1.12) 0.344 β
LDL mmol/L 1.0 - 3.0 2.3 (1.9 - 2.9) 2.2 (1.8 - 2.9) 2.4 (1.9 - 2.9) 0.080 β
Lactate mmol/L < 2.0 2.4 (1.7 - 3.1) 1.8 (1.2 - 2.8) 2.5 (1.7 - 3.3) 0.072 β
Pyridoxine
PLP nmol/L > 25.0 23.8 (16.5 - 38.4) 20.7 (16.5 - 53.7) 24.1 (15.7 - 36.8) 0.512 β
4-PA nmol/L unknown 17.4 (11.9 - 23.3) 20.7 (12.1 - 28.6) 17.0 (11.6 - 22.4) 0.212 ε
β    Student's t -test



























Total (N=184) SDSP (N=31) No SDSP (N=153)
Female sex 129 (70%) 21 (68%) 108 (71%) 0.752 §
Age > 40 years 42 (23%) 12 (40%) 30 (20%) 0.016 §
Previous/Current TB 69 (38%) 18 (58%) 51 (33%) 0.009 §
Time of TB 0.033 ¶
Currently 30 (16%) 10 (32%) 20 (13%)
< 1 year ago 13 (7%) 3 (10%) 10 (7%)
1 year ago 5 (3%) 2 (6%) 3 (2%)
2 years ago 5 (3%) 1 (3%) 4 (3%)
> 2 years ago 16 (9%) 2 (6%) 14 (9%)
Vit Bco supplement 179 (97%) 31 (100%) 148 (97%) 0.591 ¶
Vit B6 supplement 15 (8%) 8 (26%) 7 (5%) <0.001 ¶
WHO clinical stage 0.310 ¶
Stage 1 57 (32%) 8 (27%) 49 (33%)
Stage 2 58 (32%) 7 (23%) 51 (34%)
Stage 3 58 (32%) 13 (43%) 45 (30%)
Stage 4 7 (4%) 2 (7%) 5 (3%)
CD4 T-cell count 0.814 §
< 100 cells/mm 3 30 (17%) 4 (13%) 26 (17%)
100 - 200 cells/mm 3 108 (60%) 18 (60%) 90 (60%)
> 200 cells/mm 3 42 (23%) 8 (27%) 34 (23%)
Metabolic syndrome 22 (12%) 3 (10%) 19 (12%) 0.668 §
Body Mass Index 0.876 §
< 20 kg/m 2 37 (21%) 7 (24%) 30 (20%)
20 - 25 kg/m 2 77 (43%) 11 (38%) 66 (44%)
25 - 30 kg/m 2 37 (21%) 7 (24%) 30 (20%)
> 30 kg/m 2 28 (16%) 4 (14%) 24 (16%)
Alcohol last year 52 (29%) 6 (20%) 46 (31%) 0.239 §
IHDS score < 10 10 (7%) 1 (7%) 9 (7%) 1.000 ¶
¶    Fisher's exact test






























SDSP vs No SDSP 0.28 <0.001
Age * 1.11 1.03 - 1.19 <0.001
Previous/Current TB 9.16 2.22 - 37.81 <0.001
Triglycerides > 0.9 mmol/L 5.26 1.35 - 20.52 0.020
Sex (Male) 3.91 1.00 - 15.24 0.050

















Appendix I  IHDS score comparison across DSP groups 




Total (N=137) SDSP (N=15) No SDSP (N=122)
Motor Speed 3.7 ± 0.5 3.7 ± 0.5 3.8 ± 0.5 0.484 β
Psychomotor Speed 3.4 ± 0.8 3.5 ± 0.6 3.4 ± 0.8 0.580 β
Memory Recall 3.7 ± 0.6 3.8 ± 0.4 3.7 ± 0.6 0.864 β
IHDS Score 11.3 ± 1.1 10.8 ± 1.4 11.4 ± 1.0 0.851 β
Total (N=137) DSP (N=22) No DSP (N=115)
Motor Speed 3.7 ± 0.5 3.6 ± 0.5 3.8 ± 0.4 0.083 β
Psychomotor Speed 3.4 ± 0.8 3.1 ± 1.1 3.5 ± 0.7 0.035 β
Memory Recall 3.7 ± 0.6 3.7 ± 0.5 3.8 ± 0.6 0.623 β
IHDS Score 11.3 ± 1.1 10.4 ± 1.7 11.0 ± 1.1 0.026 β
DSP (N=22) ADSP (N=7) SDSP (N=15)
Motor Speed 3.6 ± 0.5 3.4 ± 0.5 3.7 ± 0.5 0.313 β
Psychomotor Speed 3.1 ± 1.1 2.1 ± 1.3 3.5 ± 0.6 0.003 β
Memory Recall 3.7 ± 0.5 3.5 ± 0.8 3.8 ± 0.4 0.298 β
IHDS Score 10.4 ± 1.7 9.1 ± 2.0 11.0 ± 1.1 0.009 β
Total (N=130) SDSP (N=15) No DSP (N=115)
Motor Speed 3.8 ± 0.4 3.7 ± 0.5 3.8 ± 0.4 0.383 β
Psychomotor Speed 3.5 ± 0.7 3.5 ± 0.6 3.5 ± 0.7 0.815 β
Memory Recall 3.8 ± 0.6 3.8 ± 0.4 3.8 ± 0.6 0.931 β
IHDS Score 11.0 ± 1.1 10.8 ± 1.4 11.5 ± 0.8 0.882 β
Total (N=122) ADSP (N=7) No DSP (N=115)
Motor Speed 3.8 ± 0.5 3.4 ± 0.5 3.8 ± 0.4 0.049 β
Psychomotor Speed 3.4 ± 0.8 2.1 ± 1.3 3.5 ± 0.7 <0.001 β
Memory Recall 3.7 ± 0.6 3.5 ± 0.8 3.8 ± 0.6 0.309 β
IHDS Score 10.9 ± 1.3 9.1 ± 2.0 11.5 ± 0.8 <0.001 β
β   Student's t -test

















Appendix J Comparison between excluded individuals and those 
that completed the study 
Table J-1: Baseline characteristics - Excluded individuals compared to those who completed 24-week 
follow-up (continuous data) 
 
Total (N=184) Excluded (N=40) Completed (N=144)
Clinical
Age years 33 (26 - 39) 32 (28 - 37) 33 (26 - 39) 0.435 β
Weight kg 61 (54 - 71) 59 (53 - 69) 62 (55 - 71) 0.380 β
Height metre 1.61 (1.56 - 1.67) 1.60 (1.56 - 1.65) 1.61 (1.56 - 1.68) 0.850 β
Body Mass Index kg/m2 20.0 - 25.0 23.2 (20.3 - 27.7) 22.5 (20.7 - 26.3) 23.4 (20.3 - 28.0) 0.521 ε
Waist : Hip ratio < 0.90 0.86 (0.81 - 0.90) 0.83 (0.80 - 0.87) 0.86 (0.82 - 0.91) 0.195 β
Systolic BP mmHg 120 - 140 110 (103 - 122) 110 (103 - 119) 111 (103 - 122) 0.865 β
Diastolic BP mmHg 80 - 90 72 (66 - 80) 74 (67 - 79) 72 (66 - 79) 0.813 ε
Haematological
CD4 T-cell count cells/mm3 > 500 158 (114 - 196) 152 (104 - 196) 158 (121 - 195) 0.862 β
White cell count x109/L 4.0 - 11.0 5.3 (4.1 - 6.5) 5.5 (4.6 - 6.5) 5.2 (4.0 - 6.5) 0.863 β
C-reactive protein mg/L < 5.0 2.8 (0.9 - 6.6) 1.3 (0.7 - 5.6) 3.0 (1.0 - 7.1) 0.149 β
Haemoglobin g/dL 11.6 - 15.6 11.8 (10.4 - 12.6) 11.8 (10.5 - 12.5) 11.8 (10.4 - 12.8) 0.666 β
MCV fL 80.0 - 100.0 92.4 (88.5 - 96.1) 93.6 (87.7 - 96.5) 92.3 (88.5 - 95.8) 0.788 β
Biochemical
Albumin g/L 38 - 54 39 (35 - 43) 42 (34 - 43) 39 (35 - 42) 0.503 β
ALT IU/L 10 - 41 19 (15 - 26) 20 (15 - 25) 19 (15 - 27) 0.609 β
Creatinine µmol/L 53 - 115 64 (55 - 73) 62 (51 - 75) 64 (56 - 73) 0.354 β
Metabolic
Fasting glucose mmol/L 4.1 - 5.6 4.7 (4.4 - 4.9) 4.7 (4.5 - 4.9) 4.7 (4.4 - 4.9) 0.724 β
Fasting insulin µU/mL 0.2 - 9.4 5.2 (2.5 - 8.6) 5.3 (3.1 - 6.7) 5.2 (2.5 - 8.6) 0.666 β
Total cholesterol mmol/L 3.1 - 5.2 3.7 (3.2 - 4.3) 3.8 (3.2 - 4.3) 3.7 (3.2 - 4.2) 0.480 β
Triglycerides mmol/L 0.5 - 2.0 0.9 (0.7 - 1.2) 0.8 (0.7 - 1.2) 0.9 (0.6 - 1.2) 0.758 β
HDL mmol/L 1.15 - 1.68 0.94 (0.75 - 1.13) 0.99 (0.77 - 1.20) 0.94 (0.75 - 1.12) 0.338 β
LDL mmol/L 1.0 - 3.0 2.3 (1.9 - 2.9) 2.4 (1.8 - 2.9) 2.3 (2.0 - 2.9) 0.815 β
Lactate mmol/L < 2.0 2.4 (1.7 - 3.1) 2.4 (1.7 - 3.4) 2.4 (1.7 - 3.1) 0.551 β
Pyridoxine
PLP nmol/L > 25.0 23.8 (16.5 - 38.4) 22.9 (13.9 - 38.4) 24.3 (17.1 - 38.4) 0.659 β
4-PA nmol/L unknown 17.4 (11.9 - 23.3) 14.7 (12.7 - 19.2) 17.6 (11.8 - 24.5) 0.254 ε
β    Student's t -test






















Table J-2: Baseline characteristics - Excluded individuals compared to those who completed 24-week 
follow-up (grouped data) 
 
 
Total (N=184) Excluded (N=40) Completed (N=144)
Female sex 129 (70%) 31 (78%) 98 (68%) 0.248
§
Age > 40 years 42 (23%) 7 (18%) 35 (24%) 0.444
§
Previous/Current TB 69 (38%) 18 (45%) 51 (35%) 0.268
§
Time of TB 0.446
¶
Currently 30 (16%) 9 (23%) 21 (15%)
< 1 year ago 13 (7%) 2 (5%) 11 (8%)
1 year ago 5 (3%) 2 (5%) 3 (2%)
2 years ago 5 (3%) 2 (5%) 3 (2%)
> 2 years ago 16 (9%) 3 (8%) 13 (9%)
Vit Bco supplement 179 (97%) 39 (98%) 140 (97%) 1.000
¶
Vit B6 supplement 15 (8%) 3 (8%) 12 (8%) 0.910
¶
WHO clinical stage 0.761
¶
Stage 1 57 (32%) 10 (27%) 47 (33%)
Stage 2 58 (32%) 14 (38%) 44 (31%)
Stage 3 58 (32%) 11 (30%) 47 (33%)
Stage 4 7 (4%) 2 (5%) 5 (4%)
CD4 T-cell count 0.394
§
< 100 cells/mm 3 30 (17%) 9 (24%) 21 (15%)
100 - 200 cells/mm 3 108 (60%) 20 (53%) 88 (62%)
> 200 cells/mm 3 42 (23%) 9 (24%) 33 (23%)
Body Mass Index 0.323
§
< 20 kg/m 2 37 (21%) 6 (16%) 31 (22%)
20 - 25 kg/m 2 77 (43%) 20 (54%) 57 (40%)
25 - 30 kg/m 2 37 (21%) 8 (22%) 29 (20%)
> 30 kg/m 2 28 (16%) 3 (8%) 25 (18%)
Alcohol last year 52 (29%) 10 (26%) 42 (30%) 0.694
§
IHDS score < 10 33 (24%) 9 (28%) 24 (23%) 0.542
§
Neuropathy status
Symptomatic DSP 31 (17%) 7 (18%) 24 (17%) 0.901
§
Asymptomatic DSP 10 (5%) 1 (3%) 9 (6%) 0.370
¶
Symptoms only 7 (4%) 2 (5%) 5 (3%) 0.693
¶
DSP 41 (22%) 8 (20%) 33 (23%) 0.482
§
¶    Fisher's exact test





























0 – 4 103 12 0.12 0.12 
4 – 12 114 20 0.18 0.28 
12 – 24 83 11 0.13 0.37 
r1 is calculated as the ratio of the number of patients who had development 
of DSP to the number of patients at risk during the interval 
R1 is the cumulative rate of development of DSP by end of interval 
Patients at risk are calculated as individuals at the specific interval without DSP 
 



























































0 – 2 111 8 0.07 0.07 
4 – 12 127 14 0.11 0.17 
12 - 24 102 6 0.06 0.22 
r1 is calculated as the ratio of the number of patients who had 
development of SDSP to the number of patients at risk during 
the interval 
R1 is the cumulative rate of development of SDSP by end of the 
interval 
 





























































0 – 4 103 4 0.04 0.04 
4 – 12 114 6 0.05 0.09 
12 - 24 83 5 0.06 0.14 
r1 is calculated as the ratio of the number of patients who had 
development of ADSP to the number of patients at risk during 
the interval 
R1 is the cumulative rate of development of ADSP by end of the 
interval 
 






















































Appendix L DSP movements for baseline to 24-week transitions 
Table L-1: Transition from baseline to week 24 showing interim movements between DSP states 
Baseline count 136 10 31 7
No DSP ADSP SDSP Symptoms Total
No DSP 76 (53%)a 5 (3%) 4 (3%) 4 (3%) 89 (62%)
ADSP 18 (13%)b 4 (3%) 1 (1%) 0 (0%) 23 (16%)
SDSP 10 (7%)c 0 (0%) 19 (13%) 1 (1%) 30 (21%)
Symptoms 2 (1%) 0 (0%) 0 (0%) 0 (0%) 2 (1%)
Total 106 (74%) 9 (6%) 24 (17%) 5 (3%) 144 (100%)
No DSP ADSP SDSP Symptoms Missed Total
No DSP 51 1 2 10 64
ADSP 2 2
SDSP 2 1 1 2 6
Symptoms 1 1
Missed 2 1 3
Total 58 0 2 3 13 76
No DSP ADSP SDSP Symptoms Missed Total
No DSP 4 2 3 9
ADSP 3 1 4
SDSP 2 1 2 5
Symptoms 0
Missed 0
Total 9 3 2 0 4 18
No DSP ADSP SDSP Symptoms Missed Total
No DSP 3 3
ADSP 2 2
SDSP 1 2 2 5
Symptoms 0
Missed 0
















a,b,c   Transition between interim visits (Week 4 to week 12) shown below
Overall transition from Baseline to Week 24

































Appendix M Neuropathy comparisons – Baseline & 24-week factors 










Age years 32 (26 - 38) 34 (26 - 40) 31 (27 - 38) 0.678 β
Weight kg 62 (56 - 71) 61 (56 - 69) 63 (56 - 72) 0.623 β
Height metre 1.61 (1.56 - 1.67) 1.61 (1.57 - 1.64) 1.61 (1.56 - 1.69) 0.373 β
Body Mass Index kg/m2 20.0 - 25.0 23.3 (20.3 - 28.0) 23.6 (20.6 - 27.8) 23.3 (20.3 - 28.0) 0.995 ε
Waist : Hip ratio < 0.90 0.86 (0.81 - 0.90) 0.85 (0.81 - 0.88) 0.86 (0.81 - 0.90) 0.662 β
Systolic BP mmHg 120 - 140 111 (103 - 122) 109 (100 - 120) 111 (104 - 122) 0.473 β
Diastolic BP mmHg 80 - 90 72 (66 - 81) 72 (67 - 78) 73 (66 - 81) 0.737 ε
Haematological
CD4 T-cell count cells/mm3 > 500 158 (118 - 193) 138 (114 - 193) 163 (125 - 193) 0.630 β
White cell count x109/L 4.0 - 11.0 5.1 (4.0 - 6.6) 5.4 (4.3 - 7.1) 5.1 (4.0 - 6.6) 0.445 ε
C-reactive protein mg/L < 5.0 2.7 (0.9 - 6.7) 2.9 (0.9 - 6.7) 2.6 (0.9 - 6.5) 0.664 β
Haemoglobin g/dL 11.6 - 15.6 11.8 (10.6 - 12.8) 11.5 (9.7 - 12.8) 11.9 (10.7 - 12.8) 0.376 β
MCV fL 80.0 - 100.0 92.1 (88.5 - 96.4) 91.6 (87.9 - 97.0) 92.2 (88.5 - 95.8) 0.762 β
Biochemical
Albumin g/L 38 - 54 39 (35 - 43) 39 (35 - 41) 39 (35 - 43) 0.627 β
ALT IU/L 10 - 41 19 (14 - 26) 16 (12 - 20) 20 (15 - 28) 0.003 β
Creatinine µmol/L 53 - 115 64 (56 - 73) 64 (58 - 77) 64 (55 - 73) 0.490 ε
Metabolic
Fasting glucose mmol/L 4.1 - 5.6 4.6 (4.4 - 4.9) 4.7 (4.4 - 4.8) 4.6 (4.4 - 4.9) 0.828 ε
Fasting insulin µU/mL 0.2 - 9.4 5.4 (2.4 - 8.6) 4.8 (2.2 - 7.6) 5.5 (2.5 - 8.9) 0.419 β
Total cholesterol mmol/L 3.1 - 5.2 3.7 (3.2 - 4.2) 3.5 (3.0 - 4.2) 3.7 (3.3 - 4.2) 0.282 β
Triglycerides mmol/L 0.5 - 2.0 0.8 (0.6 - 1.1) 0.8 (0.6 - 1.1) 0.9 (0.6 - 1.0) 0.361 β
HDL mmol/L 1.15 - 1.68 0.94 (0.74 - 1.11) 0.86 (0.71 - 1.04) 0.99 (0.74 - 1.13) 0.100 β
LDL mmol/L 1.0 - 3.0 2.3 (2.0 - 2.9) 2.3 (1.9 - 2.9) 2.4 (2.0 - 2.9) 0.567 β
Lactate mmol/L < 2.0 2.4 (1.7 - 3.1) 2.5 (1.7 - 3.3) 2.4 (1.7 - 3.0) 0.970 β
Pyridoxine
PLP nmol/L > 25.0 24.4 (17.8 - 36.7) 21.4 (18.0 - 32.3) 26.8 (17.6 - 38.5) 0.444 β
4-PA nmol/L unknown 17.5 (11.6 - 24.5) 17.0 (11.5 - 22.1) 17.7 (12.0 - 27.3) 0.535 ε
β    Student's t -test
ε    Wilcoxon rank-sum test
































Weight kg 66 (57 - 75) 65 (56 - 70) 66 (57 - 75) 0.643 β
Height metre 1.61 (1.57 - 1.67) 1.61 (1.56 - 1.64) 1.61 (1.57 - 1.69) 0.387 β
Body Mass Index kg/m2 20.0 - 25.0 24.4 (20.8 - 29.3) 25.0 (20.8 - 29.2) 24.3 (20.8 - 29.5) 0.887 ε
Waist : Hip ratio < 0.90 0.84 (0.79 - 0.88) 0.83 (0.78 - 0.86) 0.85 (0.80 - 0.88) 0.473 ε
Systolic BP mmHg 120 - 140 115 (107 - 123) 115 (109 - 124) 115 (107 - 122) 0.569 β
Diastolic BP mmHg 80 - 90 73 (69 - 79) 74 (71 - 78) 73 (69 - 80) 0.786 β
Haematological
CD4 T-cell count cells/mm3 > 500 261 (186 - 364) 298 (210 - 457) 260 (179 - 351) 0.110 β
C-reactive protein * mg/L < 5.0 4.6 (1.2 - 9.0) 4.6 (1.6 - 8.6) 4.7 (1.0 - 10.3) 0.714 ε
Virological
HIV viral load copies/mL 20 (20 - 36) 20 (20 - 44) 20 (20 - 36) 0.861 ε
Metabolic
Fasting glucose mmol/L 4.1 - 5.6 4.9 (4.7 - 5.2) 4.9 (4.6 - 5.2) 4.9 (4.7 - 5.2) 0.775 ε
Fasting insulin µU/mL 0.2 - 9.4 5.6 (2.4 - 8.7) 4.7 (2.8 - 7.9) 5.9 (2.0 - 8.7) 0.519 ε
Total cholesterol mmol/L 3.1 - 5.2 4.4 (3.9 - 5.0) 4.2 (3.7 - 5.2) 4.4 (3.9 - 4.9) 0.859 β
Triglycerides mmol/L 0.5 - 2.0 0.8 (0.6 - 1.1) 0.9 (0.7 - 1.1) 0.8 (0.6 - 1.0) 0.532 ε
HDL mmol/L 1.15 - 1.68 1.39 (1.12 - 1.63) 1.28 (0.99 - 1.55) 1.44 (1.21 - 1.72) 0.038 β
LDL mmol/L 1.0 - 3.0 2.5 (2.0 - 3.0) 2.7 (2.2 - 3.3) 2.4 (2.0 - 2.9) 0.341 β
Pyridoxine
PLP * nmol/L > 25.0 21.6 (13.7 - 34.7) 22.6 (12.9 - 32.3) 21.6 (14.7 - 35.6) 0.197 β
4-PA * nmol/L unknown 19.2 (12.5 - 28.0) 18.8 (15.1 - 23.3) 19.2 (12.2 - 30.3) 0.759 ε
*     12-week blood samples
**   SDSP at baseline cohort excluded
β      Student's t -test































Female sex 82 (68%) 20 (71%) 62 (67%) 0.688 §
Age > 40 years 24 (20%) 7 (25%) 17 (18%) 0.450 §
Previous/Current TB 42 (35%) 7 (25%) 35 (38%) 0.205 §
Time of TB
Currently 10 (8%) 0 (0%) 10 (11%) 0.155 ¶
< 1 year ago 17 (14%) 2 (7%) 15 (16%) 0.155 ¶
1 year ago 2 (2%) 1 (4%) 1 (1%) 0.155 ¶
2 years ago 2 (2%) 0 (0%) 2 (2%) 0.155 ¶
> 2 years ago 11 (9%) 4 (14%) 7 (8%) 0.155 ¶
Vit Bco supplement 119 (99%) 28 (100%) 91 (99%) 1.000 ¶
Vit B6 supplement 6 (5%) 1 (4%) 5 (5%) 1.000 ¶
WHO clinical stage
Stage 1 39 (33%) 8 (29%) 31 (34%) 0.114 ¶
Stage 2 39 (33%) 14 (50%) 25 (27%) 0.114 ¶
Stage 3 37 (31%) 5 (18%) 32 (35%) 0.114 ¶
Stage 4 4 (3%) 1 (4%) 3 (3%) 0.114 ¶
CD4 T-cell count
< 100 cells/mm 3 20 (17%) 5 (18%) 15 (17%) 0.969 §
100 - 200 cells/mm 3 74 (63%) 17 (61%) 57 (63%) 0.969 §
> 200 cells/mm
3 24 (20%) 6 (21%) 18 (20%) 0.969 §
Metabolic syndrome 16 (13%) 5 (18%) 11 (12%) 0.525 ¶
Body Mass Index
< 20 kg/m 2 26 (22%) 6 (21%) 20 (22%) 0.838 §
20 - 25 kg/m
2 48 (41%) 11 (39%) 37 (41%) 0.838 §
25 - 30 kg/m 2 23 (19%) 7 (25%) 16 (18%) 0.838 §
> 30 kg/m
2 21 (18%) 4 (14%) 17 (19%) 0.838 §
Alcohol last year 36 (31%) 9 (32%) 27 (30%) 0.830 §
IHDS score < 10 14 (10%) 3 (11%) 11 (10%) 1.000 ¶
24 week factors
CD4 T-cell count 0.561 ¶
< 100 cells/mm
3 5 (5%) 0 (0%) 5 (6%)
100 - 200 cells/mm 3 25 (23%) 6 (22%) 19 (23%)
> 200 cells/mm
3 79 (72%) 21 (78%) 58 (71%)
HIV viral load
< 200 copies/mL 76 (71%) 18 (67%) 58 (73%)
> 200 copies/mL 31 (29%) 9 (33%) 22 (28%)
Antiretroviral drugs
Stavudine 67 (56%) 18 (64%) 49 (53%) 0.304 §
Zidovudine 14 (12%) 2 (7%) 12 (13%) 0.516 ¶
Lamivudine 120 (100%) 28 (100%) 92 (100%)
Efavirenz 44 (37%) 7 (25%) 37 (40%) 0.143 §
Nevirapine 76 (63%) 21 (75%) 55 (60%) 0.143 §
Tenofovir 39 (33%) 8 (29%) 31 (34%) 0.612 §
Drug combination 0.335 ¶
3TC / NVP / TDF 20 (17%) 5 (18%) 15 (16%)
3TC / EFV / TDF 19 (16%) 3 (11%) 16 (17%)
AZT / 3TC / NVP 11 (9%) 1 (4%) 10 (11%)
AZT / 3TC / EFV 3 (3%) 1 (4%) 2 (2%)
D4T / 3TC / NVP 45 (38%) 15 (54%) 30 (33%)
D4T / 3TC / EFV 22 (18%) 3 (11%) 19 (21%)
** SDSP at baseline cohort excluded
¶    Fisher's exact test



















Table M-4: Baseline characteristics in individuals with and without HIV-SN (continuous data) 
 
Total (N=144) HIV-SN (N=48) No HIV-SN (N=96)
Clinical
Age years 33 (27 - 39) 35 (27 - 43) 32 (27 - 38) 0.099 β
Weight kg 62 (55 - 71) 61 (55 - 68) 63 (56 - 72) 0.456 β
Height metre 1.61 (1.56 - 1.68) 1.62 (1.58 - 1.68) 1.60 (1.56 - 1.68) 0.483 β
Body Mass Index kg/m2 20.0 - 25.0 23.4 (20.3 - 28.0) 23.1 (20.1 - 26.0) 23.6 (20.3 - 28.3) 0.324 ε
Waist : Hip ratio < 0.90 0.86 (0.82 - 0.91) 0.87 (0.83 - 0.92) 0.86 (0.81 - 0.90) 0.284 β
Systolic BP mmHg 120 - 140 111 (103 - 122) 109 (100 - 118) 111 (104 - 123) 0.118 β
Diastolic BP mmHg 80 - 90 72 (66 - 79) 70 (66 - 76) 73 (66 - 83) 0.088 ε
Haematological
CD4 T-cell count cells/mm3 > 500 159 (121 - 193) 159 (121 - 212) 160 (118 - 191) 0.508 β
White cell count x109/L 4.0 - 11.0 5.1 (4.0 - 6.5) 5.4 (4.0 - 6.3) 5.0 (4.0 - 7.0) 0.865 ε
C-reactive protein mg/L < 5.0 3.0 (1.0 - 7.1) 3.7 (1.4 - 11.9) 2.6 (0.9 - 6.5) 0.125 β
Haemoglobin g/dL 11.6 - 15.6 11.8 (10.5 - 12.8) 11.9 (10.2 - 12.9) 11.7 (10.5 - 12.6) 0.886 β
MCV fL 80.0 - 100.0 92.4 (88.5 - 96.0) 93.3 (89.3 - 97.0) 92.1 (88.5 - 95.5) 0.385 β
Biochemical
Albumin g/L 38 - 54 39 (35 - 42) 39 (35 - 43) 39 (35 - 42) 0.800 β
ALT IU/L 10 - 41 19 (14 - 27) 19 (14 - 26) 20 (14 - 28) 0.365 β
Creatinine µmol/L 53 - 115 64 (56 - 73) 65 (58 - 74) 64 (55 - 73) 0.443 ε
Metabolic
Fasting glucose mmol/L 4.1 - 5.6 4.7 (4.4 - 4.9) 4.7 (4.4 - 4.9) 4.6 (4.4 - 4.9) 0.192 ε
Fasting insulin µU/mL 0.2 - 9.4 5.2 (2.5 - 8.6) 4.9 (3.1 - 9.3) 5.3 (2.0 - 8.4) 0.859 β
Total cholesterol mmol/L 3.1 - 5.2 3.7 (3.2 - 4.2) 3.9 (3.2 - 4.3) 3.7 (3.2 - 4.2) 0.986 β
Triglycerides mmol/L 0.5 - 2.0 0.9 (0.6 - 1.2) 0.9 (0.6 - 1.3) 0.9 (0.7 - 1.1) 0.815 β
HDL mmol/L 1.15 - 1.68 0.94 (0.75 - 1.12) 0.93 (0.75 - 1.08) 0.97 (0.74 - 1.12) 0.284 β
LDL mmol/L 1.0 - 3.0 2.3 (2.0 - 2.9) 2.5 (2.0 - 2.9) 2.3 (2.0 - 2.8) 0.765 β
Lactate mmol/L < 2.0 2.4 (1.7 - 3.1) 2.1 (1.4 - 3.3) 2.4 (1.7 - 3.0) 0.427 β
Pyridoxine
PLP nmol/L > 25.0 24.3 (17.1 - 38.4) 20.7 (16.6 - 46.8) 26.4 (17.4 - 36.8) 0.903 β
4-PA nmol/L unknown 17.6 (11.8 - 24.5) 17.4 (11.9 - 22.7) 17.7 (11.3 - 25.5) 0.998 ε
β    Student's t -test






















Table M-5: Week 24 characteristics in individuals with and without HIV-SN (continuous data) 
 
Total (N=144) HIV-SN (N=48) No HIV-SN (N=96)
Clinical
Weight kg 66 (57 - 75) 66 (56 - 70) 66 (58 - 78) 0.341 β
Height metre 1.61 (1.57 - 1.68) 1.63 (1.58 - 1.68) 1.61 (1.57 - 1.68) 0.446 β
Body Mass Index kg/m2 20.0 - 25.0 24.4 (21.0 - 29.2) 24.1 (20.8 - 26.9) 24.8 (21.5 - 30.1) 0.180 ε
Waist : Hip ratio < 0.90 0.85 (0.80 - 0.89) 0.85 (0.82 - 0.91) 0.84 (0.79 - 0.88) 0.254 ε
Systolic BP mmHg 120 - 140 115 (109 - 124) 115 (109 - 125) 115 (107 - 122) 0.771 β
Diastolic BP mmHg 80 - 90 74 (69 - 80) 75 (69 - 80) 73 (69 - 80) 0.547 β
Haematological
CD4 T-cell count cells/mm3 > 500 272 (204 - 368) 311 (236 - 400) 260 (175 - 351) 0.018 β
C-reactive protein * mg/L < 5.0 4.5 (1.3 - 9.7) 4.5 (1.6 - 11.4) 4.5 (1.0 - 9.0) 0.426 ε
Virological
HIV viral load copies/mL 20 (20 - 56) 20 (20 - 73) 20 (20 - 47) 0.353 ε
Metabolic
Fasting glucose mmol/L 4.1 - 5.6 4.9 (4.7 - 5.2) 5.0 (4.7 - 5.2) 4.9 (4.7 - 5.2) 0.325 ε
Fasting insulin µU/mL 0.2 - 9.4 5.5 (2.5 - 8.5) 5.0 (2.9 - 8.0) 5.9 (2.2 - 8.7) 0.625 ε
Total cholesterol mmol/L 3.1 - 5.2 4.4 (3.9 - 5.1) 4.4 (3.8 - 5.2) 4.4 (3.9 - 4.9) 0.731 β
Triglycerides mmol/L 0.5 - 2.0 0.8 (0.7 - 1.1) 0.9 (0.7 - 1.1) 0.8 (0.6 - 1.0) 0.196 ε
HDL mmol/L 1.15 - 1.68 1.41 (1.12 - 1.64) 1.38 (1.08 - 1.60) 1.44 (1.17 - 1.72) 0.457 β
LDL mmol/L 1.0 - 3.0 2.5 (2.0 - 2.9) 2.5 (2.1 - 3.1) 2.4 (2.0 - 2.9) 0.421 β
Pyridoxine
PLP * nmol/L > 25.0 20.9 (13.3 - 34.7) 19.2 (11.2 - 33.2) 22.4 (14.7 - 34.8) 0.210 β
4-PA * nmol/L unknown 19.2 (12.5 - 27.7) 17.2 (12.4 - 23.3) 19.5 (12.5 - 30.5) 0.349 ε
*   12-week blood samples
β    Student's t -test
ε    Wilcoxon rank-sum test





















Table M-6: Baseline and 24-week characteristics in individuals with and without HIV-SN (grouped data) 
 
Total (N=144) HIV-SN (N=48) No HIV-SN (N=96)
Baseline factors
Female sex 98 (68%) 31 (65%) 67 (70%) 0.527 §
Age > 40 years 35 (24%) 17 (35%) 18 (19%) 0.028 §
Previous/Current TB 57 (40%) 21 (44%) 36 (38%) 0.470 §
Time of TB 0.058 ¶
Currently 11 (8%) 1 (2%) 10 (10%)
< 1 year ago 26 (18%) 12 (25%) 14 (15%)
1 year ago 4 (3%) 3 (6%) 1 (1%)
2 years ago 3 (2%) 2 (4%) 1 (1%)
> 2 years ago 13 (9%) 3 (6%) 10 (10%)
Vit Bco supplement 143 (99%) 48 (100%) 95 (99%) 1.000 ¶
Vit B6 supplement 6 (4%) 2 (4%) 4 (4%) 1.000 ¶
WHO clinical stage 0.539 ¶
Stage 1 46 (32%) 14 (29%) 32 (34%)
Stage 2 43 (30%) 16 (33%) 27 (28%)
Stage 3 49 (34%) 15 (31%) 34 (36%)
Stage 4 5 (4%) 3 (6%) 2 (2%)
CD4 T-cell count 0.266 §
< 100 cells/mm 3 22 (15%) 5 (10%) 17 (18%)
100 - 200 cells/mm 3 88 (62%) 29 (60%) 59 (63%)
> 200 cells/mm 3 32 (23%) 14 (29%) 18 (19%)
Metabolic syndrome 17 (12%) 3 (6%) 14 (15%) 0.178 ¶
Body Mass Index 0.693 §
< 20 kg/m 2 31 (22%) 12 (25%) 19 (20%)
20 - 25 kg/m
2 57 (40%) 20 (42%) 37 (39%)
25 - 30 kg/m 2 29 (20%) 10 (21%) 19 (20%)
> 30 kg/m
2 25 (18%) 6 (13%) 19 (20%)
Alcohol last year 42 (30%) 12 (25%) 30 (32%) 0.393 §
IHDS score < 10 14 (10%) 9 (20%) 5 (5%) 0.013 ¶
Week 24 factors
CD4 T-cell count 0.088 ¶
< 100 cells/mm
3 5 (4%) 0 (0%) 5 (6%)
100 - 200 cells/mm 3 27 (21%) 6 (14%) 21 (24%)
> 200 cells/mm
3 98 (75%) 38 (86%) 60 (70%)
HIV viral load < 200 copies/mL 87 (68%) 27 (61%) 60 (71%) 0.246 §
Antiretroviral drugs
Stavudine 81 (56%) 29 (60%) 52 (54%) 0.476 §
Zidovudine 17 (12%) 4 (8%) 13 (14%) 0.424 ¶
Lamivudine 144 (100%) 48 (100%) 96 (100%)
Efavirenz 60 (42%) 23 (48%) 37 (39%) 0.282 §
Nevirapine 83 (58%) 24 (50%) 59 (61%) 0.190 §
Tenofovir 47 (33%) 16 (33%) 31 (32%) 0.900 §
Drug combination 0.075 ¶
3TC / NVP / TDF 23 (16%) 8 (17%) 15 (16%)
3TC / EFV / TDF 23 (16%) 7 (15%) 16 (17%)
AZT / 3TC / TDF 1 (1%) 1 (2%) 0 (0%)
AZT / 3TC / NVP 11 (8%) 0 (0%) 11 (11%)
AZT / 3TC / EFV 5 (3%) 3 (6%) 2 (2%)
D4T / 3TC / NVP 49 (34%) 16 (33%) 33 (34%)
D4T / 3TC / EFV 32 (22%) 13 (27%) 19 (20%)
¶    Fisher's exact test




















Table M-7: Univariate Cox regression analysis of baseline risk factors for ATN 
 
 





Hazard Ratio in 
univariate analysis
Hazard Ratio 95% 
Confidence Interval
p-value
Female sex 0.88 0.43 - 1.81 0.726
Age > 40 years 1.38 0.65 - 2.92 0.404
Previous/Current TB 0.71 0.34 - 1.47 0.357
WHO clinical stage
Stage 1* 1.00
Stage 2 1.87 0.89 - 3.92 0.100
Stage 3 0.60 0.22 - 1.62 0.315
Stage 4 0.99 0.13 - 7.67 0.992
IHDS score < 10 0.50 0.19 - 1.29 0.153
Alcohol last year 0.82 0.40 - 1.69 0.584
ALT > 19 IU/L 0.51 0.25 - 1.04 0.062
HDL < 1.0 mmol/L 1.85 0.94 - 3.67 0.077
* reference category
Clinical variable
Hazard Ratio in 
univariate analysis
Hazard Ratio 95% 
Confidence Interval
p-value
Female sex 0.85 0.41 - 1.75 0.654
Age > 40 years 1.30 0.59 - 2.85 0.510
Previous/Current TB 0.59 0.28 - 1.21 0.149
WHO clinical stage
Stage 1* 1.00
Stage 2 1.88 0.90 - 3.96 0.095
Stage 3 0.54 0.20 - 1.46 0.223
Stage 4 0.78 0.10 - 6.07 0.816
IHDS score < 10 0.51 0.20 - 1.31 0.160
Alcohol last year 0.92 0.44 - 1.89 0.814
ALT > 19 IU/L 0.51 0.25 - 1.04 0.063


















Appendix N  Longitudinal analysis of possible neuropathy risk 



























Baseline 138 163 0.630 β
Week 24 298 260 43.12 (-4.65 ; 90.90) 0.077
Fasting glucose
Baseline 4.7 4.6 0.828 ε
Week 12 4.9 4.8 0.01 (-0.22 ; 0.25) 0.933
Week 24 4.9 4.9 -0.06 (-0.30 ; 0.17) 0.603
Insulin
Baseline 4.8 5.5 0.419 β
Week 12 5.0 5.3 0.52 (-1.83 ; 2.87) 0.663
Week 24 4.7 5.9 -0.07 (-2.45 ; 2.30) 0.951
Total cholesterol
Baseline 3.5 3.7 0.282 β
Week 12 3.9 4.2 -0.02 (-0.31 ; 0.27) 0.883
Week 24 4.2 4.4 0.14 (-0.16 ; 0.43) 0.360
Triglycerides
Baseline 0.8 0.9 0.361 β
Week 12 0.8 0.8 -0.15 (-0.49 ; 0.18) 0.377
Week 24 0.9 0.8 0.09 (-0.24 ; 0.43) 0.585
HDL
Baseline 0.86 0.99 0.100 β
Week 12 1.19 1.33 -0.04 (-0.19 ; 0.12) 0.645
Week 24 1.28 1.44 -0.10 (-0.26 ; 0.05) 0.204
LDL
Baseline 2.3 2.4 0.567 β
Week 12 2.4 2.4 0.09 (-0.16 ; 0.34) 0.474
Week 24 2.7 2.4 0.22 (-0.03 ; 0.46) 0.088
Systolic BP
Baseline 109 111 0.473 β
Week 12 112 115 2.22 (-3.03 ; 7.47) 0.408
Week 24 115 115 -0.59 (-5.88 ; 4.71) 0.827
Diastolic BP
Baseline 72 73 0.737 ε
Week 12 73 73 0.00 (-3.90 ; 3.91) 0.998
Week 24 74 73 0.51 (-3.43 ; 4.45) 0.800
Weight
Baseline 61 63 0.623 β
Week 12 62 65 0.61 (-1.00 ; 2.23) 0.458
Week 24 65 66 0.79 (-0.84 ; 2.42) 0.343
Body Mass Index
Baseline 23.6 23.3 0.995 ε
Week 12 25.0 24.4 0.54 (-0.19 ; 1.26) 0.147
Week 24 25.0 24.3 0.23 (-0.50 ; 0.96) 0.529
Waist : Hip Ratio
Baseline 0.85 0.86 0.662 β
Week 12 0.83 0.85 -0.01 (-0.07 ; 0.06) 0.848
Week 24 0.83 0.85 -0.02 (-0.08 ; 0.04) 0.518
C-reactive protein
Baseline 2.9 2.4 0.664 β
Week 12 2.9 2.4 2.12 (-11.85 ; 16.09) 0.766
PLP
Baseline 21.4 26.8 0.444 β
Week 12 22.6 21.6 -3.61 (-15.97 ; 8.74) 0.566
4PA
Baseline 17.0 17.7 0.535 ε
Week 12 18.8 19.2 -2.13 (-13.71 ; 9.45) 0.718
*    Group effect is the difference in mean concentrations between groups compared to baseline
**  SDSP at baseline cohort excluded
β     Student's t -test






























Baseline 159 160 0.508
β
Week 24 311 260 44.74 (4.16 ; 85.32) 0.031
Fasting glucose
Baseline 4.7 4.6 0.192 ε
Week 12 5.0 4.8 0.08 (-0.11 ; 0.28) 0.407
Week 24 5.0 4.9 0.00 (-0.20 ; 0.20) 0.993
Insulin
Baseline 4.9 5.3 0.859
β
Week 12 5.3 5.3 -0.20 (-2.18 ; 1.78) 0.842
Week 24 5.0 5.9 -0.14 (-2.14 ; 1.85) 0.890
Total cholesterol
Baseline 3.9 3.7 0.986 β
Week 12 4.1 4.2 -0.05 (-0.29 ; 0.19) 0.686
Week 24 4.4 4.4 0.07 (-0.18 ; 0.32) 0.576
Triglycerides
Baseline 0.9 0.9 0.815
β
Week 12 0.8 0.8 0.23 (-0.05 ; 0.51) 0.114
Week 24 0.9 0.8 0.08 (-0.21 ; 0.36) 0.602
HDL
Baseline 0.93 0.97 0.284
β
Week 12 1.24 1.35 0.00 (-0.13 ; 0.12) 0.943
Week 24 1.38 1.44 0.00 (-0.13 ; 0.13) 0.969
LDL
Baseline 2.5 2.3 0.765 β
Week 12 2.4 2.4 -0.09 (-0.30 ; 0.12) 0.405
Week 24 2.5 2.4 0.08 (-0.13 ; 0.29) 0.432
Systolic BP
Baseline 109 111 0.118
β
Week 12 118 114 7.28 (2.92 ; 11.64) 0.001
Week 24 115 115 4.68 (0.33 ; 9.04) 0.035
Diastolic BP
Baseline 70 73 0.088 ε
Week 12 72 73 2.94 (-0.31 ; 6.18) 0.076
Week 24 75 73 4.91 (1.66 ; 8.15) 0.003
Weight
Baseline 61 63 0.456
β
Week 12 62 65 0.30 (-1.08 ; 1.68) 0.669
Week 24 66 66 0.36 (-1.01 ; 1.72) 0.610
Body Mass Index
Baseline 23.1 23.6 0.324
ε
Week 12 23.6 24.5 0.10 (-0.52 ; 0.72) 0.748
Week 24 24.1 24.8 0.06 (-0.55 ; 0.67) 0.850
Waist : Hip Ratio
Baseline 0.87 0.86 0.284
β
Week 12 0.86 0.85 -0.01 (-0.06 ; 0.05) 0.846
Week 24 0.85 0.84 0.04 (-0.01 ; 0.10) 0.093
C-reactive protein
Baseline 3.7 2.6 0.125
β
Week 12 4.5 4.5 1.26 (-10.55 ; 13.08) 0.834
PLP
Baseline 20.7 26.4 0.903
β
Week 12 19.2 22.4 -7.57 (-17.77 ; 2.63) 0.146
4PA
Baseline 17.4 17.7 0.998 ε
Week 12 17.2 19.5 1.75 (-7.87 ; 11.38) 0.721
*   Group effect is the difference in mean concentrations between groups compared to baseline
β    Student's t -test




















Appendix O NAT2 acetylation phenotype comparisons 
 
Table O-1: NAT2 acetylation phenotype distribution between individuals with and without DSP 
 
Table O-2: NAT2 acetylation phenotype distribution between ADSP and No DSP 
 
 
Total (N=163) DSP (N=39) No DSP (N=124)
Acetylation Classification 1 0.790 §
Rapid 27 (17%) 7 (18%) 20 (16%)
Slow 136 (83%) 32 (82%) 104 (84%)
Acetylation Classification 2 0.899 ¶
Rapid 27 (17%) 7 (18%) 20 (16%)
Intermediate 123 (75%) 30 (77%) 93 (75%)
Slow 13 (8%) 2 (5%) 11 (9%)
Acetylation Classification 3 0.376 ¶
Rapid 27 (17%) 7 (18%) 20 (16%)
Intermediate 88 (54%) 18 (46%) 70 (56%)
Slow/Intermediate 35 (21%) 12 (31%) 23 (19%)
Slow 13 (8%) 2 (5%) 11 (9%)
¶
    Fisher's  exact test




Total (N=163) ADSP (N=9) No DSP (N=154)
Acetylation Classification 1 0.639 §
Rapid 27 (17%) 2 (22%) 25 (16%)
Slow 136 (83%) 7 (78%) 129 (84%)
Acetylation Classification 2 0.844 ¶
Rapid 27 (17%) 2 (22%) 25 (16%)
Intermediate 123 (75%) 7 (78%) 116 (75%)
Slow 13 (8%) 0 (0%) 13 (8%)
Acetylation Classification 3 0.643 ¶
Rapid 27 (17%) 2 (22%) 25 (16%)
Intermediate 88 (54%) 4 (44%) 84 (55%)
Slow/Intermediate 35 (21%) 3 (33%) 32 (21%)
Slow 13 (8%) 0 (0%) 13 (8%)
¶    Fisher's  exact test
§





















Table O-3: NAT2 acetylation phenotype distribution between individuals with and without SDSP 
 
 
Table O-4: NAT2 acetylation phenotype distribution between individuals with and without HIV-SN 
 
Total (N=163) SDSP (N=30) No SDSP (N=133)
Acetylation Classification 1 0.987 §
Rapid 27 (17%) 5 (17%) 22 (17%)
Slow 136 (83%) 25 (83%) 111 (83%)
Acetylation Classification 2 1.000 ¶
Rapid 27 (17%) 5 (17%) 22 (17%)
Intermediate 123 (75%) 23 (77%) 100 (75%)
Slow 13 (8%) 2 (6%) 11 (8%)
Acetylation Classification 3 0.623 ¶
Rapid 27 (17%) 5 (17%) 22 (16%)
Intermediate 88 (54%) 14 (46%) 74 (56%)
Slow/Intermediate 35 (21%) 9 (30%) 26 (20%)
Slow 13 (8%) 2 (7%) 11 (8%)
¶
    Fisher's  exact test
§






Total (N=157) HIV-SN (N=44) No HIV-SN (N=113)
Acetylation Classification 1 0.790 §
Rapid 27 (17%) 7 (16%) 20 (18%)
Slow 130 (83%) 37 (84%) 93 (82%)
Acetylation Classification 2 0.911 ¶
Rapid 27 (17%) 7 (16%) 20 (18%)
Intermediate 117 (75%) 34 (77%) 83 (73%)
Slow 13 (8%) 3 (7%) 10 (9%)
Acetylation Classification 3 0.899 ¶
Rapid 27 (17%) 7 (16%) 20 (18%)
Intermediate 84 (54%) 23 (52%) 61 (54%)
Slow/Intermediate 33 (21%) 11 (25%) 22 (19%)
Slow 13 (8%) 3 (7%) 10 (9%)
¶
    Fisher's  exact test



















Table O-5: Allele distribution between individuals with and without DSP shown in 3 genetic models 
 
SNP DSP No DSP Total p-value SNP DSP No DSP Total p-value SNP DSP No DSP Total p-value
n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%)
191 G>A 0.250 ¶ 191 G>A 0.250 ¶ 191 G>A 0.265 ¶
GG 37 (95%) 107 (86%) 144 (88%) GG 37 (95%) 107 (86%) 144 (88%) G 76 (97%) 231 (93%) 307 (94%)
GA 2 (5%) 17 (14%) 19 (12%) GA+AA 2 (5%) 17 (14%) 19 (12%) A 2 (3%) 17 (7%) 19 (6%)







CC 14 (36%) 46 (37%) 60 (37%) GG 14 (36%) 46 (37%) 60 (37%) G 49 (63%) 156 (63%) 205 (63%)
CT 21 (54%) 64 (52%) 85 (52%) GA+AA 25 (64%) 78 (63%) 103 (63%) A 29 (37%) 92 (37%) 121 (37%)
TT 4 (10%) 14 (11%) 18 (11%)
341 T>C 0.135 ¶ 341 T>C 0.076 § 341 T>C 0.217 §
TT 16 (41%) 71 (57%) 87 (53%) GG 16 (41%) 71 (57%) 87 (53%) G 54 (69%) 189 (76%) 243 (75%)
TC 22 (56%) 47 (38%) 69 (42%) GA+AA 23 (59%) 53 (43%) 76 (47%) A 24 (31%) 59 (24%) 83 (25%)
CC 1 (3%) 6 (5%) 7 (4%)
481 C>T 0.765 ¶ 481 C>T 0.718 § 481 C>T 0.927 §
CC 22 (56%) 74 (60%) 96 (59%) GG 22 (56%) 74 (60%) 96 (59%) G 60 (77%) 192 (77%) 252 (77%)
CT 16 (41%) 44 (35%) 60 (37%) GA+AA 17 (44%) 50 (40%) 67 (41%) A 18 (23%) 56 (23%) 74 (23%)







GG 19 (49%) 67 (54%) 86 (53%) GG 19 (49%) 67 (54%) 86 (53%) G 57 (73%) 186 (75%) 243 (75%)
GA 19 (49%) 52 (42%) 71 (44%) GA+AA 20 (51%) 57 (46%) 77 (47%) A 21 (27%) 62 (25%) 83 (25%)
AA 1 (3%) 5 (4%) 6 (4%)
803 A>G 0.877 § 803 A>G 0.615 § 803 A>G 0.656 §
AA 10 (26%) 27 (22%) 37 (23%) GG 10 (26%) 27 (22%) 37 (23%) G 40 (51%) 120 (48%) 160 (49%)
AG 20 (51%) 66 (53%) 86 (53%) GA+AA 29 (74%) 97 (78%) 126 (77%) A 38 (49%) 128 (52%) 166 (51%)







GG 39 (100%) 123 (99%) 162 (99%) GG 39 (100%) 123 (99%) 162 (99%) G 78 (100%) 247 (100%) 325 (100%)
GA 0 (0%) 1 (1%) 1 (1%) GA+AA 0 (0%) 1 (1%) 1 (1%) A 0 (0%) 1 (0%) 1 (0%)
AA 0 (0%) 0 (0%) 0 (0%)
¶    Fisher's exact test
§    χ2 test

















Table O-6: Allele distribution between individuals with and without SDSP shown in 3 genetic models 
 
SNP SDSP No SDSP Total SNP SDSP No SDSP Total SNP SDSP No SDSP Total
n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%)
191 G>A 0.531 ¶ 191 G>A 0.531 ¶ 191 G>A 0.544 ¶
GG 28 (93%) 116 (87%) 144 (88%) GG 28 (93%) 116 (87%) 144 (88%) G 58 (97%) 249 (94%) 307 (94%)
GA 2 (7%) 17 (13%) 19 (12%) GA+AA 2 (7%) 17 (13%) 19 (12%) A 2 (3%) 17 (6%) 19 (6%)







CC 11 (37%) 49 (37%) 60 (37%) GG 11 (37%) 49 (37%) 60 (37%) G 37 (62%) 168 (63%) 205 (63%)
CT 15 (50%) 70 (53%) 85 (52%) GA+AA 19 (63%) 84 (63%) 103 (63%) A 23 (38%) 98 (37%) 121 (37%)
TT 4 (13%) 14 (11%) 18 (11%)
341 T>C 0.377 ¶ 341 T>C 0.222 § 341 T>C 0.372 §
TT 13 (43%) 74 (56%) 87 (53%) GG 13 (43%) 74 (56%) 87 (53%) G 42 (70%) 201 (76%) 243 (75%)
TC 16 (53%) 53 (40%) 69 (42%) GA+AA 17 (57%) 59 (44%) 76 (47%) A 18 (30%) 65 (24%) 83 (25%)
CC 1 (3%) 6 (5%) 7 (4%)
481 C>T 1.000 ¶ 481 C>T 0.892 § 481 C>T 0.833 §
CC 18 (60%) 78 (59%) 96 (59%) GG 18 (60%) 78 (59%) 96 (59%) G 47 (78%) 205 (77%) 252 (77%)
CT 11 (37%) 49 (37%) 60 (37%) GA+AA 12 (40%) 55 (41%) 67 (41%) A 13 (22%) 61 (23%) 74 (23%)







GG 14 (47%) 72 (54%) 86 (53%) GG 14 (47%) 72 (54%) 86 (53%) G 43 (72%) 200 (75%) 243 (75%)
GA 15 (50%) 56 (42%) 71 (44%) GA+AA 16 (53%) 61 (46%) 77 (47%) A 17 (28%) 66 (25%) 83 (25%)
AA 1 (3%) 5 (4%) 6 (4%)
803 A>G 0.542 § 803 A>G 0.291 § 803 A>G 0.310 §
AA 9 (30%) 28 (21%) 37 (23%) GG 9 (30%) 28 (21%) 37 (23%) G 33 (55%) 127 (48%) 160 (49%)
AG 15 (50%) 71 (53%) 86 (53%) GA+AA 21 (70%) 105 (79%) 126 (77%) A 27 (45%) 139 (52%) 166 (51%)
GG 6 (20%) 34 (26%) 40 (25%)
857 G>A 1.000 ¶ 857 G>A 1.000 ¶ 857 G>A 1.000 ¶
GG 30 (100%) 132 (99%) 162 (99%) GG 30 (100%) 132 (99%) 162 (99%) G 60 (100%) 265 (100%) 325 (100%)
GA 0 (0%) 1 (1%) 1 (1%) GA+AA 0 (0%) 1 (1%) 1 (1%) A 0 (0%) 1 (0%) 1 (0%)
AA 0 (0%) 0 (0%) 0 (0%)
¶    Fisher's exact test
§    χ2 test
p-value p-value p-value

















Table O-7: Allele distribution between individuals with and without ATN shown in 3 genetic models 
ATN No ATN Total p-value ATN No ATN Total p-value ATN No ATN Total p-value
n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%)
191 G>A 0.553 ¶ 191 G>A 0.553 ¶ 191 G>A 0.564 ¶
GG 28 (85%) 110 (89%) 138 (88%) GG 28 (85%) 110 (89%) 138 (88%) G 61 (92%) 234 (94%) 295 (94%)
GA 5 (15%) 14 (11%) 19 (12%) GA+AA 5 (15%) 14 (11%) 19 (12%) A 5 (8%) 14 (6%) 19 (6%)
AA 0 (0%) 0 (0%) 0 (0%)
282 C>T 0.782 ¶ 282 C>T 0.411 § 282 C>T 0.423 §
CC 14 (42%) 43 (35%) 57 (36%) CC 14 (42%) 43 (35%) 57 (36%) C 44 (67%) 152 (61%) 196 (62%)
CT 16 (48%) 66 (53%) 82 (52%) CT+TT 19 (58%) 81 (65%) 100 (64%) T 22 (33%) 96 (39%) 118 (38%)
TT 3 (9%) 15 (12%) 18 (11%)
341 T>C 0.202 ¶ 341 T>C 0.129 § 341 T>C 0.279 §
TT 14 (42%) 71 (57%) 85 (54%) TT 14 (42%) 71 (57%) 85 (54%) T 46 (70%) 189 (76%) 235 (75%)
TC 18 (55%) 47 (38%) 65 (41%) TC+CC 19 (58%) 53 (43%) 72 (46%) C 20 (30%) 59 (24%) 79 (25%)
CC 1 (3%) 6 (5%) 7 (4%)
481 C>T 0.183 ¶ 481 C>T 0.121 § 481 C>T 0.261 §
CC 15 (45%) 75 (60%) 90 (57%) CC 15 (45%) 75 (60%) 90 (57%) C 47 (71%) 193 (78%) 240 (76%)
CT 17 (52%) 43 (35%) 60 (38%) CT+TT 18 (55%) 49 (40%) 67 (43%) T 19 (29%) 55 (22%) 74 (24%)
TT 1 (3%) 6 (5%) 7 (4%)
590 G>A 0.612 ¶ 590 G>A 0.893 § 590 G>A 0.608 §
GG 18 (55%) 66 (53%) 84 (54%) GG 18 (55%) 66 (53%) 84 (54%) G 51 (77%) 184 (74%) 235 (75%)
GA 15 (45%) 52 (42%) 67 (43%) GA+AA 15 (45%) 58 (47%) 73 (47%) A 15 (23%) 64 (26%) 79 (25%)
AA 0 (0%) 6 (5%) 6 (4%)
803 A>G 0.439 § 803 A>G 0.200 § 803 A>G 0.294 §
AA 5 (15%) 32 (26%) 37 (24%) AA 5 (15%) 32 (26%) 37 (24%) A 29 (44%) 127 (51%) 156 (50%)
AG 19 (58%) 63 (51%) 82 (52%) AG+GG 28 (85%) 92 (74%) 120 (76%) G 37 (56%) 121 (49%) 158 (50%)
GG 9 (27%) 29 (23%) 38 (24%)
857 G>A 1.000 ¶ 857 G>A 1.000 ¶ 857 G>A 1.000 ¶
GG 33 (100%) 123 (99%) 156 (99%) GG 33 (100%) 123 (99%) 156 (99%) G 66 (100%) 247 (100%) 313 (100%)
GA 0 (0%) 1 (1%) 1 (1%) GA+AA 0 (0%) 1 (1%) 1 (1%) A 0 (0%) 1 (0%) 1 (0%)
AA 0 (0%) 0 (0%) 0 (0%)
¶    Fisher's exact test
§    χ2 test


















Appendix P NAT2 acetylation comparisons after correcting for the effect of 

















Table P-1: DSP odds ratios for allelic groups after correcting for previous TB therapy – DSP vs No DSP 
 
191 G>A 191 G>A
GG * 1.00 1.00 GG * 1.00 1.00
GA 0.28 0.06 - 1.33 0.38 0.10 - 1.45 0.109 GA+AA 0.28 0.06 - 1.33 0.38 0.10 - 1.45 0.109
AA N/A N/A
282 C>T 282 C>T
CC * 1.00 1.00 CC * 1.00 1.00
CT 1.24 0.56 - 2.76 1.13 0.63 - 2.00 0.600 CT+TT 1.16 0.54 - 2.50 1.09 0.63 - 1.91 0.710
TT 0.86 0.24 - 3.12 0.95 0.37 - 2.46 0.816
341 T>C 341 T>C
TT * 1.00 1.00 TT * 1.00 1.00
TC 2.33 1.08 - 5.03 1.72 1.00 - 2.96 0.032 TC+CC 2.07 0.98 - 4.40 1.61 0.93 - 2.78 0.058
CC 0.59 0.06 - 5.48 0.68 0.11 - 4.33 0.645
481 C>T 481 C>T
CC * 1.00 1.00 CC * 1.00 1.00
CT 1.28 0.60 - 2.74 1.19 0.69 - 2.04 0.528 CT+TT 1.16 0.55 - 2.44 1.11 0.65 - 1.89 0.699
TT 0.44 0.05 - 4.03 0.55 0.09 - 3.44 0.471
590 G>A 590 G>A
GG * 1.00 1.00 GG * 1.00 1.00
GA 1.44 0.67 - 3.06 1.33 0.78 - 2.28 0.349 GA+AA 1.35 0.64 - 2.83 1.28 0.75 - 2.17 0.429
AA 0.62 0.07 - 5.89 0.74 0.12 - 4.48 0.680
803 A>G 803 A>G
AA * 1.00 1.00 AA * 1.00 1.00
AG 1.05 0.42 - 2.65 1.03 0.54 - 1.96 0.913 AG+GG 0.98 0.41 - 2.32 0.98 0.53 - 1.80 0.957
GG 0.85 0.29 - 2.46 0.90 0.42 - 1.92 0.762
857 G>A 857 G>A
GG * 1.00 1.00 GG * 1.00 1.00
GA N/A N/A GA+AA N/A N/A
AA N/A N/A
*    Reference category
SNP SNP
































Table P-2: Symptomatic DSP odds ratios for allelic groups after correcting for previous TB therapy – SDSP vs No DSP 
 
191 G>A 191 G>A
GG * 1.00 1.00 GG * 1.00 1.00
GA 0.41 0.09 - 1.94 0.50 0.13 - 1.91 0.261 GA+AA 0.41 0.09 - 1.94 0.50 0.13 - 1.91 0.261
AA N/A N/A
282 C>T 282 C>T
CC * 1.00 1.00 CC * 1.00 1.00
CT 1.10 0.45 - 2.65 1.08 0.54 - 2.17 0.839 CT+TT 1.11 0.48 - 2.58 1.11 0.58 - 2.15 0.805
TT 1.18 0.31 - 4.40 1.23 0.46 - 3.30 0.809
341 T>C 341 T>C
TT * 1.00 1.00 TT * 1.00 1.00
TC 1.90 0.82 - 4.40 1.49 0.78 - 2.83 0.133 TC+CC 1.75 0.77 - 3.98 1.42 0.75 - 2.69 0.180
CC 0.76 0.08 - 7.16 0.81 0.13 - 5.21 0.814
481 C>T 481 C>T
CC * 1.00 1.00 CC * 1.00 1.00
CT 1.01 0.43 - 2.36 0.98 0.51 - 1.89 0.986 CT+TT 0.95 0.42 - 2.17 0.94 0.49 - 1.79 0.903
TT 0.57 0.06 - 5.25 0.66 0.10 - 4.12 0.622
590 G>A 590 G>A
GG * 1.00 1.00 GG * 1.00 1.00
GA 1.55 0.67 - 3.57 1.47 0.77 - 2.79 0.303 GA+AA 1.49 0.66 - 3.36 1.42 0.76 - 2.68 0.342
AA 0.92 0.09 - 8.83 1.00 0.16 - 6.12 0.940
803 A>G 803 A>G
AA * 1.00 1.00 AA * 1.00 1.00
AG 0.85 0.32 - 2.26 0.88 0.42 - 1.81 0.743 AG+GG 0.75 0.30 - 1.87 0.79 0.40 - 1.55 0.538
GG 0.59 0.18 - 1.90 0.64 0.26 - 1.59 0.374
857 G>A 857 G>A
GG * 1.00 1.00 GG * 1.00 1.00
GA N/A N/A GA+AA N/A N/A
AA N/A N/A

































Table P-3: Incident symptoms odds ratios for allelic groups after correcting for previous TB therapy – Incident symptoms vs No symptoms 
 
191 G>A 191 G>A
GG * 1.00 1.00 GG * 1.00 1.00
GA 1.72 0.55 - 5.40 1.49 0.66 - 3.37 0.355 GA+AA 1.72 0.55 - 5.40 1.49 0.66 - 3.37 0.355
AA N/A N/A
282 C>T 282 C>T
CC * 1.00 1.00 CC * 1.00 1.00
CT 0.60 0.24 - 1.46 0.67 0.34 - 1.35 0.258 CT+TT 0.63 0.27 - 1.46 0.70 0.36 - 1.33 0.278
TT 0.77 0.18 - 3.21 0.79 0.26 - 2.40 0.717
341 T>C 341 T>C
TT * 1.00 1.00 TT * 1.00 1.00
TC 1.96 0.83 - 4.65 1.70 0.87 - 3.32 0.126 TC+CC 1.87 0.80 - 4.36 1.65 0.85 - 3.20 0.150
CC 1.07 0.11 - 10.14 1.09 0.17 - 7.06 0.951
481 C>T 481 C>T
CC * 1.00 1.00 CC * 1.00 1.00
CT 2.24 0.94 - 5.32 1.88 0.96 - 3.66 0.069 CT+TT 2.11 0.90 - 4.94 1.81 0.93 - 3.51 0.086
TT 1.13 0.12 - 10.66 1.14 0.18 - 7.36 0.916
590 G>A 590 G>A
GG * 1.00 1.00 GG * 1.00 1.00
GA 1.17 0.50 - 2.74 1.13 0.58 - 2.18 0.720 GA+AA 1.04 0.45 - 2.43 1.03 0.53 - 2.00 0.923
AA N/A N/A
803 A>G 803 A>G
AA * 1.00 1.00 AA * 1.00 1.00
AG 1.36 0.44 - 4.19 1.27 0.51 - 3.17 0.595 AG+GG 1.32 0.45 - 3.88 1.25 0.52 - 3.01 0.610
GG 1.26 0.35 - 4.50 1.21 0.43 - 3.41 0.726
857 G>A 857 G>A
GG * 1.00 1.00 GG * 1.00 1.00
GA N/A N/A GA+AA N/A N/A
AA N/A N/A

































Table P-4: ATN odds ratios for Allelic odds ratios for allelic groups after correcting for previous TB therapy – ATN vs No ATN 
 
191 G>A 191 G>A
GG * 1.00 1.00 GG * 1.00 1.00
GA 1.48 0.49 - 4.49 1.34 0.59 - 3.02 0.493 GA+AA 1.48 0.49 - 4.49 1.34 0.59 - 3.02 0.493
AA N/A N/A
282 C>T 282 C>T
CC * 1.00 1.00 CC * 1.00 1.00
CT 0.73 0.32 - 1.65 0.78 0.42 - 1.47 0.449 CT+TT 0.71 0.32 - 1.57 0.77 0.42 - 1.40 0.400
TT 0.64 0.16 - 2.57 0.69 0.22 - 2.12 0.530
341 T>C 341 T>C
TT * 1.00 1.00 TT * 1.00 1.00
TC 1.90 0.86 - 4.21 1.67 0.90 - 3.09 0.112 TC+CC 1.80 0.82 - 3.92 1.61 0.87 - 2.96 0.141
CC 0.91 0.10 - 8.24 0.96 0.15 - 6.26 0.932
481 C>T 481 C>T
CC * 1.00 1.00 CC * 1.00 1.00
CT 1.98 0.90 - 4.39 1.72 0.94 - 3.17 0.090 CT+TT 1.86 0.85 - 4.05 1.66 0.90 - 3.03 0.118
TT 0.91 0.10 - 8.23 0.96 0.15 - 6.26 0.934
590 G>A 590 G>A
GG * 1.00 1.00 GG * 1.00 1.00
GA 1.02 0.47 - 2.22 1.02 0.56 - 1.87 0.968 GA+AA 0.91 0.42 - 1.99 0.94 0.51 - 1.73 0.821
AA N/A N/A
803 A>G 803 A>G
AA * 1.00 1.00 AA * 1.00 1.00
AG 1.75 0.59 - 5.20 1.57 0.63 - 3.94 0.314 AG+GG 1.80 0.63 - 5.13 1.61 0.67 - 3.91 0.269
GG 1.92 0.57 - 6.41 1.70 0.63 - 4.58 0.292
857 G>A 857 G>A
GG * 1.00 1.00 GG * 1.00 1.00
GA N/A N/A GA+AA N/A N/A
AA N/A N/A


































Table P-5: DSP odds ratios for NAT2 acetylation after correcting for previous TB therapy – DSP vs No DSP 
 
 





Rapid * 1.00 1.00
Slow 0.97 0.37 - 2.56 0.99 0.50 - 1.97 0.947
Acetylation Classification 2
Rapid * 1.00 1.00
Intermediate 1.05 0.39 - 2.80 1.05 0.52 - 2.09 0.928
Slow 0.46 0.08 - 2.69 0.58 0.14 - 2.37 0.389
Acetylation Classification 3
Rapid * 1.00 1.00
Intermediate 0.83 0.30 - 2.34 0.89 0.42 - 1.87 0.728
Slow/Intermediate 1.70 0.54 - 5.35 1.39 0.65 - 2.95 0.361
Slow 0.46 0.08 - 2.69 0.58 0.14 - 2.37 0.389










Rapid * 1.00 1.00
Slow 1.11 0.37 - 3.29 1.04 0.45 - 2.43 0.856
Acetylation Classification 2
Rapid * 1.00 1.00
Intermediate 1.16 0.39 - 3.50 1.08 0.46 - 2.53 0.789
Slow 0.72 0.12 - 4.46 0.78 0.18 - 3.38 0.722
Acetylation Classification 3
Rapid * 1.00 1.00
Intermediate 0.96 0.30 - 3.04 0.93 0.38 - 2.30 0.940
Slow/Intermediate 1.75 0.49 - 6.22 1.43 0.56 - 3.66 0.387
Slow 0.72 0.12 - 4.46 0.78 0.18 - 3.39 0.722
























Table P-7: Incident symptoms odds ratios for NAT2 acetylation after correcting for previous TB therapy –Incident 
symptoms vs No symptoms 
 
 
Table P-8: ATN odds ratios for NAT2 acetylation after correcting for previous TB therapy ATN vs No ATN 
  
Acetylation Classification 1
Rapid * 1.00 1.00
Slow 6.72 0.86 - 52.40 5.28 0.76 - 36.86 0.069
Acetylation Classification 2
Rapid * 1.00 1.00
Intermediate 7.34 0.94 - 57.39 5.65 0.81 - 39.47 0.058
Slow 2.13 0.12 - 37.83 2.03 0.14 - 29.47 0.605
Acetylation Classification 3
Rapid * 1.00 1.00
Intermediate 7.76 0.98 - 61.70 5.87 0.83 - 41.37 0.053
Slow/Intermediate 6.20 0.68 - 56.29 5.03 0.66 - 38.65 0.105
Slow 2.13 0.12 - 37.82 2.03 0.14 - 29.46 0.605









Rapid * 1.00 1.00
Slow 2.30 0.64 - 8.22 2.03 0.67 - 6.16 0.199
Acetylation Classification 2
Rapid * 1.00 1.00
Intermediate 2.52 0.70 - 9.04 2.17 0.71 - 6.60 0.156
Slow 0.68 0.06 - 7.30 0.72 0.08 - 6.28 0.751
Acetylation Classification 3
Rapid * 1.00 1.00
Intermediate 2.55 0.69 - 9.38 2.18 0.70 - 6.73 0.159
Slow/Intermediate 2.45 0.58 - 10.41 2.16 0.64 - 7.33 0.224
Slow 0.68 0.06 - 7.30 0.72 0.08 - 6.28 0.751

























Appendix Q Vitamin B6 comparisons 
 
Table Q-1: Baseline PLP concentrations between individuals with SDSP and those without DSP, and the influence of 




Table Q-2: Baseline PLP concentrations between individuals with and without incident symptoms, and the influence of 
NAT2 acetylation phenotype 
 
 
SDSP (N) No DSP (N)
Classification 1
Rapid 27.3 (5) 23.4 (22) 0.516 β
Slow 20.1 (20) 24.4 (105) 0.607 β
Classification 2
Rapid 27.3 (5) 23.4 (22) 0.516 β
Intermediate 19.5 (18) 24.1 (94) 0.842 β
Slow 44.5 (2) 26.7 (11) 0.333 β
β    Student's t -test
Acetylation type
Median PLP concentration (nmol/L)
p-value
Incident symptoms (N) No symptoms (N)
Classification 1
Rapid 13.4 (2) 24.0 (20) 0.294 β
Slow 22.6 (29) 27.1 (76) 0.393 β
Classification 2
Rapid 13.4 (2) 24.0 (20) 0.294 β
Intermediate 21.4 (28) 27.4 (66) 0.267 β
Slow 32.3 (1) 23.6 (10) N/A
β    Student's t -test
Acetylation type


















Table Q-3: Distribution of grouped variables by baseline PLP quartiles 
 
 
Q1 Q2 Q3 Q4
(0 - 16.5) (16.5 - 23.8) (23.8 - 38.4) (38.4+)
(n=  40) (n=  40) (n=  40) (n=  39)
Female sex 29 (73) 31 (78) 29 (73) 21 (54) 0.111 §
Age > 40 years 9 (23) 10 (25) 10 (25) 10 (26) 1.000 ¶
WHO clinical stage < 2 21 (54) 25 (64) 32 (80) 22 (58) 0.078 §
IHDS score < 10 4 (14) 6 (22) 13 (38) 6 (23) 0.184 ¶
Previous / Current TB 17 (43) 13 (33) 12 (30) 17 (44) 0.488 §
Current TB 6 (15) 5 (13) 5 (13) 8 (21) 0.749 ¶
Previous TB 11 (32) 8 (23) 7 (20) 9 (29) 0.638 ¶
Vit Bco supplementation 39 (98) 39 (98) 39 (98) 38 (97) 1.000 ¶
Alcohol last year 10 (26) 14 (36) 12 (30) 8 (21) 0.492 §
Body Mass Index < 20 kg/m2 10 (26) 6 (15) 4 (10) 14 (36) 0.027 ¶
Body Mass Index > 25 kg/m2 10 (26) 14 (36) 20 (50) 13 (33) 0.170 §
CD4 T-cell count < 200 cells/mm3 31 (82) 29 (73) 31 (79) 31 (79) 0.796 ¶
Fasting glucose > 5.6 mmol/L 2 (5) 1 (3) 5 (13) 0 (0) 0.054 ¶
Slow acetylation-phenotype 30 (77) 33 (87) 30 (81) 32 (84) 0.711 ¶
¶    Fisher's exact test


























Q1 Q2 Q3 Q4
(0 - 16.5) (16.5 - 23.8) (23.8 - 38.4) ( >38.4)
(n=  40) (n=  40) (n=  40) (n=  39)
Clinical
Age years 33 ± 9 34 ± 10 34 ± 8 34 ± 8 0.805 ε
Weight kg 60.4 ± 9.9 63.1 ± 12.0 67.2 ± 13.6 64.1 ± 16.1 0.196 ε
Height metre 1.62 ± 0.08 1.61 ± 0.08 1.61 ± 0.08 1.63 ± 0.08 0.362 ε
Body Mass Index kg/m2 23.0 ± 4.0 24.5 ± 5.1 26.0 ± 5.2 24.1 ± 5.9 0.062
ε
Waist : Hip ratio 0.85 ± 0.06 0.85 ± 0.07 0.86 ± 0.07 0.88 ± 0.06 0.133 ε
Systolic BP mmHg 112 ± 17 111 ± 12 117 ± 16 113 ± 16 0.520 ε
Diastolic BP mmHg 74 ± 11 72 ± 10 76 ± 12 70 ± 11 0.030 ε
Haematological
CD4 T-cell count cells/mm3 159 ± 80 170 ± 71 151 ± 60 157 ± 50 0.814
ε
White cell count x109/L 6.0 ± 2.8 5.6 ± 2.5 5.1 ± 1.6 6.1 ± 2.8 0.484
ε
C-reactive protein mg/L 16.2 ± 24.0 8.6 ± 14.5 3.8 ± 10.3 9.8 ± 27.2 0.001 ε
Haemoglobin g/dL 11.0 ± 1.7 11.4 ± 2.3 11.8 ± 2.3 12.1 ± 1.7 0.060 ε
MCV fL 91.9 ± 6.6 90.5 ± 8.3 93.5 ± 6.6 91.0 ± 5.7 0.220 ε
Biochemical
Albumin g/L 35 ± 6 40 ± 5 41 ± 4 39 ± 4 <0.001 ε
ALT IU/L 22 ± 12 19 ± 13 24 ± 11 29 ± 16 0.001 ε
Creatinine µmol/L 66 ± 18 67 ± 20 65 ± 14 68 ± 17 0.981 ε
Metabolic
Fasting glucose mmol/L 4.7 ± 0.6 4.6 ± 0.4 4.8 ± 0.6 4.7 ± 0.4 0.830 ε
Fasting insulin µU/mL 5.2 ± 3.6 5.5 ± 3.7 6.8 ± 4.7 6.1 ± 5.5 0.512 ε
Total cholesterol mmol/L 3.5 ± 0.8 3.9 ± 0.8 4.0 ± 0.8 3.7 ± 0.7 0.115 ε
Triglycerides mmol/L 1.0 ± 0.4 0.8 ± 0.3 1.1 ± 0.5 0.9 ± 0.4 0.005 ε
HDL mmol/L 0.87 ± 0.35 1.01 ± 0.30 1.01 ± 0.35 0.99 ± 0.36 0.179 ε
LDL mmol/L 2.2 ± 0.6 2.5 ± 0.7 2.4 ± 0.6 2.4 ± 0.7 0.343 ε
Lactate mmol/L 2.4 ± 0.9 2.4 ± 1.3 2.6 ± 1.2 2.7 ± 1.3 0.752 ε
Pyridoxine
4-PA nmol/L 13.0 ± 5.2 16.4 ± 5.2 19.0 ± 9.8 37.1 ± 32.6 <0.001 ε





















Table Q-5: Distribution of 24-week continuous variables by baseline PLP quartiles 
 
 
Q1 Q2 Q3 Q4
(0 - 16.5) (16.5 - 23.8) (23.8 - 38.4) ( >38.4)
(n=  40) (n=  40) (n=  40) (n=  39)
Clinical
Weight kg 64.4 ± 10.9 65.4 ± 12.1 67.4 ± 13.6 65.1 ± 14.5 0.802 ε
Height metre 1.62 ± 0.09 1.61 ± 0.08 1.62 ± 0.09 1.63 ± 0.08 0.377 ε
Body Mass Index kg/m2 24.7 ± 4.2 25.4 ± 5.1 25.8 ± 5.0 24.6 ± 5.8 0.567
ε
Waist : Hip ratio 0.85 ± 0.05 0.85 ± 0.07 0.84 ± 0.06 0.88 ± 0.07 0.143 ε
Systolic BP mmHg 116 ± 16 117 ± 15 117 ± 15 116 ± 14 0.985 ε
Diastolic BP mmHg 76 ± 12 75 ± 11 74 ± 10 73 ± 9 0.782 ε
Haematological
C-reactive protein * mg/L 15.6 ± 29.0 17.4 ± 43.6 14.0 ± 29.9 13.6 ± 30.5 0.461 ε
Metabolic
Fasting glucose mmol/L 4.8 ± 0.4 4.9 ± 0.3 5.0 ± 0.5 5.0 ± 0.5 0.390 ε
Fasting insulin µU/mL 6.4 ± 6.1 6.4 ± 5.6 6.3 ± 4.0 6.6 ± 5.3 0.866 ε
Total cholesterol mmol/L 4.2 ± 0.9 4.5 ± 0.9 4.3 ± 0.8 4.2 ± 0.9 0.547 ε
Triglycerides mmol/L 0.8 ± 0.3 0.9 ± 0.3 1.0 ± 0.5 1.1 ± 1.9 0.292 ε
HDL mmol/L 1.26 ± 0.35 1.39 ± 0.38 1.35 ± 0.47 1.35 ± 0.54 0.484 ε
LDL mmol/L 2.5 ± 0.8 2.7 ± 0.9 2.6 ± 0.7 2.3 ± 0.6 0.480 ε
Pyridoxine
4-PA * nmol/L 20.7 ± 12.2 27.5 ± 39.7 26.3 ± 18.7 25.3 ± 35.3 0.315 ε
*   12-week blood samples


























Q1 Q2 Q3 Q4
(0 - 11.9) (11.9 - 17.4) (17.4 - 23.3) ( > 23.3)
(n=  40) (n=  40) (n=  40) (n=  39)
Female sex 32 (80) 29 (73) 27 (68) 22 (56) 0.142 §
Age > 40 years 7 (18) 9 (23) 10 (25) 13 (33) 0.474 ¶
WHO clinical stage < 2 25 (66) 27 (68) 28 (70) 20 (53) 0.388 §
IHDS score < 10 6 (20) 4 (14) 9 (30) 10 (37) 0.211 ¶
Previous / Current TB 15 (38) 13 (33) 11 (28) 20 (51) 0.151 §
Current TB 4 (10) 2 (5) 6 (15) 12 (31) 0.012 ¶
Previous TB 11 (31) 11 (29) 5 (15) 8 (30) 0.369 ¶
Vit Bco supplementation 38 (95) 40 (100) 39 (98) 38 (97) 0.757 ¶
Alcohol last year 10 (26) 12 (30) 13 (33) 9 (23) 0.767 §
Body Mass Index < 20 kg/m2 7 (18) 6 (15) 8 (21) 13 (33) 0.251 ¶
Body Mass Index > 25 kg/m2 16 (42) 13 (33) 14 (36) 14 (36) 0.849 §
CD4 T-cell count < 200 cells/mm3 29 (74) 31 (78) 30 (77) 32 (84) 0.771
¶
Fasting glucose > 5.6 mmol/L 1 (3) 2 (5) 4 (11) 1 (3) 0.450 ¶
Slow acetylation-phenotype 33 (87) 30 (83) 29 (74) 33 (85) 0.542 ¶
¶    Fisher's exact test



























Q1 Q2 Q3 Q4
(0 - 11.9) (11.9 - 17.4) (17.4 - 23.3) ( > 23.3)
(n=  40) (n=  40) (n=  40) (n=  39)
Clinical
Age years 32 ± 8 34 ± 9 34 ± 10 34 ± 9 0.738 ε
Weight kg 65.2 ± 13.2 63.2 ± 13.7 63.2 ± 11.4 63.4 ± 14.8 0.810 ε
Height metre 1.62 ± 0.07 1.60 ± 0.08 1.62 ± 0.08 1.63 ± 0.09 0.257 ε
Body Mass Index kg/m2 24.9 ± 5.6 24.6 ± 5.0 24.4 ± 5.0 23.9 ± 5.4 0.790
ε
Waist : Hip ratio 0.86 ± 0.06 0.84 ± 0.08 0.85 ± 0.07 0.87 ± 0.06 0.117 ε
Systolic BP mmHg 115 ± 15 112 ± 14 114 ± 17 112 ± 17 0.755 ε
Diastolic BP mmHg 75 ± 11 74 ± 10 74 ± 10 70 ± 12 0.097 ε
Haematological
CD4 T-cell count cells/mm3 159 ± 84 161 ± 64 168 ± 63 149 ± 49 0.660
ε
White cell count x109/L 5.8 ± 3.2 5.6 ± 1.8 5.7 ± 2.2 5.8 ± 2.6 0.912
ε
C-reactive protein mg/L 11.0 ± 18.3 9.9 ± 21.7 7.7 ± 12.6 9.6 ± 27.2 0.710 ε
Haemoglobin g/dL 11.2 ± 1.6 11.8 ± 2.0 11.4 ± 2.5 11.9 ± 1.8 0.434 ε
MCV fL 91.0 ± 6.9 90.5 ± 5.9 93.3 ± 7.7 91.9 ± 6.9 0.195 ε
Biochemical
Albumin g/L 38 ± 5 38 ± 6 39 ± 5 39 ± 4 0.933 ε
ALT IU/L 19 ± 8 24 ± 14 22 ± 16 27 ± 14 0.015 ε
Creatinine µmol/L 67 ± 17 64 ± 14 69 ± 21 67 ± 15 0.616 ε
Metabolic
Fasting glucose mmol/L 4.5 ± 0.5 4.7 ± 0.5 4.8 ± 0.5 4.7 ± 0.4 0.026 ε
Fasting insulin µU/mL 5.9 ± 4.7 6.2 ± 5.3 5.7 ± 3.3 5.9 ± 4.4 0.992 ε
Total cholesterol mmol/L 3.6 ± 0.8 3.9 ± 0.8 3.8 ± 0.7 3.8 ± 0.8 0.415 ε
Triglycerides mmol/L 0.9 ± 0.5 1.0 ± 0.4 0.9 ± 0.3 1.0 ± 0.4 0.313 ε
HDL mmol/L 0.98 ± 0.36 0.89 ± 0.31 1.01 ± 0.34 1.01 ± 0.36 0.431 ε
LDL mmol/L 2.2 ± 0.6 2.6 ± 0.7 2.5 ± 0.6 2.4 ± 0.7 0.077 ε
Lactate mmol/L 2.5 ± 1.2 2.8 ± 1.3 2.5 ± 1.2 2.3 ± 1.0 0.608 ε
Pyridoxine
PLP nmol/L 19.8 ± 14.4 23.6 ± 10.0 26.0 ± 12.9 52.8 ± 25.3 <0.001 ε






















Table Q-8: Distribution of 24-week continuous variables by baseline 4-PA quartiles 
 
 
Q1 Q2 Q3 Q4
(0 - 11.9) (11.9 - 17.4) (17.4 - 23.3) ( > 23.3)
(n=  40) (n=  40) (n=  40) (n=  39)
Clinical
Weight kg 67.2 ± 12.6 63.3 ± 11.9 66.5 ± 11.2 65.2 ± 15.1 0.338 ε
Height metre 1.63 ± 0.08 1.60 ± 0.08 1.61 ± 0.09 1.63 ± 0.08 0.151 ε
Body Mass Index kg/m2 25.5 ± 4.8 24.8 ± 5.0 25.9 ± 5.0 24.5 ± 5.4 0.519
ε
Waist : Hip ratio 0.85 ± 0.05 0.85 ± 0.08 0.86 ± 0.07 0.86 ± 0.06 0.569 ε
Systolic BP mmHg 120 ± 16 120 ± 14 114 ± 16 113 ± 13 0.212 ε
Diastolic BP mmHg 76 ± 11 77 ± 12 73 ± 10 72 ± 9 0.132 ε
Haematological
C-reactive protein * mg/L 7.3 ± 11.0 17.2 ± 39.5 22.9 ± 46.6 12.8 ± 23.7 0.803 ε
Metabolic
Fasting glucose mmol/L 4.8 ± 0.3 4.9 ± 0.5 5.0 ± 0.5 5.0 ± 0.5 0.452 ε
Fasting insulin µU/mL 6.3 ± 5.3 6.0 ± 5.6 6.7 ± 5.9 6.6 ± 4.4 0.650 ε
Total cholesterol mmol/L 4.2 ± 0.9 4.5 ± 0.9 4.4 ± 0.9 4.1 ± 0.8 0.345 ε
Triglycerides mmol/L 1.1 ± 1.9 0.9 ± 0.5 0.9 ± 0.3 0.9 ± 0.4 0.954 ε
HDL mmol/L 1.39 ± 0.41 1.41 ± 0.46 1.28 ± 0.40 1.27 ± 0.47 0.439 ε
LDL mmol/L 2.3 ± 0.9 2.7 ± 0.8 2.7 ± 0.7 2.4 ± 0.6 0.056 ε
Pyridoxine
PLP * nmol/L 25.1 ± 19.4 26.9 ± 18.1 24.6 ± 15.8 34.1 ± 38.0 0.959 ε
*   12-week blood samples

























Below 23.8 Above 23.8
(n = 80) (n = 79)
Female sex 60 (75) 50 (63) 0.110 §
Age > 40 years 19 (24) 20 (25) 0.854 §
WHO clinical stage < 2 46 (59) 54 (69) 0.182 §
IHDS score < 10 10 (18) 19 (32) 0.096 §
Previous / Current TB 30 (38) 29 (37) 0.918 §
Current TB 11 (14) 13 (16) 0.634 §
Previous TB 19 (28) 16 (24) 0.662 §
Vit Bco supplementation 78 (98) 77 (97) 1.000 ¶
Alcohol last year 24 (31) 20 (25) 0.417 §
Body Mass Index < 20 kg/m2 16 (21) 18 (23) 0.762 §
Body Mass Index > 25 kg/m2 24 (31) 33 (42) 0.169 §
CD4 T-cell count < 200 cells/mm3 60 (77) 62 (79) 0.698
§
Fasting glucose > 5.6 mmol/L 3 (4) 5 (7) 0.459 ¶
Slow acetylation-phenotype 63 (82) 62 (83) 0.891 §
¶    Fisher's exact test


























Below 23.8 Above 23.8
(n = 80) (n = 79)
Clinical
Age years 33 ± 9 34 ± 8 0.438 ε
Weight kg 61.8 ± 11.0 65.7 ± 14.9 0.178 ε
Height metre 1.62 ± 0.08 1.62 ± 0.08 0.616 ε
Body Mass Index kg/m2 23.8 ± 4.7 25.1 ± 5.6 0.188
ε
Waist : Hip ratio 0.85 ± 0.07 0.87 ± 0.07 0.075 ε
Systolic BP mmHg 111 ± 15 115 ± 16 0.231 ε
Diastolic BP mmHg 73 ± 10 73 ± 12 0.925 ε
Haematological
CD4 T-cell count cells/mm3 165 ± 75 154 ± 55 0.596
ε
White cell count x109/L 5.8 ± 2.7 5.6 ± 2.3 0.759
ε
C-reactive protein mg/L 12.3 ± 20.0 6.7 ± 20.4 0.001 ε
Haemoglobin g/dL 11.2 ± 2.0 11.9 ± 2.0 0.014 ε
MCV fL 91.2 ± 7.5 92.2 ± 6.2 0.315 ε
Biochemical
Albumin g/L 37 ± 6 40 ± 4 0.003 ε
ALT IU/L 20 ± 13 26 ± 14 0.001 ε
Creatinine µmol/L 67 ± 19 66 ± 15 0.819 ε
Metabolic
Fasting glucose mmol/L 4.6 ± 0.5 4.7 ± 0.5 0.622 ε
Fasting insulin µU/mL 5.4 ± 3.6 6.4 ± 5.1 0.323 ε
Total cholesterol mmol/L 3.7 ± 0.8 3.8 ± 0.7 0.270 ε
Triglycerides mmol/L 0.9 ± 0.4 1.0 ± 0.4 0.051 ε
HDL mmol/L 0.94 ± 0.33 1.00 ± 0.35 0.256 ε
LDL mmol/L 2.4 ± 0.7 2.4 ± 0.7 0.800 ε
Lactate mmol/L 2.4 ± 1.1 2.6 ± 1.3 0.426 ε
Pyridoxine
4-PA nmol/L 14.7 ± 5.4 27.9 ± 25.4 <0.001 ε




















Table Q-11: Distribution of 24-week continuous variables by baseline PLP medians 
 
Below 23.8 Above 23.8
(n = 80) (n = 79)
Clinical
Weight kg 64.9 ± 11.5 66.3 ± 14.0 0.900 ε
Height metre 1.61 ± 0.08 1.63 ± 0.08 0.259 ε
Body Mass Index kg/m2 25.1 ± 4.7 25.2 ± 5.4 0.889
ε
Waist : Hip ratio 0.85 ± 0.06 0.86 ± 0.07 0.442 ε
Systolic BP mmHg 117 ± 16 117 ± 14 0.937 ε
Diastolic BP mmHg 75 ± 11 73 ± 9 0.345 ε
Haematological
C-reactive protein * mg/L 16.5 ± 37.0 13.8 ± 29.9 0.440 ε
Metabolic
Fasting glucose mmol/L 4.9 ± 0.4 5.0 ± 0.5 0.134 ε
Fasting insulin µU/mL 6.4 ± 5.8 6.5 ± 4.7 0.495 ε
Total cholesterol mmol/L 4.3 ± 0.9 4.3 ± 0.8 0.921 ε
Triglycerides mmol/L 0.9 ± 0.3 1.0 ± 1.4 0.992 ε
HDL mmol/L 1.32 ± 0.37 1.35 ± 0.50 0.821 ε
LDL mmol/L 2.6 ± 0.8 2.4 ± 0.6 0.394 ε
Pyridoxine
4-PA * nmol/L 24.1 ± 29.4 25.8 ± 28.0 0.670 ε
*   12-week blood samples




















Table Q-12: Distribution of grouped variables by baseline 4-PA medians 
 
 
Below 17.4 Above 17.4
(n = 80) (n = 79)
Female sex 61 (76) 49 (62) 0.052 §
Age > 40 years 16 (20) 23 (29) 0.197 §
WHO clinical stage < 2 52 (67) 48 (62) 0.504 §
IHDS score < 10 10 (17) 19 (33) 0.047 §
Previous / Current TB 28 (35) 31 (39) 0.580 §
Current TB 6 (8) 18 (23) 0.007 §
Previous TB 22 (30) 13 (21) 0.267 §
Vit Bco supplementation 78 (98) 77 (97) 1.000 ¶
Alcohol last year 22 (28) 22 (28) 1.000 §
Body Mass Index < 20 kg/m2 13 (17) 21 (27) 0.121 §
Body Mass Index > 25 kg/m2 29 (37) 28 (36) 0.868 §
CD4 T-cell count < 200 cells/mm3 60 (76) 62 (81) 0.489
§
Fasting glucose > 5.6 mmol/L 3 (4) 5 (6) 0.719 ¶
Slow acetylation-phenotype 63 (85) 62 (79) 0.362 §
¶    Fisher's exact test


























Below 17.4 Above 17.4
(n = 80) (n = 79)
Clinical
Age years 33 ± 8 34 ± 9 0.387 ε
Weight kg 64.2 ± 13.4 63.3 ± 13.1 0.751 ε
Height metre 1.61 ± 0.07 1.62 ± 0.08 0.409 ε
Body Mass Index kg/m2 24.7 ± 5.2 24.1 ± 5.1 0.404
ε
Waist : Hip ratio 0.85 ± 0.07 0.86 ± 0.06 0.455 ε
Systolic BP mmHg 113 ± 14 113 ± 17 0.632 ε
Diastolic BP mmHg 74 ± 11 72 ± 11 0.072 ε
Haematological
CD4 T-cell count cells/mm3 160 ± 74 158 ± 57 0.855
ε
White cell count x109/L 5.7 ± 2.6 5.7 ± 2.4 0.939
ε
C-reactive protein mg/L 10.5 ± 19.9 8.6 ± 20.8 0.787 ε
Haemoglobin g/dL 11.5 ± 1.9 11.6 ± 2.2 0.498 ε
MCV fL 90.8 ± 6.4 92.6 ± 7.3 0.083 ε
Biochemical
Albumin g/L 38 ± 6 39 ± 5 0.699 ε
ALT IU/L 22 ± 12 25 ± 15 0.310 ε
Creatinine µmol/L 65 ± 16 68 ± 18 0.309 ε
Metabolic
Fasting glucose mmol/L 4.6 ± 0.5 4.8 ± 0.5 0.019 ε
Fasting insulin µU/mL 6.1 ± 5.0 5.8 ± 3.9 0.868 ε
Total cholesterol mmol/L 3.8 ± 0.8 3.8 ± 0.7 0.659 ε
Triglycerides mmol/L 1.0 ± 0.4 0.9 ± 0.4 0.786 ε
HDL mmol/L 0.94 ± 0.33 1.01 ± 0.35 0.180 ε
LDL mmol/L 2.4 ± 0.7 2.4 ± 0.7 0.502 ε
Lactate mmol/L 2.6 ± 1.3 2.4 ± 1.1 0.295 ε
Pyridoxine
PLP nmol/L 21.7 ± 12.5 39.2 ± 24.1 <0.001 ε
























Below 17.4 Above 17.4
(n = 80) (n = 79)
Clinical
Weight kg 65.3 ± 12.3 65.9 ± 13.3 0.805 ε
Height metre 1.62 ± 0.08 1.62 ± 0.09 0.736 ε
Body Mass Index kg/m2 25.1 ± 4.9 25.2 ± 5.2 0.968
ε
Waist : Hip ratio 0.85 ± 0.06 0.86 ± 0.06 0.162 ε
Systolic BP mmHg 120 ± 15 114 ± 14 0.040 ε
Diastolic BP mmHg 77 ± 11 72 ± 9 0.021 ε
Haematological
C-reactive protein * mg/L 12.3 ± 29.4 17.9 ± 37.2 0.407 ε
Metabolic
Fasting glucose mmol/L 4.9 ± 0.4 5.0 ± 0.5 0.131 ε
Fasting insulin µU/mL 6.2 ± 5.4 6.7 ± 5.2 0.273 ε
Total cholesterol mmol/L 4.4 ± 0.9 4.2 ± 0.8 0.480 ε
Triglycerides mmol/L 1.0 ± 1.4 0.9 ± 0.3 0.633 ε
HDL mmol/L 1.40 ± 0.44 1.28 ± 0.44 0.101 ε
LDL mmol/L 2.5 ± 0.8 2.5 ± 0.7 0.823 ε
Pyridoxine
PLP * nmol/L 26.0 ± 18.7 29.3 ± 29.2 0.905 ε
*   12-week blood samples
























Odds Ratio in 
univariate analysis




Female sex 0.61 0.31 - 1.20 0.150
Age > 40 years 0.90 0.44 - 1.87 0.786
Previous/Current TB 0.94 0.49 - 1.80 0.859
Current TB 0.70 0.29 - 1.67 0.418
Previous TB 1.14 0.52 - 2.47 0.748
Body Mass Index > 25 kg/m2 0.83 0.54 - 1.26 0.382
Waist : Hip ratio > 0.9 0.45 0.21 - 0.97 0.041
Diastolic BP > 80 mmHg 0.74 0.21 - 2.52 0.625
Haematological
CD4 T-cell count > 100 cells/mm3 0.97 0.42 - 2.26 0.943
C-reactive protein > 5 mg/L 2.22 1.08 - 4.55 0.029
Haemoglobin < 11.7 g/dL 0.48 0.25 - 0.90 0.023
Biochemical
Albumin > 38 g/L 2.83 1.43 - 5.61 0.003
ALT > 19 IU/L 0.43 0.23 - 0.82 0.011
Metabolic
Triglycerides > 0.9 mmol/L 0.40 0.21 - 0.76 0.005
Total cholesterol > 3.7 mmol/L 0.56 0.30 - 1.07 0.081
HDL < 1.0 mmol/L 1.85 0.58 - 5.92 0.303
Pyridoxine

















Table Q-16: Baseline DSP status grouped by PLP medians 
 
 









(n = 80) (n = 79)
DSP (n = 35) 17 (21%) 18 (23%) 0.815 §
SDSP (n = 16) 14 (18%) 2 (3%) 0.778 §
ADSP (n = 9) 3 (4%) 6 (8%) 0.328 ¶
¶    Fisher's exact test
§    χ2 test




Q1 Q2 Q3 Q4
(0 - 16.5) (16.5 - 23.8) (23.8 - 38.4) (38.4+)
(n=  40) (n=  40) (n=  40) (n=  39)
DSP (n = 35) 9 (23%) 8 (20%) 7 (18%) 11 (28%) 0.710 ¶
SDSP (n = 26) 8 (20%) 6 (15%) 3 (8%) 9 (23%) 0.290 ¶
ADSP (n = 9) 1 (3%) 2 (5%) 4 (10%) 2 (5%) 0.587 ¶
¶    Fisher's exact test























Table Q-18: Baseline DSP status grouped by 4-PA medians 
 










(n = 80) (n = 79)
DSP (n = 35) 14 (18%) 21 (27%) 0.167 §
SDSP (n = 26) 11 (14%) 15 (19%) 0.311 §
ADSP (n = 9) 3 (4%) 6 (8%) 0.328 ¶
¶    Fisher's exact test





N (% of group size)
Q1 Q2 Q3 Q4
(0 - 11.9) (11.9 - 17.4) (17.4 - 23.3) (23.3+)
(n=  40) (n=  40) (n=  40) (n=  39)
DSP (n = 35) 7 (18%) 7 (18%) 10 (25%) 11 (28%) 0.593 ¶
SDSP (n = 26) 6 (15%) 5 (13%) 7 (18%) 8 (21%) 0.745 ¶
ADSP (n = 9) 1 (3%) 2 (5%) 3 (8%) 3 (8%) 0.752 ¶
¶    Fisher's exact test
§    χ2 test
Baseline 4-PA (nmol/L)
p-valueBaseline DSP status



















Table Q-20: Week 12 DSP status grouped by PLP medians 
 
 










(n = 78) (n = 77)
ATN (n = 33) 16 (21%) 17 (22%) 0.812 §
Incident symptoms (n = 28) 15 (19%) 13 (17%) 0.636 §
Incident SDSP (n = 20) 11 (14%) 9 (12%) 0.600 §
¶    Fisher's exact test
§    χ2 test
p-value
N (% of group size)
Week 12 DSP status
Group 
size
Q1 Q2 Q3 Q4
(0 - 16.5) (16.5 - 23.8) (23.8 - 38.4) (38.4+)
(n=  40) (n=  40) (n=  40) (n=  39)
ATN (n = 33) 8 (21%) 8 (21%) 10 (26%) 7 (18%) 0.900 ¶
Incident symptoms (n = 28) 7 (18%) 8 (21%) 9 (23%) 4 (11%) 0.695 ¶
Incident SDSP (n = 20) 4 (10%) 7 (18%) 5 (13%) 4 (11%) 0.794 ¶
¶    Fisher's exact test
§    χ2 test
N (% of group size)





















Table Q-22: Week 12 DSP status grouped by 4-PA medians 
 
 









(n = 78) (n = 77)
ATN (n = 33) 19 (24%) 14 (18%) 0.348 §
Incident symptoms (n = 28) 16 (21%) 12 (16%) 0.533 §
Incident SDSP (n = 20) 12 (15%) 8 (10%) 0.432 §
¶    Fisher's exact test
§    χ2 test




N (% of group size)
Q1 Q2 Q3 Q4
(0 - 11.9) (11.9 - 17.4) (17.4 - 23.3) (23.3+)
(n=  39) (n=  39) (n=  39) (n=  38)
ATN (n = 33) 9 (23%) 10 (26%) 7 (18%) 7 (18%) 0.833 ¶
Incident symptoms (n = 28) 7 (18%) 9 (23%) 7 (18%) 5 (13%) 0.801 ¶
Incident SDSP (n = 20) 5 (13%) 7 (18%) 6 (15%) 2 (5%) 0.375 ¶
¶    Fisher's exact test
§    χ2 test
Group 
size
N (% of group size)


















Appendix R Cytokine analyses 















Baseline 0.56 0.54 0.58 0.880 ε
Week 2 1.94 1.33 (0.82 ; 1.85) <0.001 1.28 2.30 -0.50 (-1.52 ; 0.52) 0.335
Week 4 1.83 1.46 (0.95 ; 1.98) <0.001 2.01 1.83 -0.38 (-1.41 ; 0.65) 0.467
Week 12 0.77 0.48 (-0.01 ; 0.97) 0.055 0.76 0.85 -0.65 (-1.63 ; 0.33) 0.192
Interleukin-7
Baseline 2.06 2.04 2.06 0.756 ε
Week 2 9.02 7.70 (6.00 ; 9.40) <0.001 7.45 11.58 -2.07 (-5.44 ; 1.30) 0.228
Week 4 7.56 6.29 (4.57 ; 8.01) <0.001 7.00 9.18 -2.57 (-5.98 ; 0.85) 0.141
Week 12 2.66 1.29 (-0.35 ; 2.93) 0.122 2.81 2.48 -0.88 (-4.13 ; 2.37) 0.596
Interleukin-8
Baseline 3.77 3.38 4.30 0.534 ε
Week 2 3.28 -0.48 (-1.24 ; 0.27) 0.210 2.94 3.86 -0.91 (-2.40 ; 0.58) 0.233
Week 4 3.21 -0.58 (-1.34 ; 0.18) 0.136 3.13 3.21 0.56 (-0.95 ; 2.07) 0.468
Week 12 3.52 -0.88 (-1.60 ; -0.15) 0.019 3.16 3.68 0.46 (-0.97 ; 1.90) 0.527
Interleukin-12
Baseline 0.01 0.01 0.02 0.372 ε
Week 2 13.69 13.96 (6.66 ; 21.27) <0.001 8.55 17.84 -3.06 (-17.60 ; 11.48) 0.680
Week 4 9.46 14.10 (6.70 ; 21.50) <0.001 8.42 12.53 -6.96 (-21.68 ; 7.77) 0.355
Week 12 1.11 6.63 (-0.41 ; 13.68) 0.065 1.11 1.29 -8.04 (-22.06 ; 5.99) 0.261
Interleukin-13
Baseline 0.47 0.47 0.47 0.843 ε
Week 2 37.20 37.82 (30.56 ; 45.08) <0.001 25.39 57.21 -15.80 (-30.01 ; -1.59) 0.029
Week 4 32.10 28.79 (21.44 ; 36.14) <0.001 30.04 33.28 -5.58 (-19.97 ; 8.80) 0.447
Week 12 3.12 6.49 (-0.53 ; 13.51) 0.070 3.12 2.83 0.98 (-12.76 ; 14.72) 0.889
IFN-γ
Baseline 1.20 1.05 1.38 0.621 ε
Week 2 12.53 14.94 (10.29 ; 19.60) <0.001 8.42 12.82 1.99 (-7.30 ; 11.29) 0.674
Week 4 8.86 9.02 (4.32 ; 13.72) <0.001 9.52 8.86 1.56 (-7.84 ; 10.96) 0.745
Week 12 2.41 2.35 (-2.16 ; 6.86) 0.307 3.32 1.54 3.05 (-5.96 ; 12.07) 0.507
GM-CSF
Baseline 0.73 0.76 0.71 0.785 ε
Week 2 6.41 6.04 (4.67 ; 7.42) <0.001 4.62 8.37 -2.48 (-5.18 ; 0.22) 0.072
Week 4 3.39 4.27 (2.88 ; 5.66) <0.001 3.10 3.92 -0.74 (-3.47 ; 2.00) 0.598
Week 12 1.04 1.25 (-0.08 ; 2.59) 0.066 1.17 0.96 0.97 (-1.65 ; 3.58) 0.469
a    Time effect is the effect of cART on mean cytokine concentration for the entire cohort
b    Group effect is the difference in mean cytokine concentration between groups compared to baseline






















Figure R-1: Longitudinal cytokine concentrations categorized by incident symptom status (Part I) 
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Figure R-2: Longitudinal cytokine concentrations categorized by incident symptom status (Part II) 
I nterleukin-6 (Symptoms) Interleukin-6 (Symptom-free) 
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Figure R-3: Longitudinal cytokine concentrations categorized by incident symptom status (Part III) 
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TNF-α / IL-4 Baseline 0.554
Week 2 -30.61 (-47.33 ; -13.90) <0.001 38.51 (5.56 ; 71.46) 0.022
Week 4 -22.70 (-39.60 ; -5.80) 0.008 8.53 (-24.80 ; 41.85) 0.616
Week 12 -23.50 (-39.70 ; -7.30) 0.004 14.81 (-17.12 ; 46.75) 0.363
IFN-γ / IL-4 Baseline 0.881
Week 2 30.39 (-5.53 ; 66.31) 0.097 67.59 (-3.11 ; 138.29) 0.061
Week 4 13.59 (-22.70 ; 49.88) 0.463 29.73 (-41.70 ; 101.16) 0.415
Week 12 8.71 (-26.22 ; 43.64) 0.625 15.84 (-52.92 ; 84.60) 0.652
IL-6 / IL-4 Baseline 0.515
Week 2 5.34 (-21.91 ; 32.59) 0.701 52.71 (-0.92 ; 106.34) 0.054
Week 4 1.36 (-26.22 ; 28.95) 0.923 2.72 (-51.57 ; 57.00) 0.922
Week 12 21.67 (-4.69 ; 48.03) 0.107 36.35 (-15.53 ; 88.23) 0.170
TNF-α / IL-10 Baseline 1.000
Week 2 -0.30 (-0.82 ; 0.21) 0.250 0.01 (-1.02 ; 1.03) 0.987
Week 4 -0.06 (-0.59 ; 0.46) 0.811 -0.18 (-1.22 ; 0.86) 0.734
Week 12 0.20 (-0.30 ; 0.70) 0.442 -0.73 (-1.72 ; 0.27) 0.151
IFN-γ / IL-10 Baseline 0.308
Week 2 0.22 (0.12 ; 0.33) <0.001 -0.10 (-0.30 ; 0.11) 0.351
Week 4 0.19 (0.08 ; 0.29) 0.001 0.00 (-0.21 ; 0.20) 0.970
Week 12 0.19 (0.08 ; 0.29) <0.001 0.20 (0.01 ; 0.40) 0.044
IL-6 / IL-10 Baseline 0.988
Week 2 -0.07 (-2.24 ; 2.10) 0.949 -0.28 (-4.60 ; 4.04) 0.898
Week 4 0.23 (-1.96 ; 2.43) 0.835 -0.27 (-4.63 ; 4.10) 0.905
Week 12 1.69 (-0.42 ; 3.81) 0.116 -2.83 (-7.03 ; 1.38) 0.187
IL-1 / sIL1RI Baseline 0.328
Week 2 0.05 (0.04 ; 0.06) <0.001 -0.03 (-0.06 ; -0.01) 0.004
Week 4 0.03 (0.02 ; 0.04) <0.001 -0.01 (-0.03 ; 0.01) 0.309
Week 12 0.00 (-0.01 ; 0.02) 0.446 -0.01 (-0.03 ; 0.02) 0.642
IL-1 / sIL1RII Baseline 0.976
Week 2 0.00 (0.00 ; 0.00) <0.001 0.00 (0.00 ; 0.00) 0.825
Week 4 0.00 (0.00 ; 0.00) 0.054 0.00 (0.00 ; 0.00) 0.850
Week 12 0.00 (0.00 ; 0.00) 0.942 0.00 (0.00 ; 0.00) 0.898
IL-2 / sIL2rα Baseline 0.825
Week 2 0.01 (0.00 ; 0.02) 0.084 -0.03 (-0.05 ; -0.01) 0.014
Week 4 0.01 (0.00 ; 0.02) 0.283 -0.02 (-0.04 ; 0.00) 0.121
Week 12 0.00 (-0.01 ; 0.01) 0.526 -0.01 (-0.03 ; 0.01) 0.232
IL-6 / sIL6R Baseline 0.574
Week 2 -0.03 (-0.06 ; 0.01) 0.199 -0.05 (-0.13 ; 0.02) 0.177
Week 4 -0.03 (-0.06 ; 0.01) 0.198 -0.05 (-0.13 ; 0.02) 0.184
Week 12 -0.03 (-0.06 ; 0.01) 0.177 -0.05 (-0.13 ; 0.02) 0.168
IL-1 / IL1ra Baseline 0.060
Week 2 0.31 (0.15 ; 0.46) <0.001 -0.43 (-0.73 ; -0.13) 0.006
Week 4 0.16 (0.00 ; 0.32) 0.051 0.00 (-0.30 ; 0.31) 0.990
Week 12 0.03 (-0.12 ; 0.19) 0.670 0.02 (-0.28 ; 0.32) 0.895
TNF-α / sTNFRII Baseline 0.585
Week 2 -0.01 (-0.02 ; 0.01) 0.276 -0.02 (-0.06 ; 0.01) 0.134
Week 4 -0.01 (-0.02 ; 0.01) 0.273 -0.02 (-0.05 ; 0.01) 0.169
Week 12 -0.01 (-0.03 ; 0.00) 0.168 -0.02 (-0.05 ; 0.01) 0.162
TNF-α / sTNFRI Baseline 0.952
Week 2 0.00 (-0.03 ; 0.03) 0.851 -0.05 (-0.11 ; 0.00) 0.074
Week 4 0.00 (-0.03 ; 0.02) 0.765 -0.03 (-0.09 ; 0.03) 0.276
Week 12 -0.02 (-0.05 ; 0.00) 0.108 -0.03 (-0.09 ; 0.02) 0.224
Cytokine ratio


























Week 2 -0.57 (-1.16 ; 0.01) 0.056
Week 4 0.21 (-0.39 ; 0.80) 0.499
Week 12 0.00 (-0.56 ; 0.55) 0.992
Interleukin-2
Week 2 -3.67 (-7.99 ; 0.64) 0.095
Week 4 1.86 (-2.53 ; 6.25) 0.405
Week 12 -0.23 (-4.28 ; 3.82) 0.910
Interleukin-4
Week 2 -0.67 (-7.16 ; 5.81) 0.839
Week 4 0.04 (-6.55 ; 6.64) 0.989
Week 12 2.30 (-3.84 ; 8.45) 0.462
Interleukin-6
Week 2 0.86 (-5.26 ; 6.98) 0.783
Week 4 1.97 (-4.27 ; 8.22) 0.535
Week 12 4.26 (-1.44 ; 9.96) 0.143
Interleukin-10
Week 2 8.35 (-26.72 ; 43.41) 0.641
Week 4 12.69 (-23.08 ; 48.46) 0.487
Week 12 19.21 (-13.35 ; 51.78) 0.247
TNF-α
Week 2 -0.17 (-4.46 ; 4.12) 0.939
Week 4 1.45 (-2.92 ; 5.83) 0.515
Week 12 1.62 (-2.39 ; 5.62) 0.429
Cytokine & 
Visit

























Week 2 -0.55 (-1.66 ; 0.55) 0.325
Week 4 0.70 (-0.42 ; 1.83) 0.220
Week 12 0.49 (-0.53 ; 1.52) 0.345
Interleukin-7
Week 2 -1.69 (-5.39 ; 2.01) 0.371
Week 4 0.42 (-3.36 ; 4.19) 0.828
Week 12 1.20 (-2.24 ; 4.64) 0.493
Interleukin-8
Week 2 0.65 (-0.95 ; 2.26) 0.425
Week 4 1.27 (-0.36 ; 2.91) 0.127
Week 12 2.23 (0.73 ; 3.73) 0.004
Interleukin-12
Week 2 -4.97 (-20.84 ; 10.90) 0.539
Week 4 4.87 (-11.31 ; 21.06) 0.555
Week 12 7.34 (-7.44 ; 22.13) 0.330
Interleukin-13
Week 2 -17.42 (-32.80 ; -2.03) 0.026
Week 4 7.21 (-8.46 ; 22.88) 0.367
Week 12 2.37 (-12.03 ; 16.76) 0.747
IFN-γ
Week 2 3.76 (-6.37 ; 13.89) 0.467
Week 4 3.03 (-7.27 ; 13.33) 0.564
Week 12 0.90 (-8.64 ; 10.44) 0.853
GM-CSF
Week 2 -1.73 (-4.70 ; 1.24) 0.253
Week 4 0.87 (-2.16 ; 3.89) 0.574
Week 12 0.76 (-2.04 ; 3.55) 0.595
Cytokine & 
Visit

















Table R-5: Comparison of cytokine concentrations across TB groups 
 
 










Interleukin-1β 0.1 (0.1 - 0.4) 0.1 (0.0 - 0.3) 0.304
ε
Interleukin-2 1.1 (0.2 - 2.6) 0.9 (0.1 - 2.2) 0.501
ε
Interleukin-4 0.1 (0.1 - 0.1) 0.1 (0.1 - 0.1) 0.421
ε
Interleukin-5 0.5 (0.3 - 1.2) 0.6 (0.3 - 1.1) 0.696
ε
Interleukin-6 2.7 (1.9 - 3.1) 3.0 (1.8 - 6.4) 0.467
ε
Interleukin-7 1.8 (0.9 - 3.6) 2.2 (0.6 - 3.8) 0.856
ε
Interleukin-8 3.8 (2.8 - 5.5) 3.8 (2.4 - 4.9) 0.737
ε
Interleukin-10 11.8 (5.4 - 23.9) 15.5 (7.7 - 29.7) 0.345
ε
Interleukin-12 0.0 (0.0 - 1.0) 0.0 (0.0 - 1.1) 0.673
ε
Interleukin-13 0.5 (0.5 - 4.6) 0.5 (0.5 - 7.4) 0.984
ε
IFN-γ 1.3 (0.0 - 3.1) 1.2 (0.0 - 3.7) 0.993
ε
GMCSF 1.0 (0.4 - 1.5) 0.7 (0.2 - 1.7) 0.792
ε
TNF-α 8.0 (5.7 - 13.1) 6.6 (4.1 - 11.0) 0.258
ε
ε    Wilcoxon rank-sum test
Cytokine
PLP < 25 nmol/L
(n = 33)
PLP > 25 nmol/L
(n = 25)
Interleukin-1β 0.1 (0.0 - 0.3) 0.2 (0.1 - 0.4) 0.362
ε
Interleukin-2 1.0 (0.1 - 2.0) 1.0 (0.2 - 2.9) 0.465
ε
Interleukin-4 0.1 (0.1 - 0.1) 0.1 (0.1 - 0.1) 0.823
ε
Interleukin-5 0.5 (0.3 - 0.8) 0.9 (0.4 - 1.2) 0.255
ε
Interleukin-6 3.1 (2.0 - 6.1) 2.5 (1.6 - 4.0) 0.151
ε
Interleukin-7 2.2 (1.1 - 3.8) 1.9 (0.5 - 3.4) 0.495
ε
Interleukin-8 3.4 (2.4 - 4.8) 3.8 (2.7 - 5.5) 0.456
ε
Interleukin-10 14.6 (5.4 - 25.4) 16.1 (9.7 - 29.4) 0.319
ε
Interleukin-12 0.0 (0.0 - 1.1) 0.0 (0.0 - 0.6) 0.952
ε
Interleukin-13 0.5 (0.5 - 9.8) 0.5 (0.5 - 6.5) 0.739
ε
IFN-γ 2.2 (0.0 - 3.8) 0.6 (0.0 - 2.8) 0.234
ε
GMCSF 0.7 (0.1 - 1.5) 0.8 (0.4 - 1.3) 0.414
ε
TNF-α 8.2 (5.6 - 12.0) 6.0 (4.1 - 8.4) 0.113
ε





























Week 2 0.01 (-0.95 ; 0.98) 0.979 -0.32 (-1.22 ; 0.58) 0.486
Week 4 0.35 (-0.63 ; 1.32) 0.485 -0.48 (-1.37 ; 0.42) 0.298
Week 12 -0.35 (-1.34 ; 0.63) 0.484 -0.43 (-1.29 ; 0.43) 0.330
Interleukin-7
Week 2 -4.47 (-9.50 ; 0.55) 0.081 -0.99 (-5.64 ; 3.65) 0.675
Week 4 -1.37 (-6.43 ; 3.69) 0.596 0.52 (-4.12 ; 5.17) 0.825
Week 12 -3.07 (-8.19 ; 2.05) 0.240 0.06 (-4.44 ; 4.56) 0.979
Interleukin-8
Week 2 -0.51 (-2.70 ; 1.68) 0.648 -0.61 (-2.67 ; 1.45) 0.560
Week 4 -0.11 (-2.32 ; 2.10) 0.922 -0.53 (-2.59 ; 1.53) 0.614
Week 12 -0.26 (-2.49 ; 1.98) 0.822 -0.38 (-2.37 ; 1.61) 0.709
Interleukin-12
Week 2 -5.99 (-15.39 ; 3.42) 0.212 -2.74 (-11.37 ; 5.90) 0.534
Week 4 -3.74 (-13.22 ; 5.74) 0.439 0.22 (-8.41 ; 8.86) 0.959
Week 12 0.16 (-9.42 ; 9.73) 0.974 1.91 (-6.47 ; 10.29) 0.655
Interleukin-13
Week 2 -4.17 (-25.22 ; 16.87) 0.698 -6.77 (-26.04 ; 12.50) 0.491
Week 4 -0.60 (-21.81 ; 20.62) 0.956 8.83 (-10.44 ; 28.11) 0.369
Week 12 -14.37 (-35.82 ; 7.08) 0.189 3.50 (-15.20 ; 22.21) 0.713
IFN-γ
Week 2 -12.73 (-32.32 ; 6.86) 0.203 15.19 (-2.07 ; 32.45) 0.085
Week 4 -4.25 (-23.98 ; 15.48) 0.673 0.32 (-16.94 ; 17.59) 0.971
Week 12 3.70 (-16.21 ; 23.62) 0.716 4.92 (-11.89 ; 21.72) 0.566
GM-CSF
Week 2 -0.77 (-5.77 ; 4.24) 0.764 -1.03 (-5.49 ; 3.43) 0.651
Week 4 0.25 (-4.79 ; 5.29) 0.923 1.36 (-3.10 ; 5.82) 0.550
Week 12 2.77 (-2.32 ; 7.87) 0.286 2.71 (-1.63 ; 7.04) 0.221
a    Difference in mean cytokine concentration between resolved symptoms and unresolved symptoms compared to baseline
b    Difference in mean cytokine concentration between grade ≥ 2  severity and grade 1 severity compared to baseline
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